KR20170012592A - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) - Google Patents

Abstract

Describes an antigen binding protein that interacts with the pro-protein conversion enzyme Subtilisin Kexin type 9 (PCSK9). Describes a method of treating hypercholesterolemia and other diseases by administering an antigen binding protein for a pharmaceutically effective amount of PCSK9. A method for detecting the amount of PCSK9 in a sample using an antigen binding protein for PCSK9 is described.

Description

Antigen binding protein for proprotein converting enzyme subtilisin kexin type 9 (PCSK9) {ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)}

<Related application>

This application is incorporated herein by reference in its entirety, U.S. Provisional Patent Application No. 60/957,668 filed Aug. 23, 2007, U.S. Provisional Patent Application No. 61/008,965 filed Dec. 21, 2007 and filed Jan. 9, 2008 Claims priority based on US Provisional Patent Application 61/010,630.

The present invention relates to an antigen-binding protein that binds to the proprotein converting enzyme subtilisin kexin type 9 (PCSK9), and to a method for use and preparation of the antigen-binding protein.

The proprotein converting enzyme subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the level of low density lipoprotein receptor (LDLR) protein ([Horton et al., 2007]; [Seidah and Prat, 2007]). In vitro experiments showed that the addition of PCSK9 to HepG2 cells lowered the level of cell surface LDLR ([Benjannet et al., 2004]; [Lagace et al., 2006]; [Maxwell et al., 2005]; [ Park et al., 2004]). In experiments with mice, increasing PCSK9 protein levels decreased LDLR protein levels in the liver ([Benjannet et al., 2004]; [Lagace et al., 2006]; [Maxwell et al., 2005]; [Park] et al., 2004]), PCSK9 knock-out mice showed increased LDLR levels in the liver (Rashid et al., 2005). Additionally, various human PCSK9 mutations have been identified that cause increased or decreased levels of plasma LDL ([Kotowski et al., 2006]; [Zhao et al., 2006]). PCSK9 directly interacts with the LDLR protein, is transfected with LDLR, and has been shown to co-immunofluorescence with LDLR throughout the endosome pathway (Lagace et al., 2006). The degradation of LDLR by PCSK9 was not observed, and the mechanism by which it lowers the extracellular LDLR protein level is uncertain.

PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah et al., 2003). Humans have nine prohormone-proprotein convertases that can be classified between the S8A and S8B subfamily (Rawlings et al., 2006). Furin, PC1/PC3, PC2, PACE4, PC4, PC5/PC6 and PC7/PC8/LPC/SPC7 are classified within subfamily S8B. The subtilisin-like pro-domain and catalytic domain, and the direct C-terminal P domain to the catalytic domain, were revealed through the determination and NMR structure of different domains from mouse purine and PC1 (Henrich et al., 2003 ]; [Tangrea et al., 2002]). Based on the amino acid sequence similarity within this subfamily, all seven members are predicted to have similar structures (Henrich et al., 2005). SKI-1/S1P and PCSK9 are classified within subfamily S8A. Sequence comparison using these proteins also suggests the presence of a subtilisin-like pro-domain and catalytic domain ([Sakai et al., 1998]; [Seidah et al., 2003]; [Seidah et al., 1999] ]). In these proteins, the amino acid sequence at the C-terminal to the catalytic domain is more variable and does not suggest the presence of a P domain.

Prohormone-proprotein convertases are expressed as zymogens, which mature through a multi-step process. In this process, the function of the pro-domain is double. The pro-domain first acts as a chaperone and is required for proper folding of the catalytic domain (Ikemura et al., 1987). Once the catalytic domain is folded, an autocatalytic reaction takes place between the pro-domain and the catalytic domain. After the initial cleavage reaction, the pro-domain remains bound to the catalytic domain, where it acts as an inhibitor of catalytic activity (Fu et al., 2000). If conditions are correct, maturation proceeds with a second autocatalytic event at a site within the pro-domain (Anderson et al., 1997). After the second cleavage event occurs, the pro-domain and catalytic domain dissociate, resulting in an active protease.

The autocatalytic reaction of the PCSK9 enzymatic source occurs between Gln152 and Ser153 (VFAQ|SIP) (Naureckiene et al., 2003) and has been shown to be required for its secretion from cells (Seidah et al., 2003). No second autocatalytic event was observed at the site within the pro-domain of PCSK9. Purified PCSK9 consists of the following two species that can be separated by non-reducing SDS-PAGE; Pro-domain at 17 Kd, and catalytic domain + C-terminal domain at 65 Kd. PCSK9 was not isolated without its inhibitory pro-domain, and the measurement of the catalytic activity of PCSK9 was variable ([Naureckiene et al., 2003]; [Seidah et al., 2003]).

In some embodiments, the invention includes an antigen binding protein for PCSK9.

In some aspects, the invention provides A) (i) SEQ ID NOs: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64 , CDRH1 from CDRH1 in a sequence selected from the group consisting of 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (ii) SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, CDRH2 from CDRH2 in a sequence selected from the group consisting of 80, 76, 77, 78, 83, 69, 81, and 60; (iii) SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, CDRH3 from CDRH3 in a sequence selected from the group consisting of 80, 76, 77, 78, 83, 69, 81, and 60; And (iv) at least one heavy chain complementarity determining region (CDRH) selected from the group consisting of the CDRHs of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of up to four amino acids. ; B) (i) SEQ ID NOS: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, CDRL1 from CDRL1 in a sequence selected from the group consisting of 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, CDRL2 from CDRL2 in a sequence selected from the group consisting of 36, 37, 38, 39, 40, 42, 44, and 46; (iii) SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, CDRL3 from CDRL3 in a sequence selected from the group consisting of 36, 37, 38, 39, 40, 42, 44, and 46; And (iv) at least one light chain complementarity determining region (CDRL) selected from the group consisting of the CDRLs of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of up to four amino acids. ; Or C) an isolated antigen binding protein that binds PCSK9, comprising at least one heavy chain CDRH of A) and at least one light chain CDRL of B). In some embodiments, the isolated antigen binding protein comprises at least one CDRH of A) and at least one CDRL of B). In some embodiments, the isolated antigen binding protein comprises at least two CDRHs of A) and at least two CDRLs of B). In some embodiments, the isolated antigen binding protein comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3. In some embodiments, the CDRH of A) comprises (i) a CDRH1 amino acid sequence selected from CDRH1 within a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49; (ii) a CDRH2 amino acid sequence selected from CDRH2 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49; (iii) a CDRH3 amino acid sequence selected from CDRH3 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49; And (iv) CDRH of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of two or less amino acids. In addition, the CDRL of B) is (i) a CDRL1 amino acid sequence selected from CDRL1 in a sequence selected from the group consisting of SEQ ID NOs: 12, 35, 32, and 23; (ii) a CDRL2 amino acid sequence selected from CDRL2 in a sequence selected from the group consisting of SEQ ID NOs: 12, 35, 32, and 23; (iii) a CDRL3 amino acid sequence selected from CDRL3 in a sequence selected from the group consisting of SEQ ID NOs: 12, 35, 32, and 23; And (iv) the CDRLs of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of up to two amino acids; Or C) at least one of the group consisting of at least one heavy chain CDRH of A) and at least one light chain CDRL of B). In some embodiments, the CDRH of A) comprises (i) the CDRH1 amino acid sequence of the CDRH1 amino acid sequence in SEQ ID NO:67; (ii) the CDRH2 amino acid sequence of the CDRH2 amino acid sequence in SEQ ID NO: 67; (iii) the CDRH3 amino acid sequence of the CDRH3 amino acid sequence in SEQ ID NO: 67; And (iv) the CDRHs of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of up to two amino acids; The CDRL of B) is (i) the CDRL1 amino acid sequence of the CDRL1 amino acid sequence in SEQ ID NO: 12; (ii) the CDRL2 amino acid sequence of the CDRL2 amino acid sequence in SEQ ID NO: 12; (iii) the CDRL3 amino acid sequence of the CDRL3 amino acid sequence in SEQ ID NO: 12; And (iv) the CDRLs of (i), (ii), and (iii) containing one or more amino acid substitutions, deletions or insertions of up to two amino acids; Or C) at least one of the group consisting of at least one heavy chain CDRH of A) and at least one light chain CDRL of B). In some embodiments, the antigen binding protein is A) CDRH1 of the CDRH1 sequence in SEQ ID NO: 67, CDRH2 of the CDRH2 sequence in SEQ ID NO: 67, and CDRH3 of the CDRH3 sequence in SEQ ID NO: 67, and B) CDRL1 of the CDRL1 sequence in SEQ ID NO: 12, in SEQ ID NO: 12. CDRL2 of the CDRL2 sequence, and CDRL3 of the CDRL3 sequence in SEQ ID NO:12. In some embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, A heavy chain variable region (VH) having at least 80% sequence identity with an amino acid sequence selected from the group consisting of 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60, and/or sequence 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, And a light chain variable region (VL) having at least 80% sequence identity with an amino acid sequence selected from the group consisting of 38, 39, 40, 42, 44, and 46. In some embodiments, the VH is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, Has at least 90% sequence identity with an amino acid sequence selected from the group consisting of 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60, and/or VL is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, It has at least 90% sequence identity with an amino acid sequence selected from the group consisting of 42, 44, and 46. In some embodiments, the VH is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60 are selected from the group consisting of, and / or, VL is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46 are selected from the group consisting of .

In some aspects, the invention includes an isolated antigen binding protein that specifically binds to an epitope to which any ABP disclosed herein binds.

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein is A) (i) SEQ ID NOs: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53 , 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and a sequence selected from the group consisting of 60 CDRH1 having at least 80% sequence identity to CDRH1 in one of the; (ii) SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, A CDRH2 having at least 80% sequence identity to CDRH2 in one of the sequences selected from the group consisting of 80, 76, 77, 78, 83, 69, 81, and 60; And (iii) SEQ ID NOS: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79. , 80, 76, 77, 78, 83, 69, 81, and one or more heavy chains selected from at least one of the group consisting of CDRH3 having at least 80% sequence identity to CDRH3 in one of the sequences selected from the group consisting of 60 CDR (CDRH); B) (i) SEQ ID NOS: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, CDRL1 having at least 80% sequence identity to CDRL1 in one of the sequences selected from the group consisting of 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, CDRL2 having at least 80% sequence identity to CDRL2 in one of the sequences selected from the group consisting of 36, 37, 38, 39, 40, 42, 44, and 46; And (iii) SEQ ID NOS: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35 , 36, 37, 38, 39, 40, 42, 44, and one or more light chains selected from at least one of the group consisting of CDRL3 having at least 80% sequence identity to CDRL3 in one of the sequences selected from the group consisting of 46 CDR (CDRL); Or C) at least one heavy chain CDRH of A) and at least one light chain CDRL of B). In some embodiments, the antigen binding protein is A) (i) SEQ ID NOs: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91 , A CDRH1 having at least 90% sequence identity to CDRH1 in one of the sequences selected from the group consisting of 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (ii) SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, A CDRH2 having at least 90% sequence identity to CDRH2 in one of the sequences selected from the group consisting of 80, 76, 77, 78, 83, 69, 81, and 60; And (iii) SEQ ID NOS: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79. , At least one CDRH selected from at least one of the group consisting of CDRH3 having at least 90% sequence identity to CDRH3 in one of the sequences selected from the group consisting of 80, 76, 77, 78, 83, 69, 81, and 60 ; B) (i) SEQ ID NOS: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, CDRL1 having at least 90% sequence identity to CDRL1 in one of the sequences selected from the group consisting of 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, CDRL2 having at least 90% sequence identity to CDRL2 in one of the sequences selected from the group consisting of 36, 37, 38, 39, 40, 42, 44, and 46; And (iii) SEQ ID NOS: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35 , 36, 37, 38, 39, 40, 42, 44, and one or more CDRLs selected from at least one of the group consisting of CDRL3 having at least 90% sequence identity to CDRL3 in one of the sequences selected from the group consisting of 46 ; Or C) at least one heavy chain CDRH of A) and at least one light chain CDRL of B).

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein is A) (i) a CDRH3 selected from CDRH3 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, and 49. , (ii) a CDRH3 whose amino acid sequence differs from the CDRH3 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ (SEQ ID NO: 404), where X ₁ is D, A, R and the absence of amino acids It is selected from the group consisting of, X ₂ is selected from the group consisting of Y, I, G and the absence of amino acids, X ₃ is selected from the group consisting of D, A, G and amino acid members, and X ₄ is F, A, It is selected from the group consisting of L and the absence of amino acids, X ₅ is selected from the group consisting of W, L, A and the absence of amino acids, X ₆ is selected from the group consisting of S, Y, A and the absence of amino acids, and X ₇ is A, Y, R and amino acid member is selected from the group consisting of, X ₈ is selected from the group consisting of Y, P and amino acid member, X ₉ is selected from the group consisting of Y, G and amino acid member, X ₁₀ is It is selected from the group consisting of D, G and the absence of amino acids, X ₁₁ is selected from the group consisting of A, M and the absence of amino acids, X ₁₂ is selected from the group consisting of F, D and the absence of amino acids, X ₁₃ is D, A heavy chain complementarity determining region (CDRH) selected from at least one of the group consisting of V and the absence of amino acids, and X _{14 is selected from the group consisting of V and the absence of amino acids;} B) (i) CDRL3 selected from CDRL3 in a sequence selected from the group consisting of SEQ ID NOs: 12, 35, and 23, (ii) amino acid sequence of 2 or less amino acids by amino acid addition, deletion or substitution of (i) CDRL3 different from CDRL3; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ (SEQ ID NO: 405) (wherein X ₁ is selected from the group consisting of Q and G, and X ₂ is S , T, A and the amino acid member is selected from the group consisting of, X ₃ is selected from the group consisting of Y, W and the amino acid member, X ₄ is selected from the group consisting of D and the amino acid member, X ₅ is S and amino acid It is selected from the group consisting of members, X ₆ is selected from the group consisting of S and the absence of amino acids, X ₇ is selected from the group consisting of L, T and the absence of amino acids, X ₈ is the absence of amino acids, A, and S It is selected from the group, X ₉ is selected from the group consisting of the absence of amino acids, G, A, and V, X ₁₀ is selected from the group consisting of the absence of amino acids, S, Y, and V, and X ₁₁ is the absence of amino acids and V And a light chain complementarity determining region (CDRL) selected from at least one of the group consisting of CDRL3 amino acid sequences selected from the group consisting of).

In some aspects, the invention provides 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33 , 35, 36, 37, 38, 39, 40, 42, 44, 46, and an isolated antigen-binding protein comprising a light chain having an amino acid sequence selected from the group consisting of some combinations thereof.

In some embodiments, the antigen binding protein specifically binds to an epitope to which at least one antigen binding protein disclosed herein binds. In some embodiments, the isolated antigen binding protein is 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62 , 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, 60, and a heavy chain having an amino acid sequence selected from the group consisting of some combinations thereof. In some embodiments, the amino acid sequence of ABP is selected from the group consisting of SEQ ID NOs: 12, 35, 23, and some combinations thereof. In some embodiments, the heavy chain of ABP comprises CDRH3 of SEQ ID NO: 67, CDRH2 of SEQ ID NO: 67, and CDRH1 of SEQ ID NO: 67, and the light chain comprises CDRL3 of SEQ ID NO: 12, CDRL2 of SEQ ID NO: 12, and CDRL1 of SEQ ID NO: 12. In some embodiments, the isolated antigen binding protein is a monoclonal antibody, polyclonal antibody, recombinant antibody, human antibody, humanized antibody, chimeric antibody, multispecific antibody, or antibody fragment thereof. In some embodiments, the isolated antigen binding protein is a Fab fragment, Fab' fragment, F(ab') ₂ fragment, Fv fragment, diabody, or single chain antibody molecule. In some embodiments, the isolated antigen binding protein is a human antibody. In some embodiments, the isolated antigen binding protein is a monoclonal antibody. In some embodiments, the isolated antigen binding protein is of the IgG1-, IgG2-, IgG3-, or IgG4-type. In some embodiments, the isolated antigen binding protein is of the IgG4- or IgG2-type. In some embodiments, the isolated antigen binding protein is coupled to a labeling group. In some embodiments, the isolated antigen binding protein competes with the antigen binding protein described herein for binding to PCSK9. In some embodiments, the isolated antigen binding protein is a monoclonal antibody, polyclonal antibody, recombinant antibody, human antibody, humanized antibody, chimeric antibody, multispecific antibody, or antibody fragment thereof. In some embodiments, the isolated antigen binding protein is a Fab fragment, Fab' fragment, F(ab') ₂ fragment, Fv fragment, diabody, or single chain antibody molecule. In some embodiments, the isolated antigen binding protein is coupled to a labeling group. In some embodiments, the isolated antigen binding protein reduces the binding of PCSK9 to LDLR. In some embodiments, the isolated antigen binding protein reduces the amount of LDL present in the subject when administered to the subject. In some embodiments, the isolated antigen binding protein reduces the amount of serum cholesterol present in the subject when administered to the subject. In some embodiments, the isolated antigen binding protein increases the amount of LDLR present in the subject when administered to the subject.

In some aspects, the invention includes vectors comprising the nucleic acid molecules described herein. In some embodiments, the invention includes host cells comprising the nucleic acid molecules described herein.

In some aspects, the invention includes isolated antigen binding proteins that compete with the antigen binding proteins disclosed herein for binding to PCSK9.

In some aspects, the invention includes nucleic acid molecules encoding the antigen binding proteins disclosed herein.

In some aspects, the invention includes pharmaceutical compositions comprising at least one antigen binding protein described herein.

In some aspects, the invention provides a method of treating or preventing a condition associated with elevated serum cholesterol levels in a patient comprising administering to a patient in need thereof an effective amount of at least one isolated antigen binding protein disclosed herein. Includes.

In some aspects, the invention includes a method of inhibiting the binding of PCSK9 to LDLR in a subject comprising administering an effective amount of at least one antigen binding protein disclosed herein.

In some aspects, the invention includes an antigen binding protein that selectively binds to PCSK9, wherein the antigen binding protein binds to PCSK9 with a _{K d of less than 100 pM.}

In some aspects, the invention provides an elevation in a subject comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding protein disclosed herein simultaneously or sequentially with an agent that increases the availability of the LDLR protein. And a method of treating or preventing conditions associated with reduced serum cholesterol levels.

In some aspects, the invention includes a method of lowering serum cholesterol levels in a subject comprising administering to the subject an effective amount of at least one isolated antigen binding protein disclosed herein.

In some aspects, the invention lowers serum cholesterol levels in a subject comprising administering to the subject an effective amount of at least one isolated antigen binding protein disclosed herein simultaneously or sequentially with an agent that increases the utilization of the LDLR protein. Including how to tell.

In some aspects, the invention includes a method of increasing LDLR protein levels in a subject comprising administering to the subject an effective amount of at least one isolated antigen binding protein disclosed herein.

In some aspects, the invention increases the level of LDLR protein in a subject, comprising administering to the subject an effective amount of at least one isolated antigen binding protein disclosed herein simultaneously or sequentially with an agent that increases utilization of the LDLR protein. Including how to tell.

In some aspects, the present invention includes pharmaceutical compositions comprising an ABP disclosed herein, and an agent that increases the utilization of LDLR proteins. In some embodiments, the agent that increases the utilization of the LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combinations thereof.

In some aspects, the invention encompasses a method of making an antigen binding protein described herein, comprising preparing the antigen binding protein from a host cell secreting the antigen binding protein.

In some aspects, the invention includes pharmaceutical compositions comprising at least one antigen binding protein described herein, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active substance. In some embodiments, the additional active substance is selected from the group consisting of radioisotopes, radionuclides, toxins, or treatment and chemotherapy groups.

In some aspects, the invention includes a method of treating or preventing conditions associated with elevated serum cholesterol levels in a patient. The method comprises administering to a patient in need thereof an effective amount of at least one isolated antigen binding protein disclosed herein. In some embodiments, the condition is hypercholesterolemia.

In some aspects, the invention includes a method of inhibiting the binding of PCSK9 to LDLR in a patient comprising administering an effective amount of at least one antigen binding protein described herein.

In some aspects, the invention includes antigen binding proteins that bind PCSK9 with a _{K d of less than 100 pM.} In some embodiments, the antigen binding protein binds with a _{K d less than 10 pM.} In some embodiments, the antigen binding protein binds with a _{K d less than 5 pM.}

In some aspects, the invention provides an elevation in a subject comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding protein described herein simultaneously or sequentially with an agent that increases the availability of the LDLR protein. And a method of treating or preventing conditions associated with reduced serum cholesterol levels. In some embodiments, the agent that increases the utilization of the LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combinations thereof.

In some aspects, the invention includes a method of lowering serum cholesterol levels in a subject. The method comprises administering to the subject an effective amount of at least one isolated antigen binding protein described herein.

In some aspects, the invention lowers serum cholesterol levels in a subject comprising administering to the subject an effective amount of at least one isolated antigen binding protein described herein concurrently or sequentially with an agent that increases utilization of the LDLR protein. Including how to tell. In some embodiments, the agent that increases the utilization of the LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combinations thereof.

In some aspects, the invention includes methods of increasing LDLR protein levels in a subject by administering to the subject an effective amount of at least one isolated antigen binding protein provided herein.

In some aspects, the present invention provides a method of increasing LDLR protein levels in a subject by administering to the subject an effective amount of at least one isolated antigen binding protein described herein simultaneously or sequentially with an agent that increases utilization of the LDLR protein. Includes. In some embodiments, the agent that increases the utilization of LDLR protein levels comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combinations thereof.

In some aspects, the invention includes neutralizing antibodies that bind to PCSK9 and reduce the LDLR-lowering effect of PCSK9 on low density lipoprotein receptors (LDLR). In some embodiments, the antibody specifically binds to PCSK9. In some embodiments, the antibody binds to the catalytic domain of PCSK9. In some embodiments, the antibody binds to an epitope within residues 31-447 of SEQ ID NO: 3. In some embodiments, the antibody binds to PCSK9 having an amino acid sequence that is at least 90% identical to SEQ ID NO: 3.

In some aspects, the invention includes a neutralizing antigen binding protein that binds to PCSK9, wherein the antigen binding protein binds to PCSK9 at a position within residues 31-447 of SEQ ID NO: 3. In some embodiments, when the antigen binding protein binds to PCSK9, the antibody is located 8 angstroms or less from at least one of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374 , C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, Q382, W72, F150 , A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374 , V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288 , A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, Q387, S153, S188, I189, Q190, S191, D192, R194 , E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239 , G244, M247, I369, S372, C375, or C378. In some embodiments, the antibody is located 8 angstroms or less from at least one of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380 , S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, or Q382. In some embodiments, the antibody is located 5 angstroms or less from at least one of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380 , Or S381. In some embodiments, the antibody is located 5 angstroms or less from at least two of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381. In some embodiments, the antibody is located 5 angstroms or less from at least 4 of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381. In some embodiments, the antibody is located 8 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255 , Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187 , E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372 , S373, C378, F379, T385, S386, or Q387. In some embodiments, the antibody is located 5 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255 , Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or G384. In some embodiments, the antibody is located 5 angstroms or less from at least two of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or G384. In some embodiments, the antibody is located 5 angstroms or less from at least 4 of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or G384. In some embodiments, the antibody is located 8 angstroms or less from at least one of the following residues of PCSK9: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238 , K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, or C378. In some embodiments, the antibody is located 5 angstroms or less from at least one of the following residues of PCSK9: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238 , K243, S373, D374, S376, T377, or F379. In some embodiments, the antibody is located 5 angstroms or less from at least two of the following residues of PCSK9: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, or F379. In some embodiments, the antibody is located 5 angstroms or less from at least 4 of the following residues of PCSK9: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, or F379.

In some aspects, the invention includes a neutralizing antibody that binds PCSK9, which binds to PCSK9 and reduces the likelihood of PCSK9 binding to LDLR.

In some embodiments, antibodies or antigen binding molecules that bind PCSK9 are contemplated. The antibody binds to PCSK9 at a position within residues 31-447 of SEQ ID NO: 3. In some embodiments, the antibody or antigen binding molecule is located 8 angstroms or less from at least one of the following residues of PCSK9 when bound to PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, Q382, W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, Q387, S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, or C378.

In some embodiments, an isolated antibody or antigen binding molecule is provided that blocks the antibody from binding to PCSK9 within 8 angstroms of residues of PCSK9. In some embodiments, the residues of PCSK9 are selected from at least one of the following PCSK9 residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, Q382, W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, Q387, S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, or C378 .

In some embodiments, an isolated antibody or antigen binding molecule is provided that binds to PCSK9 at a position that overlaps the position where LDLR binds to PCSK9. In some embodiments, the position at which LDLR binds to PCSK9 is at least selected from the group consisting of S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, and S381. It contains one amino acid residue.

In some embodiments, an isolated antibody or antigen binding molecule that binds to PCSK9 is provided. In some embodiments, the antibody or antigen binding molecule reduces the likelihood of EGFa binding to PCSK9 within 8 angstroms of at least one of the following residues on PCSK9: S153, I154, P155, R194, D238, A239, I369, S372 , D374, C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, or Q382.

In some embodiments, an antibody, antigen binding protein, or antigen binding molecule is provided that binds to the surface of PCSK9 overlapping the surface to which EGFa binds and/or Ab 21B12 binds and/or 31H4 binds. In some embodiments, an antibody, antigen binding protein, or antigen binding molecule is provided that binds to PCSK9 in a manner similar to that shown in the figure.

In some embodiments, the embodiment is a neutralizing antibody or antigen binding protein. In some embodiments, the antigen binding protein is not LDLR or a fragment thereof (eg EGFa).

In some aspects, the invention provides an isolated neutralizing antibody, wherein when the antibody binds to PCSK9, the antibody is located 8 angstroms or less from at least one of the following residues of PCSK9: T468, R469, M470 of SEQ ID NO:3 , A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, E593, S465, G466, P467, A473 , I474, R476, G497, E498, M500, G504, K506, L507, V508, A511, N513, A514, G516, V536, T538, A539, A544, T548, D570, L571, H591, A594, S595, and H597. In some embodiments, the antibody is located 5 angstroms or less from at least one of the following residues of PCSK9: T468, R469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512 of SEQ ID NO:3. F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and E593.

In some aspects, the invention includes an isolated antigen binding protein. The antigen binding protein is A) CDRH1 of the CDRH1 sequence in SEQ ID NO: 89, CDRH2 of the CDRH2 sequence in SEQ ID NO: 89, and CDRH3 of the CDRH3 sequence in SEQ ID NO: 89, and B) CDRL1 of the CDRL1 sequence in SEQ ID NO: 32, CDRL2 of the CDRL2 sequence in SEQ ID NO: 32 And a CDRL3 sequence of the CDRL3 sequence in SEQ ID NO:32.

In some aspects, the invention comprises an isolated antigen binding protein that binds to the PCSK9 protein of SEQ ID NO: 1, wherein the binding between the isolated antigen binding protein and the variant PCSK9 protein is the isolated antigen binding protein and SEQ ID NO: 1 and/or Less than 50% of the binding between the PCSK9 proteins of SEQ ID NO:303. In some embodiments, the variant PCSK9 protein is 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129 as shown in SEQ ID NO:1. , 311, 313, 337, 519, 521, and 554 at a position selected from the group consisting of or including at least one mutation of the residue. In some embodiments, the at least one mutation is selected from the group comprising or consisting of R207E, D208R, E181R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, A413R, and E582R. In some embodiments, the at least one mutation is selected from the group consisting of D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R.

In some aspects, the invention includes an antigen binding protein that binds to the PCSK9 protein of SEQ ID NO: 303 in a first manner and a variant of PCSK9 in a second manner. The PCSK9 variant is SEQ ID NO:303 and/or SEQ ID NO:1 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129, 311, 313 , 337, 519, 521, and 554 at a position selected from the group consisting of or comprising at least one point mutation. In some embodiments, the first scheme comprises a first EC50, a first Bmax, or a first EC50 and a first Bmax. In some embodiments, the second scheme comprises a second EC50, a second Bmax, or a second EC50 and a second Bmax. The value for the first scheme is different from the value for the second scheme. In some embodiments, the first mode comprises a first EC50, the second mode comprises a second EC50, and the point mutations are R207E, D208R, E181R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, It is selected from the group consisting of or including A390R, A413R, and E582R. In some embodiments, the first EC50 is at least 20% different from the second EC50. In some embodiments, the first EC50 is at least 50% different from the second EC50. In some embodiments, the second EC50 is a greater numerical value than the first EC50. In some embodiments, the first EC50 is determined by a multiple bead binding assay. In some embodiments, the second EC50 is greater than 1 μm. In some embodiments, the antigen binding protein is a neutralizing antigen binding protein. In some embodiments, the neutralizing antigen binding protein is a competitive neutralizing antigen binding protein. In some embodiments, the neutralizing antigen binding protein is a non-competitive neutralizing antigen binding protein. In some embodiments, the first manner includes a first Bmax, and the second manner includes a second Bmax that is different from the first Bmax. The PCSK9 variant has at least one point mutation selected from the group consisting of or comprising D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R. In some embodiments, the second Bmax is about 10% of the first Bmax. In some embodiments, the first Bmax is at least 20% different than the second Bmax. In some embodiments, the first Bmax is at least 50% different than the second Bmax.

In some aspects, the invention includes an isolated antigen binding protein that binds to the PCSK9 protein of SEQ ID NO: 3, wherein the epitope of the antigen binding protein comprises at least one of the following amino acids of SEQ ID NO: 207, 208, 181, 185, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554.

In some aspects, the invention includes an isolated neutralizing antigen binding protein that binds to a PCSK9 protein comprising the amino acid sequence of SEQ ID NO: 1, wherein the neutralizing antigen binding protein reduces the LDLR-lowering effect of PCSK9 on LDLR. In some embodiments, the antigen binding protein is an LDLR non-competitive neutralizing antigen binding protein. In some embodiments, the antigen binding protein is an LDLR competitive neutralizing antigen binding protein.

In some aspects, the invention comprises an isolated antigen binding protein, wherein the antigen binding protein comprises A) CDRH1 of the CDRH1 sequence in SEQ ID NO: 49, CDRH2 of the CDRH2 sequence in SEQ ID NO: 49, and CDRH3 of the CDRH3 sequence in SEQ ID NO: 49, and B ) CDRL1 of the CDRL1 sequence in SEQ ID NO:23, the CDRL2 sequence of the CDRL2 sequence in SEQ ID NO:23, and the CDRL3 of the CDRL3 sequence in SEQ ID NO:23.

In some aspects, the invention includes a composition comprising a crystallized PCSK9 protein and an antigen binding protein that binds to PCSK9. The composition comprises a crystallized PCSK9 protein, wherein the three-dimensional structure of the PCSK9 protein can be determined with a resolution of at least about 2.2 Angstroms. In some embodiments, the antigen binding protein is an antibody or fragment thereof.

In some aspects, the invention comprises a crystallized PCSK9 protein and at least an EGFa section of an LDLR protein, wherein the PCSK9 protein binds to the EGFa section of the LDLR protein, and the crystallized PCSK9 protein has a three-dimensional structure of the PCSK9 protein of about 2.2. It can be determined with a resolution of more than angstroms. In some embodiments, the molecular model is on a computer readable medium.

In some aspects, the invention encompasses the use of an antigen binding protein described herein in the manufacture of a medicament for lowering serum cholesterol.

In some aspects, the invention encompasses the use of an antigen binding protein described herein in the manufacture of a medicament for treating or preventing conditions associated with elevated serum cholesterol levels in a subject.

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein is selected from A) (i) CDRH1 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49. CDRH1 to be, (ii) a CDRH1 whose amino acid sequence differs from CDRH1 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ (SEQ ID NO: 406) (wherein X ₁ is G, and X ₂ is from the group consisting of Y, F, and G Is selected, X ₃ is selected from the group consisting of T and S, X ₄ is selected from the group consisting of L and F, X ₅ is selected from the group consisting of T, S, and N, and X ₆ is S and It is selected from the group consisting of A, X ₇ is selected from the group consisting of Y and F, X ₈ is selected from the group consisting of G, S, and Y, X ₉ is selected from the group consisting of I, M, and W It is selected, and X ₁₀ is selected from the group consisting of S, N and H) heavy chain complementarity determining region (CDRH) selected from at least one of the group consisting of CDRH1 amino acid sequences selected from the group consisting of), B) (i) SEQ ID NO: 12 , CDRL1 selected from CDRL1 in a sequence selected from the group consisting of 32, 35, and 23; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ (SEQ ID NO: 407) (wherein X ₁ is from the group consisting of T and the absence of amino acids Is selected, X ₂ is selected from the group consisting of G and S, X ₃ is selected from the group consisting of S, T, and G, X ₄ is S, X ₅ is S, X ₆ is N, D , And is selected from the group consisting of S, X ₇ is selected from the group consisting of I, V, and N, X ₈ is selected from the group consisting of G and I, X ₉ is selected from the group consisting of A and G And, X ₁₀ is selected from the group consisting of G, Y, S, and N, X ₁₁ is selected from the group consisting of Y and N, and X ₁₂ is selected from the group consisting of D, S, T, and F. , X ₁₃ is V, and X ₁₄ is a light chain complementarity determining region (CDRL) selected from at least one of the group consisting of a CDRL1 amino acid sequence selected from the group consisting of S, N, and H). . Those of skill in the art will appreciate that a single ABP or antibody may satisfy one or more of the above options and is still within the invention described for this embodiment.

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein is selected from A) (i) CDRH2 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49. CDRH2 to be, (ii) a CDRH2 whose amino acid sequence differs from CDRH2 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ X ₁₅ X ₁₆ X ₁₇ (SEQ ID NO: 408), where X ₁ is W, It is selected from the group consisting of S, L and the absence of amino acids, X ₂ is selected from the group consisting of V, I, and E, X ₃ is selected from the group consisting of S, W, and I, X ₄ is F, S, and is selected from the group consisting of N, X ₅ is selected from the group consisting of Y, S, D, and H, X ₆ is selected from the group consisting of N, S, and G, X ₇ is S and It is selected from the group consisting of G, X ₈ is selected from the group consisting of N, Y, D, and R, X ₉ is selected from the group consisting of T, I, and E, and X ₁₀ is N, S, Y , And is selected from the group consisting of D, X ₁₁ is Y, X ₁₂ is selected from the group consisting of A and N, X ₁₃ is selected from the group consisting of Q, D, and P, X ₁₄ is K and It is selected from the group consisting of S, X ₁₅ is selected from the group consisting of L and V, X ₁₆ is selected from the group consisting of Q and K, X ₁₇ is selected from the group consisting of G and S) A heavy chain complementarity determining region (CDRH) selected from at least one of the group consisting of the selected CDRH2 amino acid sequence, B) (i) a CDRL2 selected from CDRL2 in a sequence selected from the group consisting of SEQ ID NOs: 12, 32, 35, and 23, (ii) CDRL2 whose amino acid sequence differs from CDRL2 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ (SEQ ID NO: 409) (wherein X ₁ is selected from the group consisting of G, E, S, and D, and X ₂ is N, V, And it is selected from the group consisting of Y, X ₃ is selected from the group consisting of S and N, X ₄ is selected from the group consisting of N, Q, and K, X ₅ is R, X ₆ is P, X ₇ is S) and a light chain complementarity determining region (CDRL) selected from at least one of the group consisting of a CDRL2 amino acid sequence selected from the group consisting of.

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein is selected from A) (i) CDRH3 in a sequence selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49. CDRH3 to be, (ii) a CDRH3 whose amino acid sequence differs from the CDRH3 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ (SEQ ID NO: 410) (wherein X ₁ is D and in the group consisting of the absence of amino acids Is selected, X ₂ is selected from the group consisting of Y, A and the absence of amino acids, X ₃ is selected from the group consisting of D, I and the absence of amino acids, X ₄ is selected from the group consisting of F, A and the absence of amino acids, , X ₅ is selected from the group consisting of W, A and the absence of amino acids, X ₆ is selected from the group consisting of S, L and the absence of amino acids, X ₇ is selected from the group consisting of A, Y, G and the absence of amino acids, , X ₈ is selected from the group consisting of Y, Q and the absence of amino acids, X ₉ is selected from the group consisting of G, Y, and L, X ₁₀ is selected from the group consisting of Y, D, and V, and X ₁₁ is selected from the group consisting of G, A, and P, X ₁₂ is selected from the group consisting of M and F, X ₁₃ is D, X ₁₄ is selected from the group consisting of V and Y) A heavy chain complementarity determining region (CDRH) selected from at least one of the group consisting of the selected CDRH3 amino acid sequence, and B) (i) a CDRL3 selected from CDRL3 in a sequence selected from the group consisting of SEQ ID NOs: 12, 32, 35, and 23. , (ii) a CDRL3 whose amino acid sequence differs from the CDRL3 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ (SEQ ID NO: 411) (wherein X ₁ is selected from the group consisting of Q, A, G and the absence of amino acids, , X ₂ is selected from the group consisting of S, V, T and the absence of amino acids, X ₃ is selected from the group consisting of Y, N, and W, X ₄ is selected from the group consisting of S and D, and X ₅ Is selected from the group consisting of S, Y, and D, X ₆ is selected from the group consisting of S and T, X ₇ is selected from the group consisting of L and S, and X ₈ is S, T, and N It is selected from the _{group consisting of, X 9} is selected from the group consisting of G, S, and A, X ₁₀ is selected from the group consisting of S, M, W, and Y, and X ₁₁ is V) from the group consisting of And a light chain complementarity determining region (CDRL) selected from at least one of the group consisting of the selected CDRL3 amino acid sequence. In some embodiments, any of the above amino acids may be replaced by conservative amino acid substitutions.

In some aspects, the invention includes an isolated antigen binding protein that binds PCSK9, wherein the antigen binding protein is A) (i) SEQ ID NOs: 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 , CDRH1 selected from CDRH1 in a sequence selected from the group consisting of 57, and 58, (ii) CDRH1 whose amino acid sequence differs from CDRH1 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ (SEQ ID NO: 412) (wherein X ₁ is selected from the group consisting of G, P, and A, and X ₂ is Y, W, F, T, and is selected from the group consisting of S, X ₃ is selected from the group consisting of T, P, S and A, C, V, L, and I, X ₄ is L, F, I, V, M, A, and Y are selected from the group consisting of, X ₅ is selected from the group consisting of T, P, S, and A, X ₆ is selected from the group consisting of S, T, A, and C Is selected, X ₇ is selected from the group consisting of Y, W, F, T, and S, X ₈ is selected from the group consisting of G, P, and A, and X ₉ is I, L, V, M, A heavy chain complementarity determining region selected from at least one of the group consisting of a CDRH1 amino acid sequence selected from the group consisting of A and F, and X _{10 is selected from the group consisting of S, T, A, and C)} (CDRH), B) (i) CDRL1 selected from CDRL1 in a sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24, (ii) amino acids CDRL1 whose sequence differs from CDRL1 of (i) by amino acid addition, deletion or substitution of 2 or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ (SEQ ID NO: 413) (where X ₁ is selected from the group consisting of T and S And X ₂ is selected from the group consisting of G, P, and A, X ₃ is selected from the group consisting of T and S, and X ₄ is selected from the group consisting of S, N, T, A, C, and Q Is selected, X ₅ is selected from the group consisting of S, T, A, and C, X ₆ is selected from the group consisting of D and E, and X ₇ is V, I, M, L, F, and A It is selected from the _{group consisting of, X 8} is selected from the group consisting of G, P, and A, and X ₉ is selected from the group consisting of G, A, R, P, V, L, I, K, Q, and N And X ₁₀ is selected from the group consisting of Y, W, F, T, and S, X ₁₁ is selected from the group consisting of N and Q, and X ₁₂ is Y, S, W, F, T, A, And it is selected from the group consisting of C, X ₁₃ is selected from the group consisting of V, I, M, L, F, and A, X ₁₄ is selected from the group consisting of S, T, A, and C) consisting of And a light chain complementarity determining region (CDRL) selected from at least one of the group consisting of CDRL1 amino acid sequences selected from the group.

In some aspects, the invention includes an isolated antigen binding protein that binds PCSK9, wherein the antigen binding protein is A) (i) SEQ ID NOs: 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 , A CDRH2 selected from CDRH2 in a sequence selected from the group consisting of 57, and 58, (ii) a CDRH2 whose amino acid sequence differs from the CDRH2 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ X ₁₅ X ₁₆ X ₁₇ (SEQ ID NO: 414), where X ₁ is W, Y, and is selected from the group consisting of F, X ₂ is selected from the group consisting of V, I, M, L, F, and A, X ₃ is selected from the group consisting of S, T, A, and C, and , X ₄ is selected from the group consisting of A, F, V, L, I, Y, and M, X ₅ is selected from the group consisting of Y, W, F, T, and S, and X ₆ is N and It is selected from the group consisting of Q, X ₇ is selected from the group consisting of G, P, and A, X ₈ is selected from the group consisting of N and Q, X ₉ is selected from the group consisting of T and S, X ₁₀ is selected from the group consisting of N and Q, X ₁₁ is selected from the group consisting of Y, W, F, T, and S, and X ₁₂ is selected from the group consisting of A, V, L, and I , X ₁₃ is selected from the group consisting of Q, E, N, and D, X ₁₄ is selected from the group consisting of K, R, Q, and N, and X ₁₅ is L, F, V, I, M, A and Y are selected from the group consisting of, X ₁₆ is selected from the group consisting of Q and N, X ₁₇ is selected from the group consisting of G, P, and A) consisting of a CDRH2 amino acid sequence selected from the group consisting of Heavy chain complementarity determining region (CDRH) selected from at least one of the group, B) (i) SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and a sequence selected from the group consisting of 24 CDRL2 selected from CDRL2 in, (ii) a CDRL2 whose amino acid sequence differs from CDRL2 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ (SEQ ID NO: 415) (wherein X ₁ is selected from the group consisting of E and D, and X ₂ is V, I, M, L, F , And is selected from the group consisting of A, X ₃ is selected from the group consisting of S, T, A, and C, X ₄ is selected from the group consisting of N and Q, X ₅ is R, K, Q, And it is selected from the group consisting of N, X ₆ is selected from the group consisting of P and A, X ₇ is selected from the group consisting of S, T, A, and C) consisting of a CDRL2 amino acid sequence selected from the group consisting of And a light chain complementarity determining region (CDRL) selected from at least one of the group.

In some aspects, the invention includes an isolated antigen binding protein that binds PCSK9, wherein the antigen binding protein is A) (i) SEQ ID NOs: 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 , CDRH3 selected from CDRH3 in a sequence selected from the group consisting of 57, and 58; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 416) (wherein X ₁ is selected from the group consisting of G, P, A and the absence of amino acids _{, and X 2} is Y, W, F, T, and is selected from the group consisting of S, X ₃ is selected from the group consisting of G, V, P, A, I, M, L, and F, X ₄ is selected from the group consisting of M, L, F, and I It is selected from the group, X ₅ is selected from the group consisting of D and E, X ₆ is selected from the group consisting of V, I, M, L, F, and A) consisting of a CDRH3 amino acid sequence selected from the group consisting of Heavy chain complementarity determining region (CDRH) selected from at least one of the group, B) (i) SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and a sequence selected from the group consisting of 24 CDRL3 selected from CDRL3 in, (ii) a CDRL3 whose amino acid sequence differs from CDRL3 of (i) by amino acid addition, deletion or substitution of two or less amino acids; And (iii) X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ X ₇ X ₈ X ₉ (SEQ ID NO: 417) (wherein X ₁ is selected from the group consisting of S, N, T, A, C, and Q, and , X ₂ is selected from the group consisting of S, T, A, and C, X ₃ is selected from the group consisting of Y, W, F, T, and S, and X ₄ is selected from the group consisting of T and S And X ₅ is selected from the group consisting of S, T, A, and C, X ₆ is selected from the group consisting of S, T, A, and C, and X ₇ is N, S, Q, T, A , And C is selected from the group consisting of, X ₈ is selected from the group consisting of M, V, L, F, I, and A, and X ₉ is the group consisting of V, I, M, L, F, and A A light chain complementarity determining region (CDRL) selected from at least one of the group consisting of CDRL3 amino acid sequences selected from the group consisting of).

1A shows the amino acid sequence of mature PCSK9, and the pro-domain is underlined.
Figures 1b-1e show the amino acid and nucleic acid sequences of PCSK9, the pro-domain is underlined and the signal sequence is shown in bold.
2A-2D are sequence comparison tables of various light chains of various antigen binding proteins. Figure 2c is a continuation of the sequence starting in Figure 2a. Figure 2d is a continuation of the sequence starting in Figure 2b.
3A-3D are sequence comparison tables of various heavy chains of various antigen binding proteins. 3C is a continuation of the sequence starting in FIG. 3A. 3D is a continuation of the sequence starting in FIG. 3B.
3E-3JJ depict amino acid and nucleic acid sequences for variable domains of some embodiments of antigen binding proteins.
3KK depicts amino acid sequences for various constant domains.
3ll-3bbb depict amino acid and nucleic acid sequences for variable domains of some embodiments of antigen binding proteins.
3ccc-3jjj is a sequence comparison table of various heavy and light chains of some embodiments of an antigen binding protein.
4A is a curve of binding of an antigen binding protein to human PCSK9.
Figure 4b is a curve of the binding of the antigen binding protein to human PCSK9.
Figure 4c is a curve of the binding of the antigen binding protein to cynomolgus (cynomolgus) PCSK9.
Figure 4d is the binding curve of the antigen binding protein to cynomolgus PCSK9.
4E is a curve of the binding of an antigen binding protein to mouse PCSK9.
Figure 4f is a curve of the binding of the antigen binding protein to mouse PCSK9.
5A depicts the results of SDS PAGE experiments involving PCSK9 and various antigen binding proteins, demonstrating the relative purity and concentration of the protein.
5B and 5C show graphs from Biacore solution equilibrium analysis for 21B12.
5D shows a kinematic graph from Biacore capture analysis.
5E shows a bar graph showing binning results for three ABPs.
6A is an inhibition curve of the antigen binding protein 31H4 IgG2 to PCSK9 in an in vitro PCSK9:LDLR binding assay.
6B is an inhibition curve of the antigen binding protein 31H4 IgG4 to PCSK9 in an in vitro PCSK9:LDLR binding assay.
6C is an inhibition curve of the antigen binding protein 21B12 IgG2 to PCSK9 in an in vitro PCSK9:LDLR binding assay.
6D is an inhibition curve of the antigen binding protein 21B12 IgG4 to PCSK9 in an in vitro PCSK9:LDLR binding assay.
7A is an inhibition curve of the antigen-binding protein 31H4 IgG2 in cellular LDL uptake assay, showing the effect of ABP on reducing the LDL uptake blocking effect of PCSK9.
7B is an inhibition curve of the antigen binding protein 31H4 IgG4 in the cellular LDL uptake assay, showing the effect of ABP on reducing the LDL absorption blocking effect of PCSK9.
7C is an inhibition curve of the antigen binding protein 21B12 IgG2 in the cellular LDL uptake assay, showing the effect of ABP on reducing the LDL uptake blocking effect of PCSK9.
7D is an inhibition curve of the antigen binding protein 21B12 IgG4 in cellular LDL uptake assay, showing the effect of ABP to reduce the LDL uptake blocking effect of PCSK9.
8A is a graph showing the ability of ABP 31H4 to lower serum cholesterol in mice (change relative to IgG control-treated mice) (* p<0.01).
8B is a graph showing the ability of ABP 31H4 to lower serum cholesterol in mice (time = change relative to 0 hours) (# p, 0.05).
8C is a graph showing the effect of ABP 31H4 on HDL cholesterol levels in C57Bl/6 mice (* p<0.01).
8D is a graph showing the effect of ABP 31H4 on HDL cholesterol levels in C57Bl/6 mice (# p<0.05).
9 depicts Western blot analysis of the ability of ABP 31H4 to enhance the amount of liver LDLR protein present after various time points.
10A is a graph showing the ability of antigen binding protein 31H4 to lower total serum cholesterol in wild-type mice.
10B is a graph showing the ability of antigen binding protein 31H4 to lower HDL in wild-type mice.
10C is a graph showing the serum cholesterol lowering ability of various antigen binding proteins 31H4 and 16F12.
11A depicts an infusion protocol to test the duration and ability of an antigen binding protein to lower serum cholesterol.
Fig. 11B is a graph showing the result of the protocol of Fig. 11A.
12A depicts LDLR levels in response to a combination of statin and ABP 21B12 in HepG2 cells.
12B depicts LDLR levels in response to a combination of statin and ABP 31H4 in HepG2 cells.
12C depicts LDLR levels in response to a combination of statin and ABP 25A7.1 (neutralizing antibody as opposed to “25A7” neutralizing antibody) in HepG2 cells.
12D depicts LDLR levels in response to a combination of statin and ABP 21B12 in HepG2 cells overexpressing PCSK9.
12E depicts LDLR levels in response to a combination of statin and ABP 31H4 in HepG2 cells overexpressing PCSK9.
FIG. 12F depicts LDLR levels in response to a combination of statin and ABP 25A7.1 (neutralizing antibody as opposed to “25A7” neutralizing antibody) in HepG2 cells overexpressing PCSK9.
13A shows various light chain amino acid sequences of various ABPs for PCSK9. Dots (.) indicate the absence of amino acids.
Figure 13b shows the light chain branching map (cladogram) for various ABPs against PCSK9.
13C shows various heavy chain amino acid sequences of various ABPs for PCSK9. Dots (.) indicate the absence of amino acids.
13D depicts the heavy chain phylogenetic tree (dendrogram) for various ABPs against PCSK9.
13E shows a comparison of light chain and heavy chain CDRs, and designation of groups from which consensus is derived.
13F shows the consensus sequence for Group 1 and Group 2.
13G shows consensus sequences for groups 3 and 4.
13H shows the consensus sequence for Group 1 and Group 2. Dots (.) represent the same residues.
Figure 13i shows the consensus sequence for the second group. Dots (.) represent the same residues.
13J shows the consensus sequence for groups 3 and 4. Dots (.) represent the same residues.
14A is a graph showing the ability of various ABPs (at 10 mg/kg) to lower LDL in vivo.
14B is a graph showing the ability of various ABPs (at 30 mg/kg) to lower LDL in vivo.
15A and 15B are sequence comparison tables of various light chains of various embodiments of antigen binding proteins. 15B is a continuation of the sequence starting in FIG. 15A.
15C and 15D are sequence comparison tables of various light chains of various embodiments of antigen binding proteins. 15D is a continuation of the sequence starting in FIG. 15C.
16A is a diagram of a gel used to test the ability of Ab 21B12 to bind to the ProCat or VD section of PCSK9.
16B is a diagram of a gel used to test the ability of Ab 31H4 to bind to the ProCat or VD section of PCSK9.
Fig. 17 is a structural diagram of the EGFa section of PCSK9 and LDLR.
18A is a structural diagram of PCSK9 and 31H4 Ab.
18B is a structural diagram of PCSK9 and 31H4 Ab.
19A is a structural diagram of PCSK9, 31H4 Ab, and 21B12 Ab.
19B is a structural diagram of PCSK9 and 21B12 Ab.
20A is a structural diagram of PCSK9 superimposed with the structures of antibodies 31H4 and 21B12 bound to PCSK9, and EGFa from LDLR.
20B is a diagram of a structural model of PCSK9 and LDLR.
20C is a diagram of the structural model of PCSK9 and LDLR from a separate viewpoint.
20D is a diagram of a structural model of PCSK9 and LDLR, including the structural diagrams of 31H4 and 21B12.
FIG. 20E is a diagram of the structural model of FIG. 20D rotated 90 degrees around the indicated axis.
Fig. 20F is a diagram of the structural model of Fig. 20D rotated 180 degrees around the indicated axis.
21A is a structural diagram of PCSK9 and 31A4.
21B is a structural diagram of PCSK9 and 31A4.
21C is a structural diagram of PCSK9 and 31A4.
21D is a diagram of a structural model of the full length PCSK9 and 31A4.
22 shows human ABP sequences and E. It is a set of ABP sequences that identify various differences between the ABP sequences generated for E. coli and used for the crystal structure.
23 is a table of various binning results.
23A is a first portion of a table showing various binning results.
23B is a second part of a table showing various binning results.
23C is a third part of a table showing various binning results.
23D is a fourth part of a table showing various binning results.
24A is a diagram of a Western blot under non-reducing conditions.
24B is a diagram of a Western blot under reducing conditions.
25A is a diagram of the surface coverage of PCSK9.
Fig. 25B is a diagram of the surface occupancy rate of PCSK9.
Fig. 25C is a diagram of the surface occupancy rate of PCSK9.
Fig. 25D is a diagram of the surface occupancy rate of PCSK9.
Fig. 25E is a diagram of the surface occupancy rate of PCSK9.
Fig. 25F is a diagram of the surface occupancy rate of PCSK9.
26 is a sequence comparison of the PCSK9 amino acid sequence and all residues mutated within the PCSK9 variant to examine the epitopes of various antibodies.
Fig. 27A shows the 21B12 epitope hit when mapping onto the crystal structure of PCSK9 using 21B12.
Figure 27b shows the 31H4 epitope hit when mapping onto the crystal structure of PCSK9 using 31H4 and 21B1.
Figure 27c shows the 31A4 epitope hit when mapping onto the crystal structure of PCSK9 using 31H4 and 21B12.
Figure 27D shows the 12H11 epitope hit when mapping onto the crystal structure of PCSK9 using 31H4 and 21B12.
Figure 27e shows the 3C4 epitope hit when mapping onto the crystal structure of PCSK9 using 31H4 and 21B12.
28A is a graph demonstrating the binding ability of various ABPs to various portions of PCSK9.
28B is a graph demonstrating the binding ability of various ABPs to various parts of PCSK9.
28C is a graph comparing the LDLR binding ability of two ABPs.
28D is a graph comparing the cellular LDL uptake activity of two ABPs.

Antigen binding proteins (eg antibodies and functional binding fragments thereof) that bind PCSK9 are disclosed herein. In some embodiments, the antigen binding protein binds to PCSK9 and prevents PCSK9 from functioning in various ways. In some embodiments, the antigen binding protein blocks or reduces the ability of PCSK9 to interact with other substances. For example, in some embodiments, the antigen binding protein binds PCSK9 in a manner that prevents or reduces the likelihood of PCSK9 binding to LDLR. In another embodiment, the antigen binding protein binds to PCSK9 but does not block the ability of PCSK9 to interact with LDLR. In some embodiments, the antigen binding protein is a human monoclonal antibody.

As will be appreciated by those skilled in the art in light of the present specification, altering the interaction between PCSK9 and LDLR can increase the amount of LDLR available to bind to LDL, which in turn reduces the amount of serum LDL in the subject, Decreases the subject's serum cholesterol level. Thus, antigen binding proteins to PCSK9 can be used in various methods and compositions for treating subjects who have elevated serum cholesterol levels, are at risk of elevated serum cholesterol levels, or where a reduction in their serum cholesterol levels may be beneficial. I can. Accordingly, various methods and techniques are described herein for lowering, maintaining, or preventing an increase in serum cholesterol. In some embodiments, the antigen binding protein allows binding between PCSK9 and LDLR, while the antigen binding protein prevents or reduces the adverse activity of PCSK9 on LDLR. In some embodiments, the antigen binding protein prevents or reduces the binding of PCSK9 to LDLR.

For convenience, the following sections generally outline the various meanings of the terms used herein. In accordance with this discussion, after discussing general aspects of antigen binding proteins, specific examples demonstrating the properties of various embodiments of antigen binding proteins and how they can be used are discussed.

Definition and embodiment

It is to be understood that both the above general description and the following detailed description are illustrative and illustrative only, and are not limitations of the claimed invention. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Also, the use of the terms “comprising” and other forms, such as “comprises” and “included,” is not limiting. Further, terms such as "element" or "component" include both elements and components comprising one unit and elements and components comprising more than one subunit, unless specifically stated otherwise. Also, the use of the term “moiety” may include some or all of the moiety.

Section headings, as used herein, are for the purposes of explanation only and are not to be construed as limiting the subject matter described. All documents or portions of documents cited herein, including but not limited to patents, patent applications, articles, books, and papers, are expressly incorporated herein by reference in their entirety for any purpose. When used in accordance with the present application, the following terms will be understood to have the following meanings, unless otherwise indicated:

The term “proprotein convertase subtilisin kexin type 9” or “PCSK9” refers to the polypeptide set forth in SEQ ID NOs: 1 and/or 3, or fragments thereof, and related polypeptides, which are allelic variants, splice variants, derivatives Includes, but is not limited to, variants, substitutional variants, deletion variants, and/or insertional variants including addition of N-terminal methionine, fusion polypeptides, and interspecies homologs. In certain embodiments, the PCSK9 polypeptide comprises terminal residues, such as, but not limited to, leader sequence residues, targeting residues, amino terminal methionine residues, lysine residues, tag residues and/or fusion protein residues. “PCSK9” was also referred to as FH3, NARC1, HCHOLA3, proprotein convertase subtilisin/kexin type 9, and neuronal apoptosis regulated convertase 1. The PCSK9 gene encodes a proprotein convertase protein belonging to the proteinase K subfamily of the secreted subtylase family. The term “PCSK9” refers to both the proprotein and the product produced after the autocatalytic reaction of the proprotein. When referring only to the autocatalyzed product (eg, for an antigen binding protein that selectively binds to cleaved PCSK9), the protein is "mature", "cleaved", "processed" or "active". It can be referred to as PCSK9. When referring only to the inactive form, the protein may be referred to as the "inactive", "pro-form", or "untreated" form of PCSK9. The term PCSK9 as used herein also includes naturally occurring alleles such as the mutations D374Y, S127R and F216L. The term PCSK9 also refers to a PCSK9 molecule comprising a post-translational modification of the PCSK9 amino acid sequence, e.g., a glycosylated, PEGylated PCSK9 sequence, a PCSK9 sequence from which its signal sequence is truncated, from which its pro-domain is cleaved from the catalytic domain but catalytic Includes the PCSK9 sequence that has not been separated from the domain (eg, FIGS. 1A and 1B-1E).

The term “PCSK9 activity” includes any biological effect of PCSK9. In certain embodiments, PCSK9 activity includes the ability of PCSK9 to interact with or bind to a substrate or receptor. In some embodiments, PCSK9 activity is indicated by the ability of PCSK9 to bind to the LDL receptor (LDLR). In some embodiments, PCSK9 binds to LDLR and catalyzes the reactions that accompany it. In some embodiments, PCSK9 activity includes the ability of PCSK9 to alter (eg, reduce) the utilization rate of LDLR. In some embodiments, PCSK9 activity includes the ability of PCSK9 to increase the amount of LDL in a subject. In some embodiments, PCSK9 activity includes the ability of PCSK9 to reduce the amount of LDLR available to bind LDL. In some embodiments, “PCSK9 activity” includes any biological activity resulting from PCSK9 signaling. Exemplary activities include PCSK9 binding to LDLR, PCSK9 enzyme activity that cleaves LDLR or other proteins, PCSK9 binding to proteins other than LDLR that facilitate PCSK9 action, PCSK9 that alters APOB secretion ([Sun XM et al., "Evidence for effect of mutant PCSK9 on apoliprotein B secretion as the cause of unusually severe dominant hypercholesterolemia, Human Molecular Genetics 14: 1161-1169, 2005] and [Ouguerram K et al., "Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9, Arterioscler thromb Vase Biol. 24: 1448-1453, 2004]), the role of PCSK9 in liver regeneration and neuronal cell differentiation (Seidah NG et al., "The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC- 1): Liver regeneration and neuronal differentiation" PNAS 100: 928-933, 2003), and the role of PCSK9 in liver glucose metabolism (Costet et al., "Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding. protein Ic" J. Biol. Chem. 281(10):6211-18. 2006).

The term “hypercholesterolemia” as used herein refers to a condition in which cholesterol levels are elevated beyond a desired level. In some embodiments, the term refers to an elevated serum cholesterol level. In some embodiments, the desired level takes into account various “risk factors” known to those of skill in the art (and described and referred to herein).

The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotide constituting the polynucleotide may be a ribonucleotide or a deoxyribonucleotide, or a modified form of two types of nucleotides. Such modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2′,3′-dideoxyribose, and internucleotidic linkage modifications such as phosphorothioate, phosphorodithi Oate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate and phosphoroamidate.

The term “oligonucleotide” refers to a polynucleotide comprising up to 200 nucleotides. In some embodiments, the oligonucleotide is 10 to 60 bases in length. In other embodiments, the oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides can be single-stranded or double-stranded, for example, for use in the construction of mutant genes. Oligonucleotides can be sense or antisense oligonucleotides. The oligonucleotide may include a label including a radioactive label, a fluorescent label, a hapten or an antigenic label for detection analysis. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes.

An "isolated nucleic acid molecule" refers to the DNA or RNA, mRNA, cDNA, or synthetic of the genome to which the isolated polynucleotide is not associated with all or part of the polynucleotide found in nature, or to a polynucleotide to which it is not linked Origin or some combination thereof. For the purposes of this application, it should be understood that the “nucleic acid molecule that constitutes” a particular nucleotide sequence does not include intact chromosomes. An isolated nucleic acid molecule “consisting of” a specified nucleic acid sequence may, in addition to the specified sequence, comprise up to 10 or even up to 20 coding sequences for other proteins or portions thereof, or expression of the coding region of the recited nucleic acid sequence. It may comprise regulatory sequences that are operably linked to control and/or may comprise vector sequences.

Unless otherwise specified, the left end of any single-stranded polynucleotide sequence discussed herein is the 5'end; The left-hand direction of the double-stranded polynucleotide sequence is referred to as the 5'direction. The direction of addition from 5'to 3'of nascent RNA transcripts is referred to as the direction of transcription; A sequence region on a DNA strand having the same sequence as an RNA transcript that is 5'to the 5'end of the RNA transcript is referred to as the "upstream sequence"; A sequence region on a DNA strand having the same sequence as an RNA transcript that is 3'to the 3'end of the RNA transcript is referred to as a "downstream sequence".

The term “control sequence” refers to a polynucleotide sequence capable of affecting the expression and processing of the coding sequence to which it is ligated. The nature of such control sequences can depend on the host organism. In certain embodiments, the control sequence for a prokaryote may include a promoter, a ribosome binding site, and a transcription termination sequence. For example, a control sequence for eukaryotes can include a promoter comprising one or more recognition sites for a transcription factor, a transcription enhancer sequence, and a transcription termination sequence. A “control sequence” may include a leader sequence and/or a fusion partner sequence.

The term “vector” refers to any molecule or entity (eg, nucleic acid, plasmid, bacteriophage or virus) used to deliver protein coding information into a host cell.

The term “expression vector” or “expression construct” refers to a vector suitable for transformation of a host cell, and directs and/or controls the expression of one or more heterologous coding regions operably linked thereto. Contains. The expression construct may comprise a sequence that affects or controls the transcription, translation of a coding region operably linked thereto, and, in the presence of an intron, affects RNA splicing of the coding region, thereby Not limited.

As used herein, “operably linked” means that the components to which the term applies are in a relationship that allows them to perform their own function under suitable conditions. For example, a control sequence in a vector “operably linked” to a protein coding sequence is ligated thereto such that expression of the protein coding sequence is achieved under conditions suitable for the transcriptional activity of the control sequence.

The term “host cell” refers to a cell that has been transformed or can be transformed using a nucleic acid sequence to express a gene of interest. The term includes progeny of a parental cell whether or not the progeny are identical in morphology or genetic makeup to the original parental cell, as long as the gene of interest is present.

The term "transfection" refers to the uptake of foreign or exogenous DNA by a cell, and a cell is "transfected" when the exogenous DNA is introduced into the cell membrane. Many transfection techniques are well known in the art and disclosed herein (eg, Graham et al., 1973, Virology 52:456); Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra]; [Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier]; [Chu et al., 1981, Gene 13:197]). Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term “transformation” refers to altering the genetic characteristics of a cell, which is transformed when a cell is modified to contain new DNA or RNA. For example, a cell is transformed when it is genetically modified from its natural state by introducing new genetic material through transfection, transduction, or other techniques. After transfection or transduction, the transforming DNA can be recombined with the DNA of the cell by physically integrating it into the chromosome of the cell, or it can be temporarily maintained as an episomal element without replicating, or it can be replicated independently as a plasmid. I can. A cell is considered to be "stable transformed" when the transforming DNA replicates with the division of the cell.

The term “polypeptide” or “protein” refers to a natural protein, ie a macromolecule having the amino acid sequence of a protein produced by naturally occurring and non-recombinant cells; Molecules produced by genetically engineered cells or recombinant cells and having the amino acid sequence of a native protein, or molecules having deletions, additions to, and/or substitutions from one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of the corresponding naturally occurring amino acids and polymers. The terms “polypeptide” and “protein” specifically include PCSK9 antigen binding proteins, antibodies, or sequences having deletions, additions, and/or substitutions from one or more amino acids of the antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide having an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion compared to a full-length native protein. Such fragments may also contain modified amino acids compared to native proteins. In certain embodiments, the fragment is about 5 to 500 amino acids in length. For example, a fragment is at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids in length. Useful polypeptide fragments include immunologically functional fragments of antibodies, such as binding domains. In the case of PCSK9-binding antibodies, useful fragments include, but are not limited to, a CDR region, a variable domain of a heavy and/or light chain, a portion of an antibody chain or a variable region thereof comprising only two CDRs, and the like.

The term “isolated protein” means that the protein of interest is (1) free of at least some other proteins to be normally found, (2) essentially free of other proteins from the same source, eg, from the same species, or (3) different Found by cells from the species, (4) isolated from at least about 50% of the polynucleotides, lipids, carbohydrates, or other substances associated with them in nature, or (5) with polypeptides that are not associated with nature (covalent or It is meant to be operably associated (by non-covalent interaction), or (6) not occurring in nature. Usually, “isolated protein” constitutes at least about 5%, at least about 10%, at least about 25%, or at least about 50% of a given sample. Genomic DNA, cDNA, mRNA, or other RNA of synthetic origin, or any combination thereof, can encode the isolated protein. Preferably, the isolated protein is substantially free of proteins or polypeptides or other contaminants found in its natural environment that will inhibit its treatment, diagnosis, prevention, research or other use.

The term “amino acid” includes its general meaning in the art.

A “variant” of a polypeptide (eg, an antigen binding protein, or antibody) includes an amino acid sequence in which one or more amino acid residues are inserted into and/or deleted from and/or substituted into an amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins.

The term “identity” refers to a relationship between sequences of two or more polypeptide molecules or two or more nucleic acid molecules as determined by aligning and comparing sequences. "Identity ratio" means the ratio of identical residues between amino acids or nucleotides in a compared molecule, and is calculated based on the size of the smallest of the molecules being compared. For these calculations, the gap (if any) in the alignment is preferably addressed by a specific mathematical model or computer program (ie, "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides are described in [Computational Molecular Biology, (Lesk, AM, ed.), 1988, New York: Oxford University Press]; [Biocomputing Informatics and Genome Projects, ( Smith, DW, ed.), 1993, New York: Academic Press]; [Computer Analysis of Sequence Data, Part I, (Griffin, AM, and Griffin, HG, eds.), 1994, New Jersey: Humana Press]; [von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press]; [Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press]; and [Carillo et al., 1988, SIAM J. Applied Math. 48:1073]).

In calculating the identity ratio, the sequences being compared are usually aligned in a way that provides the maximum match between the sequences. One example of a computer program that can be used to determine the identity ratio is the GCG program package, which is GAP (Devereux et al., 1984, Nucl.Acid Res. 12:387; Genetics Computer Group, University of Wisconsin). University of Wisconsin, Madison, Wisconsin, USA) The computer algorithm GAP is used to align two polypeptides or polynucleotides for which the ratio of sequence identity is to be determined. The sequences are for optimal matching of their respective amino acids or nucleotides. Aligned ("matched span" as determined by the algorithm) Gap open penalty (calculated as 3x average diagonal, where "average diagonal" is the average of the diagonals of the comparison matrix used;" Diagonal" is the score or number assigned to each complete amino acid match by a particular comparison matrix) and a gap extension penalty (usually 1/10 times the gap opening penalty), and a comparison matrix such as PAM 250 or BLOSUM 62. In certain embodiments, standard comparison matrices (Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for PAM 250 comparison matrices; literature for BLOSUM 62 comparison matrices) (See Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919) is also used by the algorithm.

Examples of parameters that can be used to determine the ratio of identity to a polypeptide or nucleotide sequence using the GAP program are:

-Algorithm: [Needleman et al., 1970, J. Mol. Biol. 48:443-453];

-Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra;

-Gap penalty: 12 (however, there is no penalty for end gaps);

-Gap length penalty: 4;

-Threshold of similarity: 0.

A specific alignment scheme for aligning two amino acid sequences can result in matching only short regions of the two sequences, and the small aligned regions are very high sequences even if there is no significant relationship between the two full-length sequences. Can have identity. Thus, the selected alignment method (GAP program) can be tailored if desired to produce alignments up to at least 50 or other numbers of contiguous amino acids of the target polypeptide.

As used herein, the 20 conventional (e.g., naturally occurring) amino acids and their abbreviations follow conventional convention (Immunology-A Synthesis (2nd Edition, ES Golub), which is incorporated herein by reference for any purpose. and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991))). Stereoisomers of the 20 conventional amino acids (e.g., D-amino acids), non-natural amino acids such as α-, α-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids are also present. It may be a component suitable for the polypeptide of the invention. Examples of unconventional amino acids include 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formyl Methionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (eg, 4-hydroxyproline). In the polypeptide notation as used herein, the left direction is the amino terminal direction and the right direction is the carboxy-terminal direction according to standard convention and convention.

Similarly, unless otherwise specified, the left end of a single stranded polynucleotide sequence is the 5'end; The left-hand direction of the double-stranded polynucleotide sequence is referred to as the 5'direction. The 5'to 3'additional direction of the initial RNA transcript is referred to as the transcription direction; A sequence region on a DNA strand that has the same sequence as the RNA and is 5'to the 5'end of the RNA transcript is referred to as the "upstream sequence"; A sequence region on a DNA strand that has the same sequence as RNA and is 3'to the 3'end of the RNA transcript is referred to as a "downstream sequence".

Conservative amino acid substitutions can usually include non-naturally occurring amino acid residues that are involved by chemical peptide synthesis rather than by synthesis within a biological system. These include peptidomimetic and other inverted or inverted forms of amino acid moieties.

Naturally occurring residues can be divided into classes based on general side chain properties:

1) hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

2) neutral hydrophilicity: Cys, Ser, Thr, Asn, Gin;

3) acidic: Asp, Glu;

4) Basic: His, Lys, Arg;

5) residues that influence chain orientation: Gly, Pro; And

6) Aromatic: Trp, Tyr, Phe.

For example, a non-conservative substitution may involve the exchange of one member of these types for a member of another type. Such substituted moieties can be introduced, for example, into a region of a human antibody that is homologous to a non-human antibody, or into a non-homologous region of the molecule.

In changing the antigen binding protein or PCSK9 protein, depending on the particular embodiment, the hydropathic index of the amino acid may be considered. Each amino acid was assigned a numerical index based on its hydrophobicity and charge characteristics. These are isoleucine (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine/cystine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamate (-3.5); Glutamine (-3.5); Aspartate (-3.5); Asparagine (-3.5); Lysine (-3.9); And arginine (-4.5).

The importance of the numerical amino acid index in imparting an interactive biological function to a protein is known in the art (Kyte et al., J. Mol. Biol., 157:105-131 (1982)). It is known that certain amino acids can be substituted for other amino acids with a similar numerical index or score and still retain similar biological activity. In making changes based on a numerical index, in certain embodiments, substitutions of amino acids whose numerical index are within ±2 are included. In certain embodiments, substitutions of amino acids with a numerical index within ±1 are included, and in certain embodiments, substitutions of amino acids within ±0.5 are included.

It is also understood in the art that substitutions of similar amino acids can be made effectively based on hydrophilicity, particularly when the biologically functional proteins or peptides produced thereby are intended for use in immunological embodiments as in the present case. In certain embodiments, the maximum local average hydrophilicity of a protein, governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., the biological properties of the protein.

The following hydrophilicity values were assigned to these amino acid residues: arginine (+3.0); Lysine (+3.0); Aspartate (+3.0±1); Glutamate (+3.0±1); Serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5±1); Alanine (-0.5); Histidine (-0.5); Cysteine (-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoleucine (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5) and tryptophan (-3.4). In making changes based on similar hydrophilicity values, in certain embodiments, substitutions of amino acids whose hydrophilicity values are within ±2 are included, and in certain embodiments, substitutions of amino acids within ±1 are included, In certain embodiments, substitutions of amino acids within ±0.5 are included. In addition, epitopes can be identified from the primary amino acid sequence based on hydrophilicity. These zones are also referred to as "epitope core zones".

Exemplary amino acid substitutions are listed in Table 1.

The term “derivative” refers to a molecule that contains chemical modifications other than insertions, deletions, or substitutions of amino acids (or nucleic acids). In certain embodiments, derivatives include covalent modifications including, but not limited to, chemical bonds with polymers, lipids, or other organic or inorganic moieties. In certain embodiments, a chemically modified antigen binding protein may have a greater circulating half-life than a chemically unmodified antigen binding protein. In certain embodiments, chemically modified antigen binding proteins can have an improved targeting capacity for the cells, tissues, and/or organs of interest. In some embodiments, the derivative antigen binding protein is covalently modified to include one or more water soluble polymer attachments including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. See, for example, U.S. Patents 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 and 4,179,337. In certain embodiments, the derivative antigen binding protein is monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate-based polymer, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymer, polypropylene oxide. /Ethylene oxide co-polymer, polyoxyethylated polyol (eg glycerol) and polyvinyl alcohol, and one or more polymers including, but not limited to, mixtures of such polymers.

In certain embodiments, the derivative is covalently modified with a polyethylene glycol (PEG) subunit. In certain embodiments, one or more water-soluble polymers are bonded at one or more specific positions of the derivative, such as at the amino terminus. In certain embodiments, one or more water-soluble polymers are randomly attached to one or more side chains of the derivative. In certain embodiments, PEG is used to improve the therapeutic dose for an antigen binding protein. In certain embodiments, PEG is used to improve therapeutic doses for humanized antibodies. This particular method is discussed, for example, in US Pat. No. 6,133,426, which is incorporated herein by reference for any purpose.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties similar to those of template peptides. These kinds of non-peptide compounds are referred to as “peptide mimetics” or “peptide mimetics” (Fauchere, J., Adv. Drug Res., 15:29 (Fauchere, J., Adv. Drug Res., 15:29), which is incorporated herein by reference for any purpose. 1986)]; [Veber & Freidinger, TINS, p.392 (1985)]; and [Evans et al., J. Med. Chem., 30:1229 (1987)]).Such compounds are often subjected to computer molecular modeling. Peptidomimetics that are structurally similar to therapeutically useful peptides can be used to produce similar therapeutic or prophylactic effects In general, peptidomimetics are paradigm polypeptides (ie, biochemical properties or pharmacological activity). having a polypeptide), e.g., structurally similar to human antibodies, by methods well known in the art _{--CH 2 NH--, --CH 2 S--,} -CH 2 -CH 2 -, - -CH=CH-(cis and trans), --COCH ₂ --, --CH(OH)CH ₂ --, and --CH ₂ SO-- Systematic substitution of one or more amino acids of the consensus sequence with the same type of D-amino acid (eg, D-lysine instead of L-lysine) can be used to generate more stable peptides in certain embodiments. , A consensus sequence or a constrained peptide comprising a substantially identical consensus sequence variation, by methods known in the art, e.g., internal cysteine residues capable of forming an intramolecular disulfide bridge that cyclizes the peptide. It can be produced by addition (see Rizo and Gierasch, Ann. Rev. Biochem., 61:387 (1992), incorporated herein by reference for any purpose).

The term “naturally occurring” as used throughout this specification in connection with a biological substance, eg, a polypeptide, nucleic acid, host cell, etc., refers to a substance found in nature or a form of substance found in nature.

As used herein, “antigen binding protein” (“ABP”) refers to any protein that binds to the specified target antigen. Herein, the target antigen specified is the PCSK9 protein or fragment thereof. “Antigen binding protein” includes, but is not limited to, antibodies and binding portions thereof, such as immunologically functional fragments. A peptibody is another example of an antigen binding protein. The term "immunologically functional fragment" (or simply "fragment") of an antibody or immunoglobulin chain (heavy or light chain) antigen binding protein as used herein, lacks at least some of the amino acids present in the full-length chain, but is still antigen-specific. It is a species of antigen-binding protein that includes a portion of an antibody capable of binding to (regardless of the manner in which the portion is obtained or synthesized). Such fragments are biologically active in that they bind to the target antigen and can compete with other antigen binding proteins, including intact antibodies, for binding to a given epitope. In some embodiments, the fragment is a neutralizing fragment. In some embodiments, fragments can block or reduce the likelihood of an interaction between LDLR and PCSK9. In one aspect, such fragments will have at least one CDR present within the full length light or heavy chain, and in some embodiments will comprise a single heavy and/or light chain or portions thereof. These biologically active fragments can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of antigen binding proteins, including intact antibodies. Immunologically functional immunoglobulin fragments include Fab, diabody (heavy chain variable domain on the same polypeptide as the light chain variable domain, linked via a peptide linker that is too short to allow pairing between two domains on the same chain), Fab′, F(ab ') ₂ , Fv, domain antibodies and single chain antibodies, including, but not limited to, can be derived from any mammalian source including, but not limited to, human, mouse, rat, camelid or rabbit. Functional portions of the antigen binding proteins disclosed herein, e.g., one or more CDRs, are covalently linked to a second protein or to a small molecule to be directed against a specific target in the body with bifunctional therapeutic properties or prolonged serum half-life. It is further contemplated that a therapeutic agent may be generated. As will be appreciated by one of skill in the art, the antigen binding protein may comprise a non-protein component. In some sections of this application, examples of ABP are described herein in terms of “number/letter/number” (eg, 25A7). In these cases, the exact name indicates the specific antibody. That is, the ABP referred to as 25A7 is not necessarily identical to the antibody referred to as 25A7.1 (unless they are explicitly taught to be identical in the specification, for example 25A7 and 25A7.3). As will be appreciated by those of skill in the art, in some embodiments LDLR is not an antigen binding protein. In some embodiments, the binding subsection of LDLR, eg, EGFa, is not an antigen binding protein. In some embodiments, the other molecule through which PCSK9 signals in vivo is not an antigen binding protein. Such an embodiment will be clearly identified as such.

Certain antigen binding proteins described herein are antibodies or are derived from antibodies. In certain embodiments, the polypeptide structure of the antigen binding protein is a monoclonal antibody, bispecific antibody, minibody, domain antibody, synthetic antibody (sometimes referred to herein as "antibody mimetic"), chimeric antibody, respectively. Based on antibodies, including but not limited to humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof. In some embodiments, the ABP comprises or consists of an avimer (a tightly binding peptide). These various antigen binding proteins are further described herein.

The “Fc” region contains two heavy chain fragments comprising _{the C H} 1 and C _{H 2 domains of an antibody.} The two heavy chain fragments are held together by two or more disulfide bonds and by the hydrophobic interaction of the _{C H 3 domain.}

“Fab fragment” includes the C _H 1 and variable regions of one light chain and one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.

"Fab fragment" is 2 of two Fab' fragments, including one light chain and a portion of one heavy chain containing a _{VH domain and a C H 1 domain, and also a region between the C H} 1 and C _{H 2 domains.} Interchain disulfide bonds may be formed between heavy chains to form F(ab') ₂ molecules.

“F(ab') ₂ fragments” include two light chains and _{two heavy chains containing part of the constant region between the C H} 1 and C _H 2 domains, so that an interchain disulfide bond between the two heavy chains Is formed. Thus, the F(ab') ₂ fragment consists of two Fab' fragments held together by disulfide bonds between the two heavy chains.

The “Fv region” includes the variable region from both the heavy and light chains, but lacks the constant region.

A “single chain antibody” is an Fv molecule in which the heavy and light chain variable regions are linked by a flexible linker to form a single polypeptide chain, which forms an antigen binding region. Single chain antibodies are discussed in detail in International Patent Application Publication WO 88/01649 and US Patents 4,946,778 and 5,260,203, the disclosure of which is incorporated herein by reference.

A “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of the heavy chain and the variable region of the light chain. In some cases, two or more V _H regions are covalently linked with a peptide linker to create a bivalent domain antibody. The two V _H regions of a bivalent domain antibody are identical or can target an antigen.

A “bivalent antigen binding protein” or “bivalent antibody” contains two antigen binding sites. In some cases, the two binding sites have the same antigen specificity. Divalent antigen binding proteins and divalent antibodies can be bispecific (see below). In certain embodiments, a bivalent antibody other than a “multispecific” or “multifunctional” antibody is generally considered to have the same respective binding sites thereof.

A “multispecific antigen binding protein” or “multispecific antibody” is one that targets more than one antigen or epitope.

A “bispecific”, “bi-specific” or “bifunctional” antigen binding protein or antibody is a hybrid antigen binding protein or antibody, each having two different antigen binding sites. Bispecific antigen binding proteins and antibodies are species of multispecific antigen binding protein antibodies, and can be produced by a variety of methods including, but not limited to, fusion of hybridomas or ligation of Fab' fragments (e.g., See Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79:315-321; Kostelny et al., 1992, J. Immunol. 148:1547-1553). The two binding sites of a bispecific antigen binding protein or antibody will bind to two different epitopes, which may be on the same or different protein targets.

An antigen binding protein is said to "specifically bind" to its target antigen when the _{dissociation constant (K d} ) is ≦10 ^{-7 M.} ABP specifically binds to an antigen with "high affinity" when _{K d} is ≤5 x 10 ^-9 _{M and "very high affinity" when K d} is ≤5 x 10 ^{-10 M} . In one embodiment, the ABP has a K _d of ≤10 ^-9 M. In one embodiment, the off-rate is <1 x 10 ^-5 . In another embodiment, ABP will bind to human PCSK9 with a K _d ^{of about 10 -9} M to 10 ^-13 M, and in another embodiment ABP will bind with a _{K d} ≤5 x 10 ^-10. As will be appreciated by those of skill in the art, in some embodiments, any or all antigen binding fragments can specifically bind to PCSK9.

An antigen binding protein is "selective" when it binds more strongly to one target than to a second target.

“Antigen binding region” means a protein, or part of a protein, that specifically binds to a specified antigen (eg, paratope). For example, this portion of an antigen binding protein that contains amino acid residues that interacts with an antigen and confers its specificity and affinity for the antigen to the antigen binding protein is referred to as an “antigen binding region”. The antigen binding region usually comprises one or more "complementary binding regions" ("CDRs"). Certain antigen binding regions also include one or more "framework" regions. “CDR” is an amino acid sequence that contributes to antigen binding specificity and affinity. The “framework” region can help maintain the appropriate conformation of the CDRs to facilitate binding between the antigen binding region and the antigen. Structurally, framework regions can be located between CDRs within an antibody. Examples of framework and CDR regions are shown in Figures 2a-3d, 3ccc-3jjj, and 15a-15d. In some embodiments, the sequence for the CDRs for the light chain of antibody 3B6 is as follows: CDR1 TLSSGYSSYEVD (SEQ ID NO: 279); CDR2 VDTGGIVGSKGE (SEQ ID NO: 280); CDR3 GADHGSGTNFVVV (SEQ ID NO: 281), FR is as follows: FR1 QPVLTQPLFASASLGASVTLTC (SEQ ID NO: 282); FR2 WYQQRPGKGPRFVMR (SEQ ID NO: 283); FR3 GIPDRFSVLGSGLNRYLTIKNIQEEDESDYHC (SEQ ID NO: 284); And FR4 FgggTKLTVL (SEQ ID NO: 285).

In certain aspects, a recombinant antigen binding protein is provided that binds to PCSK9, eg, human PCSK9. In this context, a “recombinant antigen binding protein” is a protein produced using recombinant technology, ie, through expression of a recombinant nucleic acid described herein. Methods and techniques for the production of recombinant proteins are well known in the art.

The term “antibody” refers to an intact immunoglobulin of any isotype, or fragment thereof, capable of competing with an intact antibody for specific binding to a target antigen, eg chimeric, humanized, fully human, and dual Includes specific antibodies. "Antibody" is a species of antigen binding protein. Intact antibodies will generally contain at least two full-length heavy chains and two full-length light chains, but may contain fewer chains, such as antibodies naturally occurring in camelids, which in some cases may contain only heavy chains. An antibody may be derived entirely from a single source, or may be “chimeric,” ie, different portions of the antibody may be derived from two different antibodies, as further described below. Antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas by recombinant DNA technology, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes derivatives, variants, fragments, and mutants thereof in addition to antibodies comprising two full-length heavy chains and two full-length light chains, examples of which are described below. In addition, unless expressly excluded, antibodies may be monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, respectively, unless explicitly excluded, Antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof. In some embodiments, the term also includes a peptibody.

Naturally occurring antibody structural units usually contain tetramers. Each such tetramer usually consists of two identical pairs of polypeptide chains, each pair having one full length “light chain” (in certain embodiments, about 25 kDa) and one full length “heavy chain” (in certain embodiments, About 50-70 kDa). The amino-terminal portion of each chain usually comprises a variable region of about 100 to 110 or more amino acids, which is responsible for antigen recognition. The carboxy-terminal portion of each chain usually defines a constant region that can serve as an effector function. Human light chains are usually classified as kappa and lambda light chains. Heavy chains are usually classified as mu, delta, gamma, alpha, or epsilon, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has several subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, usually, the variable and constant regions are linked by a "J" region of about 12 or more amino acids, wherein the heavy chain also comprises a "D" region of about 10 or more amino acids (e.g. , See Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)), which is incorporated by reference in its entirety for all purposes. The regions usually form the antigen binding site.

The variable regions generally exhibit the same general structure of relatively conserved framework regions (FRs) linked by three hypervariable regions (also referred to as complementarity determining regions, i.e. CDRs). The CDRs from the two chains of each pair are usually aligned by framework regions, which can enable binding to specific epitopes. From the N-terminus to the C-terminus, the light and heavy chain variable regions all generally comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is usually described in Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or in Chothia & Lesk, J. Mol. Biol., 196:901-917 (1987)]; according to the definition of [Chothia et al., Nature, 342:878-883 (1989)].

In certain embodiments, the antibody heavy chain binds the antigen in the absence of the antibody light chain. In certain embodiments, the antibody light chain binds the antigen in the absence of the antibody heavy chain. In certain embodiments, the antibody binding region binds the antigen in the absence of the antibody light chain. In certain embodiments, the antibody binding region binds the antigen in the absence of an antibody heavy chain. In certain embodiments, individual variable regions specifically bind antigens in the absence of other variable regions.

In certain embodiments, clear description of the CDRs and identification of residues comprising the binding site of the antibody are achieved by analyzing the structure of the antibody and/or by analyzing the structure of the antibody-ligand complex. In certain embodiments, this can be achieved by any of a variety of techniques known to those of skill in the art, such as X-ray crystallography. In certain embodiments, various analytical methods can be used to identify or estimate CDR regions. Examples of such methods include, but are not limited to, Kabat definitions, Chothia definitions, AbM definitions, and contact definitions.

The Kabat definition is a standard for numbering residues in antibodies, and is generally used to identify CDR regions (see, e.g., Johnson & Wu, Nucleic Acids Res., 28: 214-8 (2000). ] Reference). The Chothia definition is similar to the Kabat definition, but the Chothia definition takes into account the location of certain structural loop regions (eg, Chothia et al., J. Mol. Biol., 196: 901-17 (1986) ]; [Chothia et al., Nature, 342: 877-83 (1989)]. The AbM definition uses an integrated suite of computer programs manufactured by the Oxford Molecular Group for modeling antibody structures (eg, Martin et al., Proc Natl Acad Sci (USA)). , 86:9268-9272 (1989); “AbM™, A Computer Program for Modeling Variable Regions of Antibodies,” Oxford, UK; Oxford Molecular, Ltd). AbM definitions are described, for example, in Samueldrala et al., “Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach,” in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198 (1999). The tertiary structure of the antibody is modeled from the primary sequence using a combination of the knowledge database and ab initio method as described above. The contact definition is based on the analysis of available complex crystal structures (see, eg, MacCallum et al., J. Mol. Biol., 5:732-45 (1996)).

By convention, the CDR regions in the heavy chain are generally referred to as H1, H2, and H3, and are numbered sequentially in the direction from the amino terminus to the carboxy terminus. The CDR regions in the light chain are generally referred to as LI, L2, and L3, and are numbered sequentially in the direction from the amino terminus to the carboxy terminus.

The term “light chain” includes full length light chains and fragments thereof having sufficient variable region sequences to confer binding specificity. The full-length light chain comprises a variable region domain, ie V _L , and a constant region domain, ie C _L. The variable region domain of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa chains and lambda chains.

The term “heavy chain” includes full length heavy chains and fragments thereof having sufficient variable region sequences to confer binding specificity. The full-length heavy chain comprises a variable region domain, V _H , and three constant region domains, C _H 1, C _H 2, and C _H 3. The V _H domain is at the amino-terminus of the polypeptide and the C _H domain is at the carboxyl-terminus, where C _H 3 is closest to the carboxy-terminus of the polypeptide. The heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3 and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM and IgE.

Bispecific or bifunctional antibodies are generally artificial hybrid antibodies having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including but not limited to fusion of hybridomas or ligation of Fab' fragments (see, e.g., Songsivilai et al., Clin. Exp. Immunol., 79:315-321 (1990)]; see Kostelny et al., J. Immunol., 148:1547-1553 (1992))).

Some species of mammals also produce antibodies with only a single heavy chain.

Each individual immunoglobulin chain generally consists of several "immunoglobulin domains" each consisting of approximately 90 to 110 amino acids each and having a characteristic folding pattern. These domains are the basic units by which the antibody polypeptide is made. In humans, the IgA and IgD isoforms contain 4 heavy chains and 4 light chains; The IgG and IgE isotypes contain two heavy chains and two light chains; The IgM isoform contains 5 heavy chains and 5 light chains. The heavy chain C region generally contains one or more domains that can be responsible for effector functions. The number of heavy chain constant region domains will be determined by isotype. For example, an IgG heavy chain contains three C region domains known as _{C H} 1, C _H 2 and C _{H 3.} Antibodies provided may have any of these isotypes and subtypes. In certain embodiments of the invention, the anti-PCSK9 antibody is of the IgG2 or IgG4 subtype.

The term “variable region” or “variable domain” generally refers to a portion of the light and/or heavy chain of an antibody comprising about 120 to 130 amino terminal amino acids in the heavy chain and about 100 to 110 amino terminal amino acids in the light chain. In certain embodiments, the variable regions of different antibodies differ widely in amino acid sequence even among antibodies of the same species. The variable region of an antibody generally determines the specificity of a particular antibody for its target.

The terms “neutralizing antigen binding protein” or “neutralizing antibody” respectively refer to an antigen binding protein or antibody that binds to a ligand and prevents or reduces the biological effect of that ligand. This can be done, for example, by directly blocking the binding site on the ligand or by altering the ability of the ligand to bind to the ligand and bind through indirect means (e.g., altering the structural or energy of the ligand). In some embodiments, the term may also refer to an antigen binding protein that prevents the protein to which it binds from performing a biological function. In evaluating the binding and/or specificity of an antigen binding protein, e.g., an antibody or an immunologically functional fragment thereof, the antibody or fragment contains at least about 1-20% of the amount of the binding partner to which the excess antibody is bound to the ligand, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, When reduced to 97-98%, 98-99% or more (as measured by an in vitro competitive binding assay), the binding of a ligand to its binding partner can be substantially inhibited. In some embodiments, in the case of the PCSK9 antigen binding protein, such neutralizing molecules can reduce the ability of PCSK9 to bind LDLR. In some embodiments, the neutralizing ability is characterized and/or described through competition analysis. In some embodiments, the neutralizing ability is described in terms _{of IC 50} or EC _{50 values.} In some embodiments, ABP 27B2, 13H1, 13B5 and 3C4 are non-neutralizing ABPs, 3B6, 9C9, and 31A4 are weak neutralizing agents, and the remaining ABPs in Table 2 are strong neutralizing agents. In some embodiments, the antibody or antigen binding protein binds to PCSK9 and neutralizes it by preventing PCSK9 from binding to LDLR (or by reducing the ability of PCSK9 to bind LDLR). In some embodiments, the antibody or ABP neutralizes by binding to PCSK9 and by preventing or reducing PCSK9 mediated degradation of LDLR while still allowing PCSK9 to bind to LDLR. Thus, in some embodiments, the neutralizing ABP or antibody may still allow PCSK9/LDLR binding, but will prevent (or reduce) subsequent PCSK9 involved degradation of LDLR.

The term “target” refers to a molecule or part of a molecule to which an antigen binding protein can bind. In certain embodiments, a target may have more than one epitope. In certain embodiments, the target is an antigen. The use of “antigen” in the phrase “antigen binding protein” simply indicates that an antibody is capable of binding to a protein sequence comprising an antigen. In this context, it is not required that the protein is foreign or capable of eliciting an immune response.

When used in the context of an antigen binding protein (e.g., a neutralizing antigen binding protein or a neutralizing antibody) that competes for the same epitope, the term "competing" refers to the antigen binding protein being tested (e.g., an antibody or immunologically functional fragment thereof). ) Prevent or inhibit (e.g. reduce) specific binding of a reference antigen binding protein (e.g., a ligand, or a reference antibody) to a common antigen (e.g., PCSK9 or a fragment thereof). It refers to the competition between the antigen binding proteins to be determined. Many types of competitive binding assays to determine if one antigen binding protein competes with another, such as direct or indirect radioimmunoassay (RIA) in solid phase, direct or indirect enzyme immunoassay (EIA) in solid phase, sandwich competition assay (See, eg, Stahli et al., 1983, Methods in Enzymology 9:242-253); Direct biotin-avidin EIA in solid phase (see, eg Kirkland et al., 1986, J. Immunol. 137:3614-3619), direct labeled assay in solid phase, directly labeled sandwich assay in solid phase (e.g. See, eg Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); Direct label RIA in solid phase using I-125 label (see, eg, Morel et al., 1988, Molec. Immunol. 25:7-15); Direct biotin-avidin EIA in solid phase (see, eg, Cheung, et al., 1990, Virology 176:546-552); And directly labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82). In general, such assays involve the use of purified antigen bound to a solid surface or cell carrying either of these unlabeled test antigen binding proteins and labeled reference antigen binding proteins. Competitive inhibition is determined by determining the amount of label bound to a solid surface or cell in the presence of a test antigen binding protein. Usually, the test antigen binding protein is present in excess. The antigen-binding protein (competitive antigen-binding protein) identified by competition analysis binds to an antigen-binding protein that binds to the same epitope as the reference antigen-binding protein, and to adjacent epitopes sufficiently close to the epitope to which the reference antigen-binding protein binds so that steric hindrance occurs It includes an antigen binding protein. Additional details regarding the method for determining competitive binding are provided in the examples herein. In general, when the competing antigen binding protein is present in excess, the specific binding of the reference antigen binding protein to a common antigen is at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%. , 65-70%, 70-75% or 75% or more will be inhibited (eg, reduced). In some cases, binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97%, or 97% or more.

The term “antigen” refers to a molecule or portion of a molecule to which a selective binding agent, eg, an antigen binding protein (including eg, an antibody or immunologically functional fragment thereof), can bind. In some embodiments, an antigen can be used in an animal to produce an antibody capable of binding the antigen. Antigens may have one or more epitopes capable of interacting with different antigen binding proteins, such as antibodies.

The term “epitope” includes any determinant capable of binding an antigen binding protein, such as an antibody or T-cell receptor. An epitope is a region of an antigen to which an antigen-binding protein targeting an antigen binds, and when the antigen is a protein, it contains specific amino acids that directly contact the antigen-binding protein. Most often, epitopes are present on proteins, but in some cases may be present on other types of molecules, such as nucleic acids. Epitope determinants may include chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and/or specific charge characteristics. In general, antibodies specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and/or macromolecules.

As used herein, “substantially pure” means that the molecule of the described species is the predominant species present, ie more abundant than any other individual species in the same mixture on a molar basis. In certain embodiments, a substantially pure molecule is a composition that makes up at least 50% (on a molar basis) of all macromolecular species present in the subject species. In other embodiments, a substantially pure composition will account for at least 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In another embodiment, the species of interest cannot be detected in the composition by conventional detection methods, and the composition is thus purified to an inherent uniformity consisting of a single detectable macromolecular species.

The term “substance” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from a biological substance.

As used herein, the terms “labeled” or “labeled” refer to, for example, the inclusion of radiolabeled amino acids, or labeled avidin (eg, a fluorescent marker or enzymatic marker detectable by optical or colorimetric methods). Activity-containing streptavidin). In certain embodiments, the label or marker may also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and can be used. Examples of labels for polypeptides include, but are not limited to: radioisotopes or radionuclides (e.g. ³ H, ¹⁴ C, ¹⁵ N, ³⁵ S, ⁹⁰ Y, ⁹⁹ Tc, ¹¹¹ In, ¹²⁵ I, ¹³¹ I), fluorescent label (e.g., FITC, rhodamine, lanthanide phosphor), enzymatic label (e.g. horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase ), a chemiluminescent material, a biotinyl group, a predetermined polypeptide epitope recognized by a secondary reporter (eg, a leucine zipper pair sequence, a binding site for a secondary antibody, a metal binding domain, an epitope tag). In certain embodiments, labels are attached by spacer arms of varying lengths to reduce potential steric hindrance.

As used herein, the term “biological sample” includes, but is not limited to, an organism or any amount of material previously from an organism. Such organisms include, but are not limited to, humans, mice, monkeys, rats, rabbits, and other animals. Such substances include, but are not limited to, blood, serum, urine, cells, organs, tissues, bones, bone marrow, lymph nodes, and skin.

The term “pharmaceutical substance composition” (or substance or drug) as used herein refers to a chemical compound, composition, substance or drug capable of inducing a desired therapeutic effect when properly administered to a patient. It does not necessarily require more than one type of ingredient.

The term “therapeutically effective amount” refers to the amount of PCSK9 antigen binding protein that has been determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertained by one of skill in the art.

As used herein, the term "modulator" is a compound that changes or alters the activity or function of a molecule. For example, a modulator may increase or decrease the intensity of a specific activity or function of a molecule compared to the intensity of activity or function observed in the absence of the modulator. In certain embodiments, the modulator is an inhibitor, which reduces the intensity of at least one activity or function of the molecule. Certain exemplary activities and functions of the molecule include, but are not limited to, binding affinity, enzymatic activity, and signal transduction. Certain exemplary inhibitors include, but are not limited to, proteins, peptides, antibodies, peptibodies, carbohydrates or small organic molecules. Peptibodies are described, for example, in US Pat. No. 6,660,843 (corresponding to PCT application WO 01/83525).

The terms “patient” and “subject” are used interchangeably and refer to human and non-human animal subjects as well as subjects with a previously diagnosed disease, subjects without a previously recognized disease, subjects to be treated by a physician, and disease. Includes subjects at risk of developing disease

The terms “treat” and “treatment” include therapeutic treatment, prophylactic treatment, and use to reduce the risk of a subject developing a disease or other risk factors. Treatment includes embodiments that do not require complete cure of the disease and reduce symptoms or underlying risk factors.

The term "prevent" does not require 100% elimination of the likelihood of an event. Rather, the term indicates that the likelihood of occurrence of an event is reduced in the presence of a compound or method.

Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (eg, electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to the manufacturer's instructions or as commonly achieved or described herein. The above techniques and procedures generally follow conventional methods well known in the art, and various general and more specific references cited and discussed throughout this specification (e.g., incorporated herein by reference for any purpose. It can be performed as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)). Unless specific definitions are provided, the nomenclatures used in connection with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein and their laboratory procedures and techniques are those well known and commonly used in the art. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical formulation, formulation, and delivery, and treatment of patients.

Antigen binding protein to PCSK9

The proprotein converting enzyme subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the level of low density lipoprotein receptor (LDLR) protein ([Horton et al., 2007]; [Seidah and Prat, 2007]). PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah et al., 2003). Exemplary human PCSK9 amino acid sequences are shown as SEQ ID NOs: 1 and 3 in FIGS. 1A (the “pro” domain of the protein is underlined) and FIGS. 1B-1E (signal sequences are shown in bold and pro-domains are underlined). . An exemplary human PCSK9 coding sequence is presented as SEQ ID NO: 2 (FIGS. 1B-1E ). As described herein, the PCSK9 protein may also include a fragment of the full-length PCSK9 protein. The structure of the PCSK9 protein has recently been elucidated by two groups (Cunningham et al., Nature Structural & Molecular Biology, 2007), and Piper et al., Structure, which are incorporated herein by reference in their entirety. 15:1-8, 2007]). PCSK9 comprises a signal sequence, an N-terminal prodomain, a subtilisin-like catalytic domain and a C-terminal domain.

An antigen binding protein (ABP) that binds to PCSK9, eg human PCSK9 is provided. In some embodiments, provided antigen binding proteins are polypeptides comprising one or more complementarity determining regions (CDRs) described herein. In some antigen binding proteins, the CDRs are embedded within a “framework” region, which orients the CDR(s) so that the appropriate antigen binding properties of the CDR(s) are achieved. In some embodiments, antigen binding proteins provided herein are capable of inhibiting, blocking, reducing, or modulating the interaction between PCSK9 and LDLR. Such antigen binding proteins are denoted as “neutralizing”. In some embodiments, even if the antigen binding protein is neutralizing and binds to PCSK9, binding between PCSK9 and LDLR may still occur. For example, in some embodiments, ABP prevents or reduces the adverse effect of PCSK9 on LDLR without blocking the LDLR binding site on PCSK9. Thus, in some embodiments, ABP modulates or alters the ability of PCSK9 to cause degradation of LDLR without preventing the binding interaction between PCSK9 and LDLR. Such ABPs can be specifically described as “non-competitively neutralizing” ABPs. In some embodiments, the neutralizing ABP binds PCSK9 at a position and/or in a manner that prevents PCSK9 from binding to LDLR. Such ABPs can be specifically described as “competitively neutralizing” ABPs. Both of these neutralizing agents can cause a greater amount of free LDLR present in the subject, which binds more LDLR to LDL (and thereby reduces the amount of LDL in the subject). Again, it reduces the amount of serum cholesterol present in the subject.

In some embodiments, antigen binding proteins provided herein are capable of inhibiting PCSK9-mediated activity (including binding). In some embodiments, antigen binding proteins that bind these epitopes specifically inhibit the interaction between PCSK9 and LDLR and other physiological effects mediated by PCSK9. In some embodiments, the antigen binding protein is a human, e.g., fully human antibody against PCSK9.

In some embodiments, ABP binds to the catalytic domain of PCSK9. In some embodiments, ABP binds to mature form of PCSK9. In some embodiments, ABP binds within the prodomain of PCSK9. In some embodiments, ABP selectively binds to mature form of PCSK9. In some embodiments, ABP binds to the catalytic domain in such a way that PCSK9 binds to LDLR or is unable to bind efficiently. In some embodiments, the antigen binding protein does not bind to the c-terminus of the catalytic domain. In some embodiments, the antigen binding protein does not bind to the n-terminus of the catalytic domain. In some embodiments, ABP does not bind to the n- or c-terminus of the PCSK9 protein. In some embodiments, ABP binds to any one epitope to which an antibody discussed herein binds. In some embodiments, this can be determined by competition analysis between an antibody disclosed herein and other antibodies. In some embodiments, ABP binds to an epitope to which one of the antibodies described in Table 2 binds. In some embodiments, the antigen binding protein binds to PCSK9 in a specific conformational state to prevent PCSK9 from interacting with LDLR. In some embodiments, ABP binds to the V domain of PCSK9. In some embodiments, ABP binds to the V domain of PCSK9 and prevents (or reduces) binding of PCSK9 to LDLR. In some embodiments, ABP binds to the V domain of PCSK9 and does not prevent (or decrease) binding of PCSK9 to LDLR, while ABP prevents or reduces adverse activity mediated through PCSK9 to LDLR.

The antigen binding proteins disclosed herein have a variety of utility. For example, some antigen binding proteins are useful in specific binding assays, affinity purification of PCSK9, particularly human PCSK9 or its ligands, and screening assays to identify other antagonists of PCSK9 activity. Some antigen binding proteins are useful to inhibit the binding of PCSK9 to LDLR, or to inhibit PCSK9-mediated activity.

Antigen binding proteins can be used in a variety of therapeutic applications as described herein. For example, in some embodiments, the PCSK9 antigen binding protein prevents a condition associated with PCSK9, such as a cholesterol related disease (or “serum cholesterol related disease”), such as hypercholesterolemia, as further described herein. Useful for treatment. Other uses of antigen binding proteins include, for example, diagnosis of PCSK9-associated diseases or conditions, and screening assays to determine the presence or absence of PCSK9. Some of the antigen binding proteins described herein are useful for the treatment of prognosis, symptoms, and/or health conditions associated with PCSK9 activity.

In some embodiments, provided antigen binding proteins comprise one or more CDRs (eg, 1, 2, 3, 4, 5 or 6 CDRs). In some embodiments, the antigen binding protein comprises (a) a polypeptide structure and (b) one or more CDRs that are inserted and/or linked into the polypeptide structure. Polypeptide structures can take a variety of different forms. For example, the structure may be or include a framework of a naturally occurring antibody, or fragment or variant thereof, or may be fully synthesized in nature. Examples of various polypeptide structures are further described below.

In certain embodiments, the polypeptide structure of the antigen binding protein is a monoclonal antibody, a bispecific antibody, a minibody, a domain antibody, a synthetic antibody (sometimes referred to herein as an "antibody mimetic"), a chimeric antibody, a humanized antibody, respectively. Antibodies, including, but not limited to, antibody fusions (sometimes referred to herein as “antibody conjugates”), and portions or fragments thereof, or derived from antibodies. In some cases, the antigen binding protein is an immunological fragment of an antibody (eg, Fab, Fab', F(ab') ₂ , or scFv). Various structures are further described and defined herein.

Certain antigen binding proteins provided herein specifically and/or selectively bind human PCSK9. In some embodiments, the antigen binding protein specifically and/or selectively binds to the human PCSK9 protein having and/or consisting of residues 153-692 of SEQ ID NO: 3. In some embodiments, the ABP specifically and/or selectively binds to human PCSK9 having and/or consisting of residues 31-152 of SEQ ID NO: 3. In some embodiments, ABP selectively binds to human PCSK9 protein (SEQ ID NO: 1) shown in FIG. In some embodiments, the antigen binding protein specifically binds to the full length PCSK9 protein with or without at least a fragment and/or signal sequence of the PCSK9 protein.

In embodiments in which the antigen binding protein is used for therapeutic use, the antigen binding protein is capable of inhibiting, inhibiting, or modulating one or more biological activities of PCSK9. In one embodiment, the antigen binding protein specifically binds human PCSK9 and/or binds human PCSK9 to LDLR at least about 20%-40%, 40-60%, 60-80%, 80-85% or more. (E.g., by measuring binding in an in vitro competitive binding assay). Some of the antigen binding proteins provided herein are antibodies. In some embodiments, the ABP has a K _{d of less} than 10 ^-7 , 10 ^-8 , 10 ^-9 , 10 ^-10 , 10 ^-11 , 10 ^-12 , 10 ^-13 M (it binds more strongly). In some embodiments, ABP has an IC ₅₀ (D374Y, high affinity variant) for blocking binding of LDLR to PCSK9 is less than 1 μM, 1000 nM to 100 nM, 100 nM to 10 nM, 10 nM to 1 nM, 1000 pM to 500 pM, 500 pM to 200 pM, less than 200 pM, 200 pM to 150 pM, 200 pM to 100 pM, 100 pM to 10 pM, 10 pM to 1 pM.

An example of the IgG2 heavy chain constant domain of the anti-PCSK9 antibody of the present invention has the amino acid sequence shown in SEQ ID NO: 154, Figure 3KK.

An example of the IgG4 heavy chain constant domain of the anti-PCSK9 antibody of the present invention has the amino acid sequence shown in SEQ ID NO: 155, Figure 3KK.

An example of the kappa light chain constant domain of the anti-PCSK9 antibody of the present invention has the amino acid sequence shown in SEQ ID NO: 157, Figure 3KK.

An example of the lambda light chain constant domain of the anti-PCSK9 antibody of the present invention has the amino acid sequence shown in SEQ ID NO:156, Figure 3KK.

The variable region of an immunoglobulin chain is generally the same whole comprising a relatively conserved framework region (FR) linked by three hypervariable regions (more often referred to as “complementarity determining regions”, ie CDRs). Show structure. The CDRs from the two chains of each heavy/light chain pair mentioned above are usually aligned by framework regions, forming a structure that specifically binds to a specific epitope on the target protein (eg PCSK9). From the N-terminus to the C-terminus, the naturally occurring light and heavy chain variable regions all generally coincide with these elements in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. A numbering system was devised to assign numbers to amino acids that occupy a position within each of these domains. The numbering system is described in [Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, MD)], or [Chothia & Lesk, 1987, J. Mol. Biol. 196:901-917]; [Chothia et al., 1989, Nature 342:878-883].

Various heavy and light chain variable regions are provided herein and shown in Figures 2A-3jj and 3ll-3bbb. In some embodiments, each of these variable regions can be attached to the heavy and light chain constant regions to form a complete antibody heavy and light chain, respectively. In addition, each of the thus generated heavy and light chain sequences can be combined to form a complete antibody structure.

Specific examples of the variable regions of the light and heavy chains of the provided antibodies, and some of their corresponding amino acid sequences are summarized in Table 2.

Again, each of the exemplary variable heavy chains listed in Table 2 can be combined with any of the exemplary variable light chains shown in Table 2 to form an antibody. Table 2 shows exemplary light and heavy chain pairings found in some of the antibodies disclosed herein. In some cases, the antibody comprises at least one variable heavy chain and one variable light chain from those listed in Table 2. In other cases, the antibody contains two identical light chains and two identical heavy chains. As an example, the antibody or antigen binding protein may comprise a heavy chain and a light chain, two heavy chains, or two light chains. In some embodiments, the antigen binding protein comprises (and/or consists of) 1, 2, and/or 3 heavy and/or light chain CDRs from at least one sequence listed in Table 2. 2a-3d and other embodiments are outlined in FIGS. 3ccc-3jjj and 15a-15d). In some embodiments, all six CDRs (CDR1-3 from the light chain (CDRL1, CDRL2, CDRL3) and CDR1-3 from the heavy chain (CDRH1, CDRH2, and CDRH3)) are part of the ABP. In some embodiments, 1, 2, 3, 4, 5 or more CDRs are included within the ABP. In some embodiments, one heavy chain and one light chain CDR from the CDRs in the sequences in Table 2 are included in the ABP (the CDRs for the sequences in Table 2 are outlined in Figures 2A-3D). In some embodiments, additional options (eg, those shown in FIGS. 2A-2D, 3A-3D, and other embodiments shown in 3ccc-3jjj and 15a-15d) are also included within the ABP. Examples of CDRs and FRs for the heavy and light chains shown in Table 2 are outlined in Figures 2A-3D (another embodiment is outlined in Figures 3ccc-3jjj and 15A-15D). Optional light chain variable sequences (including CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4) are SEQ ID NOs: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, It may be selected from 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46. Optional heavy chain variable sequences (including CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4) are SEQ ID NOs: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60 may be selected. In some entries in Figures 2A-3D, variations in the sequence or alternative borders of the CDRs and FRs are identified. These substitutes are identified as "v1" after the ABP name. Since most of these substitutions are a minority in nature, only the sections with differences are shown in the table. It is understood that the remaining sections of the light or heavy chain are the same as shown for the base ABP in the other panels. Thus, for example, 19H9v1 in Fig. 2C has the same FR1, CDR1, and FR2 as 19H9 in Fig. 2A, and only the difference is indicated in Fig. 2C. For the three nucleic acid sequences (ABP 26E10, 30B9, and 31B12), additional replacement nucleic acid sequences are shown in the figure. As will be appreciated by those of skill in the art, no more than one such sequence needs to be actually used in the production of antibodies or ABPs. Indeed, in some embodiments, only one of the specific heavy or light chain nucleic acids is present or not required.

In some embodiments, ABP is encoded by a nucleic acid sequence capable of encoding any protein sequence in Table 2.

In some embodiments, ABP selectively binds to a form of PCSK9 (eg, an autocatalyzed form of a molecule) that binds to LDLR. In some embodiments, the antigen binding protein does not bind to the c-terminus of the catalytic domain (e.g., 5, 5-10, 10-15, 15-20, 20-25, 25-30, within the c-terminus, 30-40 most amino acids). In some embodiments, the antigen binding protein does not bind to the n-terminus of the catalytic domain (e.g., 5, 5-10, 10-15, 15-20, 20-25, 25-30, within the n-terminus, 30-40 most amino acids). In some embodiments, ABP binds to amino acids within amino acids 1-100 of mature PCSK9. In some embodiments, the ABP is amino acids 31-100, 100-200, 31-152, 153-692, 200-300, 300-400, 452-683, 400-500, 500-600, 31-692, 31- 449, and/or an amino acid (and/or an amino acid sequence consisting of) within 600-692. In some embodiments, ABP binds to the catalytic domain. In some embodiments, the neutralizing and/or non-neutralizing ABP binds to the pro-domain. In some embodiments, ABP binds to both the catalytic domain and the pro-domain. In some embodiments, the ABP binds to the catalytic domain to block regions on the catalytic domain that interact with the pro-domain. In some embodiments, ABP is described in Piper et al. (Structure 15:1-8 (2007)] (including its structural representation) binds to the catalytic domain at the site or surface where the pro-domain interacts. In some embodiments, the ABP binds to the catalytic domain. In some embodiments, the ABP binds to the catalytic domain without binding to the pro-domain In some embodiments, the ABP reorients the pro-domain to bind PCSK9 to LDLR. In some embodiments, ABP binds to the same epitope as surrounding residues 149-152 of the pro-domain of Piper et al. In embodiments, ABP binds to a groove on the V domain (as outlined in Piper et al.) In some embodiments, ABP binds to a histidine-rich patch proximate the groove on the V domain. In some embodiments, such an antibody (which binds to the V domain) is not neutral In some embodiments, the antibody that binds to the V domain is neutral In some embodiments, the neutralizing ABP is PCSK9 against LDLR In some embodiments, neutralizing ABP prevents PCSK9 degradation of LDLR, but does not prevent binding of PCSK9 to LDLR (eg ABP 31A4) In some embodiments, ABP is described in Piper. et al. paper] at least one histidine shown in Figure 4. In some embodiments, ABP blocks the catalytic triad in PCSK9.

In some embodiments, the antibody selectively binds a variant PCSK9 protein, e.g., D374Y, compared to wild-type PCSK9. In some embodiments, these antibodies bind the mutant at least 2 times more strongly than the wild type, preferably 2-5, 5-10, 10-100, 100-1000, 1000-10,000 times more strongly than the wild type to the mutant. (When measured through _{K d).} In some embodiments, the antibody selectively inhibits variant D374Y PCSK9 from interacting with LDLR compared to the ability of wild-type PCSK9 to interact with LDLR. In some embodiments, these antibodies block the ability of the variant to bind LDLR more strongly than the ability of the wild type, e.g., at least 2 times stronger than the wild type, preferably 2-5, 5- Blocks 10, 10-100, 100-1000 times stronger (when measured via _{IC 50).} In some embodiments, the antibody binds to and neutralizes both wild-type PCSK9 and a variant form of PCSK9, eg, D374Y at similar levels. In some embodiments, the antibody binds to PCSK9 to prevent the binding of a variant of LDLR to PCSK9. In some embodiments, the variant of LDLR is at least 50% identical to human LDLR. It is mentioned that variants of LDLR are known to those of skill in the art (eg, Brown MS et al., "Calcium cages, acid baths and recycling receptors" Nature 388: 629-630, 1997). In some embodiments, ABP can elevate the level of LDLR, which is effective in heterozygous familial hypercholesterolemia (a loss-of-function variant of LDLR is present).

In some embodiments, ABP is at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99 in the form of PCSK9 shown in FIGS. 1A and/or 1B-1E. Binds (but does not block) a variant of PCSK9 that is% or greater of identity. In some embodiments, ABP is at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95- Binds (but does not block) a variant of PCSK9 that is 99% or more identical. In some embodiments, ABP is at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99 in the form of PCSK9 shown in FIGS. 1A and/or 1B-1E. It prevents interaction with LDLR by binding to a variant of PCSK9 with% or greater identity. In some embodiments, the ABP is at least 50, 50-60, 60- 70, 70-80, 80-90, 90-95, 95-99% or more identity to the mature form of PCSK9 shown in FIGS. It binds to a variant of PCSK9 and prevents it from interacting with LDLR. In some embodiments, the variant of PCSK9 is a human variant, eg, the variant at position 474, E620G, and/or E670G. In some embodiments, the amino acid at position 474 is valine (as in other humans) or threonine (as in cynos and mice). Given the cross-reactivity data presented herein, it is believed that the antibodies of the invention will readily bind to these variants.

In some embodiments, ABP binds to an epitope to which one of the antibodies described in Table 2 binds. In some embodiments, the antigen binding protein binds to a specific conformational state of PCSK9 to prevent PCSK9 from interacting with LDLR.

Humanized antigen binding protein (e.g., antibody)

As described herein, antigen binding proteins to PCSK9 can include humanized antibodies and/or portions thereof. An important practical use of such a strategy is the "humanization" of the mouse humoral immune system.

In certain embodiments, the humanized antibody is substantially non-immunogenic in humans. In certain embodiments, a humanized antibody has substantially the same affinity for a target as an antibody from another species from which the humanized antibody is derived. See, for example, U.S. Patent 5,530,101, U.S. Patent 5,693,761; US Patent 5,693,762; See U.S. Patent 5,585,089.

In certain embodiments, amino acids of an antibody variable domain are identified that can be modified while reducing their immunogenicity while not reducing the natural affinity of the antigen binding domain. See, for example, U.S. Patents 5,766,886 and 5,869,619.

In certain embodiments, modifications of the antibody by methods known in the art are generally designed to achieve increased binding affinity for the target and/or decreased immunogenicity of the antibody in the recipient. In certain embodiments, a humanized antibody is modified to remove glycosylation sites to increase the affinity of the antibody for its cognate antigen (see, eg, Co et al., Mol. Immunol. 30 :1361-1367 (1993)] In certain embodiments, techniques such as “reshaping”, “hyperchimerization” or “veneering/resurfacing” are used. Used for the production of humanized antibodies (eg Vaswami et al., Annals of Allergy, Asthma, & Immunol. 81:105 (1998)); Roguska et al., Prot. Engineer., 9:895 -904 (1996)]; and U.S. Patent 6,072,035).In certain such embodiments, the technique usually reduces antibody immunogenicity by reducing the number of foreign moieties, but anti-individual and It does not prevent anti-allogeneic reactions Certain other methods of reducing immunogenicity are described, for example, in Gilliland et al., J. Immunol., 62(6): 3663-71 (1999). have.

In certain instances, humanized antibodies have a loss of antigen binding ability. In certain embodiments, the humanized antibody is “back mutation”. In certain such embodiments, the humanized antibody is mutated to include one or more amino acid residues found in the donor antibody. See, for example, Saldanha et al., Mol Immunol 36:709-19 (1999).

In certain embodiments, the complementarity determining regions (CDRs) of the light and heavy chain variable regions of an antibody against PCSK9 can be grafted to framework regions (FRs) from the same species or from different species. In certain embodiments, the CDRs of the light and heavy chain variable regions of an antibody against PCSK9 can be grafted onto a consensus human FR. To generate consensus human FRs, in certain embodiments, FRs from several human heavy or light chain amino acid sequences are aligned to identify consensus amino acid sequences. In certain embodiments, the FR of an antibody against the PCSK9 heavy or light chain is replaced with an FR from a different heavy or light chain. In certain embodiments, rare amino acids in the FRs of the heavy and light chains of the antibody against PCSK9 are not replaced, but the remaining FR amino acids are replaced. Rare amino acids are specific amino acids that are present at positions not normally found in the FR. In certain embodiments, the grafted variable region from an antibody against PCSK9 can be used with a different constant region than the constant region of the antibody against PCSK9. In certain embodiments, the grafted variable region is part of a single chain Fv antibody. CDR grafting is described, for example, in U.S. Pat. 525 (1986)]; [Riechmann et al., Nature, 332:323-327 (1988)]; [Verhoeyen et al., Science, 239:1534-1536 (1988)] and [Winter, FEBS Letts., 430 :92-94 (1998).

Human antigen binding protein (e.g., antibody)

As described herein, antigen binding proteins that bind PCSK9 can include human (ie, fully human) antibodies and/or portions thereof. In certain embodiments, amino acid sequences comprising heavy and light chain immunoglobulin molecules, in particular nucleotide sequences encoding sequences corresponding to variable regions, and amino acid sequences are provided. In certain embodiments, sequences corresponding to complementarity determining regions (CDRs), specifically CDR1-CDR3 are provided. According to certain embodiments, hybridoma cell lines expressing such immunoglobulin molecules are provided. According to certain embodiments, hybridoma cell lines expressing such monoclonal antibodies are provided. In certain embodiments, the hybridoma cell line is selected from the cell lines described in Table 2, e.g., at least one of 21B12, 16F12 and 31H4. In certain embodiments, purified human monoclonal antibodies to human PCSK9 are provided.

While engineered mice are expected to produce human antibodies in the absence of mouse antibodies, mouse strains lacking mouse antibody production can be engineered into large fragments of the human Ig locus. Large human Ig fragments can preserve large variable gene diversity as well as suitable regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection, and the lack of immune tolerance to human proteins, the repertoire of regenerated human antibodies within these mouse lines has a high affinity for any antigen of interest, including human antigens. Fully human antibodies can be produced. Using hybridoma technology, antigen-specific human MAbs with the desired specificity can be produced and selected. Specific exemplary methods are described in WO 98/24893, U.S. Patents 5,545,807, EP 546073, and EP 546073.

In certain embodiments, constant regions from species other than humans can be used with the human variable region(s).

The ability to clone and reconstitute megabase-sized human loci in yeast artificial chromosomes (YAC) and introduce them into the mouse germline is to account for the functional components of very large or coarse-mapped loci and human diseases. It provides a way to create a useful model of In addition, the use of such techniques to replace the mouse locus with its human equivalent can provide insight into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression. have.

Human antibodies avoid some of the problems associated with antibodies with murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can cause rapid clearance of the antibody or can generate an immune response to the antibody by the patient. To avoid the use of murine or rat derived antibodies, fully human antibodies can be generated through the introduction of functional human antibody locus into rodents, other mammals or animals so that rodents, other mammals or animals produce fully human antibodies. .

Humanized antibodies are antibodies that contain non-human antibody amino acid sequences and start initially, but at least a portion of these non-human antibody amino acid sequences have been replaced with human antibody sequences. This is as opposed to human antibodies in which the antibody is encoded (or can be encoded) by a gene possessed by humans.

Antigen binding protein variants

Other antibodies provided are variants of the above-listed ABPs formed by combinations or subparts of the variable heavy and variable light chains shown in Table 2, each of which is a sequence of Table 2 (the entire sequence or subpart of the sequence, e.g., one or more CDR) at least 50%, 50-60%, 60-70%, 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-99%, Or a variable light chain and/or a variable heavy chain having greater than 99% identity. In some cases, such antibodies contain at least one heavy chain and one light chain, while in other cases the variant form contains two identical light chains and two identical heavy chains (or subparts thereof). In some embodiments, the sequence comparison of Figures 2A-3D (and other embodiments of Figures 13A-13J and 15A-15D) can be modified by observing variations that affect binding and variations that do not appear to affect binding. It can be used to identify sections of the antibody that are present. For example, by comparing similar sequences, it is possible to identify sections that can be modified (e.g., certain amino acids), and how they can be modified while still retaining (or improving) the functionality of ABP. In some embodiments, variants of ABP comprise the consensus groups and sequences shown in FIGS. 13A, 13C, 13F, 13G, 13H, 13I and/or 13J, and variations in the sequences identified as variable in the figure are allowed. The CDRs shown in Figures 13A, 13C, 13F, and 13G are based on the Chothia method (based on the location of the structural loop regions, e.g., "Standard conformations for the canonical structures of immunoglobulins," Bissan Al-Lazikani, Arthur M. Lesk and Cyrus Chothia, Journal of Molecular Biology, 273(4): 927-948, 7 November (1997)) and Kabat's method (based on sequence variability, see, for example, Sequences of Proteins of Immunological Interest, Fifth Edition.NIH Publication No. 91-3242, Kabat et al., (1991)). Each residue determined by either method was included in the final list of CDR residues (shown in Figures 13A, 13C, 13F, and 13G). The CDRs of FIGS. 13H, 13I, and 13J were obtained only by the Kabat method. Unless otherwise specified, the defined consensus sequences, CDRs, and FRs in FIGS. 13H-13J will define and control the indicated CDRs and FRs for the ABP referenced in FIG. 13.

In certain embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, A heavy chain comprising a variable region comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from at least one of the sequences of 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60 do. In certain embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, A heavy chain comprising a variable region comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from at least one of the sequences of 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60 do. In certain embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, A heavy chain comprising a variable region comprising an amino acid sequence that is at least 99% identical to an amino acid sequence selected from at least one of the sequences of 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60 do.

In some embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and at least 90%, 90-95%, and/or 95-99 of one or more CDRs from CDRs within at least one of the sequences of 60 % Contains identical sequences. In some embodiments, there are 1, 2, 3, 4, 5 or 6 CDRs (each at least 90%, 90-95%, and/or 95-99% identical to the sequence).

In some embodiments, the antigen binding protein is SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and at least 90%, 90-95%, and/or 95-99 in one or more FRs from FRs in at least one of the sequences of 60 % Contains identical sequences. In some embodiments, there are 1, 2, 3, or 4 FRs (each at least 90%, 90-95%, and/or 95-99% identical to the sequence).

In certain embodiments, the antigen binding protein is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, A light chain comprising a variable region comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from at least one of the sequences of 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46 do. In certain embodiments, the antigen binding protein is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, A light chain comprising a variable region comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from at least one of the sequences of 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46 do. In certain embodiments, the antigen binding protein is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, A light chain comprising a variable region comprising an amino acid sequence that is at least 99% identical to an amino acid sequence selected from at least one of the sequences of 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46 do.

In some embodiments, the antigen binding protein is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, At least 90%, 90-95%, and/or 95-99 in one or more CDRs from CDRs within at least one of the sequences of 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46 % Contains identical sequences. In some embodiments, there are 1, 2, 3, 4, 5, or 6 CDRs (each at least 90%, 90-95%, and/or 95-99% identical to the sequence).

In some embodiments, the antigen binding protein is SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, At least 90%, 90-95%, and/or 95-99 in one or more FRs from FRs in at least one of the sequences of 32, 33, 35, 36, 37, 38, 39, 40, 42, 44 and 46 % Contains identical sequences. In some embodiments, there are 1, 2, 3, or 4 FRs (each at least 90%, 90-95%, and/or 95-99% identical to the sequence).

In light of this specification, one of skill in the art will be able to determine suitable variants of ABP as described herein using well-known techniques. In certain embodiments, one of skill in the art can identify suitable regions of a molecule that can be changed without destroying activity by targeting regions that are not considered important for activity. In certain embodiments, residues and portions of a molecule that are conserved between similar polypeptides can be identified. In certain embodiments, even regions that may be important for biological activity or structure may be conservative amino acid substitutions without destroying the biological activity or adversely affecting the structure of the polypeptide.

Additionally, one of skill in the art may review structure-function studies to identify residues in similar polypeptides that are important for activity or structure. Taking this comparison into account, it is possible to predict the importance of amino acid residues in proteins corresponding to amino acid residues important for activity or structure in similar proteins. One of skill in the art can select chemically similar amino acid substitutions for the predicted important amino acid residues.

One of skill in the art can also analyze the three-dimensional structure and amino acid sequence in relation to the corresponding structure within a similar ABP. Given such information, one of skill in the art can predict the alignment of amino acid residues of an antibody with respect to its three-dimensional structure. In certain embodiments, one of skill in the art may choose not to cause radical changes to amino acid residues predicted to be on the surface of the protein, as such residues may be involved in important interactions with other molecules. In addition, one of skill in the art can generate test variants containing a single amino acid substitution at each desired amino acid residue. The variants can then be screened using activity assays known to those of skill in the art. Such variants can be used to gather information about suitable variants. For example, if a change to a particular amino acid residue is found to destroy, undesirably reduce, or render unsuitable activity, then a variant with such change can be avoided. That is, based on the information gathered from such routine experimentation, one of ordinary skill in the art can easily determine which amino acids, alone or in combination with other mutations, should avoid further substitutions.

The prediction of secondary structure has been intensively reported in many academic literature ([Moult J., Curr. Op. in Biotech., 7(4):422-427 (1996)]), [Chou et al., Biochemistry, 13 (2):222-245 (1974)]; [Chou et al., Biochemistry, 113(2):211-222 (1974)]; [Chou et al., Adv. Enzymol. Relat. Areas Mol. Biol. , 47:45-148 (1978)]; [Chou et al., Ann. Rev. Biochem., 47:251-276] and [Chou et al., Biophys. J., 26:367-384 (1979) ] Reference). In addition, computer programs are currently available to help predict the secondary structure. One method for predicting the secondary structure is based on homology modeling. For example, two polypeptides or proteins with more than 30% sequence identity or more than 40% similarity often have a similar structural topology. The recent growth of the Protein Structure Database (PDB) has provided improved predictability of secondary structures, including the potential number of folds within a polypeptide or protein structure. See, eg, Holm et al., Nucl. Acid. Res., 27(1):244-247 (1999). It has been suggested that there are a limited number of folds within a given polypeptide or protein, and structure prediction will be more accurate after an important number of structures have been revealed (Brenner et al., Curr. Op. Struct. Biol., 7(3): 369-376 (1997)).

Additional methods of predicting secondary structures are described in “threading” ([Jones, D., Curr. Opin. Struct. Biol., 7(3):377-87 (1997)); [Sippl et al. , Structure, 4(1):15-19 (1996)], “Profile analysis” ([Bowie et al., Science, 253:164-170 (1991)]; [Gribskov et al., Meth. Enzym. , 183:146-159 (1990)]; [Gribskov et al., Proc. Nat. Acad. Sci. USA, 84(13):4355-4358 (1987)]), and "evolutionary linkages" ([Holm , Supra (1999) and Brenner, supra (1997)).

In certain embodiments, antigen binding protein variants include glycosylation variants in which the number and/or type of glycosylation sites are altered relative to the amino acid sequence of the parent polypeptide. In certain embodiments, protein variants contain more or fewer N-linked glycosylation sites than native proteins. The N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated X may be any amino acid residue except proline. Substitution of amino acid residues to create this sequence provides a potential new site for the addition of N-linked carbohydrate chains. Alternatively, a substitution that removes the sequence will remove the N-linked carbohydrate chain present. In addition, one or more N-linked glycosylation sites (typically naturally occurring sites) are removed and one or more new N-linked sites provide for rearrangement of the resulting N-linked carbohydrate chain. Further preferred antibody variants include cysteine variants in which one or more cysteine residues have been deleted relative to the parent amino acid sequence or have been substituted with another amino acid (eg, serine). Cysteine variants may be useful when the antibody has to be refolded into a biologically active conformation, such as after isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than native proteins, and usually have an even number of cysteines to minimize interactions due to unpaired cysteines.

According to certain embodiments, amino acid substitutions are (1) reduced susceptibility to proteolysis, (2) reduced susceptibility to oxidation, and/or (3) binding affinity to form protein complexes. And/or (4) altering binding affinity, and/or (5) imparting or altering other physicochemical or functional properties for the polypeptide. According to certain embodiments, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) are in naturally occurring sequences (in certain embodiments, in the portion of the polypeptide outside the domain(s) forming intermolecular contacts). Can be done. In certain embodiments, conservative amino acid substitutions typically do not substantially change the structural characteristics of the parent sequence (e.g., replacement amino acids do not have a tendency to break the helix occurring in the parent sequence, or It should not destroy any other kinds of secondary structures that make up the feature). Examples of polypeptide secondary and tertiary structures recognized in the art are described in Proteins, Structures and Molecular Principles (Creighton, Ed., WH Freeman and Company, New York (1984), each incorporated herein by reference); [ Introduction to Protein Structure (C. Branden & J. Tooze, eds., Garland Publishing, New York, NY (1991))]; and Thornton et al., Nature, 354:105 (1991)). .

In some embodiments, the variant is a variant of the nucleic acid sequence of ABP disclosed herein. One of skill in the art will understand that the above discussion can be used for the identification, evaluation and/or generation of ABP protein variants and also for nucleic acid sequences capable of encoding these protein variants. Thus, the nucleic acid sequence encoding the protein variant (and the nucleic acid sequence encoding the ABP in Table 2, but different from that expressly disclosed herein) are contemplated. For example, the ABP variant is SEQ ID NO: 152, 153, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, At least one nucleic acid sequence set forth in 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, or SEQ ID NO:152, 153, 92, 93, 94 , 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 , 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144 , At least 80, 80-85, 85-90 in at least 1 to 6 (and various combinations thereof) CDR(s) encoded by nucleic acid sequences within 145, 146, 147, 148, 149, 150, and 151, It may have 90-95, 95-97, 97-99% or more identity.

In some embodiments, the antibody (or nucleic acid sequence encoding it) is any nucleic acid sequence encoding a protein in Table 2 (e.g., non- Limited sequence 152, 153, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113 , 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 , 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, and 151). In one embodiment, suitable moderate stringency conditions are 5XSSC; Prewash in a solution of 0.5% SDS, 1.0 mM EDTA, pH 8.0; Overnight hybridization with 5xSSC at 50°C-65°C or hybridization with 0.5xSSC at 45°C in the case of cross-species homology; This includes two washes with 2x, 0.5x and 0.2xSSC each containing 0.1% SDS at 65° C. for 20 minutes. Such hybridization DNA sequences are also included within the scope of the present invention, and due to code degeneracy, nucleotide sequences encoding antibody polypeptides encoded by hybridization DNA sequences and amino acid sequences encoded by these nucleic acid sequences are also included. In some embodiments, a variant of a CDR comprises a nucleic acid sequence that hybridizes to one or more CDRs within the aforementioned sequences and an amino acid sequence encoded by these sequences (individual CDRs are in light of FIGS. Can easily be determined according to -3jjj and 15a-15d). The phrase “selectively hybridize” as referred to in this context means detectably and selectively combine. Polynucleotides, oligonucleotides and fragments thereof according to the invention selectively hybridize to nucleic acid strands under hybridization and washing conditions that minimize detectable amounts of detectable binding to non-specific nucleic acids. High stringency conditions can be used to achieve the selective hybridization conditions known in the art and discussed herein. In general, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and the nucleic acid sequence of interest is at least 80%, more generally preferably at least 85%, 90%, 95%, 99%, and 100 %would. Two amino acid sequences are homologous when there is partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when two sequences are aligned for maximum match. Gaps (within either of the two sequences that match) are allowed to maximize matching; A gap length of 5 or less is preferable, and 2 or less is more preferable. Alternatively and preferably, two protein sequences (or a polypeptide sequence derived from a protein of at least 30 amino acids in length) are at least 5 when using the program ALIGN using a mutation data matrix and a gap penalty of greater than 6. It is the homology of the meaning used herein when having an alignment score (in units of standard deviation). See Dayhoff, M.O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and therefor [Supplement 2, pp. 1-10] The two sequences or portions thereof are more preferably their amino acids using the ALIGN program. And is homologous if it is 50% or more identical when optimally aligned. The term "corresponds to" is homologous to all or part of the reference polynucleotide sequence (ie, identical but strictly speaking evolutionarily relevant). Or not), or the polypeptide sequence is used herein to mean that the polypeptide sequence is identical to the reference polypeptide sequence In contrast, the term “complementary to” means that the complementary sequence is homologous to all or part of the reference polynucleotide sequence. As used herein, for example, the nucleotide sequence “TATAC” corresponds to the reference sequence “TATAC” and is complementary to the reference sequence “GTATA”.

Preparation of antigen binding protein (e.g. antibody)

In certain embodiments, the antigen binding protein (eg, antibody) is produced by immunization with an antigen (eg, PCSK9). In certain embodiments, antibodies can be produced by immunization with full-length PCSK9, a soluble form of PCSK9, a catalytic domain alone, a mature form of PCSK9 shown in Figure 1A, a splice variant form of PCSK9, or a fragment thereof. In certain embodiments, the antibodies of the invention may be polyclonal or monoclonal and/or may be recombinant antibodies. In certain embodiments, an antibody of the invention is a human antibody produced, for example, by immunization of a transgenic animal capable of producing human antibodies (see, eg, PCT patent application publication WO 93/12227).

In certain embodiments, certain strategies can be used to manipulate the unique properties of the antibody, such as the affinity of the antibody for its target. Such strategies include, but are not limited to, the use of site-specific or random mutagenesis of polynucleotide molecules encoding antibodies to generate antibody variants. In certain embodiments, after such production, screening of antibody variants exhibiting a desired change, e.g., increased or decreased affinity, is carried out.

In certain embodiments, the amino acid residues targeted in the mutagenesis strategy are residues in the CDRs. In certain embodiments, amino acids within the framework regions of the variable domains are targeted. In certain embodiments, the framework regions have been shown to contribute to the target binding properties of certain antibodies. See, eg, Hudson, Curr. Opin. Biotech., 9:395-402 (1999)] and references cited therein.

In certain embodiments, a library of less effectively and more effectively screened antibody variants is produced by limiting random or site-directed mutagenesis to hypermutation sites in the CDRs, which are regions that correspond to regions susceptible to mutagenesis during the somatic affinity maturation process. . See, for example, Chowdhury & Pastan, Nature Biotech., 17: 568-572 (1999) and references cited therein. In certain embodiments, specific types of DNA elements, including, but not limited to, specific direct and inverted repeats, specific consensus sequences, specific secondary structures, and specific palindromes can be used to identify regions of hypermutation. For example, such DNA elements that can be used to identify hypermutation sites are purine (A or G), then guanine (G), then pyrimidine (C or T), then adenosine or thymidine (A or T). (I.e., A/GGC/TA/T). Another example of a DNA element that can be used to identify the hypermutation site is the serine codon A-G-C/T.

Preparation of fully human ABP (e.g., antibody)

In certain embodiments, monoclonal antibodies are generated using phage display technology. In certain embodiments, such techniques produce fully human monoclonal antibodies. In certain embodiments, a polynucleotide encoding a single Fab or Fv antibody fragment is expressed on the surface of a phage particle (eg, Hoogenboom et al., J. Mol. Biol., 227: 381 (1991)). ; [Marks et al., J Mol Biol 222: 581 (1991)]; see US Pat. No. 5,885,793). In certain embodiments, phages are “screened” to identify antibody fragments that have affinity for the target. Thus, such a specific process is similar to immune selection through display of a repertoire of antibody fragments on the surface of fibrous bacteriophage, and subsequent selection of phage by binding to its target. In such specific procedures, high affinity functional neutralizing antibody fragments are isolated. In certain such embodiments (discussed in more detail below), a complete repertoire of human antibody genes is generated by cloning a naturally rearranged human V gene from peripheral blood lymphocytes. See, for example, Mullinax et al., Proc Natl Acad Sci (USA), 87: 8095-8099 (1990).

According to a specific embodiment, the antibodies of the invention are prepared using transgenic mice that have inserted a substantial portion of the human antibody producing genome but lack the production of endogenous murine antibodies. Subsequently, such mice can produce human immunoglobulin molecules and antibodies, and production of murine immunoglobulin molecules and antibodies is deficient. The techniques used to achieve the above results are disclosed in the patents, applications, and references disclosed herein. In certain embodiments, methods such as those disclosed in PCT Patent Application Publication WO 98/24893 or Mendez et al., Nature Genetics, 15:146-156 (1997), incorporated herein by reference for any purpose, are used. I can.

In general, fully human monoclonal ABPs (eg, antibodies) specific for PCSK9 can be produced as follows. Transgenic mice containing human immunoglobulin genes are immunized with an antigen of interest, eg PCSK9, and lymphocytes (eg B-cells) are obtained from mice expressing the antibody. The recovered cells are fused with a bone marrow-type cell line to prepare an immortal hybridoma cell line, and the hybridoma cell line is screened and selected to identify hybridoma cell lines that produce antibodies specific for the antigen of interest. do. In certain embodiments, production of hybridoma cell lines that produce antibodies specific for PCSK9 are provided.

In certain embodiments, fully human antibodies are produced by exposing human splenocytes (B or T cells) to an antigen in vitro and then reconstituting the exposed cells in an immunocompromised mouse, e.g., SCID or nod/SCID. (See, eg, Brams et al., J. Immunol. 160: 2051-2058 (1998); Carballido et al., Nat. Med., 6: 103-106 (2000)). In certain such methods, implantation of human fetal tissue into SCID mice (SCID-hu) causes long-term hematopoietic reactions and human T-cell development (see, for example, McCune et al., Science, 241:1532-1639 (1988) )]; see Ifversen et al., Sem. Immunol., 8:243-248 (1996)). In certain instances, the humoral immune response in the chimeric mouse is influenced by the co-development of human T-cells in the animal (see, for example, Martensson et al., Immunol., 83:1271-179 (1994)). ] Reference). In certain methods, human peripheral blood lymphocytes are transplanted into SCID mice (see, eg, Mosier et al., Nature, 335:256-259 (1988). In certain such embodiments, the transplanted cells are primed). When treated with a priming agent, for example Staphylococcal endotoxin A (SEA), or with an anti-human CD40 monoclonal antibody, higher levels of B cell production are detected (e.g., [Martensson et al., Immunol., 84:224-230 (1995)]; see Murphy et al., Blood, 86:1946-1953 (1995)).

Thus, in certain embodiments, fully human antibodies can be produced by expression of recombinant DNA in host cells, or by expression in hybridoma cells. In other embodiments, antibodies can be produced using the phage display technology described herein.

The antibodies described herein were prepared using the XenoMouse® technology as described herein. Subsequently, such mice can produce human immunoglobulin molecules and antibodies, and production of murine immunoglobulin molecules and antibodies is deficient. The techniques used to achieve this are disclosed in the patents, applications, and references disclosed in the background section of this application. However, in particular, preferred embodiments of transgenic production of mice and of antibodies therefrom are described in U.S. Patent Application 08/759,620 (filed December 3, 1996) and International Patent Application WO 98/24893, the disclosure of which is incorporated herein by reference. (Published on June 11, 1998), and in WO 00/76310 (published on December 21, 2000). See also Mendez et al., Nature Genetics, 15:146-156 (1997), the disclosure of which is incorporated herein by reference.

Using this technique, fully human monoclonal antibodies to various antigens have been produced. Essentially, mice of the XenoMouse® strain are immunized with an antigen of interest (eg PCSK9), lymphocytes (eg B-cells) are recovered from hyperimmunized mice, and the recovered lymphocytes are transferred to a bone marrow-type cell line. Fusing to produce an immortal hybridoma cell line. These hybridoma cell lines are screened and selected to identify hybridoma cell lines that produced antibodies specific for the antigen of interest. Provided herein are methods for the production of multiple hybridoma cell lines that produce antibodies specific for PCSK9. In addition, the characterization of the antibody produced by the cell line, including analysis of the nucleotide and amino acid sequences of the heavy and light chains of the antibody, is provided herein.

Production of the XenoMouse® strain of mice is described in U.S. patent applications 07/466,008 (filed January 12, 1990), 07/610,515 (filed November 8, 1990), 07/919,297 (filed July 24, 1992), 07 /922,649 (filed on July 30, 1992), 08/031,801 (filed on March 15, 1993), 08/112,848 (filed on August 27, 1993), 08/234,145 (filed on April 28, 1994) , 08/376,279 (filed on January 20, 1995), 08/430,938 (filed on April 27, 1995), 08/464,584 (filed on June 5, 1995), 08/464,582 (filed on June 5, 1995) Filed on June 5, 1995), 08/463,191 (filed on June 5, 1995), 08/462,837 (filed on June 5, 1995), 08/486,853 (filed on June 5, 1995), 08/486,857 (June 1995) 5 filed), 08/486,859 (filed June 5, 1995), 08/462,513 (filed June 5, 1995), 08/724,752 (filed October 2, 1996), 08/759,620 (1996 Dec. 3), U.S. Patent Publication 2003/0093820 (filed on Nov. 30, 2001) and U.S. Patents 6,162,963, 6,150,584, 6,114,598, 6,075,181 and 5,939,598 and Japanese Patent 3 068 180 B2, 3 068 506 B2 and 3 068 507 It is further discussed and described in B2. In addition, European patent EP 0 463 151 B1 (registered on June 12, 1996), published international patent application WO 94/02602 (published on February 3, 1994), published international patent application WO 96/34096 (registered on October 1996) 31st publication), WO 98/24893 (published June 11, 1998), WO 00/76310 (published December 21, 2000). The disclosures of each of the patents, applications, and references cited above are incorporated herein by reference in their entirety.

Alternatively, Zenfarm International, Inc. Others, including GenPharm International, Inc., used the "minilocus" method. In the minilocus method, exogenous Ig locus is mimicked by inclusion of fragments (individual genes) from the Ig locus. Thus, at least one V _H gene, at least one D _H gene, at least one J _H gene, mu constant region, and generally a second constant region (preferably a gamma constant region) is formed into a construct for insertion into an animal. The methods include U.S. Patents 5,545,807 (Surani et al) and U.S. Patents 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,874,299, respectively. Kay), U.S. Patents 5,591,669 and 6,023,010 (Krimpenfort & Berns), U.S. Patents 5,612,205, 5,721,367, and 5,789,215 (Berns et al), and U.S. Pat. August 29, 1992), 07/575,962 (filed August 31, 1990), 07/810,279 (filed December 17, 1991), 07/853,408 (filed March 18, 1992), 07/904,068 (Filed on June 23, 1992), 07/990,860 (filed on December 16, 1992), 08/053,131 (filed on April 26, 1993), 08/096,762 (filed on July 22, 1993), 08 /155,301 (filed on November 18, 1993), 08/161,739 (filed on December 3, 1993), 08/165,699 (filed on December 10, 1993), 08/209,741 (filed on March 9, 1994) It is described in. In addition, European Patent 0 546 073 B1, international patent applications WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO, the disclosure of which is incorporated herein by reference in its entirety. See 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent 5,981,175. In addition, references to [Taylor et al., 1992], [Chen et al., 1993], [Tuaillon et al., 1993], [Choi et al., 1993], the disclosure of which are incorporated herein by reference in their entirety, are incorporated herein by reference in their entirety. ], [Lonberg et al., (1994)], [Taylor et al., (1994)], [Tuaillon et al., (1995)], and [Fishwild et al., (1996)]). .

Kirin has also demonstrated the production of human antibodies from mice into which large pieces of chromosomes or whole chromosomes have been introduced through microcellular fusion. See European patent applications 773 288 and 843 961, the disclosures of which are incorporated herein by reference. In addition, KM™ mice (a result of hybridizing Kirin's Tc mice with Medarex's Minilocus (Humab) mice) were generated. These mice carry the human IgH transchromosome of kirin mice and the kappa chain transgene of genpam mice (Ishida et al., Cloning Stem Cells, (2002) 4:91-102).

Human antibodies can also be induced by in vitro methods. Suitable examples include, but are not limited to, phage display (CAT, Morphosys, Dyax, Biosite/Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed) ribosome display (CAT), yeast display, and the like.

In some embodiments, the antibodies described herein have a human IgG4 heavy chain as well as an IgG2 heavy chain. Antibodies may also be of other human isotypes, including IgG1. Antibodies have high affinity and generally have a Kd of about 10 ^-6 to about 10 ^-13 M or less as measured by various techniques.

As will be appreciated, antibodies can be expressed in cell lines other than hybridoma cell lines. Sequences encoding specific antibodies can be used for transformation of suitable mammalian host cells. Transformation is any known for the introduction of polynucleotides into host cells, including, for example, packaging of polynucleotides in a virus (or into a viral vector) and transduction of the host cell with a virus (or vector). By the method, or by transfection procedures known in the art as exemplified in U.S. Patents 4,399,216, 4,912,040, 4,740,461 and 4,959,455, incorporated herein by reference. The transformation procedure used depends on the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art, and dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, polynucleotide(s) Includes encapsulation in liposomes, and direct microinjection of DNA into the nucleus.

Mammalian cell lines usable as a host for expression are well known in the art, and Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells ( Includes, but is not limited to, many immortalized cell lines available from the American Type Culture Collection (ATCC), including, but not limited to, Hep G2), human epithelial kidney 293 cells, and many other cell lines. . Particularly preferred cell lines are selected by determining which cell lines have high expression levels and produce antibodies with constitutive PCSK9 binding properties.

In certain embodiments, the antibody and/or ABP is produced by at least one of the following hybridomas: 21B12, 31H4, 16F12, any other hybridoma listed in Table 2 or disclosed in the Examples. In certain embodiments, the antigen binding protein has a dissociation constant (K _D ) binds to PCSK9.

In certain embodiments, the antigen binding protein comprises an immunoglobulin molecule of at least one of IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD and IgM isotypes. In certain embodiments, the antigen binding protein comprises a human kappa light chain and/or a human heavy chain. In certain embodiments, the heavy chain is of an IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD, or IgM isotype. In certain embodiments, the antigen binding protein has been cloned for expression in mammalian cells. In certain embodiments, the antigen binding protein comprises a constant region other than any of the constant regions of the IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD and IgM isotypes.

In certain embodiments, the antigen binding protein comprises a human lambda light chain and a human IgG2 heavy chain. In certain embodiments, the antigen binding protein comprises a human lambda light chain and a human IgG4 heavy chain. In certain embodiments, the antigen binding protein comprises a human lambda light chain and a human IgG1, IgG3, IgE, IgA, IgD or IgM heavy chain. In another embodiment, the antigen binding protein comprises a human kappa light chain and a human IgG2 heavy chain. In certain embodiments, the antigen binding protein comprises a human kappa light chain and a human IgG4 heavy chain. In certain embodiments, the antigen binding protein comprises a human kappa light chain and a human IgG1, IgG3, IgE, IgA, IgD or IgM heavy chain. In certain embodiments, the antigen binding protein comprises a variable region of an antibody ligated to a constant region that is neither a constant region for an IgG2 isotype nor a constant region for an IgG4 isotype. In certain embodiments, the antigen binding protein has been cloned for expression in mammalian cells.

In certain embodiments, conservative modifications to the heavy and light chains (and corresponding modifications to the coding nucleotides) of antibodies from at least one of hybridoma strains 21B12, 31H4 and 16F12 are antibodies from hybridoma strains 21B12, 31H4 and 16F12. Antibodies to PCSK9 will be produced with functional and/or chemical characteristics similar to. In contrast, in certain embodiments, a substantial modification in the functional and/or chemical properties of the antibody against PCSK9 is (a) the structure of the molecular backbone in the region of the substitution, e. The charge or hydrophobicity of the molecule at the site, or (c) their effect on maintaining the bulk of the side chains can be achieved by selecting substitutions of the amino acid sequences of the heavy and light chains that differ significantly.

For example, “conservative amino acid substitutions” may include substitution of natural amino acid residues with non-natural residues such that little or no effect on the polarity or charge of the amino acid residue at that position. In addition, any natural residue in the polypeptide may also be substituted with alanine as previously described for “alanine scanning mutagenesis”.

Desired amino acid substitutions (whether conservative or non-conservative) can be determined by one of skill in the art at the time such substitution is desired. In certain embodiments, amino acid substitutions can be used to identify important residues of the antibody to PCSK9, or to increase or decrease the affinity of the antibody to PCSK9 as described herein.

In certain embodiments, the antibodies of the invention may be expressed in cell lines other than hybridoma cell lines. In certain embodiments, sequences encoding specific antibodies can be used for transformation of suitable mammalian host cells. According to certain embodiments, transformation comprises, for example, packaging of the polynucleotide in a virus (or into a viral vector), and transduction of the host cell with a virus (or vector), the introduction of a polynucleotide into a host cell. It can be carried out by any known method for, or by transfection procedures known in the art as exemplified in U.S. Patents 4,399,216, 4,912,040, 4,740,461 and 4,959,455, incorporated herein by reference for any purpose. In a particular embodiment, the transformation procedure used depends on the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art, and dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, polynucleotide(s) Includes, but is not limited to, encapsulation in liposomes, and direct microinjection of DNA into the nucleus.

Mammalian cell lines usable as a host for expression are well known in the art, and Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells ( For example, Hep G2), and a number of immortalized cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, many other cell lines. In certain embodiments, cell lines can be selected by determining which cell lines have high expression levels and produce antibodies with constitutive HGF binding properties. Appropriate expression vectors for mammalian host cells are well known.

In certain embodiments, the antigen binding protein comprises one or more polypeptides. In certain embodiments, any of a variety of expression vector/host systems can be used to express one or more ABP components or polynucleotide molecules encoding polypeptides comprising ABP itself. Such systems include microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; Yeast transformed with a yeast expression vector; Insect cell systems infected with viral expression vectors (eg baculovirus); Plant cell systems transfected with a viral expression vector (eg, cauliflower mosaic virus CaMV, tobacco mosaic virus TMV) or transformed with a bacterial expression vector (eg, Ti or pBR322 plasmid); Or animal cell systems.

In certain embodiments, a polypeptide comprising one or more ABP components or ABP itself is expressed recombinantly in yeast. Certain such embodiments use commercially available expression systems, such as the Pichia expression system (Invitrogen, San Diego, CA, USA) according to the manufacturer's instructions. In certain embodiments, such systems rely on pre-pro-alpha sequences to direct secretion. In certain embodiments, transcription of the insert is driven by the alcohol oxidase (AOX1) promoter upon induction by methanol.

In certain embodiments, the secreted polypeptide comprising one or more ABP components or ABP itself is purified from yeast growth medium. In certain embodiments, the method used to purify the polypeptide from yeast growth medium is the same as that used to purify the polypeptide from bacterial and mammalian cell supernatant.

In certain embodiments, a nucleic acid encoding a polypeptide comprising one or more ABP components or ABP itself is cloned into a baculovirus expression vector, such as pVL1393 (PharMingen, San Diego, CA, USA). In certain embodiments, such vectors can be used according to the manufacturer's (Pharmingen) instructions to infect Spodoptera frugiperda cells and produce recombinant polypeptides in sF9 protein-free medium. In certain embodiments, the polypeptide is purified and concentrated from the medium using a heparin-sepharose column (Pharmacia).

In certain embodiments, a polypeptide comprising one or more ABP components or ABP itself is expressed in an insect system. Certain insect systems for polypeptide expression are well known to those of skill in the art. In one such system, Autographa californica nuclear polyhedron-forming virus (AcNPV) is used to express foreign genes in Spodoptera frugiperda cells or Trichoplusia larvae. It is used as a vector. In certain embodiments, a nucleic acid molecule encoding a polypeptide can be inserted into a non-essential gene of a virus, eg, a polyhedrin gene, and placed under the control of a promoter for that gene. In certain embodiments, upon successful insertion of the nucleic acid molecule, the non-essential genes will be inactivated. In certain embodiments, inactivation produces a detectable characteristic. For example, inactivation of the polyhedrin gene produces a virus that lacks the production of the coat protein.

In certain embodiments, the recombinant virus is S. It can be used to infect Frugiperda cells or Trichoflusia larvae (eg Smith et al., J. Virol., 46: 584 (1983)); and Engelhard et al., Proc. Nat. Acad. Sci. (USA), 91: 3224-7 (1994)).

In certain embodiments, one or more ABP components produced in bacterial cells or polypeptides comprising ABP itself are produced in bacteria as insoluble inclusion bodies. In certain embodiments, host cells comprising such inclusion bodies are harvested by centrifugation; Washed in 0.15 M NaCl, 10 mM Tris (pH 8), 1 mM EDTA; Treatment with 0.1 mg/ml lysozyme (Sigma, St. Louis, Mo.) for 15 minutes at room temperature. In a specific embodiment, the lysate is made transparent by sonication and the cell lysate is pelleted by centrifugation at 12,000 X g for 10 minutes. In certain embodiments, the polypeptide-containing pellet is resuspended in 50 mM Tris (pH 8) and 10 mM EDTA; Stacked on 50% glycerol; Centrifuge at 6000 X g for 30 minutes. In certain embodiments, the pellet can be resuspended in a standard phosphate buffered saline solution (PBS) free ^{of Mg++} and Ca ^++. In certain embodiments, the polypeptide is further purified by fractionating the resuspended pellet on a denatured SDS polyacrylamide gel (see, eg, Sambrook et al., supra). In certain embodiments, the gel can be immersed in 0.4 M KCl to visualize the protein, which can be excised and electroeluted in a gel development buffer lacking SDS. According to a specific embodiment, a glutathione-S-transferase (GST) fusion protein is produced in bacteria as a soluble protein. In certain embodiments, the GST fusion protein is purified using a GST purification module (Pharmacia).

In certain embodiments, it is desirable to “refold” a particular polypeptide, eg, a polypeptide comprising one or more ABP components or ABP itself. In certain embodiments, such polypeptides are produced using certain recombinant systems discussed herein. In certain embodiments, the polypeptide is “refolded” and/or oxidized to form a desired tertiary structure and/or to create a disulfide linkage. In certain embodiments, the structure and/or linkage is related to a specific biological activity of the polypeptide. In certain embodiments, refolding is accomplished using any of a number of procedures known in the art. Exemplary methods include, but are not limited to, exposing the solubilized polypeptide material to a pH of usually above 7 in the presence of a chaotropic agent. An exemplary disorder-causing agent is guanidine. In certain embodiments, the refolding/oxidation solution also contains a reducing agent and an oxidized form of the reducing agent. In certain embodiments, the reducing agent and its oxidized form are present at a rate that will produce a specific redox potential that causes disulfide shuffling to occur. In certain embodiments, such shuffling allows the formation of cysteine bridges. Exemplary redox couples include cysteine/cytamine, glutathione/dithiobisGSH, cupric chloride, dithiothreitol DTT/dithian DTT, and 2-mercaptoethanol (bME)/dithio-bME, and Not limited. In certain embodiments, a co-solvent is used to increase the efficiency of refolding. Exemplary co-solvents include, but are not limited to, glycerol, polyethylene glycols of various molecular weights, and arginine.

In certain embodiments, a polypeptide comprising one or more ABP components or ABP itself is substantially purified. Certain protein purification techniques are known to those of skill in the art. In certain embodiments, protein purification comprises crude fractionation of a polypeptide fraction from a non-polypeptide fraction. In certain embodiments, the polypeptide is purified using chromatography and/or electrophoresis techniques. Exemplary purification methods include precipitation with ammonium sulfate; Precipitation with PEG; Immunoprecipitation; Thermal denaturation followed by centrifugation; Chromatography including, but not limited to, affinity chromatography (eg, Protein-A-Sepharose), ion exchange chromatography, exclusion chromatography, and reverse phase chromatography; Gel filtration; Hydroxyapatite chromatography; Isoelectric focusing; Polyacrylamide gel electrophoresis; And combinations of the above and other techniques. In certain embodiments, the polypeptide is purified by rapid protein liquid chromatography or high pressure liquid chromatography (HPLC). In certain embodiments, purification steps may be varied, certain steps may be omitted, and suitable methods for the production of substantially purified polypeptides may be continued.

In certain embodiments, the degree of purification of the polypeptide preparation is quantified. Certain methods for quantifying the degree of purification are known to those of skill in the art. Certain exemplary methods include, but are not limited to, determination of the specific binding activity of the agent, and evaluation of the amount of polypeptide in the agent by SDS/PAGE analysis. Certain exemplary methods for evaluating the amount of purification of a polypeptide preparation include calculating the binding activity of the agent and comparing it to the binding activity of the initial extract. In certain embodiments, the result of the calculation is expressed as a “purification multiple”. The units used to indicate the amount of binding activity are determined according to the specific assay performed.

In certain embodiments, a polypeptide comprising one or more ABP components or ABP itself is partially purified. In certain embodiments, partial purification can be achieved using fewer purification steps or using different forms of the same general purification scheme. For example, in certain embodiments, cation exchange column chromatography performed using an HPLC apparatus will generally produce a larger "purification drainage" than the same technique using a low pressure chromatography system. In certain embodiments, a method that results in a lower degree of purification may have the advantage of maintaining the total recovery of the polypeptide, or the binding activity of the polypeptide.

In certain instances, the electrophoretic shift of a polypeptide can sometimes be significantly changed using SDS/PAGE of different conditions (see, for example, Capaldi et al., Biochem. Biophys. Res. Comm., 76: 425 ( 1977)]. It will be appreciated that under different electrophoretic conditions, the apparent molecular weight of the purified or partially purified polypeptide may be different.

Exemplary epitope

Provides the epitope to which the anti-PCSK9 antibody binds. In some embodiments, the epitope to which the antibodies disclosed herein bind are particularly useful. In some embodiments, antigen binding proteins that bind to any epitope to which the antibodies described herein bind are useful. In some embodiments, the epitope to which any of the antibodies listed in Table 2 and FIGS. 2 and 3 bind is particularly useful. In some embodiments, the epitope is on the catalytic domain of PCSK9.

In certain embodiments, the PCSK9 epitope can be used to prevent (eg, reduce) binding of an antigen binding protein to an anti-PCSK9 antibody or PCSK9. In certain embodiments, the PCSK9 epitope can be used to reduce the binding of an antigen binding protein to an anti-PCSK9 antibody or PCSK9. In certain embodiments, the PCSK9 epitope can be used to substantially inhibit the binding of an antigen binding protein to an anti-PCSK9 antibody or PCSK9.

In certain embodiments, the PCSK9 epitope can be used to isolate an antibody or antigen binding protein that binds PCSK9. In certain embodiments, the PCSK9 epitope can be used to generate an antibody or antigen binding protein that binds PCSK9. In certain embodiments, a PCSK9 epitope or a sequence comprising a PCSK9 epitope can be used as an immunogen to generate an antibody or antigen binding protein that binds PCSK9. In certain embodiments, the PCSK9 epitope can be administered to an animal, and antibodies that bind to PCSK9 can be subsequently obtained from the animal. In certain embodiments, a PCSK9 epitope or a sequence comprising a PCSK9 epitope can be used to inhibit normal PCSK9-mediated activity, such as the association of PCSK9 with LDLR.

In some embodiments, the antigen binding proteins disclosed herein specifically bind to the N-terminal prodomain, subtilisin-like catalytic domain, and/or C-terminal domain. In some embodiments, the antigen binding protein binds to the substrate binding groove of PCSK-9 (described in Cunningham et al., which is incorporated herein by reference in its entirety).

In some embodiments, the domain(s)/region(s) containing residues that are in contact with or buried by the antibody mutate specific residues in PCSK9 (e.g., wild-type antigen) and the antigen binding protein is mutated or It can be confirmed by determining whether it can bind to the variant PCSK9 protein. By forming many individual mutations, it is possible to identify residues that play a direct role in binding or that are sufficiently close to the antibody so that the mutation can affect the binding between the antigen binding protein and the antigen. From information about these amino acids, the domain(s) or region(s) of the antigen containing residues that are in contact with the antigen binding protein or covered by the antibody can be described. Such domains may comprise a binding epitope of an antigen binding protein. One specific example of this general method uses an arginine/glutamic acid scanning protocol (eg [Nanevicz, T., et al., 1995, J. Biol. Chem., 270:37, 21619-21625] and [ Zupnick, A., et al., 2006, J. Biol. Chem., 281:29, 20464-20473). In general, arginine and glutamic acid replace amino acids in wild-type polypeptides (usually individually), which is because these amino acids are charged and bulky and have the potential to disrupt the binding between the antigen binding protein and the antigen in the region of the antigen into which the mutation is introduced Because it has. Arginine present in the wild-type antigen is replaced with glutamic acid. A variety of such individual mutants are obtained and the collected binding results are analyzed to determine which residues affect binding.

Example 39 describes one such arginine/glutamic acid scanning of PCSK9 against the PCSK9 antigen binding protein provided herein. A series of mutant PCSK9 antigens were generated, where each mutant antigen had a single mutation. Binding of each mutant PCSK9 antigen to various PCSK9 ABPs was measured and compared to the ability of selected ABPs to bind to wild type PCSK9 (SEQ ID NO: 303).

Alteration (e.g., decrease or increase) of the binding between the antigen binding protein and the variant PCSK9, as used herein, is a change in the binding affinity of the antigen binding protein (e.g., Biacore test or bead based As measured by known methods such as assays), _{change in EC 50} , and/or change (eg decrease) in total binding capacity (eg, decrease in Bmax in a graph of antigen binding protein concentration versus antigen concentration) Proved to be) is present. Significant alteration in binding indicates that the mutated moiety is directly involved in binding to the antigen binding protein, or is present in proximity to the binding protein when the binding protein binds to the antigen.

In some embodiments, a significant decrease in binding is that the binding affinity, EC50, and/or dose between the antigen binding protein and the mutant PCSK9 antigen is different from the antigen binding protein and wild-type PCSK9 (e.g., SEQ ID NO:1 and/or SEQ ID NO: >10%, >20%, >40%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, 85% compared to the bonds between It means reduced to more than, more than 90% or more than 95%. In certain embodiments, binding is reduced below the detectable limit. In some embodiments, a significant decrease in binding is that the binding of the antigen binding protein to the variant PCSK9 protein is observed between the antigen binding protein and the wild-type PCSK9 protein (e.g., the protein of SEQ ID NO: 1 and/or SEQ ID NO: 303). It is demonstrated when less than 50% (e.g., less than 40%, 35%, 30%, 25%, 20%, 15% or 10%). Such binding measurements can be made using a variety of binding assays known in the art. A specific example of one such analysis is described in Example 39.

In some embodiments, antigen binding proteins are provided that show significantly lower binding to the variant PCSK9 protein, wherein residues in the wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303) are substituted with arginine or glutamic acid. In some embodiments, the mutations R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, A413R, E582R, D162R, R164E, compared to wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). Any one or more of E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 244) The binding of the antigen binding protein to the variant PCSK9 protein having a significantly decreased or increased. In the abbreviated notation used herein, the format is a wild-type residue: a position in the polypeptide: a mutant residue, wherein the numbering of the residues is as indicated in SEQ ID NO: 1 or SEQ ID NO: 303.

In some embodiments, compared to the wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303), positions 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413 as set forth in SEQ ID NO: 1 , 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554 with one or more (e.g., 1, 2, 3, 4, 5 or more) mutations The binding of the antigen binding protein to the body PCSK9 protein is significantly reduced or increased. In some embodiments, compared to the wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303), positions 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413 as set forth in SEQ ID NO: 1 , 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554 with one or more (e.g., 1, 2, 3, 4, 5 or more) mutations The binding of the antigen binding protein to the body PCSK9 protein decreases or increases. In some embodiments, positions 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413 within SEQ ID NO: 1 compared to wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). , 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554 with one or more (e.g., 1, 2, 3, 4, 5 or more) mutations The binding of the antigen binding protein to the body PCSK9 protein is substantially reduced or increased.

In some embodiments, the mutations R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, in SEQ ID NO: 1 or SEQ ID NO: 303 compared to wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). Mutants having one or more of A413R, E582R, D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R (e.g., 1, 2, 3, 4, 5, etc.) The binding of ABP to the PCSK9 protein is significantly reduced or increased.

In some embodiments, the mutations R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, within SEQ ID NO: 1 or SEQ ID NO: 303 compared to wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). The binding of ABP to the mutant PCSK9 protein with one or more of A413R, and E582R (eg, 1, 2, 3, 4, 5, etc.) is significantly reduced or increased. In some embodiments, binding is reduced. In some embodiments, a decrease in binding is observed as a change in EC50. In some embodiments, the change in EC50 is an increase in the numerical value of EC50 (and thus a decrease in binding).

In some embodiments, among the mutations D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R within SEQ ID NO: 1 compared to wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). The binding of ABP to the mutant PCSK9 protein having more than one (eg, 1, 2, 3, 4, 5, etc.) is significantly reduced or increased. In some embodiments, binding is reduced. In some embodiments, a decrease in binding is observed as a change in Bmax. In some embodiments, the shift in Bmax is a reduction in the maximum signal produced by ABP. In some embodiments, for amino acids that are part of an epitope, Bmax is reduced by at least 10%, e.g., at least in any of the following amounts: 20, 30, 40, 50, 60, 70, 80, 90, 95, 98 , 99, or 100% reduction indicates that in some embodiments the residue is part of an epitope.

The variant forms listed now refer to the wild-type sequence shown in SEQ ID NO: 1 or SEQ ID NO: 303, but it will be appreciated that the amino acids at the indicated positions in the allelic variant of PCSK9 may differ. Antigen binding proteins that show significantly lower binding to such allelic forms of PCSK9 are also contemplated. Thus, in some embodiments, any of the above embodiments can be compared purely to an allele sequence rather than the wild-type sequence shown in FIG.

In some embodiments, the binding of the antigen binding protein to the variant PCSK9 protein is significantly reduced in which the residue is mutated to any other residue at a selected position in the wild-type PCSK9 protein. In some embodiments, arginine/glutamic acid replacements described herein are used for identified positions. In some embodiments, alanine is used for the identified position.

As noted above, residues directly involved in binding to or covered by the antigen-binding protein can be identified from the scanning results. Thus, these residues may represent a domain or region of SEQ ID NO: 1 (or SEQ ID NO: 303 or SEQ ID NO: 3) containing the binding region(s) to which the antigen binding protein binds. As can be seen from the results summarized in Example 39, in some embodiments the antigen binding protein is amino acids 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390 of SEQ ID NO:1 or SEQ ID NO:303. , 413, 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554. In some embodiments, the antigen binding protein is amino acids 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, of SEQ ID NO: 1 or SEQ ID NO: 303, 129, 311, 313, 337, 519, 521, and 554.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 162, 164, 167, 207 and/or 208 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than 1 (eg, 2, 3, 4, or 5) identified residues are part of the region to which ABP binds. In some embodiments, ABP competes with ABP 21B12.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 185 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, ABP competes with ABP 31H4.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 439, 513, 538, and/or 539 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than 1 (eg, 2, 3, or 4) identified residues are part of the region to which ABP binds. In some embodiments, ABP competes with ABP 31A4.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 123, 129, 311, 313, 337, 132, 351, 390, and/or 413 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than 1 (eg, 2, 3, 4, 5, 6, 7, 8, or 9) identified residues are part of the region to which the ABP binds. In some embodiments, ABP competes with ABP 12H11.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 582, 519, 521, and/or 554 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than 1 (eg, 2, 3, or 4) identified residues are part of the region to which ABP binds. In some embodiments, ABP competes with ABP 3C4.

In some embodiments, the antigen binding protein binds to a fragment of SEQ ID NO: 1 or SEQ ID NO: 303 or a region described above within the full length sequence. In another embodiment, the antigen binding protein binds to a polypeptide consisting of these regions. Reference to “SEQ ID NO: 1 or SEQ ID NO: 303” indicates that one or both of these sequences may be used or related. The above syntax does not indicate that only one should be used.

As noted above, the description refers to specific amino acid positions with respect to SEQ ID NO:1. However, throughout the specification, reference is made generally to the Pro/Cat domain starting at position 31, provided in SEQ ID NO: 3. As can be seen below, SEQ ID NO: 1 and SEQ ID NO: 303 lack the signal sequence of PCSK9. Thus, any comparison between these various disclosures should take into account the above differences in numbering. In particular, any amino acid position in SEQ ID NO: 1 will correspond to an amino acid at amino acid position 30, in particular a protein in SEQ ID NO: 3. For example, position 207 of SEQ ID NO: 1 corresponds to position 237 of SEQ ID NO: 3 (full length sequence, and the numbering system generally used herein). Table 39.6 outlines how the above mentioned positions referring to SEQ ID NO: 1 (and/or SEQ ID NO: 303) correspond to SEQ ID NO: 3 (including the signal sequence). Thus, any of the above-described embodiments described with respect to SEQ ID NO: 1 (and/or SEQ ID NO: 303) are described with respect to SEQ ID NO: 3 by the corresponding positions indicated.

In some embodiments, ABP 21B12 binds an epitope comprising residues 162-167 (eg, residues D162-E167 of SEQ ID NO: 1). In some embodiments, ABP 12H11 binds an epitope comprising residues 123-132 (eg, S123-T132 of SEQ ID NO: 1). In some embodiments, ABP 12H11 binds an epitope comprising residues 311-313 (eg, A311-D313 in SEQ ID NO: 1). In some embodiments, the ABP is capable of binding to an epitope comprising any one of these strands of the sequence.

Competitive antigen binding protein

In another aspect, an antigen binding protein is provided that competes with one exemplified antibody or functional fragment that binds an epitope described herein for specific binding to PCSK9. The antigen binding protein may also bind to the same epitope or overlapping epitope as one of the antigen binding proteins exemplified herein. Antigen binding proteins and fragments that compete with the exemplified antigen binding proteins and bind to the same epitope are expected to exhibit similar functional properties. Illustrative antigen binding proteins and fragments include those described above, including those with heavy and light chains, variable region domains and CDRs included in Table 2 and/or FIGS. 2-3 and 15. Thus, as a specific example, the antigen binding protein provided is

(a) all six CDRs listed for the antibodies shown in Figures 2-3 and 15;

(b) VH and VL listed for the antibodies shown in Table 2; or

(c) for the antibodies listed in Table 2, those that compete with an antibody or antigen binding protein having two light and two heavy chains specified.

Specific therapeutic uses and pharmaceutical compositions

In certain instances, PCSK9 activity is correlated with many human disease states. For example, in certain instances, too much or too little PCSK9 activity is correlated with certain conditions, such as hypercholesterolemia. Thus, in certain instances, modulating PCSK9 activity may be therapeutically useful. In certain embodiments, a neutralizing antigen binding protein to PCSK9 is used to modulate at least one PCSK9 activity (eg, binding to LDLR). The method can treat and/or prevent and/or reduce the risk of disease associated with elevated serum cholesterol levels, or associated with elevated cholesterol levels.

As will be appreciated by those of skill in the art, in light of the present specification, diseases that may be related to, involve or be affected by altered cholesterol, LDL, or LDLR levels can be treated by various embodiments of antigen binding proteins. In some embodiments, “cholesterol related disorders” (including “serum cholesterol related disorders”) include hypercholesterolemia, heart disease, metabolic syndrome, diabetes, coronary heart disease, stroke, cardiovascular disease, Alzheimer's disease, and generally, for example. For example, elevated total serum cholesterol, elevated LDL, elevated triglycerides, elevated VLDL, and/or any one or more of dyslipidemia that may be caused by low HDL. Some non-limiting examples of primary and secondary dyslipidemia that can be treated using ABP alone or in combination with one or more other substances include metabolic syndrome, diabetes, familial complex hyperlipidemia, familial hypertriglyceridemia. Hypercholesterolemia, familial hypercholesterolemia, for example heterozygous hypercholesterolemia, homozygous hypercholesterolemia, familial defect apolipoprotein B-100; Polygenic hypercholesterolemia; Remnant removal disease, liver lipolytic enzyme deficiency; Dyslipidemia secondary to any of the drugs including dietary indiscretion, hypothyroidism, estrogen and progestin therapy, beta-blockers, and thiazide diuretics; Nephrotic syndrome, chronic renal failure, Cushing's syndrome, primary biliary cirrhosis, glycogen storage disease, liver cancer, cholestasis, acromegaly, insulinoma, isolated growth hormone deficiency, and alcohol-induced hypertriglyceridemia. ABP can also prevent or treat atherosclerotic diseases such as coronary heart disease, coronary artery disease, peripheral artery disease, stroke (ischemic and hemorrhagic), angina, or cerebrovascular disease and acute coronary syndrome, myocardial infarction. It can be useful to do. In some embodiments, the ABP is characterized by non-fatal heart attack, fatal and non-fatal stroke, certain types of heart surgery, hospitalization for heart failure, chest pain in patients with heart disease, and/or established heart disease, such as prior It is useful to reduce the risk of heart attack of the patient, cardiovascular events due to previous cardiac surgery, and/or chest pain with evidence of clogged arteries. In some embodiments, ABP and methods can be used to reduce the risk of recurrent cardiovascular events.

As will be appreciated by those skilled in the art, the application of the antigen binding proteins of the present invention may also be beneficial in diseases or conditions that are generally treatable (treatable or preventable) through the use of statins. In addition, in some embodiments, diseases or conditions for which prevention of cholesterol synthesis or increased LDLR expression may be beneficial may also be treated by various embodiments of antigen binding proteins. In addition, as will be appreciated by those of skill in the art, the use of anti-PCSK9 antibodies can be particularly useful in the treatment of diabetes. In addition to diabetes being a risk factor for coronary heart disease, insulin increases the expression of PCSK9. That is, people with diabetes have elevated plasma lipid levels (which may be related to high PCSK9 levels), and it may be beneficial to lower these levels. This is generally referred to in Costet et al. ("Hepatic PCSK9 Expression is Regulated by Nutirtional Status via Insulin and Sterol Regulatiory Element-binding Protein 1C", J. Biol. Chem., 281: 6211-6218, 2006)].

In some embodiments, the antigen binding protein is administered to people with diabetes, abdominal aortic aneurysms, atherosclerosis, and/or peripheral vascular disease to reduce their serum cholesterol levels to a more stable range. In some embodiments, the antigen binding protein is administered to a patient at risk of developing any of the diseases described herein. In some embodiments, ABP is administered to smokers who have a family history of high blood pressure or early heart attack.

In some embodiments, the subject is administered ABP if they are at moderate or greater risk for the 2004 NCEP treatment goal. In some embodiments, ABP is administered to a subject when the subject's LDL cholesterol level exceeds 160 mg/dl. In some embodiments, ABP is administered when the subject's LDL cholesterol level exceeds 130 (and is at moderate or moderately high risk depending on the 2004 NCEP treatment goal). In some embodiments, ABP is administered when the subject's LDL cholesterol level exceeds 100 (and is at high or very high risk depending on the 2004 NCEP treatment goal).

The physician will be able to select an appropriate treatment indication and target lipid level according to the individual profile of a particular patient. One widely accepted standard for guiding the treatment of hyperlipidemia is described in the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of the High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, National Institutes of Health, NIH Publication No. 02-5215 (2002)], and the entirety of his published publication is incorporated herein by reference.

In some embodiments, the antigen binding protein to PCSK9 is used to reduce the amount of PCSK9 activity from abnormally high levels or even from normal levels. In some embodiments, the antigen binding protein to PCSK9 is used to treat or prevent hypercholesterolemia, and/or in the manufacture of a medicament therefor, and/or against other cholesterol-related diseases (e.g., those shown herein). Is used. In certain embodiments, the antigen binding protein to PCSK9 is used to treat or prevent a condition such as hypercholesterolemia in which PCSK9 activity is normal. For example, in this condition, a reduction in PCSK9 activity below normal may provide a therapeutic effect.

In some embodiments, more than one antigen binding protein to PCSK9 is used to modulate PCSK9 activity.

In certain embodiments, a method of treating a cholesterol related disorder, such as hypercholesterolemia, comprising administering a therapeutically effective amount of one or more antigen binding proteins to PCSK9 and other therapeutic agents is provided.

In certain embodiments, the antigen binding protein to PCSK9 is administered alone. In certain embodiments, the antigen binding protein to PCSK9 is administered prior to administration of at least one other therapeutic agent. In certain embodiments, the antigen binding protein to PCSK9 is administered concurrently with the administration of at least one other therapeutic agent. In certain embodiments, the antigen binding protein to PCSK9 is administered after administration of at least one other therapeutic agent. In another embodiment, the antigen binding protein to PCSK9 is administered prior to administration of at least one other therapeutic agent. The therapeutic agent (in addition to the antigen binding protein) includes, but is not limited to, at least one other cholesterol-lowering agent(s) (serum and/or total body cholesterol). In some embodiments, the agent increases the expression of LDLR, which has been observed to increase serum HDL levels, decrease LDL levels, or decrease triglyceride levels. Exemplary substances are statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), nicotinic acid (niacin) (NIACOR, NIASPAN (sustained-release niacin), SLO- NIACIN (sustained-release niacin)), fibric acid (LOPID (gemfibrozil), TRICOR (fenofibrate), bile acid adsorbent (sequestrant) (QUESTRAN (cholestyramine), Colesevelam (WELCHOL), COLESTID (Colestipol)) , Cholesterol absorption inhibitors (ZETIA (ezetimibe)), nicotinic acid and statins combination (ADVICOR (lovastatin and NIASPAN), statins and absorption inhibitors (VYTORIN (ZOCOR and ZETIA)) and/or lipid modifiers. In some embodiments, ABP is a PPAR gamma agonist, PPAR alpha/gamma agonist, squalene synthase inhibitor, CETP inhibitor, anti-hypertensive agent, anti-diabetic agent (eg sulfonyl urea, insulin, GLP-1 analog, DDPIV Inhibitors), ApoB modulators, MTP inhibitors, and/or in combination with obstructive atherosclerosis treatment.In some embodiments, ABP is an agent that increases LDLR protein levels in a subject, for example, a specific agent such as statins, oncostatin M. Cytokines, estrogens, and/or certain plant components such as berberine.In some embodiments, ABP is an agent that increases serum cholesterol levels in a subject (eg certain anti-psychotics, certain HIV protease inhibitors , Dietary factors such as high fructose, sucrose, cholesterol or certain fatty acids, and certain nuclear receptor agonists and antagonists for RXR, RAR, LXR, FXR) In some embodiments, ABP is PCSK9 in a subject. In combination with substances that increase the level, eg statins and/or insulin, in combination of the two substances the undesirable side effects of the other substances can be alleviated by ABP. As will be appreciated by those of skill in the art, in some embodiments, ABP is combined with other substances/compounds. In some embodiments, ABP and other substances are administered simultaneously. In some embodiments, the ABP and the other agent are not administered simultaneously, wherein the ABP is administered before or after the other agent is administered. In some embodiments, the subject is administered ABP and other substances (which increase LDLR levels) during the same prophylactic period, disease occurrence, and/or treatment period.

The pharmaceutical compositions of the present invention can be administered in combination therapy, ie in combination with other substances. In certain embodiments, the combination therapy comprises an antigen binding protein capable of binding PCSK9 in combination with at least one anti-cholesterol agent. Materials include, but are not limited to, chemical compositions, antibodies, antigen binding regions, and combinations and conjugates synthesized in vitro. In certain embodiments, the substance may serve as an agonist, antagonist, allosteric modulator, or toxin. In certain embodiments, the substance can act to inhibit or stimulate its target (eg, activate or inhibit a receptor or enzyme), thereby promoting increased expression of LDLR or reducing serum cholesterol levels.

In certain embodiments, the antigen binding protein to PCSK9 can be administered prior to, simultaneously and after treatment with a cholesterol-lowering agent (serum and/or total cholesterol). In certain embodiments, the antigen binding protein to PCSK9 can be administered prophylactically to prevent or alleviate the expression of hypercholesterolemia, heart disease, diabetes, and/or any cholesterol related disease. In certain embodiments, the antigen binding protein to PCSK9 can be administered for treatment of an existing hypercholesterolemia condition. In some embodiments, ABP delays the onset of the disease and/or symptoms associated with the disease. In some embodiments, ABP is provided to a subject lacking any symptoms of any one cholesterol related disease or a subset thereof.

In certain embodiments, the antigen binding protein to PCSK9 is used in conjunction with certain therapeutic agents to treat a variety of cholesterol-related diseases, such as hypercholesterolemia. In certain embodiments, two or three or more substances may be administered, taking into account the condition and the desired level of treatment. In certain embodiments, the substances can be provided together by inclusion in the same formulation. In certain embodiments, the substance(s) and the antigen binding protein for PCSK9 can be provided together by inclusion in the same formulation. In certain embodiments, the substances may be formulated separately or provided together by inclusion in a treatment kit. In certain embodiments, the agent and the antigen binding protein for PCSK9 may be formulated separately or provided together by inclusion in a therapeutic kit. In certain embodiments, the materials may be provided separately. In certain embodiments, when administered by gene therapy, the gene encoding the protein material and/or the antigen binding protein for PCSK9 may be included in the same vector. In certain embodiments, the gene encoding the protein material and/or the antigen binding protein for PCSK9 may be under the control of the same promoter region. In certain embodiments, the gene encoding the protein material and/or the antigen binding protein for PCSK9 may be present in separate vectors.

In certain embodiments, the present invention provides a pharmaceutical composition comprising an antigen binding protein to PCSK9 together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant.

In certain embodiments, the present invention provides a pharmaceutical composition comprising an antigen binding protein for PCSK9 and a therapeutically effective amount of at least one additional therapeutic agent together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant. to provide.

In certain embodiments, the antigen binding protein to PCSK9 can be used in combination with at least one therapeutic agent for inflammation. In certain embodiments, the antigen binding protein to PCSK9 can be used in combination with at least one therapeutic agent for an immune disorder. Exemplary therapeutic agents for inflammatory and immune diseases include cyclooxygenase type 1 (COX-1) and cyclooxygenase type 2 (COX-2) inhibitors, 38 kDa mitogen-activated protein kinase (p38-MAPK). Small molecule modulators; Small molecule modulators of intracellular molecules involved in the inflammatory pathway include, but are not limited to, wherein the intracellular molecules include, but are not limited to, jnk, IKK, NF-κB, ZAP70, and lck. Certain exemplary therapeutic agents for inflammation are described, for example, in C.A. Dinarello & L.L. Moldawer Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis: A Primer for Clinicians Third Edition (2001) Amgen Inc. Thousand Oaks, CA].

In certain embodiments, the pharmaceutical composition will comprise more than one different antigen binding protein for PCSK9. In certain embodiments, the pharmaceutical composition will comprise more than one antigen binding protein to PCSK9, wherein the antigen binding protein to PCSK9 binds more than one epitope. In some embodiments, the various antigen binding proteins will not compete with each other for binding to PCSK9. In some embodiments, any of the antigen binding proteins shown in Table 2 and FIGS. 2 and/or 3 can be combined together in a pharmaceutical composition.

In certain embodiments, the acceptable formulation material is preferably non-toxic to the recipient at the dosage and concentration used. In some embodiments, the formulation material(s) are for subcutaneous and/or intravenous administration. In certain embodiments, the pharmaceutical composition is to modify, maintain or preserve the pH, molar osmotic pressure, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissociation or release rate, adsorption or permeation of the composition, for example. It may contain hazardous formulation materials. In certain embodiments, suitable formulation substances include amino acids (eg glycine, glutamine, asparagine, arginine or lysine); Antimicrobial agents; Antioxidants (eg ascorbic acid, sodium sulfite or sodium hydrogen sulfite); Buffers (eg borate, bicarbonate, Tris-HCl, citrate, phosphate or other organic acid); Bulking agents (eg mannitol or glycine); Chelating agents (eg ethylenediamine tetraacetic acid (EDTA)); Complexing agents (eg caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); Filler; Monosaccharides; saccharose; And other carbohydrates (eg glucose, mannose or dextrin); Proteins (eg serum albumin, gelatin or immunoglobulins); Colorants, flavors and diluents; Emulsifiers; Hydrophilic polymers (eg polyvinylpyrrolidone); Low molecular weight polypeptides; Salt forming counter ions (eg sodium); Preservatives (eg benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); Solvents (eg glycerin, propylene glycol or polyethylene glycol); Sugar alcohols (eg mannitol or sorbitol); Suspending agent; Surfactants or wetting agents (eg Pluronic, PEG, sorbitan ester, polysorbate, eg polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxafal); Stability enhancing agents (eg sucrose or sorbitol); Tonicity enhancers (eg alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); Delivery vehicle; diluent; Excipients and/or pharmaceutical adjuvants, including, but not limited to (Remington's Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, ed., Mack Publishing Company (1995)). In some embodiments, the formulation is PBS; 20 mM NaOAC (pH 5.2), 50 mM NaCl; And/or 10 mM NAOAC (pH 5.2), 9% sucrose.

In certain embodiments, the antigen binding protein and/or therapeutic molecule for PCSK9 is linked to a half-life extending vehicle known in the art. Such vehicles include, but are not limited to, polyethylene glycol, glycogen (eg, glycosylation of ABP), and dextran. Such vehicles are described, for example, in U.S. Patent Application 09/428,082 (now U.S. Patent 6,660,843) and published PCT Application WO 99/25044, incorporated herein by reference for any purpose.

In certain embodiments, the optimal pharmaceutical composition will be determined by one of skill in the art depending, for example, on the intended route of administration, mode of delivery and desired dosage (see, eg, REMINGTON'S PHARMACEUTICAL SCIENCES, supra). In certain embodiments, the composition may affect the physical state, stability, in vivo release rate and in vivo clearance rate of the antibodies of the invention.

In certain embodiments, the primary vehicle or carrier in the pharmaceutical composition may be aqueous or non-aqueous in nature. For example, in certain embodiments, a suitable vehicle or carrier may be water for injection, a physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other substances conventional in compositions for parenteral administration. In some embodiments, the saline includes isotonic phosphate-buffered saline. In certain embodiments, neutral buffered saline or saline mixed with serum albumin are additional exemplary vehicles. In certain embodiments, the pharmaceutical composition comprises a Tris buffer of about pH 7.0-8.5, or an acetate buffer of about pH 4.0-5.5, which may further comprise sorbitol or a suitable replacement therefor. In certain embodiments, a composition comprising an antigen binding protein for PCSK9 together or alone with at least one additional therapeutic agent is frozen with an optional formulation substance (Remington's pharmaceutical Sciences, supra) of the selected composition having the desired purity. It can be prepared for storage by mixing in the form of a dry cake or an aqueous solution. In addition, in certain embodiments, compositions comprising an antigen binding protein to PCSK9 together or alone with at least one additional therapeutic agent may be formulated as a lyophilisate using suitable excipients such as sucrose.

In certain embodiments, pharmaceutical compositions may be selected for parenteral delivery. In certain embodiments, the composition may be selected for inhalation or for delivery through the digestive tract, for example oral delivery. Preparation of such pharmaceutically acceptable compositions is within the capabilities of those skilled in the art.

In certain embodiments, the formulation ingredients are present in an acceptable concentration at the site of administration. In certain embodiments, the buffer is used to maintain the composition at a physiological pH or slightly lower pH, usually within a pH range of about 5 to about 8.

In certain embodiments, when parenteral administration is contemplated, the therapeutic composition comprises a pyrogen-free parenterally acceptable antigen binding protein of interest for PCSK9, either alone or with an additional therapeutic agent in a pharmaceutically acceptable vehicle. It can exist in the form of an aqueous solution. In certain embodiments, the vehicle for parenteral injection is sterile distilled water, wherein the antigen binding protein to PCSK9 is formulated as a suitably preserved sterile isotonic solution, alone or with at least one additional therapeutic agent. In certain embodiments, the formulation is then injectable microspheres, biodegradable particles, polymeric compounds (e.g., polylactic acid or polylactic acid) capable of providing controlled or sustained release of the product that can be delivered via depot injection. Glycolic acid), beads or liposomes. In certain embodiments, hyaluronic acid may also be used and may have the effect of promoting duration in the circulatory system. In certain embodiments, implantable drug delivery devices can be used to introduce the desired molecule.

In certain embodiments, pharmaceutical compositions may be formulated for inhalation. In certain embodiments, the antigen binding protein to PCSK9 can be formulated as a dry powder for inhalation alone or with at least one additional therapeutic agent. In certain embodiments, an inhalation solution comprising an antigen binding protein to PCSK9 alone or with at least one additional therapeutic agent may be formulated with a propellant for aerosol delivery. In certain embodiments, the solution may be nebulized. Pulmonary administration is further described in PCT application PCT/US94/001875, which describes the pulmonary delivery of chemically modified proteins.

It is contemplated that in certain embodiments, the formulation may be administered orally. In certain embodiments, the antigen binding protein to PCSK9 administered in the above manner uses or does not use carriers customarily used in the preparation of solid dosage forms such as tablets and capsules, alone or with at least one additional therapeutic agent. Can be formulated without. In certain embodiments, capsules can be designed to release the active portion of the formulation at a point in the gastrointestinal tract where bioavailability is maximized and destruction prior to systemic introduction is minimized. In certain embodiments, at least one additional agent may be included to facilitate absorption of the antigen binding protein to PCSK9 and/or any additional therapeutic agent. In certain embodiments, diluents, flavoring agents, low melting waxes, vegetable oils, lubricants, suspending agents, tablet disintegrants and binders may also be used.

In certain embodiments, the pharmaceutical composition may comprise an effective amount of an antigen binding protein to PCSK9, either alone or in a mixture with at least one additional therapeutic agent, with a non-toxic excipient suitable for the manufacture of tablets. In certain embodiments, solutions can be prepared in unit dosage form by dissolving the tablets in sterile water or other suitable vehicle. In certain embodiments, suitable excipients are inert diluents such as calcium carbonate, sodium carbonate or sodium bicarbonate, lactose or calcium phosphate; Or a binder such as starch, gelatin or acacia; Or lubricants such as magnesium stearate, stearic acid or talc.

Additional pharmaceutical compositions, including formulations comprising the antigen binding protein for PCSK9, together with or alone, in a sustained- or controlled-delivery formulation, will be apparent to those skilled in the art. In certain embodiments, techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, biodegradable microparticles or porous beads, and depot injections, are known to those of skill in the art. See, for example, PCT application PCT/US93/00829, which describes controlled release of porous polymeric microparticles for delivery of pharmaceutical compositions. In certain embodiments, sustained-release formulations may comprise a semi-permeable polymer matrix in the form of a molded article, for example a film or microcapsule. Sustained release matrix is a copolymer of polyester, hydrogel, polylactide (US 3,773,919 and EP 058,481), L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)) , Poly(2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981)] and [Langer, Chem. Tech. 12:98-105 (1982)]), ethylene vinyl acetate (Langer et al., 1981, supra) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). In certain embodiments, sustained release compositions may also include liposomes that can be prepared by any of a number of methods known in the art. See, eg, Eppstein et al., Proc. Natl. Acad. Sci. USA, 82:3688-3692 (1985)]; EP 036,676; See EP 088,046 and EP 143,949.

Pharmaceutical compositions used for in vivo administration are usually sterile. In certain embodiments, sterilization can be achieved by filtration through a sterile filtration membrane. In certain embodiments, when lyophilizing the composition, sterilization using the method may be performed before or after lyophilization and reconstitution. In certain embodiments, compositions for parenteral administration may be stored in lyophilized form or as a solution. In certain embodiments, the parenteral composition is generally enclosed in a container with a sterile access port, such as an intravenous solution bag or vial with a stopper pierceable with a hypodermic injection needle.

In certain embodiments, once the pharmaceutical composition is formulated, it can be stored as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder in sterile vials. In certain embodiments, the formulation can be stored in a ready-to-use form or in a form that is reconstituted prior to administration (eg, lyophilized form).

In certain embodiments, kits for producing single-dose dosage units are provided. In certain embodiments, the kit may include a first container with dried protein and a second container with an aqueous formulation. In certain embodiments, kits are provided comprising single and multi-chamber pre-filled syringes (eg, liquid syringes and lyosyringe).

In certain embodiments, the effective amount of a pharmaceutical composition comprising, alone or with at least one additional therapeutic agent, an antigen binding protein to PCSK9 to be used therapeutically will depend, for example, on the treatment environment and goals. Those of skill in the art will be skilled in the art, in accordance with the specific embodiment, the molecule to which the appropriate dosage level for treatment is partially delivered, the indication in which the antigen binding protein to PCSK9 is used alone or in combination with at least one additional therapeutic agent, the route of administration, and the patient's body It will be appreciated that it will vary depending on (weight, body surface area or organ size) and/or condition (age and overall health). In certain embodiments, the clinician may titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect. In certain embodiments, typical dosages may range from about 0.1 μg/kg to about 100 mg/kg or more, depending on the factors mentioned above. In certain embodiments, the dosage is 0.1 μg/kg to about 100 mg/kg; Alternatively 1 μg/kg to about 100 mg/kg; Alternatively, it may be from 5 μg/kg to about 100 mg/kg.

In certain embodiments, the frequency of administration will take into account the pharmacokinetic parameters of the antigen binding protein and/or any additional therapeutic agents to PCSK9 in the formulation used. In certain embodiments, the clinician will administer the composition until a dosage that achieves the desired effect is reached. Thus, in certain embodiments, the composition may be administered as a single dose, or as two or more doses over time (which may or may not contain the same amount of the molecule of interest), or continuous through an implantable device or catheter. It can be administered as an infusion. Further fine-tuning of the appropriate dosage is usually made by one of ordinary skill in the art and is within the scope of the tasks they usually perform. In certain embodiments, an appropriate dosage can be ascertained through the use of appropriate dose-response data. In some embodiments, the dosage and frequency of administration can take into account the desired cholesterol level (serum and/or total) to be achieved and the subject's current cholesterol level, LDL level and/or LDLR level, all of which are well known to those of skill in the art. You can get it by the way.

In certain embodiments, the route of administration of the pharmaceutical composition is according to known methods, e.g., oral, intravenous, intraperitoneal, intracranial (intraperitoneal), intraventricular, intramuscular, subcutaneous, intraocular, intraarterial, intraportal Or via injection by the intralesional route; By sustained release system or implantable device. In certain embodiments, the composition may be administered by bolus injection, or continuously by infusion or by an implantable device.

In certain embodiments, the composition may be administered topically via implantation of a membrane, sponge or other suitable material into which the molecule of interest is absorbed or encapsulated therefor. In certain embodiments, where an implantable device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed-release bolus or continuous administration. .

In certain embodiments, it may be desirable to use a pharmaceutical composition comprising an antigen binding protein to PCSK9 alone or in combination with at least one additional therapeutic agent in an ex vivo manner. In this case, the cells, tissues and/or organs removed from the patient are exposed to a pharmaceutical composition comprising an antigen binding protein for PCSK9 together or alone with at least one additional therapeutic agent, and thereafter cells, tissues and/or The organ is subsequently transplanted back to the patient.

In certain embodiments, the antigen binding protein for PCSK9 and/or any additional therapeutic agent can be delivered by transplanting certain cells that have been genetically engineered using methods such as those described herein to express and secrete the polypeptide. In certain embodiments, the cells may be animal or human cells, and may be autologous, heterologous or xenogeneic. In certain embodiments, cells may be immortalized. In certain embodiments, to reduce the chance of an immunological response, cells can be encapsulated to avoid invasion of surrounding tissue. In certain embodiments, the encapsulating material allows the release of the protein product(s), but is usually a biocompatible semipermeable polymeric enclosure that prevents the destruction of cells by the patient's immune system or by other harmful factors from the surrounding tissue. (enclosure) or membrane.

Based on the ability of ABPs to significantly neutralize PCSK9 activity (as demonstrated in the Examples below), these ABPs are in the treatment and prevention of symptoms and conditions arising from PCSK9-mediated activity, such as hypercholesterolemia. Will have a therapeutic effect.

Diagnostic use

In some embodiments, ABP is used as a diagnostic tool. ABP can be used to analyze the amount of PCSK9 present in a sample and/or subject. As will be appreciated by those skilled in the art, the ABP need not be a neutralizing ABP. In some embodiments, the diagnostic ABP is not a neutralizing ABP. In some embodiments, the diagnostic ABP binds to a different epitope than the neutralizing ABP binds to. In some embodiments, the two ABPs do not compete with each other.

In some embodiments, ABPs disclosed herein are used or provided in assay kits and/or methods for detection of PCSK9 in mammalian tissues or cells for screening/diagnosis of diseases or conditions associated with changes in levels of PCSK9. The kit includes an ABP that binds to PCSK9, and, if present, the binding of ABP to PCSK9, and optionally a means for indicating the PCSK9 protein level. Various means can be used to indicate the presence of ABP. For example, fluorophores, other molecular probes, or enzymes can be linked to ABP, and the presence of ABP can be observed in a variety of ways. Methods for screening for such diseases may involve the use of a kit, or simply the use of one of the disclosed ABPs, and determination of whether the ABP binds to PCSK9 in the sample. As will be appreciated by those of skill in the art, high or elevated levels of PCSK9 will cause large amounts of ABP binding to PCSK9 in the sample. Thus, the degree of ABP binding can be used to determine how much PCSK9 is present in the sample. Subjects or samples with an amount of PCSK9 greater than a predetermined amount (eg, the amount or range that a person who does not have a PCSK9 related disease will have) may be characterized as having a PCSK9 mediated disease. In some embodiments, ABP is administered to a subject taking a statin to determine if the statin increased the amount of PCSK9 in the subject.

In some embodiments, the ABP is a non-neutralizing ABP and is used to determine the amount of PCSK9 in a subject receiving ABP and/or statin treatment.

Example

The following examples, including the experiments performed and the results achieved, are provided for illustrative purposes only and should not be construed as limiting the invention.

Example 1

Immunization and titration

Generation of anti-PCSK9 antibodies and hybridomas

XenoMouse® mice (Abgenix, Fremont, Calif.), which are mice containing human immunoglobulin genes, to antibodies against the mature form of PCSK9 (sequences are shown in Figure 1A, and the pro-domain is underlined). Was created in. Two groups of XenoMouse® mice, group 1 and group 2, were used to generate antibodies against PCSK9. Group 1 included mice of XenoMouse® strain XMG2-KL producing fully human IgG2κ and IgG2λ antibodies. Group 1 mice were immunized with human PCSK9. PCSK9 was prepared using standard recombinant techniques using the GenBank sequence (NM_174936) as a reference. Group 2 included mice of XenoMouse® strain XMG4-KL producing fully human IgG4κ and IgG4λ antibodies. Group 2 mice were also immunized with human PCSK9.

Two groups of mice were injected with antigen 11 times according to the schedule in Table 3. Upon initial immunization, each mouse was injected with a total of 10 μg of antigen delivered intraperitoneally into the abdomen. The subsequent boost was a dose of 5 μg, and the injection was alternately performed by intraperitoneal injection into the abdomen and subcutaneous injection at the base of the tail. For intraperitoneal injection, the antigen is prepared as an emulsion using TiterMax® Gold (Sigma, Cat# T2684), and the antigen is mixed with Alum (aluminum phosphate) and CpG oligos for subcutaneous injection. At injections 2 to 8 and 10, each mouse was injected with a total of 5 μg of antigen in an adjuvant alum gel. A final injection of 5 μg of antigen per mouse was delivered in Phospho buffered saline and delivered to two sites: 50% IP to the abdomen and 50% SQ at the base of the tail. The immunization program is summarized in Table 3 below.

The protocol used for titration of XenoMouse animals was as follows: A Costar 3368 medium binding plate was coated with 8 μg/ml of Neutravadin (50 μl/well), and 1XPBS/0.05% Ah at 4° C. Incubated overnight in Gide. They were washed using TiterTek 3-cycle wash using RO water. Plates were blocked with 250 μl of 1XPBS/1% milk and incubated for at least 30 minutes at RT. The blocks were washed off using Titertech 3-cycle wash using RO water. Then 2 μg/ml of b-human PCSK9 (50 μl/well) in 1XPBS/1% milk/10 mM Ca ^{2+ (analytical diluent) was captured and incubated for 1 hr at RT.} It was then washed using Titertech 3-cycle wash using RO water. For the primary antibody, serum was titrated from 1:100 to 1:3 in duplicate. This was done in assay diluent (50 μl/well) and incubated for 1 hr at RT. It was then washed using Titertech 3-cycle wash using RO water. The secondary antibody was 400 ng/ml goat anti-human IgG Fc HRP (50 μl/well) in assay diluent. It was incubated for 1 hr at RT. It was then washed using Titertech 3-cycle wash using RO water, and dried by tapping on a paper towel. For the substrate, a one-step TMB solution (Neogen, Lexington, Kentucky, USA) was used (50 μl/well), which was developed at RT for 30 minutes.

The protocol according to the ELISA assay was as follows: For the sample containing b-PCSK.9 without V5His tag, the following protocol was used: Using a Costa 3368 medium binding plate (Corning Life Sciences) I did. Plates were coated with 8 μg/ml neutravadin (50 μl/well) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek M384 plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. Plates were blocked with 250 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed with an M384 plate washer. A 3-cycle wash was performed. The capture sample was b-hu PCSK9 without V5 tag and was added at 2 μg/ml (40 μl/well) in ^{1XPBS/1% milk/10 mM Ca 2+.} The plate was then incubated for 1 hour at room temperature. A 3-cycle wash was performed. Serum was titrated 1:3 in duplicate from 1:100, and column H was blank for serum. Titration was performed in a volume of 50 μl/well in assay diluent. The plate was incubated for 1 hour at room temperature. Subsequently, a 3-cycle wash was performed. 100 ng/ml (1:4000) of goat anti-human IgG Fc HRP (50 μl/well) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate and incubated for 1 hour at room temperature.} The plate was washed once again using a 3-cycle wash. The plate was then tapped with a paper towel to dry. Finally, step 1 TMB (neogen) (50 μl/well) was added to the plate and quenched at room temperature after 30 minutes with 1N hydrochloric acid (50 μl/well). OD was read immediately at 450 nm using a Titertech plate reader.

Positive controls for detecting plate bound PCSK9 were soluble LDL receptor (R&D Systems, Cat #2148LD/CF) and polyclonal rabbit anti-PCSK9 titrated 1:3 in duplicate from 3 μg/ml in assay diluent. It was an antibody (Caymen Chemical #10007185). LDLR was detected using goat anti-LDLR (R&D Systems, Cat #AF2148) and rabbit anti-goat IgGFc HRP at a concentration of 400 ng/ml; Rabbit polyclonal antibodies were detected using goat anti-rabbit IgG Fc in an assay diluent at a concentration of 400 ng/ml. The negative controls were naive XMG2-KL and XMG4-KL serum titrated from 1:100 to 1:3 in duplicate in the assay diluent.

For samples containing b-PCSK9 without the V5His tag, the following protocol was used: A Costa 3368 medium binding plate (Corning Life Sciences) was used. Plates were coated with 8 μg/ml neutravadin (50 μl/well) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed with a Titertek M384 plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. Plates were blocked with 250 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed using an M384 plate washer. A 3-cycle wash was performed. The capture sample was a V5 tagged b-hu PCSK9 and was added at 2 μg/ml (40 μl/well) in ^{1XPBS/1% milk/10 mM Ca 2+.} The plate was then incubated for 1 hour at room temperature. A 3-cycle wash was performed. Serum was titrated 1:3 in duplicate from 1:100, and column H was blank for serum. Titration was performed in a volume of 50 μl/well in assay diluent. The plate was incubated for 1 hour at room temperature. Next, the plates were washed using an M384 plate washer operated using a 3-cycle wash. 400 ng/ml of goat anti-human IgG Fc HRP in 1XPBS/1% milk/10 mM Ca ²⁺ was added to the plate at 50 μl/well, and the plate was incubated for 1 hour at room temperature. The plate was washed once again using a 3-cycle wash. The plate was then tapped with a paper towel to dry. Finally, step 1 TMB (neogen) (50 μl/well) was added to the plate, and the plate was quenched at room temperature after 30 minutes with 1N hydrochloric acid (50 μl/well). OD was read immediately at 450 nm using a Titertech plate reader.

Positive controls were LDLR and rabbit anti-PCSK9 titrated 1:3 in duplicate from 3 μg/ml in the assay diluent. LDLR was detected using goat anti-LDLR (R&D Systems, Cat #AF2148) and rabbit anti-goat IgG Fc HRP at a concentration of 400 ng/ml; Rabbit polyclonal antibodies were detected using goat anti-rabbit IgG Fc at a concentration of 400 ng/ml in an assay diluent. Human anti-His 1.2,3 and anti-V5 1.7.1 were titrated 1:3 in duplicate from 1 μg/ml in the assay diluent; Both were detected using goat anti-human IgG Fc HRP at a concentration of 400 ng/ml in assay diluent. Negative controls were naive XMG2-KL and XMG4-KL serum titrated from 1:100 to 1:3 in duplicate in the assay diluent.

The titer of antibodies against human PCSK9 was tested by ELISA assay on mice immunized with soluble antigens as described. The ELISA data are summarized in Table 4, indicating the presence of several mice that appeared to be specific for PCSK9. See, for example, Table 4. Thus, at the end of the immunization program, 10 mice (bold font in Table 4) were selected for harvesting, and splenocytes and lymphocytes were isolated from the spleen and lymph nodes, respectively, as described herein.

Example 2

Recovery of lymphocytes, isolation of B-cells, fusion and generation of hybridomas

In this example, a method of harvesting immune cells and generating hybridomas is outlined. Selected immunized mice were sacrificed by cervical dislocation, draining lymph nodes were harvested and collected from each cohort. B cells were separated from lymphoid tissue by polishing in DMEM to release cells from the tissue, and the cells were suspended in DMEM. Cells were counted and 0.9 ml DMEM per 100 million lymphocytes was added to the cell pellet to gently but completely resuspend the cells.

Lymphocytes were mixed with non-secretory myeloma P3X63Ag8.653 cells (cat.# CRL 1580) (Kearney et al., (1979) J. Immunol. 123, 1548-1550) purchased from ATCC at a ratio of 1:4. The cell mixture was gently pelleted by centrifugation for 4 minutes at 400 xg. After decanting the supernatant, the cells were gently mixed using a 1 ml pipette. A preheated PEG/DMSO solution (Sigma, cat# P7306) (1 ml per 1 million B-cells) was slowly added over 1 minute with gentle stirring, followed by mixing for 1 minute. Then, preheated IDMEM (2 ml per 1 million B cells) (glutamine-free DMEM, L-glutamine, pen/strep, MEM non-essential amino acids (all from Invitrogen) were added over 2 minutes with gentle stirring. Finally, preheated IDMEM ( ^{8 ml per 10 6} B-cells) was added over 3 minutes.

The fused cells were centrifuged at 400 xg for 6 minutes, and 20 ml of selective medium per 1 million B-cells (DMEM (Invitrogen), 15% FBS supplemented with L-glutamine (Hyclone)), pen/ strep, MEM non-essential amino acids, sodium pyruvate, 2-mercaptoethanol (all from Invitrogen), HA-azaserine hypoxanthine and OPI (oxaloacetate, pyruvate, bovine insulin) (both sigma) and IL- 6 (Boehringer Mannheim)). The cells were incubated at 37° C. for 20-30 minutes, then resuspended in 200 ml of selection medium, cultured in a T175 flask for 3-4 days, and then plated in 96 wells. Thus, hybridomas producing antigen binding proteins for PCSK9 were produced.

Example 3

Selection of PCSK9 antibody

This example outlines methods for characterizing and selecting various PCSK9 antigen binding proteins. Binding of the secreted antibody (produced from hybridomas produced in Examples 1 and 2) to PCSK9 was evaluated. The choice of antibody was based on the binding data and inhibition, and affinity of PCSK9 binding to LDLR. Binding to soluble PCSK9 was analyzed by ELISA as described below. Binding affinity was quantified using Biacore® (Surface Plasmon Resonance).

Primary screen

A first screen was performed for antibodies that bind to wild-type PCSK9. A primary screen was performed on two crops. The first screen included ELISA analysis and was performed using the following protocol:

A costa 3702 medium bound 384 well plate (Corning Life Sciences) was used. Plates were coated with Neutravadin (40 μl/well volume) at a concentration of 4 μg/ml in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was washed again. Again, a 3-cycle wash was performed. The capture sample was biotinylated-PCSK9 without V5 tag, and was added at 0.9 μg/ml (40 μl/well volume) ^{in 1XPBS/1% milk/10 mM Ca 2+.} The plate was then incubated for 1 hour at room temperature. Next, the plates were washed using a Titertech plate washer operated using a 3-cycle wash. 10 μl of the supernatant was transferred into 40 μl of 1XPBS/1% milk/10 mM Ca ²⁺ and incubated for 1.5 hours at room temperature. Again, the plates were washed using a Titertech plate washer operated using a 3-cycle wash. 40 μl/well of goat anti-human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate and incubated for 1 hour at room temperature.} The plate was washed once again using a 3-cycle wash. Finally, 40 μl/well of 1st step TMB (neogen) was added to the plate, and quenching using 40 μl/well of 1N hydrochloric acid was performed at room temperature after 30 minutes. OD was read immediately at 450 nm using a Titertech plate reader.

A total of 3104 antigen specific hybridomas were identified from two crops by the primary screen. Based on the highest ELISA OD, 1500 hybridomas per harvest were run for a total of 3000 positives.

Confirmation screening

Then, 3000 positives were rescreened for binding to wild-type PCSK9 to confirm that stable hybridomas were established. Screening was performed as follows: Costa 3702 medium bound 384 well plates (Corning Life Sciences) were used. Plates were coated with 3 μg/ml neutravadin (40 μl/well volume) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed with an M384 plate washer. A 3-cycle wash was performed. The capture sample was b-PCSK9 without V5 tag and ^{was added at 0.9 μg/ml in 1XPBS/1% milk/10 mM Ca 2+} in a volume of 40 μl/well. The plate was then incubated for 1 hour at room temperature. Next, the plate was washed using a 3-cycle wash. 10 μl of the supernatant was transferred into 40 μl of 1XPBS/1% milk/10 mM Ca ²⁺ and incubated for 1.5 hours at room temperature. Again, the plates were washed using a Titertech plate washer operated using a 3-cycle wash. 40 μl/well of goat anti-human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate, and the plate was incubated at room temperature for 1 hour.} I did. The plate was washed once again using a Titertek plate washer operated using a 3-cycle wash. Finally, 40 µl/well of 1st step TMB (neogen) was added to the plate and quenched at room temperature after 30 minutes with 40 µl/well of 1N hydrochloric acid. OD was read immediately at 450 nm using a Titertek plate reader. A total of 2441 positives were repeated on the second screen. These antibodies were then used in subsequent screening.

Mouse cross-reactivity screening

Subsequently, a panel of hybridomas were screened for cross-reactivity to mouse PCSK9 to see if the antibody was able to bind to both human and mouse PCSK9. The following protocol was used in cross-reactive screening: Costa 3702 medium bound 384 well plates (Corning Life Sciences) were used. Plates were coated with 3 μg/ml neutravadin (40 μl/well volume) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. The capture sample was biotinylated-mouse PCSK9 and ^{was added at 1 μg/ml in 1XPBS/1% milk/10 mM Ca 2+} in a volume of 40 μl/well. The plate was then incubated for 1 hour at room temperature. Next, the plates were washed using a Titertek plate washer operated using a 3-cycle wash. 50 μl of the supernatant was transferred to the plate and incubated for 1 hour at room temperature. Again, the plate was washed using a 3-cycle wash. 40 μl/well of goat anti-human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate, and the plate was incubated at room temperature for 1 hour.} I did. The plate was washed once again using a 3-cycle wash. Finally, 40 µl/well of 1st step TMB (neogen) was added to the plate and quenched at room temperature after 30 minutes with 40 µl/well of 1N hydrochloric acid. OD was read immediately at 450 nm using a Titertek plate reader. It was observed that 579 antibodies cross-react with mouse PCSK9. These antibodies were then used in subsequent screening.

D374Y mutant binding screening

The D374Y mutation in PCSK9 has been reported in the human population (eg [Timms KM et al., "A muntation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree", Hum. Genet. 114: 349-353, 2004). ). The samples were then screened for binding to the mutant PCSK9 sequence comprising the mutation D374Y to determine if the antibody was specific for wild type or bound to the D374Y form of PCSK9. The protocol for screening was as follows: Costa 3702 medium bound 384 well plates (Corning Life Sciences) were used in screening. Plates were coated with 4 μg/ml neutravadin (40 μl/well volume) in 1XPBS/0.05% azide. Plates were incubated overnight at 40°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. Plates were coated with biotinylated human PCSK9 D374Y at a concentration of 1 μg/ml in 1XPBS/1% milk/10 mM Ca ^{2+ and incubated for 1 hour at room temperature.} The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. The final exhausted hybridoma culture supernatant was diluted 1:5 (10 ml + 40 ml) in ^{PBS/milk/Ca 2+ and incubated for 1 hour at room temperature.} Next, 1 μg/ml of 40 μl/well of rabbit anti-human PCSK9 (Cayman Chemical) and human anti-His 1.2.3 1:2 in 1XPBS/1% milk/10 mM Ca ^{2+ were prepared.} After titration onto a plate, it was incubated at room temperature for 1 hour. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. 40 μl/well of goat anti-human IgG Fc HRP at a concentration of 100 ng/ml (1:4000) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate and incubated for 1 hour at room temperature.} . 40 μl/well of goat anti-rabbit IgG Fc HRP at a concentration of 100 ng/ml (1:4000) in 1XPBS/1% milk/10 mM Ca ^{2+ was added to the plate, and the plate was incubated at room temperature for 1 hour.} I did. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. Finally, 40 µl/well of 1st step TMB (neogen) was added to the plate and quenched at room temperature after 30 minutes with 40 µl/well of 1N hydrochloric acid. OD was read immediately at 450 nm using a Titertek plate reader. More than 96% of the positive hits for wild-type PCSK9 antibodies also bound mutant PCSK9.

Large-scale receptor ligand blocking screening

To screen for antibodies that block PCSK9 binding to LDLR, an assay was developed using the D374Y PCSK9 mutant. Mutants were used for this assay, as they have a higher binding affinity for LDLR, so that more sensitive receptor ligand blocking assays can be developed. The following protocol was used in receptor ligand blocking screening: Costa 3702 medium bound 384 well plates (Corning Life Sciences) were used in screening. Plates were coated with 2 μg/ml of goat anti-LDLR (R&D, Cat #AF2148) (volume of 40 μl/well) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. The capture sample was LDLR (R&D, Cat #2148LD/CF) and was added at a volume of 40 μl/well at 0.4 μg/ml in ^{1XPBS/1% milk/10 mM Ca 2+.} The plate was then incubated for 1 hour and 10 minutes at room temperature. At the same time, 20 ng/ml of biotinylated human D374Y PCSK9 was incubated with 15 microliters of hybridoma depleted supernatant in Nunc polypropylene plates, and the depleted supernatant concentration was diluted 1:5. The plate was then pre-incubated at room temperature for about 1 hour and 30 minutes. Next, the plates were washed using a Titertek plate washer operated using a 3-cycle wash. 50 μl/well of the pre-incubated mixture was transferred onto an LDLR coated ELISA plate and incubated for 1 hour at room temperature. To detect LDLR-bound b-PCSK9, 500 ng/ml of 40 μl/well streptavidin HRP in assay diluent was added to the plate. The plate was incubated for 1 hour at room temperature. The plate was washed again using a Titertek plate washer. A 3-cycle wash was performed. Finally, 40 µl/well of 1st step TMB (neogen) was added to the plate and quenched at room temperature after 30 minutes with 40 µl/well of 1N hydrochloric acid. OD was read immediately at 450 nm using a Titertek plate reader. Screening identified 384 antibodies that well blocked the interaction between PCSK9 and LDLR, and 100 antibodies strongly blocked the interaction (OD<0.3). These antibodies inhibited the binding interaction of PCSK9 and LDLR by more than 90% (more than 90% inhibition).

Receptor ligand binding assay for a subset of blockers

The receptor ligand assay was then repeated using mutant enzymes for the 384 member subset of the neutralizing agent identified in the first large scale receptor ligand inhibition assay. The same protocol as performed in large scale receptor ligand blocking screening was used in the 384 member blocker subset assay screening. Initial screening data was confirmed through such repeated screening.

Through screening of the 384 member subset, 85 antibodies that blocked the interaction between the PCSK9 mutant enzyme and LDLR by more than 90% were identified.

Receptor ligand binding assay for blockers that bind wild-type PCSK9 rather than the D374Y mutant

In an initial panel of 3000 sup, there were 86 antibodies that appeared to specifically bind wild-type PCSK9 and not the huPCSK9(D374Y) mutant. These 86 sups were tested for their ability to block the binding of wild-type PCSK9 to the LDLR receptor. The following protocol was used: Costa 3702 medium bound 384 well plates (Corning Life Sciences) were used in screening. Plates were coated with 10 μg/ml anti-His 1.2.3 (40 μl/well volume) in 1XPBS/0.05% azide. Plates were incubated overnight at 4°C. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Alabama). A 3-cycle wash was performed. The plate was blocked with 90 μl of 1XPBS/1% milk and incubated for about 30 minutes at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. LDLR (R&D Systems, #2148LD/CF or R&D Systems, #2148LD) ^{was added at 5 μg/ml in 1XPBS/1% milk/10 mM Ca 2+} in a volume of 40 μl/well. The plate was then incubated for 1 hour at room temperature. Next, the plates were washed using a Titertek plate washer operated using a 3-cycle wash. Simultaneously, biotinylated human wild-type PCSK9 was pre-incubated with hybridoma depleted supernatant in Nunc polypropylene plates. 22 μl of hybridoma sup was transferred to 33 μl of b-PCSK9 at a concentration of 583 ng/ml in 1XPBS/1% milk/10 mM Ca ^{2+, and final b-PCSK9 concentration = 350 ng/ml and depleted supernatant was 1} Provided at a final dilution of :2.5. Plates were pre-incubated at room temperature for about 1 hour and 30 minutes. 50 μl/well of the pre-incubated mixture was transferred onto an LDLR captured ELISA plate and incubated for 1 hour at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. 500 ng/ml of 40 μl/well streptavidin HRP in assay diluent was added to the plate. The plate was incubated for 1 hour at room temperature. The plate was then washed using a Titertek plate washer. A 3-cycle wash was performed. Finally, 40 µl/well of 1st step TMB (neogen) was added to the plate and quenched at room temperature after 30 minutes with 40 µl/well of 1N hydrochloric acid. OD was read immediately at 450 nm using a Titertek plate reader.

Screening results

Based on the analysis results described, several hybridoma strains were identified to produce antibodies that exhibit the desired interaction with PCSK9. A manageable number of clones from each line was isolated using limiting dilution. Clones were designated by hybridoma major number (eg, 21B12) and clone number (eg, 21B12.1). In general, no differences were detected between the different clones of a particular week by the functional assays described herein. In some cases, clones that behave differently in functional assays were identified from specific strains, e.g., 25A7.1 was found not to block PCSK9/LDLR, whereas 25A7.3 (referred to herein as 25A7) neutralized. It was a castle. The isolated clones were each expanded in 50-100 ml of hybridoma medium and grown to a depleted state (ie, less than about 10% cell viability). The concentration and potency of antibodies against PCSK9 in the supernatant of these cultures were determined by ELISA and in vitro functional tests as described herein. As a result of the screening described herein, a hybridoma with the highest titer antibody against PCSK9 was identified. Selected hybridomas are shown in FIGS. 2A-3D and Table 2.

Example 4.1

Production of human 31H4 IgG4 antibody from hybridoma

In this example, a method of producing one of the antigen binding proteins from hybridoma strains is generally described. In the production run, 50 ml of depleted supernatant was used after protein A purification. Integra production will be scaled up and carried out later. Hybridoma strain 31H4 was grown in 20 ml of medium (Integra medium, Table 5) in a T75 flask. When the hybridoma became almost confluent in the T75 flask, it was transferred to an Integra flask (Integra Biosciences, Integra CL1000, cat# 90 005).

An Integra flask is a cell culture flask divided by a membrane into two chambers, a small chamber and a large chamber. ^{A hybridoma cell volume of 20-30 ml with a minimum cell density of 1×10 6} cells/ml from the 31H4 hybridoma line was placed in Integra medium in a small chamber of an Integra flask (see Table 5 for the components of Integra medium). Integra medium alone (1 L) was placed in the large chamber of the Integra flask. The membrane separating the two chambers is permeable to small molecular weight nutrients, but impermeable to hybridoma cells and antibodies produced by these cells. Thus, hybridoma cells and antibodies produced by these hybridoma cells were retained in a small chamber.

After 1 week, the medium was removed from both chambers of the Integra flask and replaced with fresh Integra medium. Media collected from the small chamber was held separately. After 2 weeks of growth, the medium from the small chamber was harvested again. The medium collected at Week 1 from the hybridoma strain was combined with the media collected at Week 2 from the hybridoma strain. The collected medium sample produced from the hybridoma strain was centrifuged to remove cells and debris (15 minutes at 3000 rpm), and the resulting supernatant was filtered (0.22 μm). The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or by binding ion exchange chromatography on an anion exchange resin such as Q Sepharose resin. The specific IEX condition for the 31H4 protein is Q-Sepharose HP at pH 7.8-8.0. Antibodies were eluted with a gradient of 10 mM-500 mM NaCl in 25 column volumes.

Example 4.2

Production of recombinant 31H4 human IgG2 antibody from transfected cells

In this example, a method for producing a 31H4 IgG2 antibody from transfected cells is outlined. 293 cells for transient expression and CHO cells for stable expression were transfected with plasmids encoding the 31H4 heavy and light chains. The conditioned medium from the transfected cells was recovered by removing the cells and cell lysates. The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or by binding ion exchange chromatography on an anion exchange resin such as Q Sepharose resin. The specific IEX condition for the 31H4 protein is Q-Sepharose HP at pH 7.8-8.0. Antibodies were eluted with a gradient of 10 mM-500 mM NaCl in 25 column volumes.

Example 5.

Production of human 21B12 IgG4 antibody from hybridomas

In this example, a method for producing a 21B12 IgG4 antibody from hybridomas is outlined. Hybridoma strain 21B12 was grown in medium (Integra medium, Table 5) in a T75 flask. When hybridomas became almost confluent in a T75 flask, they were transferred to an Integra flask (Integra Biosciences, Integra CL1000, cat# 90 005).

An Integra flask is a cell culture flask divided by a membrane into two chambers, a small chamber and a large chamber. ^{A hybridoma cell volume of 20-30 ml with a minimum cell density of 1×10 6} cells/ml from the 21B12 hybridoma strain was placed in Integra medium in a small chamber of an Integra flask (see Table 5 for the components of Integra medium). Integra medium alone (1 L) was placed in the large chamber of the Integra flask. The membrane separating the two chambers is permeable to small molecular weight nutrients, but impermeable to hybridoma cells and antibodies produced by these cells. Thus, hybridoma cells and antibodies produced by these hybridoma cells were retained in a small chamber. After 1 week, the medium was removed from both chambers of the Integra flask and replaced with fresh Integra medium. Media collected from the small chamber was held separately. After 2 weeks of growth, the medium from the small chamber was harvested again. The medium collected at Week 1 from the hybridoma strain was combined with the media collected at Week 2 from the hybridoma strain. The collected medium sample produced from the hybridoma strain was centrifuged to remove cells and debris (15 minutes at 3000 rpm), and the resulting supernatant was filtered (0.22 μm). The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or by binding ion exchange chromatography on an anion exchange resin such as a Q Sepharose resin. The specific IEX condition for the 21B12 protein is Q-Sepharose HP at pH 7.8-8.0. Antibodies were eluted with a gradient of 10 mM-500 mM NaCl in 25 column volumes.

Example 6

Production of human 21B12 IgG2 antibody from transfected cells

In this example, a method for producing 21B12 IgG2 antibody from transfected cells is outlined. Cells (293 cells for transient expression and CHO cells for stable expression) were transfected with plasmids encoding the 21B12 heavy and light chains. Conditioned medium from hybridoma cells was recovered by removing cells and cell debris. The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or binding ion exchange chromatography on a cation exchange resin such as an SP-Sepharose resin. The specific IEX condition for the 21B12 protein was SP-Sepharose HP at pH 5.2. Antibodies were eluted in 25 column volumes of buffer containing a gradient of 10 mM-500 mM NaCl in 20 mM sodium acetate buffer.

Example 7.

Production of human 16F12 IgG4 antibody from hybridoma

In this example, a method for producing antibody 16F12 IgG4 from hybridomas is outlined. Hybridoma strain 16F12 was grown in medium (see Table 5) in T75 flasks. When hybridomas became almost confluent in a T75 flask, they were transferred to an Integra flask (Integra Biosciences, Integra CL1000, cat# 90 005).

An Integra flask is a cell culture flask divided by a membrane into two chambers, a small chamber and a large chamber. ^{A hybridoma cell volume of 20-30 ml with a minimum cell density of 1×10 6} cells/ml from the 16F12 hybridoma line was placed in Integra medium in a small chamber of an Integra flask (see Table 5 for the components of Integra medium). Integra medium alone (1 L) was placed in the large chamber of the Integra flask. The membrane separating the two chambers is permeable to small molecular weight nutrients, but impermeable to hybridoma cells and antibodies produced by these cells. Thus, hybridoma cells and antibodies produced by these hybridoma cells were retained in a small chamber.

After 1 week, the medium was removed from both chambers of the Integra flask and replaced with fresh Integra medium. Media collected from the small chamber was held separately. After 2 weeks of growth, the medium from the small chamber was harvested again. The medium collected at Week 1 from the hybridoma strain was combined with the media collected at Week 2 from the hybridoma strain. The collected medium sample produced from the hybridoma strain was centrifuged to remove cells and debris (15 minutes at 3000 rpm), and the resulting supernatant was filtered (0.22 μm). The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or by binding ion exchange chromatography on an anion exchange resin such as Q Sepharose resin. The specific IEX condition for the 16F12 protein is Q Sepharose HP at pH 7.8-8.0. Antibodies were eluted with a gradient of 10 mM-500 mM NaCl in 25 column volumes.

Example 8

Production of human 16F12 IgG2 antibody from transfected cells

In this example, a method for producing a 16F12 IgG2 antibody from transfected cells is outlined. Cells (293 cells for transient expression and CHO cells for stable expression) were transfected with plasmids encoding 16F12 heavy and light chains. Conditioned medium from hybridoma cells was recovered by removing cells and cell debris. The cleared conditioned medium was loaded onto a Protein A Sepharose column. Optionally, the medium can be concentrated first and then loaded onto a Protein A Sepharose column. Nonspecific binding was removed by extensive PBS washing. The bound antibody protein on the Protein A column was recovered from the Protein A column by standard acidic antibody elution (eg 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography, or by binding ion exchange chromatography on a cation exchange resin such as SP Sepharose resin. The specific IEX condition for the 16F12 protein is SP Sepharose HP at pH 5.2. Antibodies were eluted in 25 column volumes of buffer containing a gradient of 10 mM-500 mM NaCl in 20 mM sodium acetate buffer.

Example 9

Sequence analysis of antibody heavy and light chains

Subsequently, the nucleic acid and amino acid sequences of the light and heavy chains of the antibody were determined by Sanger (dideoxy) nucleotide sequencing. Subsequently, the amino acid sequence was estimated for the nucleic acid sequence. The nucleic acid sequence of the variable domain is shown in Figures 3E-3JJ.

The cDNA sequences for the lambda light chain variable regions of 31H4, 21B12 and 16F12 were determined and are presented as SEQ ID NOs: 153, 95 and 105, respectively.

The cDNA sequences for the heavy chain variable regions of 31H4, 21B12 and 16F12 were determined and are presented as SEQ ID NOs: 152, 94 and 104, respectively.

The lambda light chain constant region (SEQ ID NO: 156), and the IgG2 and IgG4 heavy chain constant region (SEQ ID NO: 154 and 155) are shown in Figure 3KK.

The predicted polypeptide sequence was determined from each cDNA sequence. Predicted the predicted polypeptide sequence for the lambda light chain variable region of 31H4, 21B12 and 16F12, presented as SEQ ID NOs: 12, 23, and 35, respectively, and the lambda light chain constant region of 31H4, 21B12 and 16F12 (SEQ ID NO: 156), heavy chain variable region Predicted and presented as SEQ ID NOs: 67, 49 and 79, respectively. IgG2 and IgG4 heavy chain constant regions (SEQ ID NOs: 154 and 155).

FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 segmentation is shown in Figures 2a-3d.

Based on the sequence data, the germline genes from which the respective heavy or light chain variable regions are derived were determined. The identity of germline genes is indicated after the corresponding hybridoma line in Figs. 2A-3D, and each is indicated by a unique sequence. In addition, Figures 2a-3d show the determined amino acid sequence for the further characterized antibody.

Example 8

Determination of the isoelectric point of three antibodies

The theoretical pi of the antibody based on the amino acid sequence is 7.36 for 16F12; 8.47 for 21B12; It was determined to be 6.84 for 31H4.

Example 9

Characterization of the binding of antibodies to PCSK9

After identifying many antibodies that bind to PCSK9, several methods were used to quantify the binding and further determine the binding properties. In one aspect of the study, a Biacore affinity analysis was performed. In another aspect of the study, a KinExA® affinity analysis was performed. The samples and buffers used in these studies are shown in Table 6 below.

Biacore® affinity measurement

Biacore® (surface plasmon resonance apparatus, Biacore, Inc. (Biacore, Inc., Piscataway, NJ, USA)) affinity analysis of the 21B12 antibody against PCSK9 described in this example was performed according to the manufacturer's instructions. Performed.

Briefly, surface plasmon resonance experiments were performed using a Biacore 2000 optical biosensor (Biacore, GE Healthcare, Piscataway, NJ). Each individual anti-PCSK9 antibody was immobilized on a study grade CM5 biosensor chip by amine-coupling at a level that gave a maximum analyte binding response (Rmax) of 200 or less resonance units (RU). The concentration of PCSK9 protein was different at 2-fold intervals (analyte) and injected onto the surface of the immobilized antibody (for 1.5 minutes at a flow rate of 100 μl/min). Fresh HBS-P buffer (pH 7.4, 0.01 M Hepes, 0.15 M NaCl, 0.005% surfactant P-20, Biacore) supplemented with 0.01% BSA was used as the binding buffer. The binding affinity of each anti-PCSK9 antibody was measured in separate experiments for each human, mouse, and cynomolgus monkey PCSK9 protein at pH 7.4 (concentrations used were 100, 50, 25, 12.5, 6.25, 3.125, and 0 nM).

In addition, the binding affinity of the antibody to human PCSK9 was pH 6.0 with HBS-P buffer (pH 6.0, 0.01 M Hepes, 0.15 M NaCl, 0.005% surfactant P-20, Biacore) supplemented with 0.01% BSA. Measured at 6.0. The obtained binding signal was proportional to the free PCSK9 in solution. The dissociation equilibrium constant (K _D ) uses a double-curved single site homogeneous binding model (KinExA® software, Sapidyne Instruments Inc., Boyce, Idaho, USA)) (n=1 for 6.0 pH runs). And obtained from nonlinear regression analysis of the competition curve. Interestingly, the antibodies were shown to show stronger binding affinity at lower pH (Kd was 12.5, 7.3, and 29 pM for 31H4, 21B12 and 16F12, respectively).

Antibody binding kinetic parameters including k _a (association rate constant), k _d (dissociation rate constant), and K _D (dissociation equilibrium constant) were determined using the BIA Assessment 3.1 computer program (Biacore, Inc.). Lower dissociation equilibrium constants indicate greater affinity of the antibody for PCSK9. _{The K D} values determined by Biacore® affinity analysis are shown in Table 7.1 below.

<Table 7.1>

Table 7.2 _{presents the k on} and k _off rates.

<Table 7.2>

KinExA® affinity measurement

KinExA® (Sapidin Instruments Inc.) affinity analysis of 16F12 and 31H4 was performed according to the manufacturer's instructions. Briefly, Reacti-Gel™ (6x) (Pierce) was precoated with either human, V5-tagged cyno PCSK9 protein or His-tagged mouse PCSK9 protein and blocked with BSA. Then, 10 or 100 pM of antibody 16F12 or antibody 31H4 and one PCSK9 protein were incubated with various concentrations (0.1 pM-25 nM) of PCSK9 protein for 8 hours at room temperature and then passed through PCSK9-coated beads. . The amount of bead-bound 16F12 or 31H4 was quantified by a fluorescent (Cy5) labeled goat anti-human IgG (H+L) antibody (Jackson Immuno Research). The binding signal is proportional to the concentration of free 16F12 or 31H4 in binding equilibrium. The equilibrium dissociation constant (K _D ) was obtained from the nonlinear regression of two sets of competition curves using a single site homogeneous binding model. KinExA® Pro software was used in the analysis. The binding curves generated in this assay are presented in Figures 4a-4f.

The 16F12 and 31H4 antibodies showed similar affinity for human and cyno PCSK9, but about 10-250 times lower affinity for mouse PCSK9. Of the two antibodies tested using the KinExA® system, antibody 31H4 showed higher affinity for both human and cyno PCSK9, with 3 and 2 pM K _{D, respectively.} 16F12 showed a slightly weaker affinity with 15 pM K _D for human PCSK9 and 16 pM K _{D for cyno PCSK9.}

The results of the KinExA® affinity analysis are summarized in Table 8.1 below.

<Table 8.1>

In addition, SDS PAGE was performed to examine the quality and quantity of the sample, and is shown in FIG. 5A. cPCSK9 was found to be about 50% less from the active binding concentration calculated on the gel and also from the KinExA® assay. Thus, the K _D of mAb against cPCSK9 was adjusted as 50% of the active cPCSK9 of the present invention.

A Biacore solution equilibrium binding assay was used to determine the Kd value for ABP 21B12. 21B12.1 showed little signal when using KinExA analysis, and therefore Biacore solution equilibrium analysis was applied. Since no significant binding was observed for binding of the antibody to the immobilized PCSK9 surface, the 21B12 antibody was immobilized in flow cell 4 of the CM5 chip using amine coupling at a density of about 7000 RU. Flow cell 3 was used as a background control. 0.3, 1, and 3 nM of human PCSK9 or cyno PCSK9 were mixed with serial dilutions (range 0.001-25 nM) of 21B12.1 antibody samples in PBS + 0.1 mg/ml BSA, 0.005% P20. The binding of free PCSK9 in the mixed solution was measured by injection onto the surface of the 21B12.1 antibody. The 100% PCSK9 binding signal on the 21B12.1 surface was determined in the absence of mAb in solution. Reduced PCSK9 binding reaction at increasing concentrations of mAb indicated PCSK9 binding to mAb in solution that blocked PCSK9 from binding to the immobilized peptibody surface. By plotting the PCSK9 binding signal versus mAb concentration, K _D was calculated from 3 sets of curves (fixed PCSK9 concentrations of 0.3, 1 and 3 nM) using a single site homogeneous binding model in KinExA Pro™ software. Although cPCSK9 has a lower protein concentration observed from KinExA assay and SDS-gel, the concentration of cPCSK9 _{was not used in the calculation of K D} and so its concentration was not adjusted here. The results are presented in Table 8.2 and FIGS. 5b-5d below. Figure 5b presents the results from solution equilibrium analysis at three different hPCSK9 concentrations for hPCSK9. Figure 5c presents a similar set of results for mPCSK9. Figure 5d presents the results from the Biacore capture analysis.

<Table 8.2>

Example 10

Epitope binning

Competition ELISA was used for anti-PCSK9 antibody binning. Briefly, to determine if two antibodies belong to the same epitope bin, one antibody (mAb1) was first coated on an ELISA plate (NUNC) at 2 μg/ml by overnight incubation. The plate was then washed with 3% BSA and blocked. Meanwhile, 30 ng/ml of biotinylated hPCSK9 was incubated with the second antibody (mAb2) for 2 hours at room temperature. The mixture was applied to the coated mAb1 and incubated for 1 hour at room temperature. The ELISA plate was then washed and incubated for 1 hour at 1:5000 dilution with neutravidin-HRP (Pierce). After further washing, the plate was incubated with the TMB substrate and the signal was detected at 650 nm using a Titertek plate reader. Antibodies with the same binding profile were pooled together into the same epitope bin. The results of the antibody binning study are presented in Table 8.3.

<Table 8.3>

Further testing of epitope binning was performed using Biacore. Three mAbs, 16F12, 21B12 and 31H4, were immobilized on flow cells 2, 3 and 4 at a density of about 8000 RU. 5 nM PCSK9 from human, mouse and cyno was injected onto the mAb surface to reach about 100-500 RU. Then, 10 nM mAb was injected onto the PCSK9 surface. Then, the binding of 3 mAbs to 3 different PCSK9 proteins on 3 mAbs was recorded.

If the two mAbs have similar epitopes on the antigen, mAb1 will not show binding to the antigen already bound to mAb2. If the two mAbs have different epitopes on the antigen, mAb1 will show binding to the antigen bound to mAb2. In Figure 5e, these epitope binning results are shown in graphical form for three mAbs on human PCSK9. Similar patterns were observed for mPCSK9 and cPCSK9. As shown in the graph, 16F12 and 31H4 appear to share similar epitopes, and 21B12 appear to have different epitopes.

Example 11

Efficacy of 31H4 and 21B12 to block D374Y PCSK9/LDLR binding

This example provides IC50 values for two antibodies in blocking the ability of PCSK9 D374Y to bind to LDLR. Clear 384 well plates (Costar) were coated with 2 μg/ml of goat anti-LDL receptor antibody (R&D Systems) diluted in buffer A (100 mM sodium cacodylate, pH 7.4). The plate was thoroughly washed with buffer A, then blocked with buffer B (1% milk in buffer A) for 2 hours. After washing, the plates were incubated with 0.4 μg/ml LDL receptor (R&D Systems) diluted in _{buffer C (buffer B supplemented with 10 mM CaCl 2) for 1.5 hours.} Simultaneously with the incubation, 20 ng/ml of biotinylated D374Y PCSK9 was incubated with various concentrations of 31H4 IgG2, 31H4 IgG4, 21B12 IgG2 or 21B12 IgG4 antibodies, or buffer A alone (control) diluted in buffer A. The plate containing the LDL receptor was washed, and the biotinylated D374Y PCSK9/antibody mixture was transferred to the plate and incubated for 1 hour at room temperature. Binding of biotinylated D374Y to the LDL receptor was detected by incubation with 500 ng/ml streptavidin-HRP (Biosource) in buffer C followed by TMB substrate (KPL). The signal was quenched with 1N HCl and the absorbance was read at 450 nm.

The results of this binding study are shown in Figures 6a-6d. _{Briefly, IC 50} values were determined for each antibody, 199 pM for 31H4 IgG2 (FIG. 6A ), 156 pM for 31H4 IgG4 (FIG. 6B ), 170 pM for 21B12 IgG2 (FIG. 6C ), And 169 pM for 21B12 IgG4 (FIG. 6D ).

In addition, the antibody blocked the binding of wild-type PCSK9 to LDLR in this assay.

Example 12

Cell LDL uptake assay

This example demonstrates the ability of various antigen binding proteins to reduce LDL uptake by cells. Human HepG2 cells were inoculated in DMEM medium (Mediatech, Inc) supplemented with 10% FBS at a concentration of ⁵ ×10 5 cells/well in a 96-well plate (Costa) with a black transparent bottom, and 37° C. Incubated overnight in (5% CO _{2 ).} To form PCSK9 and antibody complex, 2 μg/ml of D374Y human PCSK9 was diluted in absorption buffer (DMEM with 1% FBS) at room temperature for 1 hour with various concentrations of antibody, or absorption buffer alone (control). Incubated at. After washing the cells with PBS, the D374Y PCSK9/antibody mixture was transferred to the cells, followed by LDL-BODIPY (Invitrogen) diluted in absorption buffer to a final concentration of 6 μg/ml. After incubation at 37° C. (5% CO ₂ ) for 3 hours, the cells were thoroughly washed with PBS, and the cell fluorescence signals were transferred to Safire™ (TECAN) at 480-520 nm (excitation) and 520-600 nm (emission). Detected by.

The results of the cell uptake assay are shown in Figs. 7A-7D. _{Briefly, IC 50} values were determined for each antibody, 16.7 nM for 31H4 IgG2 (FIG. 7A ), 13.3 nM for 31H4 IgG4 (FIG. 7B ), 13.3 nM for 21B12 IgG2 (FIG. 7C ), It was found to be 18 nM (FIG. 7D) for 21B12 IgG4. This result demonstrates that the applied antigen binding protein can reduce the effect of PCSK9 (D374Y) blocking LDL uptake by cells. Antibodies also blocked the effect of wild-type PCSK9 in this assay.

Example 13

Serum cholesterol-lowering effect of 31H4 antibody in a 6-day study

To evaluate total serum cholesterol (TC) lowering in wild-type (WT) mice via antibody therapy against PCSK9 protein, the following procedure was performed.

Male WT mice (C57BL/6 weeks, 9-10 weeks old, 17-27 g) obtained from Jackson Laboratory (Bar Harbor, Maine) were fed standard food throughout the experimental period (Harland-Teklad (Harland -Teklad), Diet 2918). Mice were administered anti-PCSK9 antibody 31H4 (2 mg/ml in PBS) or control IgG (2 mg/ml in PBS) at a level of 10 mg/kg via the tail vein of the mouse at T=0. Naive mice were also prepared separately as naive controls. The administration group and sacrifice time are shown in Table 9.

Mice were sacrificed by _{CO 2} asphyxiation at predetermined time points shown in Table 9. Blood was collected through the vena cava into the Eppendorf tube and allowed to coagulate for 30 minutes at room temperature. Then, the sample was centrifuged at 12,000xg for 10 minutes in a table-top centrifuge to separate the serum. Serum total cholesterol and HDL-C were measured using a Hitachi 912 clinical analyzer and a Roche/Hidachi TC and HDL-C kit.

The experimental results are shown in Figs. 8A-8D. Briefly, mice administered with antibody 31H4 showed reduced serum cholesterol levels over the course of the experiment (FIGS. 8A and 8B ). In addition, it is noted that the mice also showed reduced HDL levels (FIGS. 8C and 8D ). 8A and 8C, the percentage change is a value compared to the control IgG at the same time point ( ^* P<0.01, #P<0.05). For Figures 8B and 8D, the percent change is the value compared to the total serum cholesterol and HDL levels measured in naive animals at t=0 hr ( ^* P<0.01, #P<0.05).

Regarding lowered HDL levels, one of skill in the art will appreciate that a decrease in HDL in mice does not indicate that a decrease in HDL will occur in humans, but only further reflects a decrease in serum cholesterol levels in the organism. Note that, unlike humans, which carry most of the serum cholesterol on LDL particles, mice transport most of the serum cholesterol within high-density lipoprotein (HDL) particles. In mice, the measurement of total serum cholesterol is most closely similar to serum HDL-C levels. Mouse HDL contains apolipoprotein E (apoE), a ligand for the LDL receptor (LDLR) and is allowed to be cleared by LDLR. Therefore, the HDL test is an appropriate indicator for this example in mice (knowing that a decrease in HDL is not expected for humans). In contrast, for example, human HDL does not contain apoE and is not a ligand for LDLR. Since the PCSK9 antibody increases LDLR expression in mice, the liver can clear more HDL and lower serum HDL-C levels.

Example 14

Effect of antibody 31H4 on LDLR levels in a 6-day study

This example demonstrates that antigen binding proteins alter LDLR levels in subjects over time as predicted. Western blot analysis was performed to confirm the effect of antibody 31H4 on LDLR levels. 50-100 mg of liver tissue obtained from mice sacrificed as described in Example 13 were homogenized in 0.3 ml of RIPA buffer (Santa Cruz Biotechnology Inc.) containing the complete protease inhibitor (Roche). The homogenate was incubated on ice for 30 minutes and centrifuged to pellet the cell lysate. The protein concentration in the supernatant was measured using a BioRad protein assay reagent (BioRad laboratories). 100 μg of protein was denatured at 70° C. for 10 minutes and separated on a 4-12% Bis-Tris SDS gradient gel (Invitrogen). Proteins were transferred to 0.45 μm PVDF membrane (Invitrogen) and in wash buffer containing 5% fat-free milk (50 mM Tris PH 7.5, 150 mM NaCl, 2 mM CaCl ₂ and 0.05% Tween 20) for 1 hour at room temperature Blocked. The blot was then probed with goat anti-mouse LDLR antibody (R&D system) 1:2000 or anti-β actin (sigma) 1:2000 for 1 hour at room temperature. Blots were washed briefly and incubated with bovine anti-goat IgG-HRP (Santa Cruz Biotechnology Inc.) 1:2000 or goat anti-mouse IgG-HRP (Upstate) 1:2000. After 1 hour of incubation at room temperature, the blot was thoroughly washed and immunoreactive bands were detected using the ECL Plus kit (Amersham biosciences). Western blot showed an increase in the LDLR protein level in the presence of antibody 31H4 as shown in FIG. 9.

Example 15

Serum cholesterol-lowering effect of antibody 31H4 in a 13-day study

To assess total serum cholesterol (TC) lowering in wild-type (WT) mice through antibody therapy against PCSK9 protein in the 13-day study, the following procedure was performed.

Male WT mice (C57BL/6 weeks, 9-10 weeks old, 17-27 g) obtained from Jackson Laboratories to male WT mice (C57BL/6 weeks, 9-10 weeks old, 17-27 g) throughout the experiment. Standard diet (Harland-Teklad, Diet 2918) was fed. Mice were administered anti-PCSK9 antibody 31H4 (2 mg/ml in PBS) or control IgG (2 mg/ml in PBS) at a level of 10 mg/kg via the tail vein of the mouse at T=0. Naive mice were also prepared separately as naive controls.

The administration group and time of sacrifice are shown in Table 10. Animals were sacrificed, and livers were extracted and prepared as in Example 13.

When extending the 6-day experiment to the 13-day study, the same serum cholesterol lowering effect observed in the 6-day study was also observed in the 13-day study. More specifically, animals dosed with 10 mg/kg showed a 31% reduction in serum cholesterol on day 3, which gradually returned to the pre-dose level by day 13. 10A shows the results of this experiment. Figure 10c shows the results of repeating the above procedure using 31H4 at a dose of 10 mg/kg, and 16F12, another antibody at 10 mg/kg. The administration group and time of sacrifice are shown in Table 11.

As shown in Figure 10C, both 16F12 and 31H4 showed a significant and substantial reduction in total serum cholesterol after only a single dose and provided an advantage over 1 week (more than 10 days). The results of the repeated 13-day study were consistent with the results of the first 13-day study, and a 26% reduction in serum cholesterol levels was observed on the third day. For FIGS. 10A and 10B, the percentage change is a value compared to the control IgG at the same time point ( ^* P<0.01). For Figure 10c, the percentage change is the value compared to the control IgG at the same time point ( ^* P<0.05).

Example 16

Effect of antibody 31H4 on HDL levels in a 13-day study

HDL levels for the animals of Example 15 were also tested. HDL levels decreased in mice. More specifically, animals dosed with 10 mg/kg showed a 33% decrease in HDL levels on day 3, which gradually returned to pre-dose levels by day 13. Fig. 10b shows the experimental results. On day 3 there was a decrease in HDL levels of 34%. Figure 10b shows the results of the repeated 13 days experiment.

As will be appreciated by those of skill in the art, antibodies will lower mouse HDL, but are not expected to occur in humans due to differences in HDL in humans and other organisms (eg mice). Thus, a decrease in mouse HDL does not indicate a decrease in human HDL.

Example 17

Repeated administration of the antibody sustains the benefits of the antigen binding peptide.

The experiments of Examples 15 and 16 were repeated using the dosing schedule shown in FIG. The results are shown in Fig. 11B. As can be seen from the graph of FIG. While showing a prolonged decrease in total serum cholesterol, mice receiving only control injections ultimately showed an increase in their total serum cholesterol. For FIG. 11, the percent change is the value compared to naive animals at t=0 hours ( ^* P<0.01, ^** P<0.001).

The results of this example show that, unlike other cholesterol treatment methods in which repeated application causes a decrease in efficacy due to biological adjustments in the subject, the method of the present invention does not appear to suffer from this problem over the duration of the test. In addition, this suggests that the recovery of total serum cholesterol or HDL cholesterol levels to baseline observed in the preceding examples is not due to some resistance to the treatment caused by the subject, but due to a lack of antibody utilization in the subject.

Example 18

Epitope Mapping of Human Anti-PCSK9 Antibodies

This example outlines a method of determining whether a residue in PCSK9 forms or is part of an epitope for the antigen binding protein disclosed herein for PCSK9.

To determine the epitope to which a specific ABP of the present invention binds, the epitope of ABP can be mapped using a synthetic peptide derived from a specific PCSK9 peptide sequence.

The SPOT peptide array (Sigma Genosys) can be used to study the molecular interactions of human anti-PCSK9 antibodies with their peptide epitopes. The SPOT technology is based on solid-phase synthesis of peptides in a manner suitable for systematic analysis of antibody epitopes. Syntheses of custom aligned oligopeptides are commercially available from Sigma-Genesis. A peptide array of overlapping oligopeptides derived from the amino acid sequence of the PCSK9 peptide can be obtained. The array may contain a series of 12-mer peptides as spots on a polypropylene membrane sheet. The peptide array can reach the full length of the PCSK9 mature sequence. Each successive peptide can be split by one residue from the preceding peptide, resulting in a superimposed overlapping library of arrayed oligopeptides. Membrane bearing the peptide can be reacted with different anti-PCSK9 antibodies (1 μg/ml). Binding of mAbs to membrane-bound peptides can be assessed by enzyme linked immunosorbent assay using HRP-conjugated secondary antibodies followed by enhanced chemiluminescence (ECL).

In addition, functional epitopes can be mapped by combinatorial alanine scanning. In this process, a combinatorial alanine-scanning strategy can be used to identify amino acids in the PCSK9 protein required for interaction with anti-PCSK9 ABP. To achieve this, a second set of SPOT arrays can be used for alanine scanning. A panel of variant peptides with an alanine substitution at each of the 12 residues can be scanned as above. Thereby, the epitope for ABP for human PCSK9 may be mapped and identified.

In an alternative, assuming that the epitope is possible in conformation, a combination of alanine scanning and/or arginine scanning to identify the epitope, antibody FAB/PCSK9 co-crystallization, and limited proteolysis/LC-MS (liquid chromatography- Mass spectrometry) can be used.

Example 19

Use of PCSK9 antibody for treatment of cholesterol-related diseases

Human patients exhibiting cholesterol-related disorders (reduction of cholesterol (eg serum cholesterol) may be beneficial) are administered a therapeutically effective amount of PCSK9 antibody 31H4 (or eg 21B12 or 16F12). Periodically during treatment, the patient is monitored to determine if symptoms of the disease have diminished. After treatment, patients receiving treatment with the PCSK9 antibody were found to have reduced serum cholesterol levels compared to patients not treated.

Example 20

Use of PCSK9 antibody for treatment of hypercholesterolemia

A human patient exhibiting symptoms of hypercholesterolemia is administered a therapeutically effective amount of a PCSK9 antibody, eg, 31H4 (or eg, 21B12 or 16F12). Periodically during treatment, human patients are monitored to determine if serum cholesterol levels have been reduced. After treatment, patients receiving treatment with the PCSK9 antibody were found to have reduced serum cholesterol levels compared to untreated arthritis patients.

Example 21

For the prevention of coronary heart disease and/or recurrent cardiovascular events

Use of PCSK9 antibody

Identify human patients at risk of developing coronary heart disease. Patients are administered a therapeutically effective amount of a PCSK9 antibody, eg, 31H4 (or eg, 21B12 or 16F12), alone or simultaneously or sequentially with a statin, eg, simvastatin. Periodically during treatment, the human patient is monitored to determine if the patient's total serum cholesterol level changes. Throughout prophylactic treatment, patients receiving treatment with PCSK9 antibodies have been found to have reduced serum cholesterol compared to untreated patients, thus reducing the risk for coronary heart disease or recurrent cardiovascular events.

Example 22

Use of PCSK9 antibody as a diagnostic agent

To diagnose patients with high levels of PCSK9 production, an enzyme linked immunosorbent assay (ELISA) for detection of PCSK9 antigen in a sample can be used. In the assay, wells of microtiter plates, eg 96-well microtiter plates or 384-well microtiter plates, were adsorbed for several hours with the first fully human monoclonal antibody raised against PCSK9. The immobilized antibody serves as a capture antibody against any PCSK9 that may be present in the test sample. Wells were washed and treated with a blocker such as milk protein or albumin to prevent non-specific adsorption of the analyte.

Subsequently, the wells were treated with a test sample suspected of containing PCSK9, or a solution containing a standard amount of antigen. The sample can be, for example, a serum sample from a subject suspected of having a level of circulating antigen considered as a diagnosis of a health condition.

After washing off the test sample or standard, the wells were treated with a second fully human monoclonal PCSK9 antibody labeled by conjugation with biotin. Monoclonal or mouse or other species origin can also be used. The labeled PCSK9 antibody serves as a detection antibody. After washing off excess second antibody, the wells were treated with avidin-conjugated horseradish peroxidase (HRP) and a suitable chromogenic substrate. The concentration of antigen in the test sample was determined by comparison with a standard curve prepared from a standard sample.

The ELISA assay provides a highly specific and very sensitive assay for the detection of PCSK9 antigen in test samples.

Determination of PCSK9 protein concentration in a subject

PCSK9 levels in human serum can be quantified by sandwich ELISA. Two fully human monoclonal PCSK9 antibodies from sandwich ELISA recognize different epitopes on the PCSK9 molecule. Alternatively, monoclonal antibodies from mouse or other species can be used. ELISA was carried out as follows: 50 μl of capture PCSK9 antibody at a concentration of 2 μg/mL in _{coating buffer (0.1 M NaHCO 3, pH 9.6) was coated on an ELISA plate (Fisher).} After incubating overnight at 4° C., the plate was treated with 200 μl of blocking buffer (0.5% BSA in PBS, 0.1% Tween 20, 0.01% thimerosal) for 1 hour at 25° C. Plates were washed (3x) with 0.05% Tween 20 (wash buffer, WB) in PBS. Normal or patient serum (Clinomics, Bioreclaimation) was diluted in blocking buffer containing 50% human serum. Plates were incubated overnight at 4° C. with serum samples, washed with WB, and then incubated at 25° C. for 1 hour with 100 μl/well of biotinylated detection PCSK9 antibody. After washing, the plate was incubated with HRP-streptavidin for 15 minutes, washed as before, and then treated with 100 μl/well of o-phenylenediamine (sigma developing solution) in _{H 2} O _{2 for color development.} I did. The reaction was stopped with 50 μl/well of H ₂ SO ₄ (2M) and analyzed at 492 nm using an ELISA plate reader. The concentration of PCSK9 antigen in the serum sample was calculated by comparison to the dilution of the purified PCSK9 antigen using a 4-parameter curve fitting program.

Determination of PCSK9 variant protein concentration in a subject

The steps outlined above can be performed using the antibodies described herein that bind both wild-type PCSK9 and variant PCSK9 (D374Y). Next, to determine whether PCSK9 present in the subject is a wild-type or a D374Y variant, an antibody that binds wild-type but does not bind to the mutant can be used (again using a protocol similar to that outlined above). As will be appreciated by those of skill in the art, results that are positive for both rounds will be wild-type, whereas results that are positive for the first round but not positive for the antibody of the second round will contain the D374Y mutation. There are high-frequency mutations in the population for which substances such as ABP, which are known and disclosed herein, may be particularly useful.

Example 23

Use of PCSK9 antigen binding protein to prevent hypercholesterolemia

Human patients at risk of developing hypercholesterolemia were identified through family history analysis and/or lifestyle, and/or current cholesterol levels. Subjects were administered a therapeutically effective amount of PCSK9 antibody 31H4 (or eg 21B12 or 16F12) regularly (eg, once weekly). Periodically during treatment, the patient is monitored to determine if serum cholesterol levels have been reduced. After treatment, subjects receiving prophylactic treatment with the PCSK9 antibody were found to have lowered serum cholesterol levels compared to subjects not treated.

Example 24

PCSK9 ABP further upregulated LDLR in the presence of statins.

This example demonstrates that ABP against produced PCSK9 further increases LDLR utilization when used in the presence of a statin, indicating that additional benefits can be achieved by using a combination of the two.

HepG2 cells were seeded in DMEM containing 10% fetal calf serum (FBS) and grown to -90% fusion. Cells were treated with indicated amounts of mebinoline (statin, Sigma) and PCSK9 ABP (FIGS. 12A-12C) in DMEM containing 3% FBS for 48 hours. Total cell lysate was prepared. 50 mg of total protein was separated by gel electrophoresis and transferred to a PVDF membrane. Immunoblot was performed using rabbit anti-human LDL receptor antibody (Fitzgerald) or rabbit anti-human b-actin antibody. The enhanced chemiluminescence results are shown in the top panels of FIGS. 12A-12C. The intensity of the band was quantified by ImageJ software and normalized by b-actin. The relative levels of LDLR are shown in the lower panels of Figs. 12A-12C. ABP 21B12 and 31H4 are PCSK9 neutralizing antibodies, while 25A7.1 are non-neutralizing antibodies.

HepG2-PCSK9 cells were also generated. These cells are stable HepG2 cell lines transfected with human PCSK9. Cells were seeded in DMEM containing 10% fetal calf serum (FBS) and grown to -90% fusion. Cells were treated with indicated amounts of mebinoline (Sigma) and PCSK9 ABP (Figs. 12D-12F) in DMEM containing 3% FBS for 48 hours. Total cell lysate was prepared. 50 mg of total protein was separated by gel electrophoresis and transferred to a PVDF membrane. Immunoblots were performed using rabbit anti-human LDL receptor antibody (Fitzgerald) or rabbit anti-human b-actin antibody. The enhanced chemiluminescence results are shown in the top panel. The intensity of the band was quantified by ImageJ software and normalized by b-actin.

As can be seen from the results presented in Figures 12A-12F, increasing amounts of neutralizing antibodies and increasing amounts of statins generally increased LDLR levels. This increase in the effect on increasing levels of ABP is particularly evident in FIGS. 12D-12F, where cells were also transfected with PCSK9, allowing ABP to exhibit their effects to a higher degree.

Interestingly, the effect of ABP concentration on LDLR levels increased dramatically when PCSK9 was produced by cells, as evidenced by the results of comparing FIGS. 12D-12F to 12A-12C. In addition, it is evident that neutralizing ABPs (21B12 and 31H4) increase LDLR levels even more in the presence of statins than 25A7.1 ABP (non-neutralizing agents), which was added by the use of both statins and ABPs for PCSK9. Prove that you can achieve the benefits of

Example 25

Consensus sequence

Consensus sequences were determined using standard phylogenetic analysis of the CDRs corresponding to _{V H} and V _L of anti-PCSK9 ABP. The consensus sequence was determined by keeping the CDRs contiguous within the same sequence corresponding _{to V H} or V _L. Briefly, _{the amino acid sequence corresponding to the entire variable domain of V H} or V _L was converted to the FASTA format for ease of comparison alignment processing and phylogenetic inference. The framework regions of these sequences are then replaced with artificial linker sequences ("bbbbbbbbbb" placeholders, non-specific nucleic acid constructs), so that the CDRs are still contiguous within the same sequence corresponding _{to V H} or V _L While not introducing any amino acid positions that aggravate bias due to concurrent events (eg, unrelated antibodies that accidentally share a common germline framework heritage). Subsequently, the V _H or V _L sequence of the above format was processed with a sequence similarity alignment query using a program using a standard ClutalW-like algorithm (Thompson et al., 1994, Nucleic Acids Res. 22:4673-4680). Reference). A gap creation penalty of 8.0 was used with a gap extension penalty of 2.0. The program is similarly used to create and explain the similarities and differences of sequence groups through branch length comparison and group classification, UPGMA (unweighted pair group method using arithmetic mean) or neighbor-joining method ( [See Saitou and Nei, 1987, Molecular Biology and Evolution 4:406-425]) was used to create a phylogenetic tree based on sequence similarity alignment. Both methods produced similar results, but ultimately used the UPGMA-derived branching map, as the method used a simpler and more conservative set of hypotheses. UPGMA-derived branching maps were created, where sequences of similar groups were defined as having less than 15 substitutions per 100 residues between individual sequences in the group (see legend in the branch map drawing for scale). ), was used to define a consensus sequence collection. The comparison results are shown in Figs. 13A-13J. In Figure 13E, groups were selected so that the sequence in the light chain of that clade is also a clade in the heavy chain and has less than 15 substitutions.

As will be appreciated by those of skill in the art, the results presented in Figures 13A-13J show the importance of certain amino acids (e.g., conserved amino acids), and which amino acid positions can be similarly altered (e.g. Provides a number of guidelines for positions with different amino acids).

Example 26

Mouse model for PCSK9 and ABP ability to lower LDL in vivo

To generate mice overexpressing human PCSK9, 3 week old WT C57Bl/6 mice were recombinantly modified to express human PCSK9 to determine the exact titer that would provide a measurable increase in LDL-cholesterol in mice. Various concentrations of adeno-associated virus (AAV) were administered via tail vein administration. Using this particular virus expressing human PCSK9, it was determined that 4.5 x 10E12 pfu of virus would generate a LDL-cholesterol level of about 40 mg/dL in circulating blood (normal level of LDL in WT mice is about 10 mg /dL). Human PCSK9 levels in these animals were found to be about 13 μg/mL. Colonies of mice were generated using the above injection criteria.

One week after injection, mice were evaluated for LDL-cholesterol levels and randomly assigned to different treatment groups. The animals were then administered a single bolus injection of either 10 mg/kg or 30 mg/kg of 16F12, 21B12, or 31H4 antigen binding protein via tail vein injection. IgG2 ABP was administered to animals in a separate group as an administration control. Subsequently, subgroups of animals (n=6-7) were euthanized 24 and 48 hours after ABP administration. There was no effect on LDL-cholesterol levels after IgG2 administration at both doses. Both 31H4 and 21B12 showed significant LDL-cholesterol lowering compared to the IgG2 control until 48 hours after administration (shown in FIGS. 14A and 14B at two different doses). 16F12 shows a moderate LDL-cholesterol lowering response, and levels return to baseline of about 40 mg/dL at 48 hours. These data are consistent with the in vitro binding data (Biacore and Kinexa), which shows an approximately equivalent binding affinity between 31H4 and 21B12 for human PCSK9, and a smaller affinity for 16F12.

As can be seen from the results, total cholesterol and HDL-cholesterol were reduced by PCSK9 ABP in the model (both total and HDL-C rise beyond WT mice due to overexpression of PCSK9). While cholesterol reduction in this model appears to occur over a relatively short period of time, it is believed to be due to the superphysiologically high levels of human PCSK9 present in this model. In addition, assuming that expression is dominated by AAV, there is no regulation of PCSK9 expression. In these figures, ( ^* ) represents P<0.05 compared to the LDL-cholesterol level observed in animals injected with the IgG2 control at the same time point, and ( ^** ) represents P<0.005. Serum human PCSK9 at the level of 13 μg/ml in mice increased by about 520 times beyond the endogenous mouse PCSK9 level (~25 ng/ml), and by about 75 times beyond the average human serum level (~175 ng/ml) Corresponds to Thus, antigen binding proteins will be much more effective in humans.

As will be appreciated by those of skill in the art, these results demonstrate the suitability of the mouse model in testing the ability of an antigen binding protein to alter serum cholesterol in a subject. One of skill in the art will also appreciate that the use of mouse HDL to monitor serum cholesterol levels in mice is useful for monitoring mouse serum cholesterol levels, but is not an indication of the effect of ABP on human HDL in humans. For example, Cohen et al. ("Sequence variations in PCSK9, low LDL, and protection against coronary heart disease", N Engl J Med, 354:1264-1272, 2006) found that PCSK9 function-loss for human HDL levels. The lack of any effect of the (loss-of-function) mutation was demonstrated (the entirety of which is incorporated herein by reference). Thus, one of skill in the art will appreciate that ABP's ability to lower mouse HDL (lacking LDL) is not an indication of ABP's ability to lower human HDL. Indeed, as shown by Cohen, this is unlikely to happen for neutralizing antibodies in humans.

Example 27

31H4 and 21B12 bind to the ProCat zone of PCSK9.

In this example, one method for determining where various antibodies bind to PCSK9 is described.

The ProCat (31-449 of SEQ ID NO: 3) or V domain (450-692 of SEQ ID NO: 3) of the PCSK9 protein was combined with antibodies 31H4 or 21B12. Samples were analyzed by Native PAGE for complex formation. As can be seen in Figures 16A and 16B, there was a gel shift for the ProCat/31H4 and ProCat/21B12 samples, demonstrating that the antibody binds to the ProCat domain.

Example 28

The LDLR EGFa domain binds to the catalytic domain of PCSK9.

In this example, the analyzed crystal structure of PCSK9 ProCat (31-454 of SEQ ID NO: 3) bound to the LDLR EGFa domain (293-334) at 2.9 Å resolution is presented (conditions for this are described in the examples below).

A diagram of the structure of PCSK9 bound to EGFa is shown in Figure 17. The crystal structure (and its figure in Figure 17) shows that the EGFa domain of LDLR binds to the catalytic domain of PCSK9. In addition, the interaction of PCSK9 and EGFa appears to occur across the surface of PCSK9 between residues D374 and S153 in the structure shown in Figure 17.

The specific core PCSK9 amino acid residue of the interaction interface with the LDLR EGFa domain was defined as the PCSK9 residue present within 5 Å of the EGFa domain. Core residues are: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, and S381.

The boundary PCSK9 amino acid residue of the interaction interface with the LDLR EGFa domain was defined as the PCSK9 residue located 5-8 Å from the EGFa domain. Border residues are: W156, N157 , L158, E159, H193, E195, H229 , R237, G240, K243, D367, I368, G370 , A371, S373, S376, and Q382. The underlined residues are those that are almost or completely embedded in PCSK9.

As those skilled in the art can see, the results of this example demonstrate where PCSK9 and EGFa interact. Thus, antibodies that interact with or block any of these residues may be useful as antibodies that inhibit the interaction between PCSK9 and the EGFa domain of LDLR (and/or LDLR in general). In some embodiments, an antibody that interacts with or inhibits any of the above residues when bound to PCSK9, and is within 15-8, 8, 8-5, or 5 angstroms of said residues, is useful for binding PCSK9 to LDLR. It is considered to provide inhibition.

Example 29

31H4 interacts with amino acid residues from both the pro-domain and catalytic domain of PCSK9.

In this example, the crystal structure of the full-length PCSK9 (N533A mutant of SEQ ID NO: 3) bound to the Fab fragment of 31H4 determined at 2.3 Å resolution is shown (conditions for this will be described in the Examples below). The structure shown in Figures 18A and 18B shows that 31H4 binds to PCSK9 in the region of the catalytic site and contacts amino acid residues from both the prodomain and the catalytic domain.

The structure shown also allows the identification of the specific core PCSK9 amino acid residue at the interaction interface of 31H4 with PCSK9. It is defined as a residue present within 5 Å of the 31H4 protein. Core residues are: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349 , T350, L351, E366, D367, D374, V380, S381, Q382, S383, and G384.

In addition, the above structure was used to identify the boundary PCSK9 amino acid residue for the interaction interface with 31H4. These residues are the PCSK9 residues in 5-8 Å of the 31H4 protein. Border residues are: K69, D70, P71, S148, V149 , D186 , T187, E211, D212, G213, R218, Q219, C223, D224, G227 , H229 , L253, N254, G259, P288 , A290 , G291 , G316 , R319, Y325, V346, G352 , T353 , G365 , I368, I369, S372, S373, C378, F379, T385 , S386 , and Q387. The amino acid residues that are completely buried within the PCSK9 protein are underlined.

As will be appreciated by those of skill in the art, FIG. 18B depicts the interaction between the CDRs and PCSK9 on the antigen binding protein. Thus, using this model one of skill in the art can ascertain which residues and/or CDRs are particularly important within the paratope, and which residues are less important to the paratope. As can be seen in Figure 18B, the heavy chain CDR1, CDR2, and CDR3 are most directly involved in the binding of the antigen binding protein to the epitope, where the CDRs from the light chain are relatively farther from the epitope. Therefore, it is clear that larger mutations in the light chain CDRs are possible without unduly inhibiting the binding of the antigen-binding protein to PCSK9. In some embodiments, residues in structures that directly interact are conserved (or alternatively conservatively replaced), while residues that do not directly interact with each other can be altered to a greater degree. Thus, those skilled in the art can predict which residues and regions of the antigen binding protein can be changed, given the teachings of the present invention, without unduly inhibiting the ability of the antigen binding protein to bind to PCSK9. For example, the residue closest to PCSK9 is the one that plays a more important role in the binding of the antigen binding protein to PCSK9, possibly when the antigen binding protein binds to PCSK9. As noted above, these residues can be divided into those within 5 angstroms of PCSK9 and between 5 and 8 angstroms. The specific core 31H4 amino acid residue of the interaction interface with PCSK9 was defined as the 31H4 residue within 5 Å of the PCSK9 protein. For heavy chain, residues within 5 angstroms include: T28, S30, S31, Y32, S54, S55, S56, Y57, I58, S59, Y60, N74, A75, R98, Y100, F102, W103, S104, A105, Y106, Y107, D108, A109, and D111. For the light chain, residues within 5 angstroms include: L48, S51, Y93, and S98. For the heavy chain, residues 5-8 Å from the PCSK9 protein include: G26, F27, F29, W47, S50, I51, S52, S53, K65, F68, T69, I70, S71, R72, D73, K76, N77, D99, D101, F110, and V112. For the light chain, residues within 5-8 angstroms of PCSK9 are A31, G32, Y33, D34, H36, Y38, I50, G52, N55, R56, P57, S58, D94, S95, S96, L97, G99, and S100. Includes.

As one of skill in the art will appreciate, the results from Example 29 demonstrate that antibodies to PCSK9 interact with PCSK9 and can still block PCSK9 from interacting with EGFa (and thus LDLR). Thus, antigen binding proteins that interact with any of these PCSK9 residues, or that block any of these residues (e.g., from other antigen binding proteins that bind to these residues), interact with PCSK9 and EGFa (and thus LDLR). It may be useful as an antibody that inhibits. Thus, in some embodiments, an antigen binding protein that interacts with any of the residues or interacts with a residue within 5 Å of the residue is contemplated to provide useful inhibition of PCSK9 binding to LDLR. Similarly, antigen binding proteins that block any of these residues (eg, which can be determined through competition assays) may also be useful for inhibition of PCSK9/LDLR interactions.

Example 30

21B12 binds to the catalytic domain of PCSK9, has a unique binding site from 31H4, and can bind to PCSK9 at the same time as 31H4.

In this example, the crystal structure of PCSK9 ProCat (31-449 in SEQ ID NO: 3) bound to Fab fragments of 31H4 and 21B12 determined at a resolution of 2.8 Å is shown (conditions for this will be described in the examples below). The crystal structures shown in FIGS. 19A and 19B show that 31H4 and 21B12 have a unique binding site on PCSK9, and both antigen binding proteins can bind to PCSK9 at the same time. The structure shows that 21B12 interacts with amino acid residues from the catalytic domain of PCSK9. In this structure, the interaction between PCSK9 and 31H4 is similar to that observed previously.

The specific core PCSK9 amino acid residue of the interaction interface with 21B12 was defined as the PCSK9 residue present within 5 Å of the 21B12 protein. Core residues are: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, and F379.

The boundary PCSK9 amino acid residues of the interaction interface with 21B12 were defined as the PCSK9 residues at 5-8 Å from the 21B12 protein. Border residues are: I154, T187, H193, E195, I196 , M201, V202, C223, T228 , S235 , G236 , A239, G244, M247, I369, S372, C375, and C378. Amino acid residues that are almost or completely embedded within the PCSK9 protein are underlined.

As will be appreciated by those of skill in the art, FIG. 19B depicts the interaction between the CDRs and PCSK9 on the antigen binding protein. Thus, using this model one of skill in the art can ascertain which residues and/or CDRs are particularly important within the paratope, and which residues are less important to the paratope. As can be seen from the structure, the heavy chain CDR2 and light chain CDR1 appear to interact closely with the epitope. Next, heavy chain CDR1, heavy chain CDR3 and light chain CDR3 appear to be close to the epitope, but not as close to the first set of CDRs. Finally, the light chain CDR2 appears to be at a distance from the epitope. Therefore, it is clear that larger mutations are possible within the farther CDRs without unduly inhibiting the binding of the antigen-binding protein to PCSK9. In some embodiments, residues in structures that directly interact are conserved (or alternatively conservatively replaced), while residues that do not directly interact with each other can be altered to a greater degree. Thus, those skilled in the art can predict which residues and regions of the antigen binding protein can be changed, given the teachings of the present invention, without unduly inhibiting the ability of the antigen binding protein to bind to PCSK9. For example, the residue closest to PCSK9 is the one that plays a more important role in the binding of the antigen binding protein to PCSK9, possibly when the antigen binding protein binds to PCSK9. As noted above, these residues can be divided into those within 5 angstroms of PCSK9 and between 5 and 8 angstroms. The specific core 21B12 amino acid residue of the interaction interface with PCSK9 was defined as the 21B12 residue within 5 Å of the PCSK9 protein. For heavy chain, residues within 5 angstroms include: T30, S31, Y32, G33, W50, S52, F53, Y54, N55, N57, N59, R98, G99, Y100, and G101. For the light chain, residues within 5 angstroms include: G30, G31, Y32, N33, S34, E52, Y93, T94, S95, T96, and S97. For the heavy chain, residues 5-8 Å from the PCSK9 protein include: T28, L29, I34, S35, W47, V51, G56, T58, Y60, T72, M102, and D103. For the light chain, residues within 5-8 angstroms of PCSK9 include: S26, V29, V35, Y51, N55, S92, M98, and V99.

As one of skill in the art can see, the results from Example 30 demonstrate that the antigen binding protein for PCSK9 interacts with PCSK9 and can still block PCSK9 from interacting with EGFa (and thus LDLR). Thus, antigen binding proteins that interact with or block any of these PCSK9 residues may be useful as antibodies that inhibit the interaction of PCSK9 and EGFa (and thus LDLR). Thus, in some embodiments, an antibody that interacts with any of the residues or interacts with a residue within 5 Å of the residue is contemplated to provide useful inhibition of PCSK9 binding to LDLR. Similarly, antigen binding proteins that block any of these residues (eg, which can be determined through competition assays) may also be useful for inhibition of PCSK9/LDLR interactions.

Example 31

Interaction between EGFa, PCSK9, and antibody

The structure of the ternary composite (PCSK9/31H4/21B12) from the above example was covered on the PCSK9/EGFa structure (determined as described in Example 28), and the result of this combination is shown in Fig. 20A. This figure demonstrates a region on PCSK9 that can be usefully targeted to inhibit PCSK9 interaction with EGFa. The figure shows that 31H4 and 21B12 partially overlap the position of the EGFa domain of LDLR and sterically inhibit their binding to PCSK9. In addition, as can be seen from the structure, 21B12 directly interacts with a subset of amino acid residues specifically involved in binding to the LDLR EGFa domain.

As described above, analysis of the crystal structure determines the specific amino acids involved in the interaction between PCSK9 and the partner protein (the core and boundary regions of the interface on the PCSK9 surface), and the spatial requirements of these partner proteins to interact with PCSK9. Confirmed. The structure proposes a method to inhibit the interaction between PCSK9 and LDLR. First, as described above, when the residue is shared with the binding site of the EGFa domain of LDLR, binding of the substance to PCSK9 will inhibit the interaction between PCSK9 and LDLR. Second, substances that bind to the outside of the residues in common can sterically inhibit the EGFa domain of LDLR or the N- or C-terminal region of the EGFa domain to prevent the interaction between PCSK9 and LDLR.

In some embodiments, residues that are involved in both EGFa binding and close to the region to which the aforementioned antigen binding proteins bind are particularly useful for manipulating PCSK9 binding to LDLR. For example, amino acid residues from interfaces that are common in both the core region and the border region for different binding partners are listed in Table 12 below. Amino acid residues that are completely buried within the PCSK9 protein are underlined.

As will be appreciated by those of skill in the art, in some embodiments, the antigen binding protein binds and/or blocks at least one of the aforementioned residues.

Example 32

Structural interaction of LDLR and PCSK9

The PCSK9 ProCat (31-454 of SEQ ID NO: 3)/EGFa complex structure was used to construct a model of full-length PCSK9 bound to the full-length representation of LDLR. The structure of the full length PCSK9 ¹ (Piper, DE et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure 15, 545-52 (2007)) was covered over the PCSK9 ProCat 31-454 from the complex, and a low pH The conformational structure of LDLR (Rudenko, G. et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 298, 2353-8 (2002)) was covered over the EGFa domain from the complex. Drawings of the model are shown in Figs. 20B and 20C. EGFa domains are indicated by text boxes in the figure. The figure shows the region of the LDLR just outside of the EGFa binding domain that lies in close proximity to PCSK9. Figures 20D-20F show this interaction with mesh surface representations of antibodies 31H4 and 21B12 from three different angles. As is apparent from the figure, the antibody not only inhibits and/or can interact with the interaction of LDLR with PCSK9 at the actual binding site, it appears that steric interaction also occurs.

In view of the above results, it is clear that the antigen binding protein that binds to PCSK9 can also inhibit the interaction between PCSK9 and LDLR by colliding with various regions of LDLR (not only the sites where LDLR and PCSK9 interact). For example, it may collide with repeat 7 (R7), EGFb domain, and/or β-propeller domain.

Embodiments of antigen-binding molecules that block or bind to PCSK9 and EGFa interactions

As will be appreciated by those skilled in the art, Examples 28-32 and their accompanying drawings show how and where EGFa interacts with PCSK9, and the two representative neutralizing antigen binding proteins 21B12 and 31H4 interact with PCSK9 and their neutralizing effects. Provides a detailed description of how to represent. Therefore, those skilled in the art can easily identify antigen-binding molecules capable of similarly reducing the binding between EGFa (including LDLR) and PCSK9 by identifying other antigen-binding molecules that bind at or near at least one of the same positions on PCSK9. will be. Relevant sites (or epitopes) on PCSK9 are identified in the figures and description of the invention, but it may also be advantageous to describe these sites as being within a set distance from residues identified as close to the EGFa binding site. In some embodiments, the antigen binding molecule will bind to or be within 30 angstroms of one or more of the following residues (numbered with respect to SEQ ID NO: 3): S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, Q382, W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, Q387, S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, or C378. In some embodiments, the antigen binding molecule binds within 30 angstroms of one or more of the following residues (numbered with respect to SEQ ID NO: 3): S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377 , C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, or Q382. In some embodiments, the antigen binding molecule binds within 30 angstroms of one or more of the following residues (numbered with respect to SEQ ID NO: 3): W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222 , S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148 , V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365 , I368, I369, S372, S373, C378, F379, T385, S386, or Q387. In some embodiments, the antigen binding molecule binds within 30 angstroms of one or more of the following residues (numbered with respect to SEQ ID NO: 3): S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200 , D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372 , C375, or C378.

In some embodiments, the antigen binding molecule binds within 30, 30-25, 25-20, 20-15, 15-8, 8, 8-5, 5, 5-4, 4 Angstroms or less from one or more of the above residues. . In some embodiments, the antigen binding molecule, when bound to PCSK9, is within at least one such distance to more than one such residue. For example, in some embodiments, the antigen binding molecule is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75 or more of the above residues Is within one listed distance (e.g., 30, 30-25, 25-20, 20-15, 15-8, 8, 8-5, 5, 5-4, 4 or less). In some embodiments, the antigen binding molecule is at least 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70- identified in each group of its subgroups. 80, 80-90, 90-95, 95-99, 99-100% of residues (eg, only surface residues within a group) are within one listed distance. Unless stated otherwise specifically, the distance between the antigen-binding molecule and PCSK9 is the shortest distance between the covalently bonded atom on PCSK9 and the covalently bonded atom of the antigen-binding molecule, PCSK9 and the nearest atoms of the antigen-binding molecule. Similarly, unless specifically stated otherwise, the distance between a residue (on antigen-binding molecule or PCSK9) and another protein (PCSK9 or antigen-binding molecule, respectively) is the closest covalent bond of another protein from the closest position on the identified residue. It is the distance to the part. In some embodiments, distance can be measured from the backbone of the amino acid chain. In some embodiments, the distance can be measured between the paratope and the edge and the edge of the epitope (closest to each other). In some embodiments, the distance may be measured between the center of the surface of the paratope and the center of the surface of the epitope. As will be appreciated by those of skill in the art, the description of the invention is applicable to each individual set of residues listed herein. For example, this range is generally considered and is specifically contemplated for the 8 angstrom residues listed in Examples 28-32 and the 5 angstrom residues listed in Examples 28-32.

In some embodiments, the antigen binding molecule binds to a surface on PCSK9 to which at least one of EGFa, 21B12, or 31H4 binds. In some embodiments, the antigen binding molecule binds to PCSK9 at a position that overlaps with the site of the interaction between PCSK9 and EFGa, Ab 31H4, and/or Ab 21B12 (as described in the Examples and Figures above). In some embodiments, the antigen binding molecule binds to PCSK9 at a location further away from one of the residues listed above. In some embodiments, the antigen binding molecule may still be an effective neutralizing antigen binding molecule.

In some embodiments, the structure of the catalytic domain of PCSK9 can be described as being entirely triangular (as shown in Figure 19A). 31H4 is shown to be bonded to the first side of the triangle. 21B12 is shown to be joined to the second side of the triangle, and the third side of the triangle is positioned toward the bottom of the page, just above the cover of “Fig. 19A”. In some embodiments, antigen binding molecules that bind to the first and/or second side of the catalytic domain of PCSK9 can directly or sterically inhibit the binding of EGFa to PCSK9 and thus may be useful as neutralizing antibodies. As will be appreciated by one of skill in the art, if the antigen binding molecule is too large, for example a whole antibody, the antigen binding molecule does not need to bind directly to the EGFa binding site to inhibit the binding of EGFa to PCSK9.

As will be appreciated by those of skill in the art, although the EGFa domain of LDLR has been used in many instances, the model and structure are still applicable to how the full-length LDLR protein will interact with PCSK9. Indeed, the additional structure present on the full-length LDLR protein presents an additional protein space that can be further blocked by one of the antigen binding molecules. Thus, if an antigen-binding molecule blocks or inhibits the binding of EGFa to PCSK9, it will probably be at least as effective as the full-length LDLR protein, if not more. Similarly, antigen binding molecules that block the various residues involved to inhibit EGFa binding or are within a set distance will probably be as effective as full-length LDLR, if not more.

As will be appreciated by one of skill in the art, any molecule that blocks or binds to (or is within the listed distances) the PCSK9 residue described above, or inhibits one or more interactions described in the Examples and Figures above, is EGFa (or Generally LDLR) and PCSK9 can be used to inhibit the interaction. Thus, the molecule need not be limited to an antigen binding "protein", as any antigen binding molecule may also serve the required purpose. Examples of antigen binding molecules include aptamers, which may be oligonucleotides or peptide molecules. Other examples of antigen binding molecules include abimers, peptibodies, small molecules and polymers, and modified versions of EGFa that can increase their affinity and/or half-life for PCSK9, e.g., mutations of amino acids, glycosylation, peg. Fusions, Fc fusions, and Avimer fusions. As will be appreciated by those of skill in the art, in some embodiments, LDLR is not an antigen binding molecule. In some embodiments, the binding subsection of LDLR, e.g., EGFa, is not an antigen binding molecule. In some embodiments, the other molecule through which PCSK9 signals in vivo is not an antigen binding molecule. Such an embodiment will be clearly identified as such.

Example 33

Expression and purification of protein samples

This example describes some embodiments of a method for preparing and purifying (including LDLR EGFa domains) various embodiments of the PCSK9 protein/variant. PCSK9 protein/variant (e.g., PCSK9 31-692 N533A, PCSK9 449TEV and PCSK9 ProCat 31-454) in Hi-5 insect cells infected with baculovirus N-terminal honeybee melitin signal peptide followed by His ₆ tag Was expressed with. PCSK9 protein was purified by nickel affinity chromatography, ion exchange chromatography and size exclusion chromatography. The melittin-His ₆ tag was removed during purification by cleavage with TEV protease. PCSK9 ProCat (31-449) and V domain (450-692) samples were generated using the construct PCSK9 449TEV. This construct had a TEV protease cleavage site inserted between PCSK9 residues 449 and 450. For the full-length N555A variant for crystallography, the PCSK9 31-454 fragment, and the PCSK9 449TEV variant for crystallography, the protein product after rTEV also included the initial GAMG sequence. Thus, after rTEV cleavage, these proteins were GAMG-PCSK9. In addition, the PCSK9 449TEV protein included the sequence "ENLYFQ" (SEQ ID NO: 403) inserted between H449 and G450 of SEQ ID NO: 3. After cleavage with rTEV, the PCSK9 ProCat protein generated from this construct was GAMG-PCSK9 (31-449)-ENLYFQ, and the V domain generated from this construct was PCSK9 (450-692) of SEQ ID NO: 3.

21B12 and 31H4 Fab fragments were transferred to E. Expressed in E. coli. These proteins were purified by nickel affinity chromatography, size exclusion chromatography and ion exchange chromatography.

LDLR EGFa domain (293-334) was used as a GST fusion protein. Expressed in E. coli. The EGFa domain was purified by ion exchange chromatography, glutathione sepharose affinity chromatography and size exclusion chromatography. The GST protein was removed during purification by digestion with the PreScission protease.

Example 34

Complex formation and crystallization

In this example, a method of manufacturing the composite and crystal used in the structural test example will be described.

The PCSK9 31-692 N533A/31H4 complex was prepared by mixing a 1.5 molar excess of 31H4 Fab with PCSK9. The complex was purified by size exclusion chromatography to remove excess 31H4 Fab. PCSK9 31-692 N533A/31H4 complex crystallizes in 0.1 M Tris pH 8.3, 0.2 M sodium acetate, 15% PEG 4000, 6% dextran sulfate sodium salt (Mr 5000).

The PCSK9 ProCat 31-449/31H4/21B12 complex was prepared by first mixing a 1.5 molar excess of 31H4 Fab with PCSK9 31-449. The complex was separated from excess 31H4 by purification on a size exclusion chromatography column. Then, a 1.5 molar excess of 21B12 Fab was added to the PCSK9 31-449/31H4 complex. The ternary complex was separated from excess 21B12 by purification on a size exclusion chromatography column. The PCSK9 ProCat 31-449/31H4/21B12 complex crystallizes in 0.1 M Tris pH 8.5, 0.2 M ammonium monophosphate, 50% MPD.

The PCSK9 ProCat 31-454/EGFa complex was prepared by mixing a 1.2 molar excess of the EGFa domain with PCSK9 31-454. The PCSK9 ProCat 31-454/EGFa domain complex crystallizes in 0.2 M potassium formate, 20% PEG 3350.

Example 35

Data collection and structure determination

This example describes a method of collecting a dataset and determining a structure for the structure checking example.

Initial datasets for the PCSK9 31-692 N533A/31H4 and PCSK9 ProCat 31-449/31H4/21B12 crystals were collected on a Rigaku FR-E X-ray source. PCSK9 ProCat 31-454/EGFa datasets, and higher resolution datasets for PCSK9 31-692 N533A/31H4 and PCSK9 ProCat 31-449/31H4/21B12 crystals were collected from Berkeley Advanced Light Source beamline 5.0.2 I did. All datasets were processed using denzo/scalepack or HKL2000 (Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities. Acta Crystallogr A 59, 228-34 (2003) )).

The PCSK9/31H4 crystal grows into a C2 space group with unit cell dimensions a=264.9, b=137.4, c=69.9Å, and β=102.8°, and diffracts with 2.3Å resolution. The PCSK9/31H4 structure is the starting exploration model, using the PCSK9 structure (Piper, DE et al. The crystal structure of PCSK9: a regulator of plasma LDL-colesterol.Structure 15, 545-52 (2007)), using the program MOLREP (The CCP4). suite: programs for protein crystallography.Acta Crystallogr D Biol Crystallogr 50, 760-3 (1994)). While the PCSK9 31-692 solution was fixed and maintained, the antibody variable domain was used as a search model. While the PCSK9 31-692/antibody variable domain solution was immobilized and maintained, the antibody constant domain was used as a search model. The complete structure was improved using multiple rounds of model building using Quanta and refinement using cnx (Brunger, AT et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta) Crystallogr D Biol Crystallogr 54, 905-21 (1998)).

_{The PCSK9/31H4/21B12 crystal grows into a P2 1} 2 ₁ 2 space group with unit cell dimensions a=138.7, b=246.2, c=51.3Å, and diffracts with a resolution of 2.8Å. The PCSK9/31H4/21B12 structure was revealed by molecular replacement using the program MOLREP using the PCSK9 ProCat/31H4 variable domain as the starting search model. While immobilizing and maintaining the PCSK9 ProCat/31H4 variable domain, a search for the antibody constant domain was performed. While the PCSK9 ProCat/31H4/21B12 constant domain was immobilized and maintained, the antibody variable domain was used as a search model. The complete structure was improved using multiple rounds of model construction using Quanta and fine-tuning using cnx.

_{The PCSK9/EGFa domain crystal grows into a space group P6 5} 22 with unit cell dimensions a = b = 70.6 and c = 321.8 Å, and diffracts with a resolution of 2.9 Å. The PCSK9/EGFa domain structure was revealed by molecular replacement using the program MOLREP using PCSK9 ProCat as the starting exploratory model. Analysis of the electron density map showed a clear electron density for the EGFa domain. The LDLR EGFa domain was manually fitted, and the model was improved using multiple rounds of model construction using Quanta and fine-tuning using cnx.

The core interacting interfacial amino acids were determined to be all amino acid residues having at least one atom within 5 Å from the PCSK9 partner protein. 5 Å was chosen as the core region cutoff distance to ensure that the atoms are within van der Waals radius + possible water-mediated hydrogen bonds. Border Interaction Interfacial amino acids were determined to be all amino acid residues that had at least one atom within 8 Å from the PCSK9 partner protein but were not included in the core interaction list. 8 Å or less were chosen as the border region cutoff distance to allow for the length of the extended arginine amino acid. Amino acids satisfying these distance criteria were calculated using the program PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System. (Palo Alto, 2002)).

Example 36

Crystal structure of PCSK9 and 31A4

The crystal structure of the 31A4/PCSK9 complex was determined.

Expression and purification of protein samples

PCSK9 449TEV (PCSK9 construct with TEV protease cleavage site inserted between residues 449 and 450, numbered according to SEQ ID NO: 3) was followed by the N-terminal honeybee melitin signal peptide in Hi-5 insect cells infected with baculovirus. It was expressed with _{His 6 tag.} PCSK9 protein was first purified by nickel affinity chromatography. The TEV protease was used to remove the melittin-His ₆ tag and cleave the PCSK9 protein between the catalytic and V domains. The V domain was further purified by ion exchange chromatography and size exclusion chromatography. The 31A4 Fab fragment was transferred to E. It was expressed in E. coli. The protein was purified by nickel affinity chromatography, size exclusion chromatography and ion exchange chromatography.

Complex formation and crystallization

The PCSK9 V domain/31A4 complex was prepared by mixing a 1.5 molar excess of PCSK9 V domain with the 31A4 Fab. The complex was separated from the excess PCSK9 V domain by purification on a size exclusion chromatography column. The PCSK9 V domain/31A4 complex crystallized in 1.1 M succinic acid pH 7, 2% PEG MME 2000.

Data collection and structure determination

Datasets for PCSK9 V domain/31A4 crystals were collected on a Rigaku FR-E x-ray source and processed with denzo/scalepack (Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities.Acta Crystallogr A 59, 228-34 (2003)).

_{The PCSK9 V domain/31A4 crystal grows into a P2 1} 2 ₁ 2 ₁ space group with unit cell dimensions a = 74.6, b = 131.1, c = 197.9 Å, with two complex molecules per asymmetric unit, and diffracts with a resolution of 2.2 Å. . The PCSK9 V domain/31A4 structure is a starting exploration model using the V domain of the PCSK9 structure (Piper, DE et al. The crystal structure of PCSK9: a regulator of plasma LDL-colesterol. Structure 15, 545-52 (2007)). It was revealed by molecular replacement using the program MOLREP (CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-3 (1994)). While the PCSK9 450-692 solution was fixed and maintained, the antibody variable domain was used as a search model. After initial refinement, the antibody constant domains were manually fitted. The complete structure was improved using multiple rounds of model construction using Quanta and fine-tuning using cnx (Brunger, AT et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54, 905-21 (1998)).

The core interacting interfacial amino acids were determined to be all amino acid residues having at least one atom within 5 Å from the PCSK9 partner protein. 5 Å was chosen as the core region cutoff distance to ensure that the atoms are within the Van der Waals radius + possible water-mediated hydrogen bonds. Border Interaction Interfacial amino acids were determined to be all amino acid residues that had at least one atom within 8 Å from the PCSK9 partner protein but were not included in the core interaction list. 8 Å or less were chosen as the border region cutoff distance to allow for the length of the extended arginine amino acid. Amino acids satisfying these distance criteria were calculated using the program PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System. (Palo Alto, 2002)). Distance was calculated using the V domain “A” and 31A4 “L1,Hl” complexes.

The crystal structure of the PCSK9 V domain bound to the Fab fragment of 31A4 was determined at a resolution of 2.2 Å. A diagram of the crystal structure is provided in Figs. 21A-21D. 21A-21C show that 31A4 Fab binds to the PCSK9 V domain in the region of subdomains 1 and 2.

A model of full length PCSK9 bound to 31A4 Fab was prepared. The structure of the full-length PCSK9 was covered over the PCSK9 V domain from the complex. A diagram of the model is shown in Fig. 21D. Highlights the site of interaction between the EGFa domain of LDLR and PCSK9.

Analysis of the structure showed the position where the antibody interacts with PCSK9, and it was demonstrated that an antibody that did not bind to the LDLR binding surface of PCSK9 can still inhibit the degradation of LDLR mediated through PCSK9 (results are shown below. When looking in combination with Examples 40 and 41). In addition, the analysis of the crystal structure allows the identification of specific amino acids involved in the interaction between the PCSK9 and the 31A4 antibody. In addition, the core and boundary regions of the interface on the PCSK9 surface were also determined. The specific core PCSK9 amino acid residue of the interaction interface with 31A4 was defined as the PCSK9 residue present within 5 Å of the 31A4 protein. Core residues are T468, R469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and It is E593. The boundary of the interaction interface with 31A4 PCSK9 amino acid residues were defined as the PCSK9 residues at 5-8 Å from the 31A4 protein. Border residues are: S465, G466, P467, A473, I474, R476, G497 , E498 , M500, G504, K506, L507, V508, A511 , N513 , A514, G516, V536, T538, A539, A544, T548 , D570, L571, H591, A594, S595, and H597. Amino acid residues that are almost or completely embedded within the PCSK9 protein are underlined. As indicated herein, the numbering refers to the amino acid position of SEQ ID NO: 3 (adjusted as shown herein).

The specific core 31A4 amino acid residue of the interaction interface with PCSK9 was defined as the 31A4 residue present within 5 Å of the PCSK9 protein. The core residues for the 31A4 antibody are as follows: heavy chain: G27, S28, F29, S30, A31, Y32, Y33, E50, N52, H53, R56, D58, K76, G98, Q99, L100, and V101; Light chain: S31, N32, T33, Y50, S51, N52, N53, Q54, W92, and D94. The boundary 31A4 amino acid residue of the interaction interface with PCSK9 was defined as the 31A4 residue located 5-8 Å from the PCSK9 protein. The border residues for 31A4 are as follows: heavy chain: V2, G26, W34, N35, W47, I51, S54, T57, Y59, A96, R97, P102, F103, and D104; Light chain: S26, S27, N28, G30, V34, N35, R55, P56, K67, V91, D93, S95, N97, G98, and W99.

The crystal structure also indicated the spatial requirements of the ABP of its interaction with PCSK9. As can be seen from the above structure, surprisingly, antibodies that bind to PCSK9 can still inhibit the function of PCSK9 without directly preventing the interaction of PCSK9 with LDLR.

In some embodiments, any antigen binding protein that binds to, covers, or inhibits the interaction of 31A4 with any of the above residues can be used to bind or neutralize PCSK9. In some embodiments, ABP binds or interacts with at least one of the following PCSK9 (SEQ ID NO: 3) residues: T468, R469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and E593. In some embodiments, the ABP is within 5 angstroms of one or more of the residues. In some embodiments, ABP binds or interacts with at least one of the following PCSK9 (SEQ ID NO: 3) residues: S465, G466, P467, A473, I474, R476, G497 , E498 , M500, G504, K506, L507, V508, A511 , N513 , A514, G516, V536, T538, A539, A544, T548, D570, L571, H591, A594, S595, and H597. In some embodiments, the ABP is at 5 to 8 angstroms of one or more of the residues. In some embodiments, the ABP is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, or Interacts with, blocks, or is within 8 angstroms of 50 such residues.

The coordinates for the crystal structures discussed in the above examples are in Table 35.1 (full length PCSK9 and 31H4), Table 35.2 (PCSK9 and EGFa), Table 35.3 (PCSK9, 31H4, and 21B12), and Table 35.4 (PCSK9 and 31A4). present. Relevant regions or residues of the structure of PCSK9 shown at their corresponding positions on the structure from the figures and/or coordinates (15, 15-8, 8, 8-5, 5 angstroms from EGFa, or the position at which the antibody interacts with PCSK9. Antigen binding proteins and molecules that interact with (including regions or residues within) are also contemplated.

The antibody described in the coordinates is E. It was produced in E. coli and thus has some minor amino acid differences from fully human antibodies. For the heavy and light chains of 21B12 and the light chain for 31H4 the first residue in the variable region was glutamic acid instead of glutamine. In addition to the differences in the sequence of the variable regions, there were also some differences in the constant regions of the antibodies described by coordinates (also due to the fact that the antibodies were generated in E. coli). Figure 22 highlights the difference in the constant regions of the 21B12, 31H4, and 31A4 Fabs (generated within E. coli) compared to SEQ ID NOs:156 and 155 (via underlined shading, or boldface). For 21B12 31H4, and 31A4, the light chain constant sequence is similar to human lambda (SEQ ID NO: 156). The underlined glycine residue is the insertion between the position where the 21B12 and 31H4 variable sequences stop and the lambda sequence begins.

For both 21B12 and 31H4, the heavy chain constant region is similar to human IgG4 (SEQ ID NO: 155). The differences highlighted in Figure 22 are presented in Table 36.1:

<Table 36.1>

It also has the same distinction as described above for 31A4, but there are three additional differences. As shown in Figure 22, there are two additional amino acids at the beginning, which are E. It results from incomplete processing of the signal peptide in E. coli expression. In addition, there is one additional substitution in the 31A4 heavy chain constant region compared to SEQ ID NO: 155, which is an adjustment of L (in SEQ ID NO: 155) to H. Finally, 31A4 has glutamine as the initial amino acid of Fab, rather than the above-described adjustment for glutamic acid for 21B12 and 31H4.

For all three antibodies, the ends of the heavy chain (dark gray text boxes) are also different, but the amino acids do not appear in the coordinates because they are not ordered within the structure. As will be appreciated by those of skill in the art, the his-tag is not a required part of the ABP, unless explicitly asserted by the statement that the ABP sequence "comprises a histidine tag" while referring to the specific sequence number including the histidine tag. Should not be considered as part of the sequence of.

Example 37

Epitope Mapping-Binning

In addition to the set of Example 10, a separate set of binning experiments were performed. As in Example 10, ABPs competing with each other can be thought of as binding to the same site on the target, and in conventional terms are said to "bin" together.

A variation of the multiplexed binning method described in Jia, et al., J. Immunological Methods, 288 (2004) 91-98 was used. Individual bead codes of streptavidin-coated Luminex beads were combined with 100 μl 0.5 μg/ml biotinylated monovalent mouse-anti-human IgG capture antibody (BD Pharmingen, #555785). After incubating in the dark at room temperature for 1 hour, it was washed 3x with PBSA (phosphate buffered saline (PBS) + 1% bovine serum albumin (BSA)). Each bead cord was separately incubated with 100 µl 2 µg/ml anti-PCSK9 antibody (coating antibody) for 1 hour, and then washed 3x with PBSA. After collecting the beads, they were distributed to a 96-well filter plate (Millipore, #MSBVN1250). 100 μl of 2 μg/ml purified PCSK9 protein was added to half of the wells. Buffer was added to the other half as a control. The reaction was incubated for 1 hour and then washed. 100 μl of 2 μg/ml anti-PCSK9 antibody (detection Ab) was added to all wells, incubated for 1 hour, and washed. Unrelated human-IgG (Jackson, #009-000-003) was run as another control. 20 μl of PE-conjugated monovalent mouse-anti-human IgG (BD Pharmingen, #555787) was added to each well, incubated for 1 hour and then washed. Beads were resuspended in 100 μl PBSA and a minimum of 100 events/bead codes were collected on a BioPlex instrument (BioRad).

The median fluorescence intensity (MFI) of the antibody pair without PCSK9 was subtracted from the signal of the corresponding reaction containing PCSK9. For pairs of antibodies in different bins that are considered to be bound simultaneously, therefore, the subtracted signal must be three times that of an antibody competing with itself and three times that of an antibody competing with an unrelated antibody.

Data therefrom are shown in Figs. 23A-23D. The ABP is divided into 5 bins. The shaded text boxes indicate ABPs that can bind to PCSK9 at the same time. Unshaded text boxes indicate ABPs competing with each other for binding. A summary of the results is presented in Table 37.1.

<Table 37.1>

Bin 1 (Compete with ABP 21B12) and Bin 3 (Compete with 31H4) are mutually exclusive; Bin 2 competes with bins 1 and 3; Bin 4 does not compete with bins 1 and 3. In this example, bin 5 is presented as a "catch all" bin describing ABPs that do not fit in other bins. Thus, the identified ABPs in each bin represent different kinds of epitope positions on PCSK9, some of which overlap each other.

As will be appreciated by one of skill in the art, if the reference ABP prevents binding of the probe ABP, the antibody is said to be in the same bin. The order in which the ABPs are used can be important. If ABP A is used as a reference ABP and blocks binding of ABP B, then the opposite is not always true: ABP B used as reference ABP will not necessarily block ABP A. There are many factors that play a role here: binding of ABP can lead to conformational changes at the target, preventing binding of the second ABP, or epitopes that overlap but are not completely obstructed by the second ABP still inhibit binding. It can be made to have a sufficiently high-affinity interaction with the target to allow. ABPs with much higher affinity may have a greater ability to repel blocking ABPs. In general, if competition is observed in either order, the ABPs are said to bin together, and if the two ABPs are able to block each other, it appears that the epitopes probably overlap more completely.

Example 38

Epitope Mapping-Western Blot

In this example, it is verified whether the epitope for the tested ABP is linear or conformational. To determine which antibody has a conformational epitope, denatured reducing and denatured non-reducing Western blots were performed. Antibodies that bind to the denatured reducing western blot have a linear epitope and are not conformational. The results are presented in FIGS. 24A and 24B. For the blot, 0.5 μg/lane of purified full-length human PCSK9 was developed in 4-12% NuPAGE Bis-Tris gel and MES SDS running buffer. Blots were probed using 1 μg/ml anti-PCSK9 antibody (except 0.5 μg/ml 31G11). A 1:5000 monkey-anti-human-IR700 secondary antibody was used and read on a LiCOR instrument. Antibody 13H1 bound on the pro-domain of PCSK9. All other antibodies showed results consistent with the conformational epitope. These gels separated the pro-domain from the rest of the protein, and the pro-domain was developed at about 15 kDa. Additionally, 3C4 and 31A4 have been shown to bind to the conserved conformational epitope by disulfide bonds, indicating that these antibodies bind to PCSK-9 under denaturing conditions in which disulfide bonds are preserved (left), but the sample This is because reducing (right) removes the bond.

Example 39

Epitope mapping-arginine/glutamic acid scanning

Representative ABPs from each bin (of Example 37) were selected for further epitope analysis. An arginine/glutamic acid-scanning strategy was performed to map ABP that binds to PCSK9. As a background, the method determines whether a residue is part of a structural epitope, meaning a residue in the antigen that is in contact with or is buried by the antibody. Arginine and glutamic acid side chains are charged and bulky, and can disrupt antibody binding even if mutated residues are not directly involved in antibody binding.

Residue selection

The crystal structure of PCSK9 was used to select residues to be mutated for epitope mapping. The methods used to select the residues to be mutated included both computational mechanisms and interaction structure analysis. The PCSK9 structure contained a gap of missing residues, and 30 amino acids at the N- (i.e. signal sequence) end and 10 amino acids at the C-terminus were missing. Internal missing residues were modeled on the structure, while N- and C-terminal missing residues were not. The solvent exposure ratio for each residue was calculated: the surface area of each residue (SA1) in terms of the protein is the surface area of the residue in the trimer in the presence of flanking glycine with a conserved backbone structure ( SA2). Residues (R10) with solvent exposure ratios greater than 10%, and 40 missing terminal residues were selected. From these, proline and glycine with a positive Φ angle were excluded to reduce the likelihood of misfolding. The number of residues to be mutated in the V domain was reduced by using a solvent exposure ratio of 37% with visual inspection of the whole protein so that the total number of mutations was 285. Various orientations of the surface of PCSK9 identifying these various types are shown in FIGS. 25A-25F. In these figures, the lightest color indicates areas that are not selected or excluded from selection, and darker gray color indicates selected residues.

Cloning and expression

Once the residues to be changed were identified, various residues were changed. Human PCSK9 was cloned into the pTT5 vector with the C-terminal Flag-His tag. Mutants were prepared from the original construct by site-directed mutagenesis using the QuikChange II kit (Stratagene). Sense and antisense oligonucleotides used for mutagenesis were designed using Amgen's MutaGenie software. All PCSK9 constructs were expressed in 24-well plates in transiently-transfected 293-6E cells and re-installed into three 96-well plates with non-mutated PCSK9 controls (wild type, WT) in each plate. I did. The expression level and integrity of the recombinant protein in the conditioned medium were examined by Western blot. Of the 285 mutants originally selected, 41 failed in cloning or expression. 244 mutants were used for epitope mapping. The alignment of the PCSK9 parental sequence and a representative PCSK9 sequence with 244 mutated residues is shown in FIG. 26. Separate constructs were prepared containing a single mutation. For epitope sequences comprising changes in binding and inventions based on epitopes, sequences are provided with reference to SEQ ID NO: 1 and/or SEQ ID NO: 303. The sequence in Figure 26 was the sequence used for this binding epitope study. Those of skill in the art will appreciate that the results of this study also apply to other PCSK9 variants disclosed herein (eg, SEQ ID NOs: 1 and 3, and other allelic variants).

Five antibodies representing each bin were selected for precise epitope mapping. These were 21B12, 31H4, 12H11, 31A4, 3C4. All conformational epitope antibodies. Three, namely 21B12, 31H4, and 31A4 were also crystallized with PCSK9 as described above.

Structural and functional epitopes

Epitopes can be further defined structurally or functionally. Functional epitopes are generally a subset of structural epitopes and have moieties that directly contribute to the affinity of the interaction (eg hydrogen bonding, ionic interaction). Structural epitopes can be thought of as patches of targets covered by antibodies.

The scanning mutagenesis used were arginine and glutamic acid scans. These two side chains were chosen because of their large steric volume and charge, allowing mutations to occur within the structural epitope to have a greater effect on antibody binding. Arginine is commonly used except when the WT residue is arginine, and in these cases the residue is mutated to glutamic acid to change the charge.

For the purpose of epitope mapping, antibody binding to PCSK9 and PCSK9 mutants was simultaneously measured using a bead-based multiplexing assay. The antibody binding to the mutant was then compared to its binding to the wild type in the same well. The variants were divided into 3 groups: Group 1: 81 variants + 2 wt control + 1 negative control + 1 other PCSK9 supernatant; Group 2: 81 variant + 2 wt control + 2 negative control; And Group 3: 82 variants + 2 wt control + 1 negative control.

The analysis was run as follows: 85 sets of color-coded streptavidin-coated LumAvidin beads (LumiNex) were biotinylated with anti-pentaHis antibody (Qiagen, #1019225 ) And (RT) at room temperature for 1 hour, and then washed 3 times in PBS, 1% BSA, 0.1% Tween 20. Each color coded bead set was then bound to PCSK9 mutant, wild type, or negative control overnight at 4° C. in 150 μl supernatant.

A set of color coded beads (each associated with a specific protein) was washed and collected. At this point, there were 3 pools of 85 bead sets, where one pool was for each group of mutants and controls. Beads from each pool were aliquoted into 24 wells (3 columns) of a 96-well filter plate (Millipore, #MSBVN1250). 100 μl of anti-PCSK9 antibody in 4-fold dilution was added to 9 columns for triple points, incubated for 1 hour at RT and washed. 100 μl of 1:200 dilution phycoerythrin (PE)-conjugated anti-human IgG Fc (Jackson Immunoresearch, #109-116-170) was added to each well and for 1 hour Incubated at RT and washed.

Beads were resuspended in 1% BSA in PBS, shaken for 10 minutes, and read on a BioPlex instrument (BioRad). The instrument identifies each bead by its color-code, identifying the specific protein associated with the color-code. At the same time, the instrument measures the amount of antibody bound to the beads by the fluorescence intensity of the PE dye. The antibody binding to each mutant can then be compared directly to its binding to the wild type in the same pool. IL-17R chimera E was used as a negative control. All mutants tested are shown in Table 39.1 (see sequence numbering used in Figures 1A and 26).

<Table 39.1>

Bead Variability Study

Prior to running the epitope mapping binding assay, confirmation experiments were performed to evaluate “bead area” versus “bead area” (B-B) variability. In the confirmation experiment, all beads were conjugated with the same wild type control protein. Thus, the difference between the bead regions is purely due to the B-B variance and is not confused by the difference between wild type and mutant proteins. The titration of the antibody was run in 12 different wells.

The purpose of this statistical analysis was to estimate the B-B variability of the estimated EC50 of the binding curve. The estimated B-B standard deviation (SD) was then used to construct the EC50 confidence intervals of wild-type and mutant proteins during curve comparison experiments.

A four parameter logistic model was fitted to the binding data for each bead region. The resulting file containing curve quality control (QC) results, and parameter estimates for the Top (max), Bottom (min), Hillslope (slope) and natural log (xmid) of the EC50 of the curve are used as raw data for analysis. I did. The B-B variability for each parameter was then estimated by fitting a mixed effect model using the SAS PROC MIXED procedure. Only curves with “good” QC status were included in the analysis. The final mixed effect model included only residuals (ie individual bead regions) as random effects. The least squares mean (LS-mean) for each parameter was also estimated by the mixed effect model. B-B SD was calculated by taking the square root of the B-B variance. The fold of change between the LS-mean + 2SD and the LS-mean-2SD (representing approximately the upper and lower 97.5 percentiles of the population) was also calculated. The results are shown in Table 39.2.

<Table 39.2>

Identification of residues within a structural epitope

A residue was considered part of a structural epitope (“hit”) if it altered antibody binding when mutating it to arginine or glutamic acid. This appears to be a shift in the EC50 or a decrease in maximal signal compared to antibody binding to the wild type. Statistical analysis of antibody binding curves for wild-type and mutants was used to identify statistically significant EC50 shifts. The analysis considers the variance in the analysis and curve fitting.

Hit check based on EC50 comparison

EC50 and Bmax values were generated from a weighted 4-parameter logistic model fitted to binding data using S-PLUS (Insightful Corporation, Seattle, WA) with VarPower software. The EC50 of the mutant binding curve and the wild type binding curve were compared. Statistically significant differences were identified as hits for further consideration. Curves with “nofit” or “badfit” flags were excluded from the analysis.

Variance of the EC50 estimate

Two sources of variance, the injection from the curved fit and the bead-bead variance, were considered in the comparison of the EC50 estimates. Wild-type and mutants were linked to different beads because their differences are confused with bead-bead differences (described above). The curve fit variance was estimated by the standard error of the log EC50 estimate. Bead-bead dispersion was determined experimentally using an experiment (described above) in which a wild-type control was connected to each one bead. The bead variance of the EC50 estimate of the wild-type binding curve from the above experiment was used to estimate the bead-bead variance in the actual epitope mapping experiment.

Test for EC50 shift between mutant and wild type

Comparison of the two EC50s (log scale) was performed using Student's t-test. The t-statistic was calculated as the ratio between the delta (absolute difference between EC50 estimates) and the standard deviation of the delta. The variance of the delta was estimated by the sum of three components, the variance estimate of the EC50 for the mutant and wild-type curves in nonlinear regression, and two times the bead-bead variance estimated from a separate experiment. The fold 2 for bead-bead variance was due to the assumption that both mutant and wild-type beads had the same variance. The degrees of freedom of the standard deviation of the delta were calculated using Satterthwaite's (1946) approximation. Individual p-values and confidence intervals (95% and 99%) were derived based on Student's t distribution for each comparison. In the case of multiple wild-type controls, a conservative method was taken by selecting the wild-type control most similar to the mutant, ie, selecting the one with the maximum p-value.

Multiplicity adjustment was important to control false positive(s) while running multiple tests simultaneously. Two types of multiplicity adjustment were performed for this analysis: family wise error (FWE) control and false discovery rate (FDR) control. The FWE method controls the likelihood that one or more hits are not real; The FDR method controls the expected proportion of false positives among the selected hits. The former method is more conservative and less powerful than the latter method. There are many methods available for both methods for analysis; Hochberg's (1988) method for FWE analysis, and Benjamini-Hochberg's (1995) FDR method for FDR analysis were selected. Adjusted p-values for both methods were calculated.

result

EC50 move

Mutations whose EC50 differs significantly from the wild type, e.g., with a false discovery rate adjusted p-value of 0.01 or less for the full assay are considered to be part of the structural epitope. All hits also had a Familywise Type I error rate adjusted p-value of less than 0.01 for each antibody, except for residue R185E for antibody 31H4 with a FWE adjusted p-value of 0.0109 per antibody. Residues within the structural epitopes of various antibodies determined by EC50 shift are shown in Table 39.3 (point mutations refer to SEQ ID NOs: 1 and 303).

<Table 39.3>

Maximum signal reduction

The maximum signal percent was calculated using the curve fitting (BmaxPerWT) and the maximum signal from the raw data points (RawMaxPerWT). A mutation that reduces the antibody binding maximal signal by ≥70% compared to the wild-type signal, or when all other antibodies are at least 40% of the wild-type, reduces the signal of one antibody by >50% compared to the other antibody and is found to be part of the epitope. Was considered. Table 39.4 indicates the residues within the structural epitope as determined by the decrease in the maximal signal (italic).

<Table 39.4>

Table 39.5 shows a summary of all hits for various antibodies.

<Table 39.5>

To further examine how these residues form some or all of the relevant epitopes, the above-described positions were mapped into various crystal structure models, and the results are shown in FIGS. 27A-27E. Figure 27A depicts the 21B12 epitope hit when mapped onto the crystal structure of PCSK9 using the 21B12 antibody. The structure identifies the PCSK9 residues as follows: light gray indicates unmutated residues (excluding residues explicitly indicated on the structure), darker gray indicates mutated residues (a few of which are not expressed). Clearly indicated residues were tested (regardless of the shade indicated in the figure) and resulted in significant changes in EC50 and/or Bmax. Epitope hits were based on the Bmax shift. In this figure, 31H4 is behind 21B12.

Figure 27B depicts the 31H4 epitope hit when mapped onto the crystal structure of PCSK9 using the 31H4 and 21B12 antibodies. The structure identifies the PCSK9 residues as follows: light gray indicates unmutated residues (excluding residues explicitly indicated on the structure), darker gray indicates mutated residues (a few of which are not expressed). Clearly indicated residues were tested (regardless of the shade indicated in the figure) and resulted in significant changes in EC50 and/or Bmax. Epitope hits were based on EC50 shifts.

Figure 27C depicts the 31A4 epitope hit when mapped onto the crystal structure of PCSK9 using the 31H4 and 21B12 antibodies. The structure identifies the PCSK9 residues as follows: light gray indicates unmutated residues (excluding residues explicitly indicated on the structure), darker gray indicates mutated residues (a few of which are not expressed). Clearly indicated residues were tested (regardless of the shade indicated in the figure) and resulted in significant changes in EC50 and/or Bmax. Epitope hits were based on EC50 shifts. The 31A4 antibody is known to bind to the V-domain of PCSK9, which appears to be consistent with the results presented in Figure 27C.

Figure 27D depicts the 12H11 epitope hit when mapped onto the crystal structure of PCSK9 using 31H4 and 21B12 antibodies. The structure identifies the PCSK9 residues as follows: light gray indicates unmutated residues (excluding residues explicitly indicated on the structure), darker gray indicates mutated residues (a few of which are not expressed). Clearly indicated residues were tested (regardless of the shade indicated in the figure) and resulted in significant changes in EC50 and/or Bmax. 12H11 competes with 21B12 and 31H4 in the binning assay described above.

Figure 27E depicts the 3C4 epitope hit when mapped onto the crystal structure of PCSK9 using 31H4 and 21B12 antibodies. The structure identifies the PCSK9 residues as follows: light gray indicates unmutated residues (excluding residues explicitly indicated on the structure), darker gray indicates mutated residues (a few of which are not expressed). Clearly indicated residues were tested (regardless of the shade indicated in the figure) and resulted in significant changes in EC50 and/or Bmax.

3C4 does not compete with 21B12 and 31H4 in binning analysis. 3C4 binds to the V-domain in the domain binding assay (results of Example 40, see FIGS. 28A and 28B).

There are approximately 12 mutants expected to affect binding (based on crystal structure), but this experiment surprisingly demonstrated that they did not. As will be appreciated by those of skill in the art, the results presented above are in good agreement with the crystal structure of these antibodies and the binding of PCSK9. This demonstrates that the structural data provided and the corresponding functional data suitably identify key residues and regions of the interaction of neutralizing ABP and PCSK9. Accordingly, a variant of ABP having the ability to bind to the above-described region is suitably provided by the description of the present invention.

As will be appreciated by those skilled in the art, the B-max drop and the EC50 move hit may be considered to present the same phenomenon, but strictly speaking, the B-max drop alone does not reflect the affinity loss itself, but instead some The proportion of the antibody reflects the destruction of the epitope. There is no overlap in the hits determined by B-max and EC50, but mutations with a strong effect on binding may not allow the generation of useful binding curves, and therefore EC50 cannot be determined for these variants.

As will be appreciated by those of skill in the art, ABPs in the same bin (except bin 5, which is a generic generic bin, as described above) probably bind to overlapping sites on the target protein. Thus, the epitope and related residues can generally be extended to all such ABPs in the same bin.

To further examine the results with respect to ABP 31H4, according to the crystal structure, position E181R, which was predicted to interact with R185 to form part of the surface that interacts with ABP, was also altered (E181R). The results were not statistically significant by themselves but demonstrated 31H4 interacting with E181R when combined with the crystal structure (data not shown). Thus, position 181 also appears to form part of the epitope for 31H4 ABP.

As described above, the binding data and epitope characterization refer to the PCSK9 sequence (SEQ ID NO: 1) that does not contain the first 30 amino acids of PCSK9. Thus, the numbering system of the protein fragment, and the sequence number representing the fragment, were shifted by 30 amino acids compared to data and experiments using the full-length PCSK9 numbering system (e.g., those used in the crystal study data described above). . Thus, in order to compare these results, an extra 30 amino acids must be added at a position within each of the epitope mapping results. For example, position 207 of SEQ ID NO: 1 (or SEQ ID NO: 303) correlates to position 237 of SEQ ID NO: 3 (full length sequence, and the numbering system used throughout the rest of the specification). Table 39.6 outlines how the above mentioned positions referring to SEQ ID NO: 1 (and/or SEQ ID NO: 303) are correlated with SEQ ID NO: 3 (including the signal sequence).

<Table 39.6>

Accordingly, embodiments described herein with reference to SEQ ID NO: 1 can also be described by their corresponding positions described above with reference to SEQ ID NO: 3.

Example 40

PCSK9 domain binding assay

In this example, the location on PCSK9 to which various ABPs are bound was examined.

Clear 96 well maxisorp plates (NUNC) were coated overnight with 2 μg/ml of various anti-PCSK9 antibodies diluted in PBS. The plate was thoroughly washed with PBS/0.05% Tween-20, and then blocked with 3% BSA/PBS for 2 hours. After washing, the plate was diluted for 2 hours in a general assay diluent (Immunochemistry Technologies, LLC) full-length PCSK9 (aa 31-692 of SEQ ID NO: 3), procat PCSK9 (aa 31- of SEQ ID NO: 3). 449) or v-domain PCSK9 (aa 450-692 of SEQ ID NO: 3). Plates were washed and rabbit polyclonal biotinylated anti-PCSK9 antibody (D8774) recognizing procat and v-domain and full length PCSK9 was added at 1 μg/ml (in 1% BSA/PBS). Combined full-length, procat or v-domain PCSK9 was incubated with neutravidin-HRP (Thermo Scientific) 200 ng/ml (in 1% BSA/PBS), followed by incubation with TMB substrate (KPL), followed by 650 It was detected by measuring the absorbance at nm. The results presented in Figures 28A and 28B demonstrate the ability of various ABSs to bind to various parts of PCSK9. 28B, ABP 31A4 binds to the V domain of PCSK9.

Example 41

Neutralizing, non-competitive antigen binding protein

This example demonstrates a method for identifying and characterizing antigen binding proteins that are non-competitive with LDLR for binding to PCSK9, but still neutralizing for PCSK9 activity. That is, the antigen binding protein will not block PCSK9 from binding to LDLR, but will prevent or reduce PCSK9 mediated LDLR degradation.

Clear 384 well plates (Costar) were coated with 2 μg/ml of goat anti-LDL receptor antibody (R&D Systems) diluted in buffer A (100 mM sodium cacodylate, pH 7.4). The plate was thoroughly washed with buffer A, then blocked with buffer B (1% milk in buffer A) for 2 hours. After washing, the plates were incubated with 0.4 μg/ml LDL receptor (R&D Systems) diluted in _{buffer C (buffer B supplemented with 10 mM CaCl 2) for 1.5 hours.} Simultaneously with the incubation, 20 ng/ml of biotinylated D374Y PCSK9 was incubated with 100 ng/ml of antibody diluted in buffer A, or buffer A alone (control). The plate containing the LDL receptor was washed, and the biotinylated D374Y PCSK9/antibody mixture was transferred to the plate and incubated for 1 hour at room temperature. Binding of biotinylated D374Y to the LDL receptor was detected by incubation with 500 ng/ml streptavidin-HRP (biosource) in buffer C followed by TMB substrate (KPL). The signal was quenched with 1N HCl and the absorbance was read at 450 nm. The results are shown in Figure 28C, which shows that ABP 31H4 inhibits LDLR binding, whereas ABP 31A4 does not inhibit LDLR binding to PCSK9. Combining the results of Example 40 with those shown in Figs. 28A and 28B, it is clear that 31A4 ABP binds to the V domain of PCSK9 and does not block the interaction of PCSK9 with LDLR.

Next, the ability of ABP 31A4 to serve as a neutralizing ABP was further confirmed through cellular LDL uptake analysis (as described in the above Examples). The results of the LDL absorption assay are shown in Fig. 28D. As shown in Figure 28D, ABP 31A4 exhibits significant PCSK9 neutralizing ability. Thus, in view of Example 40 and the present results, it is clear that ABP is still useful as a neutralizing PCSK9 ABP and can bind to PCSK9 without blocking the PCSK9 and LDLR binding interactions.

Inclusion of References

All references cited herein, including patents, patent applications, papers, textbooks, etc., and references cited therein, do not exist, but are incorporated herein by reference in their entirety. In the event that any definition or term set forth in a reference incorporated by reference is different from the terms and discussion provided herein, the terms and definitions herein apply.

Equivalent

The above specification is considered sufficient to enable a person skilled in the art to practice the present invention. The above description and examples set out in detail certain preferred embodiments of the present invention, and describe the best mode contemplated by the inventors. However, no matter how detailed the invention may appear herein to be described in detail, it will be understood that the invention may be practiced in many ways, and the invention is to be construed in accordance with the appended claims and any equivalents thereof.

<Table 35.1>

<Table 35.2>

<Table 35.3>

<Table 35.4>

SEQUENCE LISTING <110> Jackson, Simon Mark Walker, Nigel P.C. Piper, Derek E. Shen, Wenyan King, Chadwick Terence Ketchem, Randal Robert Mehlin, Christopher Carabeo, Teresa <120> ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE (PCSK9) <130> APMOL.003C10 <140> US 13/860,016 <141> 2013-04-10 <150> US 13/655,984 <151> 2012-10-19 <150> US 12/474,176 <151> 2009-05-28 <150> US 12/197,093 <151> 2008-08-22 <150> US 61/086,133 <151> 2008-08-04 <150> US 61/010,630 <151> 2008-01-09 <150> US 61/008,965 <151> 2007-12-21 <150> US 60/957,668 <151> 2007-08-23 <160> 575 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 662 <212> PRT <213> Homo sapiens <400> 1 Gln Glu Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg 1 5 10 15 Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala 20 25 30 Thr Phe His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr 35 40 45 Val Val Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr 50 55 60 Ala Arg Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys 65 70 75 80 Ile Leu His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met 85 90 95 Ser Gly Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr 100 105 110 Ile Glu Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu 115 120 125 Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro 130 135 140 Asp Gly Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln 145 150 155 160 Ser Asp His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu 165 170 175 Asn Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys 180 185 190 Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp 195 200 205 Ala Gly Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn 210 215 220 Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe 225 230 235 240 Ile Arg Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu 245 250 255 Leu Pro Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln 260 265 270 Arg Leu Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe 275 280 285 Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile 290 295 300 Thr Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr 305 310 315 320 Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu 325 330 335 Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln 340 345 350 Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met 355 360 365 Met Leu Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg 370 375 380 Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro 385 390 395 400 Glu Asp Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro 405 410 415 Ser Thr His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser 420 425 430 Ala His Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala 435 440 445 Pro Asp Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys 450 455 460 Arg Arg Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg 465 470 475 480 Ala His Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys 485 490 495 Cys Leu Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala 500 505 510 Glu Ala Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val 515 520 525 Leu Thr Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His 530 535 540 Lys Pro Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly 545 550 555 560 His Arg Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu 565 570 575 Glu Cys Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Gly Gln Val 580 585 590 Thr Val Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu 595 600 605 Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys 610 615 620 Val Val Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu 625 630 635 640 Ala Val Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln 645 650 655 Ala Ser Gln Glu Leu Gln 660 <210> 2 <211> 2076 <212> DNA <213> Homo sapiens <400> 2 atgggcaccg tcagctccag gcggtcctgg tggccgctgc cactgctgct gctgctgctg 60 ctgctcctgg gtcccgcggg cgcccgtgcg caggaggacg aggacggcga ctacgaggag 120 ctggtgctag ccttgcgctc cgaggaggac ggcctggccg aagcacccga gcacggaacc 180 acagccacct tccaccgctg cgccaaggat ccgtggaggt tgcctggcac ctacgtggtg 240 gtgctgaagg aggagaccca cctctcgcag tcagagcgca ctgcccgccg cctgcaggcc 300 caggctgccc gccggggata cctcaccaag atcctgcatg tcttccatgg ccttcttcct 360 ggcttcctgg tgaagatgag tggcgacctg ctggagctgg ccttgaagtt gccccatgtc 420 gactacatcg aggaggactc ctctgtcttt gcccagagca tcccgtggaa cctggagcgg 480 attacccctc cgcggtaccg ggcggatgaa taccagcccc ccgacggagg cagcctggtg 540 gaggtgtatc tcctagacac cagcatacag agtgaccacc gggaaatcga gggcagggtc 600 atggtcaccg acttcgagaa tgtgcccgag gaggacggga cccgcttcca cagacaggcc 660 agcaagtgtg acagtcatgg cacccacctg gcaggggtgg tcagcggccg ggatgccggc 720 gtggccaagg gtgccagcat gcgcagcctg cgcgtgctca actgccaagg gaagggcacg 780 gttagcggca ccctcatagg cctggagttt attcggaaaa gccagctggt ccagcctgtg 840 gggccactgg tggtgctgct gcccctggcg ggtgggtaca gccgcgtcct caacgccgcc 900 tgccagcgcc tggcgagggc tggggtcgtg ctggtcaccg ctgccggcaa cttccgggac 960 gatgcctgcc tctactcccc agcctcagct cccgaggtca tcacagttgg ggccaccaat 1020 gcccaggacc agccggtgac cctggggact ttggggacca actttggccg ctgtgtggac 1080 ctctttgccc caggggagga catcattggt gcctccagcg actgcagcac ctgctttgtg 1140 tcacagagtg ggacatcaca ggctgctgcc cacgtggctg gcattgcagc catgatgctg 1200 tctgccgagc cggagctcac cctggccgag ttgaggcaga gactgatcca cttctctgcc 1260 aaagatgtca tcaatgaggc ctggttccct gaggaccagc gggtactgac ccccaacctg 1320 gtggccgccc tgccccccag cacccatggg gcaggttggc agctgttttg caggactgtg 1380 tggtcagcac actcggggcc tacacggatg gccacagcca tcgcccgctg cgccccagat 1440 gaggagctgc tgagctgctc cagtttctcc aggagtggga agcggcgggg cgagcgcatg 1500 gaggcccaag ggggcaagct ggtctgccgg gcccacaacg cttttggggg tgagggtgtc 1560 tacgccattg ccaggtgctg cctgctaccc caggccaact gcagcgtcca cacagctcca 1620 ccagctgagg ccagcatggg gacccgtgtc cactgccacc aacagggcca cgtcctcaca 1680 ggctgcagct cccactggga ggtggaggac cttggcaccc acaagccgcc tgtgctgagg 1740 ccacgaggtc agcccaacca gtgcgtgggc cacagggagg ccagcatcca cgcttcctgc 1800 tgccatgccc caggtctgga atgcaaagtc aaggagcatg gaatcccggc ccctcagggg 1860 caggtgaccg tggcctgcga ggagggctgg accctgactg gctgcagcgc cctccctggg 1920 acctcccacg tcctgggggc ctacgccgta gacaacacgt gtgtagtcag gagccgggac 1980 gtcagcacta caggcagcac cagcgaagag gccgtgacag ccgttgccat ctgctgccgg 2040 agccggcacc tggcgcaggc ctcccaggag ctccag 2076 <210> 3 <211> 692 <212> PRT <213> Homo sapiens <400> 3 Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu 20 25 30 Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu 35 40 45 Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe 50 55 60 His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val 65 70 75 80 Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg 85 90 95 Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu 100 105 110 His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly 115 120 125 Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu 130 135 140 Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg 145 150 155 160 Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly 165 170 175 Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp 180 185 190 His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val 195 200 205 Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp 210 215 220 Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly 225 230 235 240 Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln 245 250 255 Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg 260 265 270 Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro 275 280 285 Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu 290 295 300 Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp 305 310 315 320 Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val 325 330 335 Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly 340 345 350 Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile 355 360 365 Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly 370 375 380 Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu 385 390 395 400 Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile 405 410 415 His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp 420 425 430 Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr 435 440 445 His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His 450 455 460 Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro Asp 465 470 475 480 Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg 485 490 495 Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His 500 505 510 Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu 515 520 525 Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala 530 535 540 Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr 545 550 555 560 Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro 565 570 575 Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg 580 585 590 Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys 595 600 605 Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Gly Gln Val Thr Val 610 615 620 Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly 625 630 635 640 Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val 645 650 655 Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val 660 665 670 Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser 675 680 685 Gln Glu Leu Gln 690 <210> 4 <211> 112 <212> PRT <213> Homo sapiens <400> 4 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 5 <211> 112 <212> PRT <213> Homo sapiens <400> 5 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Glu Pro Pro Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser His Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Val 85 90 95 Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 6 <211> 107 <212> PRT <213> Homo sapiens <400> 6 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 7 <211> 107 <212> PRT <213> Homo sapiens <400> 7 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Ile Ser Asn Tyr 20 25 30 Leu Ser Trp Tyr Leu Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 85 90 95 Ile Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 8 <211> 107 <212> PRT <213> Homo sapiens <400> 8 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 9 <211> 107 <212> PRT <213> Homo sapiens <400> 9 Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 10 <211> 107 <212> PRT <213> Homo sapiens <400> 10 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ile Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Tyr Leu Leu Ile 35 40 45 Tyr Ala Ala Ala Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 11 <211> 111 <212> PRT <213> Homo sapiens <400> 11 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 12 <211> 111 <212> PRT <213> Homo sapiens <400> 12 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Ser Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 13 <211> 111 <212> PRT <213> Homo sapiens <400> 13 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala His 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Thr Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Asn Ser 85 90 95 Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 14 <211> 108 <212> PRT <213> Homo sapiens <400> 14 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 15 <211> 109 <212> PRT <213> Homo sapiens <400> 15 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 16 <211> 109 <212> PRT <213> Homo sapiens <400> 16 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Ile Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 17 <211> 109 <212> PRT <213> Homo sapiens <400> 17 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Ile Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 18 <211> 109 <212> PRT <213> Homo sapiens <400> 18 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Ala Val Leu 100 105 <210> 19 <211> 109 <212> PRT <213> Homo sapiens <400> 19 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys Pro Pro Lys Leu 35 40 45 Lys Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 20 <211> 109 <212> PRT <213> Homo sapiens <400> 20 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 21 <211> 109 <212> PRT <213> Homo sapiens <400> 21 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 22 <211> 109 <212> PRT <213> Homo sapiens <400> 22 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 23 <211> 109 <212> PRT <213> Homo sapiens <400> 23 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 24 <211> 109 <212> PRT <213> Homo sapiens <400> 24 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Arg 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Asn Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 25 <211> 108 <212> PRT <213> Homo sapiens <400> 25 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 26 <211> 109 <212> PRT <213> Homo sapiens <400> 26 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Thr Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 27 <211> 108 <212> PRT <213> Homo sapiens <400> 27 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser 85 90 95 Ser Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 28 <211> 110 <212> PRT <213> Homo sapiens <400> 28 Leu Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln Tyr Ser Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser 85 90 95 Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 29 <211> 108 <212> PRT <213> Homo sapiens <400> 29 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 30 <211> 109 <212> PRT <213> Homo sapiens <400> 30 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Leu Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 31 <211> 109 <212> PRT <213> Homo sapiens <400> 31 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Pro Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 32 <211> 110 <212> PRT <213> Homo sapiens <400> 32 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 33 <211> 109 <212> PRT <213> Homo sapiens <400> 33 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu 100 105 <210> 34 <211> 110 <212> PRT <213> Homo sapiens <400> 34 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 35 <211> 110 <212> PRT <213> Homo sapiens <400> 35 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110 <210> 36 <211> 110 <212> PRT <213> Homo sapiens <400> 36 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110 <210> 37 <211> 110 <212> PRT <213> Homo sapiens <400> 37 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ser Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110 <210> 38 <211> 110 <212> PRT <213> Homo sapiens <400> 38 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110 <210> 39 <211> 110 <212> PRT <213> Homo sapiens <400> 39 Gln Ser Val Leu Thr Gln Pro Pro Thr Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110 <210> 40 <211> 110 <212> PRT <213> Homo sapiens <400> 40 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Ser Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 41 <211> 110 <212> PRT <213> Homo sapiens <400> 41 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 42 <211> 110 <212> PRT <213> Homo sapiens <400> 42 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Asn Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 43 <211> 107 <212> PRT <213> Homo sapiens <400> 43 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val 85 90 95 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 44 <211> 106 <212> PRT <213> Homo sapiens <400> 44 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asn Thr Lys Trp Pro Leu Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Asn Thr Val Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 45 <211> 116 <212> PRT <213> Homo sapiens <400> 45 Gln Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Thr Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Asn Tyr Lys 20 25 30 Val Asp Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met 35 40 45 Arg Val Gly Thr Gly Gly Ile Val Gly Ser Lys Gly Asp Gly Ile Pro 50 55 60 Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr Leu Thr Ile 65 70 75 80 Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys Gly Ala Asp 85 90 95 His Gly Ser Gly Ser Asn Phe Val Val Val Phe Gly Gly Gly Thr Lys 100 105 110 Leu Thr Val Leu 115 <210> 46 <211> 116 <212> PRT <213> Homo sapiens <400> 46 Gln Pro Val Leu Thr Gln Pro Leu Phe Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Thr Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu 20 25 30 Val Asp Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met 35 40 45 Arg Val Asp Thr Gly Gly Ile Val Gly Ser Lys Gly Glu Gly Ile Pro 50 55 60 Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr Leu Thr Ile 65 70 75 80 Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys Gly Ala Asp 85 90 95 His Gly Ser Gly Thr Asn Phe Val Val Val Phe Gly Gly Gly Thr Lys 100 105 110 Leu Thr Val Leu 115 <210> 47 <211> 114 <212> PRT <213> Homo sapiens <400> 47 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 48 <211> 115 <212> PRT <213> Homo sapiens <400> 48 Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Ser Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 49 <211> 115 <212> PRT <213> Homo sapiens <400> 49 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Gly Thr Met Thr Thr Asp Pro Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 50 <211> 115 <212> PRT <213> Homo sapiens <400> 50 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Gly Thr Met Thr Thr Asp Pro Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 51 <211> 115 <212> PRT <213> Homo sapiens <400> 51 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 52 <211> 115 <212> PRT <213> Homo sapiens <400> 52 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Ser Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 53 <211> 115 <212> PRT <213> Homo sapiens <400> 53 Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 54 <211> 115 <212> PRT <213> Homo sapiens <400> 54 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Val Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 55 <211> 115 <212> PRT <213> Homo sapiens <400> 55 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 56 <211> 115 <212> PRT <213> Homo sapiens <400> 56 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 57 <211> 115 <212> PRT <213> Homo sapiens <400> 57 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 58 <211> 115 <212> PRT <213> Homo sapiens <400> 58 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Pro Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Glu Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Val Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Tyr Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 59 <211> 113 <212> PRT <213> Homo sapiens <400> 59 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 60 <211> 115 <212> PRT <213> Homo sapiens <400> 60 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Thr Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 61 <211> 116 <212> PRT <213> Homo sapiens <400> 61 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Trp Gly Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 62 <211> 119 <212> PRT <213> Homo sapiens <400> 62 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys His Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Val Trp Gly His Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 63 <211> 116 <212> PRT <213> Homo sapiens <400> 63 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Trp Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 64 <211> 119 <212> PRT <213> Homo sapiens <400> 64 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 65 <211> 119 <212> PRT <213> Homo sapiens <400> 65 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Phe 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys 85 90 95 Thr Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 66 <211> 123 <212> PRT <213> Homo sapiens <400> 66 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Asp Phe Trp Ser Gly Tyr Tyr Thr Ala Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 67 <211> 123 <212> PRT <213> Homo sapiens <400> 67 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 68 <211> 112 <212> PRT <213> Homo sapiens <400> 68 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110 <210> 69 <211> 117 <212> PRT <213> Homo sapiens <400> 69 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Glu Val Gly Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 70 <211> 117 <212> PRT <213> Homo sapiens <400> 70 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Val Leu Met Val Tyr Ala Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 71 <211> 121 <212> PRT <213> Homo sapiens <400> 71 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 72 <211> 121 <212> PRT <213> Homo sapiens <400> 72 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 73 <211> 116 <212> PRT <213> Homo sapiens <400> 73 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 100 105 110 Thr Val Ser Ser 115 <210> 74 <211> 123 <212> PRT <213> Homo sapiens <400> 74 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Thr Gly Pro Leu Lys Leu Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 75 <211> 116 <212> PRT <213> Homo sapiens <400> 75 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Ala Ala Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 100 105 110 Thr Val Ser Ser 115 <210> 76 <211> 122 <212> PRT <213> Homo sapiens <400> 76 Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 77 <211> 122 <212> PRT <213> Homo sapiens <400> 77 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly His Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 78 <211> 122 <212> PRT <213> Homo sapiens <400> 78 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 79 <211> 122 <212> PRT <213> Homo sapiens <400> 79 Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 80 <211> 122 <212> PRT <213> Homo sapiens <400> 80 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 81 <211> 122 <212> PRT <213> Homo sapiens <400> 81 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Gly Leu Ala Ala Arg Pro Gly Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 82 <211> 122 <212> PRT <213> Homo sapiens <400> 82 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ile Ala Val Ala Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 83 <211> 122 <212> PRT <213> Homo sapiens <400> 83 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ile Ala Val Ala Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 84 <211> 117 <212> PRT <213> Homo sapiens <400> 84 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 85 <211> 122 <212> PRT <213> Homo sapiens <400> 85 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30 Asp Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ile Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Gly Val Thr Thr Tyr Tyr Tyr Ala Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 86 <211> 120 <212> PRT <213> Homo sapiens <400> 86 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Glu Asp Thr Ala Met Val Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 87 <211> 121 <212> PRT <213> Homo sapiens <400> 87 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Tyr Asn Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Glu Asp Thr Ala Met Val Pro Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 88 <211> 115 <212> PRT <213> Homo sapiens <400> 88 Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Gln Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 89 <211> 116 <212> PRT <213> Homo sapiens <400> 89 Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ala Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Ser Gly Arg Thr Asp Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Lys Gln Phe Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Gln Leu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 90 <211> 115 <212> PRT <213> Homo sapiens <400> 90 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 91 <211> 121 <212> PRT <213> Homo sapiens <400> 91 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Lys Asn Tyr Ser 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Gly Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Gly Gly Pro Thr Ala Ala Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 92 <211> 345 <212> DNA <213> Homo sapiens <400> 92 cagattcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta ccccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag cgtcaccatg accacagaca catccacgag cacagtctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctct 345 <210> 93 <211> 327 <212> DNA <213> Homo sapiens <400> 93 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 tacccaggca aaccccccaa actcaagatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 94 <211> 345 <212> DNA <213> Homo sapiens <400> 94 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta caccttaacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg gtcagttttt ataatggtaa cacaaactat 180 gcacagaagc tccagggcag aggcaccatg accacagacc catccacgag cacagcctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctct 345 <210> 95 <211> 327 <212> DNA <213> Homo sapiens <400> 95 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aagcccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc aattcatata caagcaccag catggtattc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 96 <211> 345 <212> DNA <213> Homo sapiens <400> 96 caggttcagc tggtgcagtc tggagctgaa gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta caccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagctttt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctct 345 <210> 97 <211> 327 <212> DNA <213> Homo sapiens <400> 97 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctattcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 98 <211> 345 <212> DNA <213> Homo sapiens <400> 98 cagattcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta caccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagctttt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt atttctgtgc gagaggttac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 99 <211> 327 <212> DNA <213> Homo sapiens <400> 99 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcgtg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctggc cgtccta 327 <210> 100 <211> 345 <212> DNA <213> Homo sapiens <400> 100 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta caccttaacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg gtcagttttt ataatggtaa cacaaactat 180 gcacagaagc tccagggcag aggcaccatg accacagacc catccacgag cacagcctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 101 <211> 327 <212> DNA <213> Homo sapiens <400> 101 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aagcccccaa actcatgatt tatgaggtca ctaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc aactcatata caagcaccag catggtgttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 102 <211> 363 <212> DNA <213> Homo sapiens <400> 102 caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60 acctgcactg tctctggtgg ctccatcagc agtggtggtt actactggag ctggatccgc 120 cagcacccag ggaagggcct ggagtggatt gggtacatat ataacagtgg gagcacctac 180 tacaacccgt ccctcaagag tcgagttacc atatcagtag acacgtctaa gaaccagttc 240 tccctgaagc tgagctctgt gactgccgcg gacacggccg tgtattactg tgcgagagag 300 gatacagcta tggttcctta ctttgactac tggggccagg gaaccctggt caccgtctcc 360 tca 363 <210> 103 <211> 333 <212> DNA <213> Homo sapiens <400> 103 cagtctgtac tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60 tcctgcactg ggagcagctc caacatcggg gcacattatg atgtgcactg gtaccagcag 120 gttccaggaa cagcccccaa actcctcatc tatggtaaca cctatcggcc ctcaggggtc 180 cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc 240 caggctgagg atgaggctga ttattactgc cagtcctatg acaacagcct gagtggtgtg 300 gtattcggcg gagggaccaa gctgaccgtc cta 333 <210> 104 <211> 366 <212> DNA <213> Homo sapiens <400> 104 caggtgcacc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcaac agctttggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atctggtctg atggaagtga tgaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagccata 300 gcagccctct actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 105 <211> 330 <212> DNA <213> Homo sapiens <400> 105 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagctc caacattggg aataattttg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gactataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag tgcttatgtc 300 ttcggaactg ggaccagggt caccgtccta 330 <210> 106 <211> 366 <212> DNA <213> Homo sapiens <400> 106 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagc agctttggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atatggaatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagccata 300 gcagccctct actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 107 <211> 330 <212> DNA <213> Homo sapiens <400> 107 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagctc caacattggg aataattttg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gactataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagtctgag tggttatgtc 300 ttcggaactg ggaccagggt caccgtccta 330 <210> 108 <211> 366 <212> DNA <213> Homo sapiens <400> 108 caggtgcacc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcaac agctttggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atatggtctg atggaagtga taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagccata 300 gcagccctct actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 109 <211> 330 <212> DNA <213> Homo sapiens <400> 109 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagttc caacattggg aataattttg tatcctggta ccagcagttc 120 ccaggaacag cccccaaact cctcatttat gactataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag ttcttatgtc 300 ttcggaactg ggaccagggt caccgtccta 330 <210> 110 <211> 366 <212> DNA <213> Homo sapiens <400> 110 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagc agctttggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atatggaatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagccata 300 gcagccctct actactacta cggtatggac gtctggggcc acgggaccac ggtcaccgtc 360 tcctca 366 <210> 111 <211> 330 <212> DNA <213> Homo sapiens <400> 111 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagctc caacattggg aataattttg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gactataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag tggttatgtc 300 ttcggaactg ggaccagggt caccgtccta 330 <210> 112 <211> 366 <212> DNA <213> Homo sapiens <400> 112 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagc agctttggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atatggaatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagccata 300 gcagccctct actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 113 <211> 330 <212> DNA <213> Homo sapiens <400> 113 cagtctgtgt tgacgcagcc gcccacagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagctc caacattggg aataattttg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gactataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ctactgcgga acatgggata gcagcctgag tggttatgtc 300 ttcggaactg ggaccagggt caccgtccta 330 <210> 114 <211> 366 <212> DNA <213> Homo sapiens <400> 114 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagg agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcactt atatggcatg atggaagtaa tacatactat 180 gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagaggtata 300 gcagtggctt actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 115 <211> 330 <212> DNA <213> Homo sapiens <400> 115 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcagctc caacattggg aataattttg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gacagtaata agcgaccctc agggattcct 180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tggacatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag tgcttatgtt 300 ttcggaactg ggaccaaggt caccgtccta 330 <210> 116 <211> 363 <212> DNA <213> Homo sapiens <400> 116 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc agctatgcca tgaactgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcaact attagtggta gtggtgataa cacatactac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaaaagttt 300 gtactaatgg tgtatgctat gcttgactac tggggccagg gaaccctggt caccgtctcc 360 tca 363 <210> 117 <211> 321 <212> DNA <213> Homo sapiens <400> 117 gacatcctga tgacccagtc tccatcctcc ctgtctgcat ctgttggaga cagagtcacc 60 atcacttgcc gggcaagtca gagcattagc agttatttaa attggtatca gcagaaacca 120 gggaaagccc ctaaggtcct gatctatgct gcctccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcaacag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag agttacagtt cccccatcac cttcggccaa 300 gggacacgac tggagattaa a 321 <210> 118 <211> 363 <212> DNA <213> Homo sapiens <400> 118 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc cgggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc agctatgcca tgaactgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcaact attagtggta gtggtggtaa cacatactac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaaaagttt 300 gtactaatgg tgtatgctat gcttgactac tggggccagg gaaccctggt caccgtctcc 360 tca 363 <210> 119 <211> 321 <212> DNA <213> Homo sapiens <400> 119 gacatccaga tgacccagtc tccatcctcc ctatctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca gagcattagc atctatttaa attggtatca gcagaagcca 120 gggaaagccc cttacctcct gatctatgct gcagccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag agttacagtg cccccatcac cttcggccaa 300 gggacacgac tggagattaa a 321 <210> 120 <211> 345 <212> DNA <213> Homo sapiens <400> 120 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc actgaaggtc 60 tcctgcaagg cttctggtta cagtttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggaggtga ggagtctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 121 <211> 327 <212> DNA <213> Homo sapiens <400> 121 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aatacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 122 <211> 345 <212> DNA <213> Homo sapiens <400> 122 caggttcagc tggtgcagtc tggagctgag gtgaagaggc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta caccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgttt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggagctga ggagcctgag ctctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 123 <211> 327 <212> DNA <213> Homo sapiens <400> 123 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctattcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 124 <211> 345 <212> DNA <213> Homo sapiens <400> 124 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta ccccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggagttga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 125 <211> 327 <212> DNA <213> Homo sapiens <400> 125 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aatacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 126 <211> 345 <212> DNA <213> Homo sapiens <400> 126 caggttcagt tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta cgccttgacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 127 <211> 327 <212> DNA <213> Homo sapiens <400> 127 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccaacag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcagggatt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 128 <211> 345 <212> DNA <213> Homo sapiens <400> 128 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta cagctttacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtaa cacaaactat 180 gcacagaagt tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 atggaactga ggagcctgag atctgacgac acggccgtgt attactgtgc gagaggctac 300 gttatggacg tctggggcca agggaccacg gtcaccgtct cctca 345 <210> 129 <211> 327 <212> DNA <213> Homo sapiens <400> 129 cagtctgccc tgactcagcc tgcctccgtt tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt gcttataact ctgtctcctg gtaccaacag 120 cacccaggca aagcccccaa acgcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc agctcatata caagcaccaa catggtattc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 130 <211> 363 <212> DNA <213> Homo sapiens <400> 130 caggtacagt tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60 acctgtgcca tctccgggga cagtgtctct agcaacagtg ctgcttggaa ctggatcagg 120 cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat 180 aaaaattatt cagtatctgt gaaaagtcga ataaccatca acccagacac atccaagaac 240 cagttctctc tgcaactgaa ctctgtgact cccggggaca cggctgtgta ttactgtgca 300 agaggggggc caactgctgc ttttgactac tggggccagg gaaccctggt caccgtctcc 360 tca 363 <210> 131 <211> 330 <212> DNA <213> Homo sapiens <400> 131 ctttctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgatgttggg aattataacc ttgtctcctg gtaccaacag 120 tattcaggca aagcccccaa actcatgatt tatgaggtca gtaagcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgacaat ctctgggctc 240 caggctgagg acgaggctga ttattactgc tgctcatatg caggtagtag cactttggtt 300 ttcggcggag ggaccaagct gaccgtccta 330 <210> 132 <211> 357 <212> DNA <213> Homo sapiens <400> 132 gaggtgcagt tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgtag tctctggatt cacctttagt agctattgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtat attactgtgc gagagagtca 300 aactggggat ttgcttttga tatctggggc caagggacaa tggtcaccgt ctcttca 357 <210> 133 <211> 327 <212> DNA <213> Homo sapiens <400> 133 cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaagactg taaactggta ccaacaggtc 120 ccaggaacgg cccccaaact cctcatctat aggaataatc agcggccctt aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttattgtgca gcatgggatg acagcctgaa ttgggtgttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 134 <211> 357 <212> DNA <213> Homo sapiens <400> 134 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagt cgctattgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcatg atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatt tccagagaca acgccaagaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagtca 300 aactggggat ttgcttttga tgtctggggc cacgggacaa tggtcaccgt ctcttca 357 <210> 135 <211> 327 <212> DNA <213> Homo sapiens <400> 135 cagtctgtgc tgactcagcc accctcagcg tctgggcccc ccggacagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaatactg taaactggta ccagcagctc 120 ccaggaacgg cccccaaact cctcatctat agtaataatc ggcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa ttgggtgttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 136 <211> 351 <212> DNA <213> Homo sapiens <400> 136 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcaact attagtggta gtggtggtag gacatattac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagaagtt 300 ggcagtccct ttgactactg gggccaggga accctggtca ccgtctcctc a 351 <210> 137 <211> 330 <212> DNA <213> Homo sapiens <400> 137 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60 tcctgctctg gaagcaactc caacattggg aataattatg tatcctggta ccagcagctc 120 ccaggaacag cccccaaact cctcatttat gacaataata agcgaccctc agggattcct 180 gaccgattct ctggctccaa ctctggcacg tcagccaccc tgggcatcac cggactccag 240 actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag tgctgtggta 300 ttcggcggag ggaccaagct gaccgtccta 330 <210> 138 <211> 366 <212> DNA <213> Homo sapiens <400> 138 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcaatt atatggtatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacactgtat 240 cttcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gaggaggggg 300 ggtctggcag ctcgtccggg cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 139 <211> 318 <212> DNA <213> Homo sapiens <400> 139 tcctatgagc tgactcagcc accctcagtg tctgtgtccc caggacagac agccagaatc 60 acctgctctg gagataaatt gggggataaa tatgcttgct ggtatcagca gaaaccaggc 120 cagtcccctg tgctggtcat ctatcaaaat accaagtggc ccttagggat ccctgagcga 180 ttctctggct ccaagtctgg gaacacagtc actctgacca tcagcgggac ccaggctatg 240 gatgaggctg actattactg tcaggcgtgg gacagcagca ctgtggtatt cggcggaggg 300 accaagctga ccgtccta 318 <210> 140 <211> 366 <212> DNA <213> Homo sapiens <400> 140 caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60 acctgcactg tctctggtgg ctccatcagc agtagtgatt actactggag ctggatccgc 120 cagcacccag ggaagggcct ggagtggatt gggtacatct attacagtgg gagcacctac 180 tacaacccgt ccctcaagag tcgaattacc atatcagtag acacgtctaa gaacctgttc 240 tccctgaagt tgagctctgt gactgccgcg gacacggccg tgtattactg tgcgagaggg 300 ggggtgacta cgtactacta cgctatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 141 <211> 321 <212> DNA <213> Homo sapiens <400> 141 gacatacaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca gcgcattagc aactatttaa gttggtatct gcagaaacca 120 gggattgccc ctaagctcct gatctatgct gcatccagtt tgcagagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaatct 240 gaagattttg caacttacta ctgtcaacag agttacagta ccccgctcat tttcggcgga 300 gggaccaagg tggagatcaa a 321 <210> 142 <211> 369 <212> DNA <213> Homo sapiens <400> 142 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtga taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagact 300 ggtcccttga aactctacta ctacggtatg gacgtctggg gccaagggac cacggtcacc 360 gtctcctca 369 <210> 143 <211> 336 <212> DNA <213> Homo sapiens <400> 143 gatattgtga tgactcagtc tccactctcc ctgtccgtca cccctggaga gccgccctcc 60 atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaactt tttgaattgg 120 tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc tcatcgggcc 180 tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actggaaatc 240 agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagttct acaaactcca 300 ttcactttcg gccctgggac caaagtggat atcaaa 336 <210> 144 <211> 357 <212> DNA <213> Homo sapiens <400> 144 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggact cacctttagt aacttttgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attcctgtac gagagagtca 300 aactggggat ttgcttttga tatctggggc caagggacaa tggtcaccgt ctcttca 357 <210> 145 <211> 327 <212> DNA <213> Homo sapiens <400> 145 cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaaaactg taaactggta ccagcagttc 120 ccaggaacgg cccccaaact cctcatctat agtaataatc ggcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa ttgggtgttc 300 ggcgcaggga ccaagctgac cgtccta 327 <210> 146 <211> 345 <212> DNA <213> Homo sapiens <400> 146 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta cacctttacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcactt acaatggtaa cacaaactat 180 gcacagaagg tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 atggagctga ggagcctgag atctgacgac acggccgttt attactgtgc gagagggtat 300 actcgggact actggggcca gggaaccctg gtcaccgtct cctca 345 <210> 147 <211> 348 <212> DNA <213> Homo sapiens <400> 147 cagcctgtgc tgactcagcc actttttgca tcagcctccc tgggagcctc ggtcacactc 60 acctgcaccc tgagcagcgg ctacagtagt tatgaagtgg actggtatca gcagagacca 120 gggaagggcc cccggtttgt catgcgagtg gacactggtg ggattgtggg atccaagggg 180 gaaggcatcc ctgatcgctt ctcagttttg ggctcaggcc tgaatcggta tctgaccatc 240 aagaacatcc aggaagagga tgagagtgac taccactgtg gggcagacca tggcagtggg 300 accaacttcg tggtggtatt cggcggaggg accaagctga ccgtccta 348 <210> 148 <211> 348 <212> DNA <213> Homo sapiens <400> 148 caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60 acctgcgctg tctatggtgg gtccttcagt gcgtactact ggaactggat ccgccagccc 120 ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagaac cgactacaac 180 ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaagca gttctccctg 240 aagctgaact ctgtgaccgc cgcggacacg gctgtgtatt actgtgcgag agggcagctc 300 gtcccctttg actactgggg ccagggaacc ctggtcaccg tctcttca 348 <210> 149 <211> 330 <212> DNA <213> Homo sapiens <400> 149 cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaatactg taaattggta tcagcaactc 120 ccaggaacgg cccccaaact cctcatctat agtaataatc agcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgca gtatgggatg acagcctgaa tggttgggtg 300 ttcggcggag ggaccaagct gaccgtccta 330 <210> 150 <211> 345 <212> DNA <213> Homo sapiens <400> 150 caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta cacctttccc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcagagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 atggaggtga ggagcctgag atctgacgac acggccgtgt tttactgtgc gagaggctac 300 gttatggacg tctggggcca agggaccacg gtcaccgtct cctct 345 <210> 151 <211> 327 <212> DNA <213> Homo sapiens <400> 151 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt cgttataatt ctgtctcctg gtaccaacac 120 cacccaggca aagcccccaa agtcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctactcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc agctcatata caagcagcag cgttgtattc 300 ggcggaggga ccaaactgac cgtccta 327 <210> 152 <211> 369 <212> DNA <213> Homo sapiens <400> 152 gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catttcctac 180 gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt atttctgtgc gagagattac 300 gatttttgga gtgcttacta tgatgctttt gatgtctggg gccaagggac aatggtcacc 360 gtctcttca 369 <210> 153 <211> 333 <212> DNA <213> Homo sapiens <400> 153 cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60 tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcag 120 cttccaggaa cagcccccaa actcctcatc tctggtaaca gcaatcggcc ctcaggggtc 180 cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc 240 caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg 300 gtattcggcg gagggaccaa gctgaccgtc cta 333 <210> 154 <211> 326 <212> PRT <213> Homo sapiens <400> 154 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp 180 185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 195 200 205 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 275 280 285 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 290 295 300 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 305 310 315 320 Ser Leu Ser Pro Gly Lys 325 <210> 155 <211> 327 <212> PRT <213> Homo sapiens <400> 155 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 156 <211> 105 <212> PRT <213> Homo sapiens <400> 156 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 1 5 10 15 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 20 25 30 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 35 40 45 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 50 55 60 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 65 70 75 80 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 85 90 95 Lys Thr Val Ala Pro Thr Glu Cys Ser 100 105 <210> 157 <211> 106 <212> PRT <213> Homo sapiens <400> 157 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 1 5 10 15 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 20 25 30 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 35 40 45 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 50 55 60 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 65 70 75 80 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 85 90 95 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 158 <211> 14 <212> PRT <213> Homo sapiens <400> 158 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Ser Val Ser 1 5 10 <210> 159 <211> 14 <212> PRT <213> Homo sapiens <400> 159 Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser 1 5 10 <210> 160 <211> 14 <212> PRT <213> Homo sapiens <400> 160 Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Ser Val Ser 1 5 10 <210> 161 <211> 14 <212> PRT <213> Homo sapiens <400> 161 Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Ser Val Ser 1 5 10 <210> 162 <211> 7 <212> PRT <213> Homo sapiens <400> 162 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 163 <211> 7 <212> PRT <213> Homo sapiens <400> 163 Glu Val Thr Asn Arg Pro Ser 1 5 <210> 164 <211> 9 <212> PRT <213> Homo sapiens <400> 164 Ser Ser Tyr Thr Ser Thr Ser Met Val 1 5 <210> 165 <211> 9 <212> PRT <213> Homo sapiens <400> 165 Asn Ser Tyr Thr Ser Thr Ser Met Val 1 5 <210> 166 <211> 9 <212> PRT <213> Homo sapiens <400> 166 Ser Ser Tyr Thr Ser Thr Asn Met Val 1 5 <210> 167 <211> 9 <212> PRT <213> Homo sapiens <400> 167 Ser Ser Tyr Thr Ser Ser Ser Val Val 1 5 <210> 168 <211> 10 <212> PRT <213> Homo sapiens <400> 168 Gly Tyr Pro Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 169 <211> 10 <212> PRT <213> Homo sapiens <400> 169 Gly Tyr Ser Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 170 <211> 10 <212> PRT <213> Homo sapiens <400> 170 Gly Tyr Ala Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 171 <211> 10 <212> PRT <213> Homo sapiens <400> 171 Gly Tyr Thr Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 172 <211> 10 <212> PRT <213> Homo sapiens <400> 172 Gly Tyr Ser Phe Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 173 <211> 10 <212> PRT <213> Homo sapiens <400> 173 Gly Tyr Thr Phe Pro Ser Tyr Gly Ile Ser 1 5 10 <210> 174 <211> 17 <212> PRT <213> Homo sapiens <400> 174 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 175 <211> 17 <212> PRT <213> Homo sapiens <400> 175 Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 1 5 10 15 Gly <210> 176 <211> 17 <212> PRT <213> Homo sapiens <400> 176 Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 177 <211> 17 <212> PRT <213> Homo sapiens <400> 177 Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 178 <211> 17 <212> PRT <213> Homo sapiens <400> 178 Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 179 <211> 17 <212> PRT <213> Homo sapiens <400> 179 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Glu Lys Leu Gln 1 5 10 15 Gly <210> 180 <211> 6 <212> PRT <213> Homo sapiens <400> 180 Gly Tyr Gly Met Asp Val 1 5 <210> 181 <211> 6 <212> PRT <213> Homo sapiens <400> 181 Gly Tyr Val Met Asp Val 1 5 <210> 182 <211> 13 <212> PRT <213> Homo sapiens <400> 182 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Phe Val Ser 1 5 10 <210> 183 <211> 7 <212> PRT <213> Homo sapiens <400> 183 Asp Tyr Asn Lys Arg Pro Ser 1 5 <210> 184 <211> 7 <212> PRT <213> Homo sapiens <400> 184 Asp Ser Asn Lys Arg Pro Ser 1 5 <210> 185 <211> 11 <212> PRT <213> Homo sapiens <400> 185 Gly Thr Trp Asp Ser Ser Leu Ser Gly Tyr Val 1 5 10 <210> 186 <211> 11 <212> PRT <213> Homo sapiens <400> 186 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 187 <211> 11 <212> PRT <213> Homo sapiens <400> 187 Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val 1 5 10 <210> 188 <211> 10 <212> PRT <213> Homo sapiens <400> 188 Gly Phe Thr Phe Ser Ser Phe Gly Met His 1 5 10 <210> 189 <211> 10 <212> PRT <213> Homo sapiens <400> 189 Gly Phe Thr Phe Asn Ser Phe Gly Met His 1 5 10 <210> 190 <211> 10 <212> PRT <213> Homo sapiens <400> 190 Gly Phe Thr Phe Arg Ser Tyr Gly Met His 1 5 10 <210> 191 <211> 17 <212> PRT <213> Homo sapiens <400> 191 Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 192 <211> 17 <212> PRT <213> Homo sapiens <400> 192 Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 193 <211> 17 <212> PRT <213> Homo sapiens <400> 193 Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 194 <211> 17 <212> PRT <213> Homo sapiens <400> 194 Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 195 <211> 13 <212> PRT <213> Homo sapiens <400> 195 Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 196 <211> 13 <212> PRT <213> Homo sapiens <400> 196 Gly Ile Ala Val Ala Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 197 <211> 13 <212> PRT <213> Homo sapiens <400> 197 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 198 <211> 13 <212> PRT <213> Homo sapiens <400> 198 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 199 <211> 7 <212> PRT <213> Homo sapiens <400> 199 Ser Asn Asn Arg Arg Pro Ser 1 5 <210> 200 <211> 7 <212> PRT <213> Homo sapiens <400> 200 Arg Asn Asn Gln Arg Pro Leu 1 5 <210> 201 <211> 10 <212> PRT <213> Homo sapiens <400> 201 Ala Ala Trp Asp Asp Ser Leu Asn Trp Val 1 5 10 <210> 202 <211> 10 <212> PRT <213> Homo sapiens <400> 202 Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser 1 5 10 <210> 203 <211> 10 <212> PRT <213> Homo sapiens <400> 203 Gly Leu Thr Phe Ser Asn Phe Trp Met Ser 1 5 10 <210> 204 <211> 10 <212> PRT <213> Homo sapiens <400> 204 Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser 1 5 10 <210> 205 <211> 17 <212> PRT <213> Homo sapiens <400> 205 Asn Ile Lys His Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 206 <211> 17 <212> PRT <213> Homo sapiens <400> 206 Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 207 <211> 10 <212> PRT <213> Homo sapiens <400> 207 Glu Ser Asn Trp Gly Phe Ala Phe Asp Val 1 5 10 <210> 208 <211> 10 <212> PRT <213> Homo sapiens <400> 208 Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile 1 5 10 <210> 209 <211> 11 <212> PRT <213> Homo sapiens <400> 209 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 210 <211> 11 <212> PRT <213> Homo sapiens <400> 210 Arg Ala Ser Gln Ser Ile Ser Ile Tyr Leu Asn 1 5 10 <210> 211 <211> 7 <212> PRT <213> Homo sapiens <400> 211 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 212 <211> 7 <212> PRT <213> Homo sapiens <400> 212 Ala Ala Ala Ser Leu Gln Ser 1 5 <210> 213 <211> 9 <212> PRT <213> Homo sapiens <400> 213 Gln Gln Ser Tyr Ser Ser Pro Ile Thr 1 5 <210> 214 <211> 9 <212> PRT <213> Homo sapiens <400> 214 Gln Gln Ser Tyr Ser Ala Pro Ile Thr 1 5 <210> 215 <211> 10 <212> PRT <213> Homo sapiens <400> 215 Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn 1 5 10 <210> 216 <211> 17 <212> PRT <213> Homo sapiens <400> 216 Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 217 <211> 17 <212> PRT <213> Homo sapiens <400> 217 Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 218 <211> 12 <212> PRT <213> Homo sapiens <400> 218 Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr 1 5 10 <210> 219 <211> 11 <212> PRT <213> Homo sapiens <400> 219 Arg Ala Ser Gln Arg Ile Ser Asn Tyr Leu Ser 1 5 10 <210> 220 <211> 16 <212> PRT <213> Homo sapiens <400> 220 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Phe Leu Asn 1 5 10 15 <210> 221 <211> 14 <212> PRT <213> Homo sapiens <400> 221 Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Leu Val Ser 1 5 10 <210> 222 <211> 14 <212> PRT <213> Homo sapiens <400> 222 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 223 <211> 14 <212> PRT <213> Homo sapiens <400> 223 Thr Gly Ser Ser Ser Asn Ile Gly Ala His Tyr Asp Val His 1 5 10 <210> 224 <211> 13 <212> PRT <213> Homo sapiens <400> 224 Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 225 <211> 11 <212> PRT <213> Homo sapiens <400> 225 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 226 <211> 12 <212> PRT <213> Homo sapiens <400> 226 Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu Val Asp 1 5 10 <210> 227 <211> 7 <212> PRT <213> Homo sapiens <400> 227 Leu Gly Ser His Arg Ala Ser 1 5 <210> 228 <211> 7 <212> PRT <213> Homo sapiens <400> 228 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 229 <211> 7 <212> PRT <213> Homo sapiens <400> 229 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 230 <211> 7 <212> PRT <213> Homo sapiens <400> 230 Gly Asn Thr Tyr Arg Pro Ser 1 5 <210> 231 <211> 7 <212> PRT <213> Homo sapiens <400> 231 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 232 <211> 7 <212> PRT <213> Homo sapiens <400> 232 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 233 <211> 7 <212> PRT <213> Homo sapiens <400> 233 Gln Asn Thr Lys Trp Pro Leu 1 5 <210> 234 <211> 7 <212> PRT <213> Homo sapiens <400> 234 Val Asp Thr Gly Gly Ile Val 1 5 <210> 235 <211> 9 <212> PRT <213> Homo sapiens <400> 235 Gln Gln Ser Tyr Ser Thr Pro Leu Ile 1 5 <210> 236 <211> 9 <212> PRT <213> Homo sapiens <400> 236 Met Gln Val Leu Gln Thr Pro Phe Thr 1 5 <210> 237 <211> 10 <212> PRT <213> Homo sapiens <400> 237 Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val 1 5 10 <210> 238 <211> 11 <212> PRT <213> Homo sapiens <400> 238 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 239 <211> 11 <212> PRT <213> Homo sapiens <400> 239 Gln Ser Tyr Asp Asn Ser Leu Ser Gly Val Val 1 5 10 <210> 240 <211> 11 <212> PRT <213> Homo sapiens <400> 240 Ala Val Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 241 <211> 11 <212> PRT <213> Homo sapiens <400> 241 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 242 <211> 9 <212> PRT <213> Homo sapiens <400> 242 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 243 <211> 18 <212> PRT <213> Homo sapiens <400> 243 Ser Asp Tyr His Cys Gly Ala Asp His Gly Ser Gly Thr Asn Phe Val 1 5 10 15 Val Val <210> 244 <211> 10 <212> PRT <213> Homo sapiens <400> 244 Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 245 <211> 10 <212> PRT <213> Homo sapiens <400> 245 Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 1 5 10 <210> 246 <211> 10 <212> PRT <213> Homo sapiens <400> 246 Gly Phe Thr Phe Ser Ser Tyr Gly Met His 1 5 10 <210> 247 <211> 10 <212> PRT <213> Homo sapiens <400> 247 Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn 1 5 10 <210> 248 <211> 12 <212> PRT <213> Homo sapiens <400> 248 Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser 1 5 10 <210> 249 <211> 12 <212> PRT <213> Homo sapiens <400> 249 Gly Gly Ser Ile Ser Ser Ser Asp Tyr Tyr Trp Ser 1 5 10 <210> 250 <211> 10 <212> PRT <213> Homo sapiens <400> 250 Gly Gly Ser Phe Ser Ala Tyr Tyr Trp Asn 1 5 10 <210> 251 <211> 12 <212> PRT <213> Homo sapiens <400> 251 Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn 1 5 10 <210> 252 <211> 17 <212> PRT <213> Homo sapiens <400> 252 Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 253 <211> 17 <212> PRT <213> Homo sapiens <400> 253 Thr Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 254 <211> 17 <212> PRT <213> Homo sapiens <400> 254 Val Ile Trp Tyr Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 255 <211> 17 <212> PRT <213> Homo sapiens <400> 255 Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 256 <211> 17 <212> PRT <213> Homo sapiens <400> 256 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 257 <211> 16 <212> PRT <213> Homo sapiens <400> 257 Tyr Ile Tyr Asn Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 258 <211> 16 <212> PRT <213> Homo sapiens <400> 258 Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 259 <211> 16 <212> PRT <213> Homo sapiens <400> 259 Glu Ile Asn His Ser Gly Arg Thr Asp Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 260 <211> 18 <212> PRT <213> Homo sapiens <400> 260 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Lys Asn Tyr Ser Val Ser Val 1 5 10 15 Lys Ser <210> 261 <211> 6 <212> PRT <213> Homo sapiens <400> 261 Gly Tyr Thr Arg Asp Tyr 1 5 <210> 262 <211> 8 <212> PRT <213> Homo sapiens <400> 262 Glu Val Gly Ser Pro Phe Asp Tyr 1 5 <210> 263 <211> 14 <212> PRT <213> Homo sapiens <400> 263 Glu Thr Gly Pro Leu Lys Leu Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 264 <211> 13 <212> PRT <213> Homo sapiens <400> 264 Arg Gly Gly Leu Ala Ala Arg Pro Gly Gly Met Asp Val 1 5 10 <210> 265 <211> 14 <212> PRT <213> Homo sapiens <400> 265 Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val 1 5 10 <210> 266 <211> 11 <212> PRT <213> Homo sapiens <400> 266 Glu Asp Thr Ala Met Val Pro Tyr Phe Asp Tyr 1 5 10 <210> 267 <211> 12 <212> PRT <213> Homo sapiens <400> 267 Gly Gly Val Thr Thr Tyr Tyr Tyr Ala Met Asp Val 1 5 10 <210> 268 <211> 8 <212> PRT <213> Homo sapiens <400> 268 Gly Gln Leu Val Pro Phe Asp Tyr 1 5 <210> 269 <211> 9 <212> PRT <213> Homo sapiens <400> 269 Gly Gly Pro Thr Ala Ala Phe Asp Tyr 1 5 <210> 270 <211> 109 <212> PRT <213> Homo sapiens <400> 270 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Phe Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 271 <211> 109 <212> PRT <213> Homo sapiens <400> 271 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Phe Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Arg 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Asn Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 272 <211> 109 <212> PRT <213> Homo sapiens <400> 272 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Pro Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 273 <211> 109 <212> PRT <213> Homo sapiens <400> 273 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Pro Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Phe Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 274 <211> 106 <212> PRT <213> Homo sapiens <400> 274 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 275 <211> 106 <212> PRT <213> Homo sapiens <400> 275 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asn Thr Lys Trp Pro Leu Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Asn Thr Val Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 276 <211> 107 <212> PRT <213> Homo sapiens <400> 276 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val 85 90 95 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 277 <211> 107 <212> PRT <213> Homo sapiens <400> 277 Ser Tyr Glu Leu Ile Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Arg Lys Pro Gly Gln Ser Pro Ile Leu Val Ile Tyr 35 40 45 Gln Asp Thr Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val 85 90 95 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 278 <211> 120 <212> PRT <213> Homo sapiens <400> 278 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Thr Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Ser Tyr Ser Ser Gly Trp Phe Glu Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 279 <211> 12 <212> PRT <213> Homo sapiens <400> 279 Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu Val Asp 1 5 10 <210> 280 <211> 12 <212> PRT <213> Homo sapiens <400> 280 Val Asp Thr Gly Gly Ile Val Gly Ser Lys Gly Glu 1 5 10 <210> 281 <211> 13 <212> PRT <213> Homo sapiens <400> 281 Gly Ala Asp His Gly Ser Gly Thr Asn Phe Val Val Val 1 5 10 <210> 282 <211> 22 <212> PRT <213> Homo sapiens <400> 282 Gln Pro Val Leu Thr Gln Pro Leu Phe Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Thr Leu Thr Cys 20 <210> 283 <211> 15 <212> PRT <213> Homo sapiens <400> 283 Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met Arg 1 5 10 15 <210> 284 <211> 32 <212> PRT <213> Homo sapiens <400> 284 Gly Ile Pro Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr 1 5 10 15 Leu Thr Ile Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys 20 25 30 <210> 285 <211> 10 <212> PRT <213> Homo sapiens <400> 285 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 1 5 10 <210> 286 <211> 108 <212> PRT <213> Homo sapiens <400> 286 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val 100 105 <210> 287 <211> 108 <212> PRT <213> Homo sapiens <400> 287 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Ile Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val 100 105 <210> 288 <211> 108 <212> PRT <213> Homo sapiens <400> 288 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val 100 105 <210> 289 <211> 122 <212> PRT <213> Homo sapiens <400> 289 Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly His Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 290 <211> 122 <212> PRT <213> Homo sapiens <400> 290 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val 35 40 45 Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Gly Leu Ala Ala Arg Pro Gly Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 291 <211> 121 <212> PRT <213> Homo sapiens <400> 291 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser 115 120 <210> 292 <211> 119 <212> PRT <213> Homo sapiens <400> 292 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Gly Leu Pro Gly Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 293 <211> 327 <212> DNA <213> Homo sapiens <400> 293 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aagcccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc aactcatata caagcaccag catggtattc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 294 <211> 327 <212> DNA <213> Homo sapiens <400> 294 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 295 <211> 318 <212> DNA <213> Homo sapiens <400> 295 tcctatgagc tgactcagcc accctcagtg tccgtgtccc caggacagac agccagaatc 60 acctgctctg gagataaatt gggggataaa tatgcttgct ggtatcagca gaagccaggc 120 cagtcccctg tgctggtcat ctatcaaaat accaagtggc ccttagggat ccctgagcga 180 ttctctggct ccaagtctgg gaacacagtc actctgacca tcagcgggac ccaggctatg 240 gatgaggctg actattactg tcaggcgtgg gacagcagca ctgtggtatt cggcggaggg 300 accaagctga ccgtccta 318 <210> 296 <211> 327 <212> DNA <213> Homo sapiens <400> 296 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aagcccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc aattcatata caagcaccag catggtattc 300 ggcggaggga ccaagctgac cgtccta 327 <210> 297 <211> 215 <212> PRT <213> Homo sapiens <400> 297 Glu Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 298 <211> 230 <212> PRT <213> Homo sapiens <400> 298 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Gly Thr Met Thr Thr Asp Pro Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Asp Glu Val Asp 210 215 220 His His His His His His 225 230 <210> 299 <211> 217 <212> PRT <213> Homo sapiens <400> 299 Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Ser Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 300 <211> 238 <212> PRT <213> Homo sapiens <400> 300 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Ala Ala Asp Glu Val Asp His His His His His His 225 230 235 <210> 301 <211> 218 <212> PRT <213> Homo sapiens <400> 301 Ala Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 1 5 10 15 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly 20 25 30 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 35 40 45 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 50 55 60 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 65 70 75 80 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Asp 85 90 95 Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 165 170 175 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 180 185 190 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 195 200 205 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 302 <211> 231 <212> PRT <213> Homo sapiens <400> 302 Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ala Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Ser Gly Arg Thr Asp Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Lys Gln Phe Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Gln Leu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser His Ser Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Asp Glu Val 210 215 220 Asp His His His His His His 225 230 <210> 303 <211> 680 <212> PRT <213> Homo sapiens <400> 303 Gln Glu Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg 1 5 10 15 Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala 20 25 30 Thr Phe His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr 35 40 45 Val Val Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr 50 55 60 Ala Arg Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys 65 70 75 80 Ile Leu His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met 85 90 95 Ser Gly Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr 100 105 110 Ile Glu Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu 115 120 125 Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro 130 135 140 Asp Gly Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln 145 150 155 160 Ser Asp His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu 165 170 175 Asn Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys 180 185 190 Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp 195 200 205 Ala Gly Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn 210 215 220 Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe 225 230 235 240 Ile Arg Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu 245 250 255 Leu Pro Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln 260 265 270 Arg Leu Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe 275 280 285 Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile 290 295 300 Thr Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr 305 310 315 320 Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu 325 330 335 Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln 340 345 350 Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met 355 360 365 Met Leu Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg 370 375 380 Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro 385 390 395 400 Glu Asp Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro 405 410 415 Ser Thr His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser 420 425 430 Ala His Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala 435 440 445 Pro Asp Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys 450 455 460 Arg Arg Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg 465 470 475 480 Ala His Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys 485 490 495 Cys Leu Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala 500 505 510 Glu Ala Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val 515 520 525 Leu Thr Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His 530 535 540 Lys Pro Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly 545 550 555 560 His Arg Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu 565 570 575 Glu Cys Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val 580 585 590 Thr Val Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu 595 600 605 Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys 610 615 620 Val Val Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu 625 630 635 640 Ala Val Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln 645 650 655 Ala Ser Gln Glu Leu Gln Gly Ser Ser Asp Tyr Lys Asp Asp Asp Lys 660 665 670 His His His His His His His His 675 680 <210> 304 <211> 680 <212> PRT <213> Homo sapiens <400> 304 Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Leu Arg Arg Arg 1 5 10 15 Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg His Arg Arg Arg Arg 20 25 30 Arg Phe Arg Arg Cys Arg Arg Arg Pro Trp Arg Arg Pro Gly Arg Tyr 35 40 45 Val Val Val Leu Arg Arg Arg Arg Arg Arg Ser Arg Ser Arg Glu Thr 50 55 60 Ala Glu Glu Leu Gln Arg Arg Ala Arg Glu Glu Gly Arg Arg Thr Lys 65 70 75 80 Ile Arg Arg Arg Phe Arg Gly Leu Leu Pro Gly Phe Leu Val Arg Met 85 90 95 Arg Arg Arg Leu Arg Arg Leu Ala Arg Arg Leu Pro Arg Val Arg Tyr 100 105 110 Ile Glu Glu Asp Ser Ser Val Phe Arg Gln Arg Ile Pro Arg Asn Arg 115 120 125 Arg Glu Ile Arg Pro Pro Arg Tyr Arg Ala Arg Arg Arg Arg Pro Pro 130 135 140 Arg Gly Gly Arg Arg Val Glu Val Tyr Leu Leu Asp Thr Arg Ile Arg 145 150 155 160 Arg Arg His Glu Glu Ile Arg Gly Arg Val Arg Arg Arg Arg Phe Arg 165 170 175 Arg Arg Pro Arg Arg Arg Arg Arg Glu Arg Glu Glu Arg Arg Arg Arg 180 185 190 Cys Asp Arg Arg Gly Thr His Leu Ala Gly Val Val Ser Gly Glu Arg 195 200 205 Ala Gly Val Ala Arg Arg Ala Arg Met Arg Ser Leu Glu Val Leu Asn 210 215 220 Cys Arg Gly Arg Gly Arg Val Ser Gly Thr Leu Ile Gly Leu Glu Arg 225 230 235 240 Ile Glu Arg Arg Arg Arg Arg Arg Pro Arg Arg Pro Leu Val Val Leu 245 250 255 Leu Pro Leu Ala Gly Arg Tyr Ser Glu Val Leu Asn Arg Ala Cys Arg 260 265 270 Arg Leu Ala Glu Arg Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe 275 280 285 Glu Asp Asp Ala Cys Arg Tyr Ser Pro Ala Arg Ala Pro Glu Val Ile 290 295 300 Thr Val Gly Ala Thr Asn Arg Arg Arg Arg Pro Val Arg Arg Gly Arg 305 310 315 320 Arg Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Arg 325 330 335 Arg Ile Ile Gly Ala Ser Ser Arg Cys Ser Arg Cys Arg Arg Arg Arg 340 345 350 Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Arg 355 360 365 Met Leu Arg Arg Arg Pro Arg Leu Arg Arg Ala Arg Leu Arg Gln Glu 370 375 380 Leu Arg Arg Arg Ser Arg Arg Arg Arg Ile Arg Arg Arg Arg Phe Pro 385 390 395 400 Arg Arg Arg Glu Arg Leu Thr Pro Arg Leu Val Ala Arg Leu Pro Pro 405 410 415 Arg Arg Arg Arg Arg Gly Arg Arg Leu Phe Cys Arg Thr Val Trp Ser 420 425 430 Arg Arg Ser Gly Pro Arg Glu Arg Ala Arg Ala Ile Ala Glu Cys Ala 435 440 445 Pro Arg Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys 450 455 460 Arg Arg Gly Glu Arg Met Glu Arg Gln Gly Gly Lys Leu Val Cys Arg 465 470 475 480 Ala His Asn Ala Arg Arg Gly Arg Gly Val Tyr Ala Ile Ala Arg Cys 485 490 495 Cys Leu Leu Pro Gln Ala Arg Cys Ser Val His Arg Ala Pro Pro Ala 500 505 510 Arg Arg Arg Arg Gly Thr Glu Val Arg Cys Arg Arg Arg Gly His Val 515 520 525 Leu Thr Gly Cys Ser Ser His Trp Arg Arg Arg Asp Arg Gly Thr Arg 530 535 540 Lys Pro Pro Arg Leu Arg Pro Glu Gly Arg Pro Arg Gln Cys Val Gly 545 550 555 560 His Arg Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu 565 570 575 Glu Cys Arg Arg Arg Arg Arg Arg Ile Pro Ala Pro Arg Glu Arg Val 580 585 590 Thr Val Arg Cys Arg Arg Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu 595 600 605 Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Arg Asp Asn Thr Cys 610 615 620 Val Val Arg Ser Glu Asp Arg Arg Arg Arg Arg Arg Arg Arg Arg Glu 625 630 635 640 Arg Val Thr Ala Val Ala Ile Cys Cys Glu Ser Glu His Leu Ala Gln 645 650 655 Ala Ser Gln Glu Leu Gln Gly Ser Ser Asp Tyr Lys Asp Asp Asp Lys 660 665 670 His His His His His His His His 675 680 <210> 305 <211> 14 <212> PRT <213> Homo sapiens <400> 305 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Ser Val Ser 1 5 10 <210> 306 <211> 7 <212> PRT <213> Homo sapiens <400> 306 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 307 <211> 9 <212> PRT <213> Homo sapiens <400> 307 Ser Ser Tyr Thr Ser Thr Ser Met Val 1 5 <210> 308 <211> 5 <212> PRT <213> Homo sapiens <400> 308 Ser Tyr Gly Ile Ser 1 5 <210> 309 <211> 17 <212> PRT <213> Homo sapiens <400> 309 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 310 <211> 6 <212> PRT <213> Homo sapiens <400> 310 Gly Tyr Gly Met Asp Val 1 5 <210> 311 <211> 14 <212> PRT <213> Homo sapiens <400> 311 Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Ser Val Ser 1 5 10 <210> 312 <211> 7 <212> PRT <213> Homo sapiens <400> 312 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 313 <211> 9 <212> PRT <213> Homo sapiens <400> 313 Ser Ser Tyr Thr Ser Ser Ser Val Val 1 5 <210> 314 <211> 17 <212> PRT <213> Homo sapiens <400> 314 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Glu Lys Leu Gln 1 5 10 15 Gly <210> 315 <211> 6 <212> PRT <213> Homo sapiens <400> 315 Gly Tyr Val Met Asp Val 1 5 <210> 316 <211> 14 <212> PRT <213> Homo sapiens <400> 316 Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Ser Val Ser 1 5 10 <210> 317 <211> 9 <212> PRT <213> Homo sapiens <400> 317 Ser Ser Tyr Thr Ser Thr Asn Met Val 1 5 <210> 318 <211> 17 <212> PRT <213> Homo sapiens <400> 318 Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 319 <211> 9 <212> PRT <213> Homo sapiens <400> 319 Asn Ser Tyr Thr Ser Thr Ser Met Val 1 5 <210> 320 <211> 17 <212> PRT <213> Homo sapiens <400> 320 Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 1 5 10 15 Gly <210> 321 <211> 7 <212> PRT <213> Homo sapiens <400> 321 Glu Val Thr Asn Arg Pro Ser 1 5 <210> 322 <211> 14 <212> PRT <213> Homo sapiens <400> 322 Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser 1 5 10 <210> 323 <211> 17 <212> PRT <213> Homo sapiens <400> 323 Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 324 <211> 17 <212> PRT <213> Homo sapiens <400> 324 Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 325 <211> 13 <212> PRT <213> Homo sapiens <400> 325 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Phe Val Ser 1 5 10 <210> 326 <211> 7 <212> PRT <213> Homo sapiens <400> 326 Asp Tyr Asn Lys Arg Pro Ser 1 5 <210> 327 <211> 11 <212> PRT <213> Homo sapiens <400> 327 Gly Thr Trp Asp Ser Ser Leu Ser Gly Tyr Val 1 5 10 <210> 328 <211> 5 <212> PRT <213> Homo sapiens <400> 328 Ser Phe Gly Met His 1 5 <210> 329 <211> 17 <212> PRT <213> Homo sapiens <400> 329 Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 330 <211> 13 <212> PRT <213> Homo sapiens <400> 330 Ala Ile Ala Ala Leu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 331 <211> 7 <212> PRT <213> Homo sapiens <400> 331 Asp Ser Asn Lys Arg Pro Ser 1 5 <210> 332 <211> 11 <212> PRT <213> Homo sapiens <400> 332 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 333 <211> 5 <212> PRT <213> Homo sapiens <400> 333 Ser Tyr Gly Met His 1 5 <210> 334 <211> 17 <212> PRT <213> Homo sapiens <400> 334 Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 335 <211> 13 <212> PRT <213> Homo sapiens <400> 335 Gly Ile Ala Val Ala Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 336 <211> 17 <212> PRT <213> Homo sapiens <400> 336 Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 337 <211> 11 <212> PRT <213> Homo sapiens <400> 337 Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val 1 5 10 <210> 338 <211> 17 <212> PRT <213> Homo sapiens <400> 338 Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 339 <211> 13 <212> PRT <213> Homo sapiens <400> 339 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 340 <211> 7 <212> PRT <213> Homo sapiens <400> 340 Ser Asn Asn Arg Arg Pro Ser 1 5 <210> 341 <211> 10 <212> PRT <213> Homo sapiens <400> 341 Ala Ala Trp Asp Asp Ser Leu Asn Trp Val 1 5 10 <210> 342 <211> 4 <212> PRT <213> Homo sapiens <400> 342 Tyr Trp Met Ser One <210> 343 <211> 17 <212> PRT <213> Homo sapiens <400> 343 Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 344 <211> 10 <212> PRT <213> Homo sapiens <400> 344 Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile 1 5 10 <210> 345 <211> 13 <212> PRT <213> Homo sapiens <400> 345 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 346 <211> 5 <212> PRT <213> Homo sapiens <400> 346 Arg Tyr Trp Met Ser 1 5 <210> 347 <211> 17 <212> PRT <213> Homo sapiens <400> 347 Asn Ile Lys His Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 348 <211> 10 <212> PRT <213> Homo sapiens <400> 348 Glu Ser Asn Trp Gly Phe Ala Phe Asp Val 1 5 10 <210> 349 <211> 7 <212> PRT <213> Homo sapiens <400> 349 Arg Asn Asn Gln Arg Pro Leu 1 5 <210> 350 <211> 5 <212> PRT <213> Homo sapiens <400> 350 Ser Tyr Trp Met Ser 1 5 <210> 351 <211> 5 <212> PRT <213> Homo sapiens <400> 351 Asn Phe Trp Met Ser 1 5 <210> 352 <211> 10 <212> PRT <213> Homo sapiens <400> 352 Arg Ala Ser Gln Ser Ile Ser Tyr Leu Asn 1 5 10 <210> 353 <211> 6 <212> PRT <213> Homo sapiens <400> 353 Ala Ala Ser Leu Gln Ser 1 5 <210> 354 <211> 8 <212> PRT <213> Homo sapiens <400> 354 Gln Gln Ser Tyr Ser Pro Ile Thr 1 5 <210> 355 <211> 11 <212> PRT <213> Homo sapiens <400> 355 Arg Ala Ser Gln Ser Ile Ser Ile Tyr Leu Asn 1 5 10 <210> 356 <211> 7 <212> PRT <213> Homo sapiens <400> 356 Ala Ala Ala Ser Leu Gln Ser 1 5 <210> 357 <211> 9 <212> PRT <213> Homo sapiens <400> 357 Gln Gln Ser Tyr Ser Ala Pro Ile Thr 1 5 <210> 358 <211> 11 <212> PRT <213> Homo sapiens <400> 358 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 359 <211> 7 <212> PRT <213> Homo sapiens <400> 359 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 360 <211> 9 <212> PRT <213> Homo sapiens <400> 360 Gln Gln Ser Tyr Ser Ser Pro Ile Thr 1 5 <210> 361 <211> 5 <212> PRT <213> Homo sapiens <400> 361 Ser Tyr Ala Met Asn 1 5 <210> 362 <211> 16 <212> PRT <213> Homo sapiens <400> 362 Thr Ile Ser Gly Ser Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 363 <211> 12 <212> PRT <213> Homo sapiens <400> 363 Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr 1 5 10 <210> 364 <211> 17 <212> PRT <213> Homo sapiens <400> 364 Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 365 <211> 17 <212> PRT <213> Homo sapiens <400> 365 Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 366 <211> 10 <212> PRT <213> Homo sapiens <400> 366 Gly Tyr Ser Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 367 <211> 10 <212> PRT <213> Homo sapiens <400> 367 Gly Tyr Ala Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 368 <211> 10 <212> PRT <213> Homo sapiens <400> 368 Gly Tyr Thr Leu Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 369 <211> 10 <212> PRT <213> Homo sapiens <400> 369 Gly Tyr Ser Phe Thr Ser Tyr Gly Ile Ser 1 5 10 <210> 370 <211> 10 <212> PRT <213> Homo sapiens <400> 370 Gly Tyr Thr Phe Pro Ser Tyr Gly Ile Ser 1 5 10 <210> 371 <211> 10 <212> PRT <213> Homo sapiens <400> 371 Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser 1 5 10 <210> 372 <211> 10 <212> PRT <213> Homo sapiens <400> 372 Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser 1 5 10 <210> 373 <211> 10 <212> PRT <213> Homo sapiens <400> 373 Gly Leu Thr Phe Ser Asn Phe Trp Met Ser 1 5 10 <210> 374 <211> 10 <212> PRT <213> Homo sapiens <400> 374 Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn 1 5 10 <210> 375 <211> 10 <212> PRT <213> Homo sapiens <400> 375 Gly Phe Thr Phe Asn Ser Phe Gly Met His 1 5 10 <210> 376 <211> 10 <212> PRT <213> Homo sapiens <400> 376 Gly Phe Thr Phe Arg Ser Tyr Gly Met His 1 5 10 <210> 377 <211> 16 <212> PRT <213> Homo sapiens <400> 377 Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Val Asp Ser Val Lys Gly 1 5 10 15 <210> 378 <211> 16 <212> PRT <213> Homo sapiens <400> 378 Asn Ile Lys His Asp Gly Ser Glu Lys Tyr Val Asp Ser Val Lys Gly 1 5 10 15 <210> 379 <211> 16 <212> PRT <213> Homo sapiens <400> 379 Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 380 <211> 16 <212> PRT <213> Homo sapiens <400> 380 Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 381 <211> 16 <212> PRT <213> Homo sapiens <400> 381 Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 382 <211> 16 <212> PRT <213> Homo sapiens <400> 382 Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 383 <211> 16 <212> PRT <213> Homo sapiens <400> 383 Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 384 <211> 16 <212> PRT <213> Homo sapiens <400> 384 Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Val Asp Ser Val Lys Gly 1 5 10 15 <210> 385 <211> 10 <212> PRT <213> Homo sapiens <400> 385 Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile 1 5 10 <210> 386 <211> 10 <212> PRT <213> Homo sapiens <400> 386 Glu Ser Asn Trp Gly Phe Ala Phe Asp Val 1 5 10 <210> 387 <211> 6 <212> PRT <213> Homo sapiens <400> 387 Gly Tyr Val Met Asp Val 1 5 <210> 388 <211> 11 <212> PRT <213> Homo sapiens <400> 388 Arg Ala Ser Gln Ser Ile Ser Ile Tyr Leu Asn 1 5 10 <210> 389 <211> 14 <212> PRT <213> Homo sapiens <400> 389 Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser 1 5 10 <210> 390 <211> 14 <212> PRT <213> Homo sapiens <400> 390 Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Ser Val Ser 1 5 10 <210> 391 <211> 14 <212> PRT <213> Homo sapiens <400> 391 Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Ser Val Ser 1 5 10 <210> 392 <211> 7 <212> PRT <213> Homo sapiens <400> 392 Arg Asn Asn Gln Arg Pro Leu 1 5 <210> 393 <211> 7 <212> PRT <213> Homo sapiens <400> 393 Ala Ala Ala Ser Leu Gln Ser 1 5 <210> 394 <211> 9 <212> PRT <213> Homo sapiens <400> 394 Gln Gln Ser Tyr Ser Ala Pro Ile Thr 1 5 <210> 395 <211> 9 <212> PRT <213> Homo sapiens <400> 395 Asn Ser Tyr Thr Ser Thr Ser Met Val 1 5 <210> 396 <211> 9 <212> PRT <213> Homo sapiens <400> 396 Ser Ser Tyr Thr Ser Ser Ser Val Val 1 5 <210> 397 <211> 10 <212> PRT <213> Homo sapiens <400> 397 Ala Ala Trp Asp Asp Ser Leu Asn Trp Val 1 5 10 <210> 398 <211> 11 <212> PRT <213> Homo sapiens <400> 398 Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val 1 5 10 <210> 399 <211> 11 <212> PRT <213> Homo sapiens <400> 399 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 400 <211> 116 <212> PRT <213> Homo sapiens <400> 400 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Ser Ser Gly Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 401 <211> 118 <212> PRT <213> Homo sapiens <400> 401 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser 115 <210> 402 <211> 115 <212> PRT <213> Homo sapiens <400> 402 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Trp Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser 115 <210> 403 <211> 6 <212> PRT <213> Homo sapiens <400> 403 Glu Asn Leu Tyr Phe Gln 1 5 <210> 404 <211> 14 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa= D, A, R or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=Y, I, G or no amino acid <220> <221> VARIANT <222> 3 <223> Xaa=D, A, G or no amino acid <220> <221> VARIANT <222> 4 <223> Xaa=F, A, L or no amino acid <220> <221> VARIANT <222> 5 <223> Xaa=W, L, A or no amino acid <220> <221> VARIANT <222> 6 <223> Xaa=S, Y, A or no amino acid <220> <221> VARIANT <222> (7)...(7) <223> Xaa=A, Y, R or no amino acid <220> <221> VARIANT <222> (8)...(8) <223> Xaa=Y, P or no amino acid <220> <221> VARIANT <222> (9)...(9) <223> Xaa=Y, G or no amino acid <220> <221> VARIANT <222> (10)...(10) <223> Xaa=D, G or no amino acid <220> <221> VARIANT <222> (11)...(11) <223> Xaa=A, M or no amino acid <220> <221> VARIANT <222> (12)...(12) <223> Xaa=F,D or no amino acid <220> <221> VARIANT <222> (13)...(13) <223> Xaa=D, V or no amino acid <220> <221> VARIANT <222> (14)...(14) <223> Xaa=V or no amino acid <400> 404 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 405 <211> 11 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=Q or G <220> <221> VARIANT <222> 2 <223> Xaa=S, T, A or no amino acid <220> <221> VARIANT <222> 3 <223> Xaa=Y, W or no amino acid <220> <221> VARIANT <222> 4 <223> Xaa=D or no amino acid <220> <221> VARIANT <222> 5 <223> Xaa=S or no amino acid <220> <221> VARIANT <222> 6 <223> Xaa=S or no amino acid <220> <221> VARIANT <222> (7)...(7) <223> Xaa=L, T or no amino acid <220> <221> VARIANT <222> (8)...(8) <223> Xaa=A, S or no amino acid <220> <221> VARIANT <222> (9)...(9) <223> Xaa=G, A, V or no amino acid <220> <221> VARIANT <222> (10)...(10) <223> Xaa=S, Y, V or no amino acid <220> <221> VARIANT <222> (11)...(11) <223> Xaa=V or no amino acid <400> 405 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 406 <211> 10 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=G <220> <221> VARIANT <222> 2 <223> Xaa=Y, F or G <220> <221> VARIANT <222> 3 <223> Xaa=T or S <220> <221> VARIANT <222> 4 <223> Xaa=L or F <220> <221> VARIANT <222> 5 <223> Xaa=T, S or N <220> <221> VARIANT <222> 6 <223> Xaa=S or A <220> <221> VARIANT <222> (7)...(7) <223> Xaa=Y or F <220> <221> VARIANT <222> (8)...(8) <223> Xaa=G, S or Y <220> <221> VARIANT <222> (9)...(9) <223> Xaa=I, M or W <220> <221> VARIANT <222> (10)...(10) <223> Xaa=S, N or H <400> 406 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 407 <211> 14 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=T or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=G or S <220> <221> VARIANT <222> 3 <223> Xaa=S, T or G <220> <221> VARIANT <222> 4 <223> Xaa=S <220> <221> VARIANT <222> 5 <223> Xaa=S <220> <221> VARIANT <222> 6 <223> Xaa=N, D or S <220> <221> VARIANT <222> (7)...(7) <223> Xaa=I, V or N <220> <221> VARIANT <222> (8)...(8) <223> Xaa=G or I <220> <221> VARIANT <222> (9)...(9) <223> Xaa=A or G <220> <221> VARIANT <222> (10)...(10) <223> Xaa=G, Y, S or N <220> <221> VARIANT <222> (11)...(11) <223> Xaa=Y or N <220> <221> VARIANT <222> (12)...(12) <223> Xaa=D, S, T or F <220> <221> VARIANT <222> (13)...(13) <223> Xaa=V <220> <221> VARIANT <222> (14)...(14) <223> Xaa=S, N or H <400> 407 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 408 <211> 17 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=W, S, L or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=V, I or E <220> <221> VARIANT <222> 3 <223> Xaa=S, W or I <220> <221> VARIANT <222> 4 <223> Xaa=F, S or N <220> <221> VARIANT <222> 5 <223> Xaa=Y, S, D or H <220> <221> VARIANT <222> 6 <223> Xaa=N, S or G <220> <221> VARIANT <222> (7)...(7) <223> Xaa=S or G <220> <221> VARIANT <222> (8)...(8) <223> Xaa=N, Y, D or R <220> <221> VARIANT <222> (9)...(9) <223> Xaa=T, I or E <220> <221> VARIANT <222> (10)...(10) <223> Xaa=N, S, Y or D <220> <221> VARIANT <222> (11)...(11) <223> Xaa=Y <220> <221> VARIANT <222> (12)...(12) <223> Xaa=A and N <220> <221> VARIANT <222> (13)...(13) <223> Xaa=Q, D or P <220> <221> VARIANT <222> (14)...(14) <223> Xaa=K or S <220> <221> VARIANT <222> (15)...(15) <223> Xaa=L or V <220> <221> VARIANT <222> (16)...(16) <223> Xaa=Q or K <220> <221> VARIANT <222> (17)...(17) <223> Xaa=G or S <400> 408 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa <210> 409 <211> 7 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=G, E, S or D <220> <221> VARIANT <222> 2 <223> Xaa=N, V or Y <220> <221> VARIANT <222> 3 <223> Xaa=S or N <220> <221> VARIANT <222> 4 <223> Xaa=N, Q or K <220> <221> VARIANT <222> 5 <223> Xaa=R <220> <221> VARIANT <222> 6 <223> Xaa=P <220> <221> VARIANT <222> (7)...(7) <223> Xaa=S <400> 409 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 410 <211> 14 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=D or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=Y, A or no amino acid <220> <221> VARIANT <222> 3 <223> Xaa=D, I or no amino acid <220> <221> VARIANT <222> 4 <223> Xaa=F, A or no amino acid <220> <221> VARIANT <222> 5 <223> Xaa=W, A or no amino acid <220> <221> VARIANT <222> 6 <223> Xaa=S, L or no amino acid <220> <221> VARIANT <222> (7)...(7) <223> Xaa=A, Y, G or no amino acid <220> <221> VARIANT <222> (8)...(8) <223> Xaa=Y, Q or no amino acid <220> <221> VARIANT <222> (9)...(9) <223> Xaa=G, Y or L <220> <221> VARIANT <222> (10)...(10) <223> Xaa=Y, D or V <220> <221> VARIANT <222> (11)...(11) <223> Xaa=G, A or P <220> <221> VARIANT <222> (12)...(12) <223> Xaa=M or F <220> <221> VARIANT <222> (13)...(13) <223> Xaa=D <220> <221> VARIANT <222> (14)...(14) <223> Xaa=V or Y <400> 410 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 411 <211> 11 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=Q, A, G or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=S, V, T or no amino acid <220> <221> VARIANT <222> 3 <223> Xaa=Y, N or W <220> <221> VARIANT <222> 4 <223> Xaa=S or D <220> <221> VARIANT <222> 5 <223> Xaa=S, Y or D <220> <221> VARIANT <222> 6 <223> Xaa=S or T <220> <221> VARIANT <222> (7)...(7) <223> Xaa=L or S <220> <221> VARIANT <222> (8)...(8) <223> Xaa=S, T or N <220> <221> VARIANT <222> (9)...(9) <223> Xaa=G, S or A <220> <221> VARIANT <222> (10)...(10) <223> Xaa=S, M, W or Y <220> <221> VARIANT <222> (11)...(11) <223> Xaa=V <400> 411 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 412 <211> 10 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=G, P or A <220> <221> VARIANT <222> 2 <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> 3 <223> Xaa=T, P, S, A, C, V, L or I <220> <221> VARIANT <222> 4 <223> Xaa=L, F, I, V, M, A or Y <220> <221> VARIANT <222> 5 <223> Xaa=T, P, S or A <220> <221> VARIANT <222> 6 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> (7)...(7) <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> (8)...(8) <223> Xaa=G, P or A <220> <221> VARIANT <222> (9)...(9) <223> Xaa=I, L, V, M, A or F <220> <221> VARIANT <222> (10)...(10) <223> Xaa=S, T, A or C <400> 412 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 413 <211> 14 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=T or S <220> <221> VARIANT <222> 2 <223> Xaa=G, P or A <220> <221> VARIANT <222> 3 <223> Xaa=T or S <220> <221> VARIANT <222> 4 <223> Xaa=S, N, T, A, C or Q <220> <221> VARIANT <222> 5 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> 6 <223> Xaa=D or E <220> <221> VARIANT <222> (7)...(7) <223> Xaa=V, I, M, L, F or A <220> <221> VARIANT <222> (8)...(8) <223> Xaa=G, P or A <220> <221> VARIANT <222> (9)...(9) <223> Xaa=G, A, R, P, V, L, I, K, Q or N <220> <221> VARIANT <222> (10)...(10) <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> (11)...(11) <223> Xaa=N or Q <220> <221> VARIANT <222> (12)...(12) <223> Xaa=Y, S, W, F, T, S, T, A or C <220> <221> VARIANT <222> (13)...(13) <223> Xaa=V, I, M, L, F, or A <220> <221> VARIANT <222> (14)...(14) <223> Xaa=S, T, A or C <400> 413 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 414 <211> 17 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=W, Y or F <220> <221> VARIANT <222> 2 <223> Xaa=V, I, M, L, F or A <220> <221> VARIANT <222> 3 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> 4 <223> Xaa=A, F, V, L, I, Y or M <220> <221> VARIANT <222> 5 <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> 6 <223> Xaa=N or Q <220> <221> VARIANT <222> (7)...(7) <223> Xaa=G, P or A <220> <221> VARIANT <222> (8)...(8) <223> Xaa=N or Q <220> <221> VARIANT <222> (9)...(9) <223> Xaa=T or S <220> <221> VARIANT <222> (10)...(10) <223> Xaa=N or Q <220> <221> VARIANT <222> (11)...(11) <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> (12)...(12) <223> Xaa=A, V, L or I <220> <221> VARIANT <222> (13)...(13) <223> Xaa=Q, E, N or D <220> <221> VARIANT <222> (14)...(14) <223> Xaa=K, R, Q or N <220> <221> VARIANT <222> (15)...(15) <223> Xaa=L, F, V, I, M, A or Y <220> <221> VARIANT <222> (16)...(16) <223> Xaa=Q or N <220> <221> VARIANT <222> (17)...(17) <223> Xaa=G, P or A <400> 414 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa <210> 415 <211> 7 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=E or D <220> <221> VARIANT <222> 2 <223> Xaa=V, I, M, L, F or A <220> <221> VARIANT <222> 3 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> 4 <223> Xaa=N or Q <220> <221> VARIANT <222> 5 <223> Xaa=R, K, Q or N <220> <221> VARIANT <222> 6 <223> Xaa=P or A <220> <221> VARIANT <222> (7)...(7) <223> Xaa=S, T, A or C <400> 415 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 416 <211> 6 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=G, P, A or no amino acid <220> <221> VARIANT <222> 2 <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> 3 <223> Xaa=G, V, P, A, I, M, L or F <220> <221> VARIANT <222> 4 <223> Xaa=M, L, F or I <220> <221> VARIANT <222> 5 <223> Xaa=D or E <220> <221> VARIANT <222> 6 <223> Xaa=V, I, M, L, F or A <400> 416 Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 417 <211> 9 <212> PRT <213> Homo sapiens <220> <221> VARIANT <222> 1 <223> Xaa=S, N, T, A, C or Q <220> <221> VARIANT <222> 2 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> 3 <223> Xaa=Y, W, F, T or S <220> <221> VARIANT <222> 4 <223> Xaa=T or S <220> <221> VARIANT <222> 5 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> 6 <223> Xaa=S, T, A or C <220> <221> VARIANT <222> (7)...(7) <223> Xaa=N, S, Q, T, A or C <220> <221> VARIANT <222> (8)...(8) <223> Xaa=M, V, L, F, I or A <220> <221> VARIANT <222> (9)...(9) <223> Xaa=V, I, M, L, F or A <400> 417 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 418 <211> 363 <212> DNA <213> Homo sapiens <400> 418 caggtgcagg tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcacc ggctactata tacactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcaaccctc acagtggtgg cgcaaactat 180 gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac 240 atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagaggcaac 300 tggaactacg actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 360 tca 363 <210> 419 <211> 121 <212> PRT <213> Homo sapiens <400> 419 Gln Val Gln Val Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro His Ser Gly Gly Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asn Trp Asn Tyr Asp Tyr Tyr Gly Met Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 420 <211> 321 <212> DNA <213> Homo sapiens <400> 420 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcgagtca ggacattagc aattatttag cctggtatca gcagaaacca 120 gggaaagttc ctaagctcct gatctatgct gcatccactt tgcaatcagg ggtcccatct 180 cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctacagcct 240 gaagatgttg caacttattt ctgtcaaagg tatcagattg ccccattcac tttcggccct 300 gggaccaagg tggatatcaa a 321 <210> 421 <211> 107 <212> PRT <213> Homo sapiens <400> 421 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Phe Cys Gln Arg Tyr Gln Ile Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 422 <211> 366 <212> DNA <213> Homo sapiens <400> 422 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atctggtatg atggaagtac taaatactat 180 gcagactccg tgaagggccg atccaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gaggtcagtg 300 gctggttacc actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 423 <211> 122 <212> PRT <213> Homo sapiens <400> 423 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Thr Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 424 <211> 324 <212> DNA <213> Homo sapiens <400> 424 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaggctat tatgcaacct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctatggtaaa aactaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taactcccgg gacagcattg gtaaccatct ggtgttcggc 300 ggagggacca agctgaccgt ccta 324 <210> 425 <211> 108 <212> PRT <213> Homo sapiens <400> 425 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Tyr Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ile Gly Asn His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 426 <211> 366 <212> DNA <213> Homo sapiens <400> 426 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggct tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggttag atggaagtaa taaatactat 180 gcagactccg tgaagggccg atccaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gaggtcagtg 300 gctggttacc actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 427 <211> 122 <212> PRT <213> Homo sapiens <400> 427 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Leu Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 428 <211> 324 <212> DNA <213> Homo sapiens <400> 428 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaagttat tatggaagct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctttggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taactcacgg gacatcattg gtgaccatct gctgttcggc 300 ggagggacca agctgaccgt ccta 324 <210> 429 <211> 108 <212> PRT <213> Homo sapiens <400> 429 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Gly 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Phe 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ile Ile Gly Asp His 85 90 95 Leu Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 430 <211> 366 <212> DNA <213> Homo sapiens <400> 430 caggtgcagc tggtggagtc tgggggaggc gtggtccagt ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagg aactatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtttg atggaagtaa taaatactat 180 gcagactccg tgaagggccg atccaccatc tccagagaca attccaagaa cacgctgtat 240 ctgctaatga acagcctgag agccgaggac acggctgtgt attactgtgc gaggtcagtg 300 gctggttacc actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 431 <211> 122 <212> PRT <213> Homo sapiens <400> 431 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 432 <211> 324 <212> DNA <213> Homo sapiens <400> 432 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccagg gagacagcct cagaagctat tatgcaagct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 atctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taaatcccgg gacatcattg gtgaccatct ggtgttcggc 300 ggagggacca aactgaccgt ccta 324 <210> 433 <211> 108 <212> PRT <213> Homo sapiens <400> 433 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Ile Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ile Ile Gly Asp His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 434 <211> 342 <212> DNA <213> Homo sapiens <400> 434 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgt gagagatcgg 300 ggactggact ggggccaggg aaccctggtc accgtctcct ca 342 <210> 435 <211> 114 <212> PRT <213> Homo sapiens <400> 435 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Asp Arg Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser <210> 436 <211> 324 <212> DNA <213> Homo sapiens <400> 436 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaggctat tatgcaagct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taagtcccgg gacagcagtg gtgaccatct ggtgttcggc 300 ggagggacca agctgaccgt ccta 324 <210> 437 <211> 108 <212> PRT <213> Homo sapiens <400> 437 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asp His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 438 <211> 366 <212> DNA <213> Homo sapiens <400> 438 caggtgcagg tggtggagtc tgggggaggc gtggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt aactatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atttggtatg atggaagtag taaatactat 180 gcagactccg tgaagggccg atccaccatc tccagagaca attccaagaa cacggtgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gaggtcagtg 300 gctggttacc actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 439 <211> 122 <212> PRT <213> Homo sapiens <400> 439 Gln Val Gln Val Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 440 <211> 324 <212> DNA <213> Homo sapiens <400> 440 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaggctat tatgcaagct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taagtcccgg gacagcagtg gtgaccatct ggtgttcggc 300 ggagggacca agctgaccgt ccta 324 <210> 441 <211> 108 <212> PRT <213> Homo sapiens <400> 441 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asp His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 442 <211> 366 <212> DNA <213> Homo sapiens <400> 442 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagtctc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtta taaagactat 180 gcagactccg tgaagggccg atccaccatc tccagagaca actccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attattgtgc gaggtcagtg 300 gctggttacc actactacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 <210> 443 <211> 122 <212> PRT <213> Homo sapiens <400> 443 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Tyr Lys Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 444 <211> 324 <212> DNA <213> Homo sapiens <400> 444 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaacctat tatgcaagct ggtaccagca gaagccaaga 120 caggccccta ttcttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aatcacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taaatcccgg gacatcattg gtaaccatct gctgttcggc 300 ggagggacta agctgaccgt ccta 324 <210> 445 <211> 108 <212> PRT <213> Homo sapiens <400> 445 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Ile Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ile Ile Gly Asn His 85 90 95 Leu Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 446 <211> 375 <212> DNA <213> Homo sapiens <400> 446 caggtgcagc tggtggcgtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccctcagt agctatggca tgcactgggt ccgccaggct 120 ccaggccagg ggctggagtg ggtggcagtc atatggtatg atggaagtaa caaatactat 180 gcagcctccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagtctgag agccgaggac acggctgtgt attactgtgc gagagggggt 300 ggttcgggga gtcatcgcta ctactactac ggtatggacg tctggggcca agggaccacg 360 gtcaccgtct cctca 375 <210> 447 <211> 125 <212> PRT <213> Homo sapiens <400> 447 Gln Val Gln Leu Val Ala Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Ala Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Gly Ser Gly Ser His Arg Tyr Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 448 <211> 324 <212> DNA <213> Homo sapiens <400> 448 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaacctat tatgcaagct ggtaccagca gaagccaaga 120 caggccccta ttcttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacctcagg aatcacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taaatcccgg gacatcattg gtaaccatct gctgttcggc 300 ggagggacta agctgaccgt ccta 324 <210> 449 <211> 108 <212> PRT <213> Homo sapiens <400> 449 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Ile Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ile Ile Gly Asn His 85 90 95 Leu Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 450 <211> 366 <212> DNA <213> Homo sapiens <400> 450 caggtgcaag tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt aactatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaggtaa taaatactat 180 gcagactccg tgaagggccg atccatcatc tccagagaca attccaagag cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgttt attattgtgc gaggtcagtg 300 gctggttacc attattacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 gcctca 366 <210> 451 <211> 122 <212> PRT <213> Homo sapiens <400> 451 Gln Val Gln Val Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Gly Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Ile Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ala Ser 115 120 <210> 452 <211> 327 <212> DNA <213> Homo sapiens <400> 452 cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaaccagcag tgacgttggt ggttataact ctgtctcctg gtaccaacag 120 cacccaggca aaccccccaa actcatgatt tatgaggtca gtaatcggcc ctcagggatt 180 tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttatttctgc agctcatata caagcaccag catggtcttc 300 ggcggaggga ccaagctggc cgtccta 327 <210> 453 <211> 109 <212> PRT <213> Homo sapiens <400> 453 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Met Val Phe Gly Gly Gly Thr Lys Leu Ala Val Leu 100 105 <210> 454 <211> 366 <212> DNA <213> Homo sapiens <400> 454 caggtgcaag tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt aactatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaggtaa taaatactat 180 gcagactccg tgaagggccg atccatcatc tccagagaca attccaagag cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgttt attattgtgc gaggtcagtg 300 gctggttacc attattacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360 gcctca 366 <210> 455 <211> 122 <212> PRT <213> Homo sapiens <400> 455 Gln Val Gln Val Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Gly Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Ile Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ala Ser 115 120 <210> 456 <211> 324 <212> DNA <213> Homo sapiens <400> 456 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaggctat tatgcaagct ggtaccagca gaagccaaga 120 caggcccctg tacttgtcat ctatggtaaa aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccacgtcagg aaacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taactcccgg gacaacattg gtgaccatct ggtgttcggc 300 ggagggacca agctgaccgt ccta 324 <210> 457 <211> 108 <212> PRT <213> Homo sapiens <400> 457 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ile Gly Asp His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 458 <211> 381 <212> DNA <213> Homo sapiens <400> 458 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctccggatt cacctttagt agctattgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccagc ataaaacaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaggaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatctt 300 gtattaatgg tgtatgatat agactactac tactacggta tggacgtctg gggccaaggg 360 accacggtca ccgtctcctc a 381 <210> 459 <211> 127 <212> PRT <213> Homo sapiens <400> 459 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Val Leu Met Val Tyr Asp Ile Asp Tyr Tyr Tyr Tyr 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 460 <211> 336 <212> DNA <213> Homo sapiens <400> 460 gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120 tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180 tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300 ctcactttcg gcggagggac caaggtagag atcaaa 336 <210> 461 <211> 112 <212> PRT <213> Homo sapiens <400> 461 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 462 <211> 381 <212> DNA <213> Homo sapiens <400> 462 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctccggatt cacctttagt aactattgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccagc ataaaacaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcgccatc tccagagaca acgccaagaa ctcactgttt 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatctt 300 gtactaatgg tgtatgatat agactactac tactacggta tggacgtctg gggccaaggg 360 accacggtca ccgtctcctc a 381 <210> 463 <211> 127 <212> PRT <213> Homo sapiens <400> 463 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Val Leu Met Val Tyr Asp Ile Asp Tyr Tyr Tyr Tyr 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 464 <211> 336 <212> DNA <213> Homo sapiens <400> 464 gatattgtga tgactcagtc tccactctcc ctgcctgtca cccctggaga gccggcctcc 60 atctcttgca ggtctagtca gagcctcctg catagtaatg ggtacaacta tttggattgg 120 tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180 tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cacatcttac actgaaaatc 240 agcagagtgg aggctgagga tgttggagtt tattactgca tgcaaactct acaaactccg 300 ctcactttcg gcggagggac caaggtggag atcaaa 336 <210> 465 <211> 112 <212> PRT <213> Homo sapiens <400> 465 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr His Leu Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr 85 90 95 Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 466 <211> 342 <212> DNA <213> Homo sapiens <400> 466 caggtgcagc tggtggagtc tgggggaggc gtggcccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatactatg atggaattaa taaacactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatcgg 300 ggactggact ggggccaggg aaccctggtc accgtctcct ca 342 <210> 467 <211> 114 <212> PRT <213> Homo sapiens <400> 467 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Ala Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Tyr Tyr Asp Gly Ile Asn Lys His Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser <210> 468 <211> 339 <212> DNA <213> Homo sapiens <400> 468 gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 atcaactgca agtccagcca gagtgtttta tacagctcca acagtaagaa ctacttagtt 120 tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc ctctacccgg 180 gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240 atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatagtact 300 ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 339 <210> 469 <211> 113 <212> PRT <213> Homo sapiens <400> 469 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Ser Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys <210> 470 <211> 357 <212> DNA <213> Homo sapiens <400> 470 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggact cacctttagt aacttttgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaaatga taaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagtca 300 aactggggat ttgcttttga tatctggggc caagggacaa tggtcaccgt ctcttca 357 <210> 471 <211> 119 <212> PRT <213> Homo sapiens <400> 471 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Phe 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Asn Asp Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 472 <211> 327 <212> DNA <213> Homo sapiens <400> 472 cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaaaactg taaactggta ccagcagttc 120 ccaggaacgg cccccaaact cctcatctat agtaataatc ggcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa ttgggtgttc 300 ggcgcaggga ccaagctgac cgtccta 327 <210> 473 <211> 109 <212> PRT <213> Homo sapiens <400> 473 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu 100 105 <210> 474 <211> 357 <212> DNA <213> Homo sapiens <400> 474 gaggtgcagc tggtggagtc tgggggaggt ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggact cacctttagt aacttttgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagtca 300 aactggggat ttgcttttga tatctggggc caagggacaa tggtcaccgt ctcttca 357 <210> 475 <211> 119 <212> PRT <213> Homo sapiens <400> 475 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Phe 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 476 <211> 327 <212> DNA <213> Homo sapiens <400> 476 cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga agtaaaactg taaactggta ccagcagttc 120 ccaggaacgg cccccaaact cctcatctat agtaataatc ggcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgca acatgggatg acagactgaa ttgggtgttc 300 ggcgcaggga ccaagctgac cgtccta 327 <210> 477 <211> 109 <212> PRT <213> Homo sapiens <400> 477 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Arg Leu 85 90 95 Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu 100 105 <210> 478 <211> 366 <212> DNA <213> Homo sapiens <400> 478 caggtcacct tgaaggagtc tggtcctgtg ctggtgaaac ccacagagac cctcacgctg 60 acctgcaccg tctctgggtt ctcactcagc aatgttagaa tgggtgtgag ctggatccgt 120 cagcccccag ggaaggccct ggagtggctt gcacacattt tttcgaatga cgaaaattcc 180 tacagaacat ctctgaagag caggctcacc atctccaagg acacctccaa aagccaggtg 240 gtccttacca tgaccaacat ggaccctgtg gacacagcca catattactg tgcacggata 300 gtgggagcta caacggatga tgcttttgat atctggggcc aagggacaat ggtcaccgtc 360 tcttca 366 <210> 479 <211> 122 <212> PRT <213> Homo sapiens <400> 479 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Val 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Asn Ser Tyr Arg Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Val Gly Ala Thr Thr Asp Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 480 <211> 324 <212> DNA <213> Homo sapiens <400> 480 tcctatgtgc tgactcagcc accctcggtg tcagtggccc caggacagac ggccaggatt 60 acctgtgggg gaaacaacat tggaagtaaa agtgtgcact ggtaccagca gaagccaggc 120 caggcccctg tgctggtcgt ctatgatgat agcgaccggc cctcagggat ccctgagcga 180 ttctctggct ccaactctgg gaacacggcc accctgacca tcagcagggt cgaagccggg 240 gatgaggccg acttttactg tcaggtgtgg gatagtagta gtgatcctgt ggtattcggc 300 ggagggacca agctgaccgt ccta 324 <210> 481 <211> 108 <212> PRT <213> Homo sapiens <400> 481 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr 35 40 45 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Phe Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 482 <211> 381 <212> DNA <213> Homo sapiens <400> 482 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagt aactattgga tgacctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccagc ataaagcaag atggaagtga gagatactat 180 gtggactctg tgaagggccg attcaccatc tcccgagaca ccgccaagaa ctctctgtat 240 ctccaaatga acagcctgcg agccgaggac acggctgtgt attactgtgc gagacctctt 300 gtactaatgg tgtatgctct acactactac tactacggta tggacgtctg gggccacggg 360 accacggtca ccgtctcctc a 381 <210> 483 <211> 127 <212> PRT <213> Homo sapiens <400> 483 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ser Ile Lys Gln Asp Gly Ser Glu Arg Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Pro Leu Val Leu Met Val Tyr Ala Leu His Tyr Tyr Tyr Tyr 100 105 110 Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 484 <211> 336 <212> DNA <213> Homo sapiens <400> 484 gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120 tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180 tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300 ctcactttcg gcggagggac caaggtggag atcaaa 336 <210> 485 <211> 112 <212> PRT <213> Homo sapiens <400> 485 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 486 <211> 100 <212> PRT <213> Homo sapiens <400> 486 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile 100 <210> 487 <211> 98 <212> PRT <213> Homo sapiens <400> 487 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 488 <211> 98 <212> PRT <213> Homo sapiens <400> 488 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 489 <211> 93 <212> PRT <213> Homo sapiens <400> 489 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 85 90 <210> 490 <211> 94 <212> PRT <213> Homo sapiens <400> 490 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys 85 90 <210> 491 <211> 89 <212> PRT <213> Homo sapiens <400> 491 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys 85 <210> 492 <211> 87 <212> PRT <213> Homo sapiens <400> 492 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys 85 <210> 493 <211> 49 <212> PRT <213> Homo sapiens <400> 493 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly <210> 494 <211> 98 <212> PRT <213> Homo sapiens <400> 494 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 495 <211> 98 <212> PRT <213> Homo sapiens <400> 495 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 496 <211> 88 <212> PRT <213> Homo sapiens <400> 496 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys 85 <210> 497 <211> 90 <212> PRT <213> Homo sapiens <400> 497 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys 85 90 <210> 498 <211> 87 <212> PRT <213> Homo sapiens <400> 498 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys 85 <210> 499 <211> 13 <212> PRT <213> Homo sapiens <400> 499 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 500 <211> 10 <212> PRT <213> Homo sapiens <400> 500 Gly Phe Thr Phe Ser Asn Tyr Trp Met Ser 1 5 10 <210> 501 <211> 17 <212> PRT <213> Homo sapiens <400> 501 Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 502 <211> 18 <212> PRT <213> Homo sapiens <400> 502 Asp Leu Val Leu Met Val Tyr Asp Ile Asp Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 503 <211> 16 <212> PRT <213> Homo sapiens <400> 503 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 504 <211> 7 <212> PRT <213> Homo sapiens <400> 504 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 505 <211> 9 <212> PRT <213> Homo sapiens <400> 505 Met Gln Thr Leu Gln Thr Pro Leu Thr 1 5 <210> 506 <211> 25 <212> PRT <213> Homo sapiens <400> 506 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser 20 25 <210> 507 <211> 12 <212> PRT <213> Homo sapiens <400> 507 Gly Phe Ser Leu Ser Asn Ala Arg Met Gly Val Ser 1 5 10 <210> 508 <211> 12 <212> PRT <213> Homo sapiens <400> 508 Gly Phe Ser Leu Ser Asn Val Arg Met Gly Val Ser 1 5 10 <210> 509 <211> 14 <212> PRT <213> Homo sapiens <400> 509 Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala 1 5 10 <210> 510 <211> 25 <212> PRT <213> Homo sapiens <400> 510 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser 20 25 <210> 511 <211> 10 <212> PRT <213> Homo sapiens <400> 511 Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser 1 5 10 <210> 512 <211> 10 <212> PRT <213> Homo sapiens <400> 512 Gly Leu Thr Phe Ser Asn Phe Trp Met Ser 1 5 10 <210> 513 <211> 10 <212> PRT <213> Homo sapiens <400> 513 Gly Phe Thr Phe Ser Asn Tyr Trp Met Thr 1 5 10 <210> 514 <211> 14 <212> PRT <213> Homo sapiens <400> 514 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 1 5 10 <210> 515 <211> 25 <212> PRT <213> Homo sapiens <400> 515 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser 20 25 <210> 516 <211> 25 <212> PRT <213> Homo sapiens <400> 516 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Ala Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser 20 25 <210> 517 <211> 10 <212> PRT <213> Homo sapiens <400> 517 Gly Phe Thr Phe Ser Ser Tyr Gly Met His 1 5 10 <210> 518 <211> 14 <212> PRT <213> Homo sapiens <400> 518 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 1 5 10 <210> 519 <211> 16 <212> PRT <213> Homo sapiens <400> 519 His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Ser Thr Ser Leu Lys Ser 1 5 10 15 <210> 520 <211> 16 <212> PRT <213> Homo sapiens <400> 520 His Ile Phe Ser Asn Asp Glu Asn Ser Tyr Arg Thr Ser Leu Lys Ser 1 5 10 15 <210> 521 <211> 33 <212> PRT <213> Homo sapiens <400> 521 Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Val Leu Thr 1 5 10 15 Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg 20 25 30 Ile <210> 522 <211> 11 <212> PRT <213> Homo sapiens <400> 522 Val Gly Ala Thr Thr Asp Asp Ala Phe Asp Ile 1 5 10 <210> 523 <211> 11 <212> PRT <213> Homo sapiens <400> 523 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 1 5 10 <210> 524 <211> 11 <212> PRT <213> Homo sapiens <400> 524 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5 10 <210> 525 <211> 11 <212> PRT <213> Homo sapiens <400> 525 Trp Gly His Gly Thr Thr Val Thr Val Ser Ser 1 5 10 <210> 526 <211> 17 <212> PRT <213> Homo sapiens <400> 526 Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 527 <211> 17 <212> PRT <213> Homo sapiens <400> 527 Asn Ile Lys Gln Asp Gly Asn Asp Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 528 <211> 17 <212> PRT <213> Homo sapiens <400> 528 Ser Ile Lys Gln Asp Gly Ser Glu Arg Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 529 <211> 32 <212> PRT <213> Homo sapiens <400> 529 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 530 <211> 32 <212> PRT <213> Homo sapiens <400> 530 Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 531 <211> 32 <212> PRT <213> Homo sapiens <400> 531 Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 532 <211> 32 <212> PRT <213> Homo sapiens <400> 532 Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 533 <211> 10 <212> PRT <213> Homo sapiens <400> 533 Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile 1 5 10 <210> 534 <211> 18 <212> PRT <213> Homo sapiens <400> 534 Pro Leu Val Leu Met Val Tyr Ala Leu His Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 535 <211> 17 <212> PRT <213> Homo sapiens <400> 535 Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 536 <211> 17 <212> PRT <213> Homo sapiens <400> 536 Val Ile Tyr Tyr Asp Gly Ile Asn Lys His Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 537 <211> 32 <212> PRT <213> Homo sapiens <400> 537 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 538 <211> 5 <212> PRT <213> Homo sapiens <400> 538 Asp Arg Gly Leu Asp 1 5 <210> 539 <211> 11 <212> PRT <213> Homo sapiens <400> 539 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 <210> 540 <211> 23 <212> PRT <213> Homo sapiens <400> 540 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys 20 <210> 541 <211> 15 <212> PRT <213> Homo sapiens <400> 541 Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr 1 5 10 15 <210> 542 <211> 23 <212> PRT <213> Homo sapiens <400> 542 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys 20 <210> 543 <211> 17 <212> PRT <213> Homo sapiens <400> 543 Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu 1 5 10 15 Ala <210> 544 <211> 17 <212> PRT <213> Homo sapiens <400> 544 Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Ser Lys Asn Tyr Leu 1 5 10 15 Val <210> 545 <211> 15 <212> PRT <213> Homo sapiens <400> 545 Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 1 5 10 15 <210> 546 <211> 22 <212> PRT <213> Homo sapiens <400> 546 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys 20 <210> 547 <211> 13 <212> PRT <213> Homo sapiens <400> 547 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 548 <211> 13 <212> PRT <213> Homo sapiens <400> 548 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 549 <211> 15 <212> PRT <213> Homo sapiens <400> 549 Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 1 5 10 15 <210> 550 <211> 15 <212> PRT <213> Homo sapiens <400> 550 Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 1 5 10 15 <210> 551 <211> 22 <212> PRT <213> Homo sapiens <400> 551 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys 20 <210> 552 <211> 22 <212> PRT <213> Homo sapiens <400> 552 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys 20 <210> 553 <211> 11 <212> PRT <213> Homo sapiens <400> 553 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 554 <211> 15 <212> PRT <213> Homo sapiens <400> 554 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 1 5 10 15 <210> 555 <211> 15 <212> PRT <213> Homo sapiens <400> 555 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr 1 5 10 15 <210> 556 <211> 32 <212> PRT <213> Homo sapiens <400> 556 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 20 25 30 <210> 557 <211> 32 <212> PRT <213> Homo sapiens <400> 557 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr His Leu Thr 1 5 10 15 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 20 25 30 <210> 558 <211> 9 <212> PRT <213> Homo sapiens <400> 558 Met Gln Ala Leu Gln Thr Pro Leu Thr 1 5 <210> 559 <211> 10 <212> PRT <213> Homo sapiens <400> 559 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 1 5 10 <210> 560 <211> 7 <212> PRT <213> Homo sapiens <400> 560 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 561 <211> 32 <212> PRT <213> Homo sapiens <400> 561 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys 20 25 30 <210> 562 <211> 9 <212> PRT <213> Homo sapiens <400> 562 Gln Gln Tyr Tyr Ser Thr Pro Trp Thr 1 5 <210> 563 <211> 10 <212> PRT <213> Homo sapiens <400> 563 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 1 5 10 <210> 564 <211> 7 <212> PRT <213> Homo sapiens <400> 564 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 565 <211> 7 <212> PRT <213> Homo sapiens <400> 565 Ser Asn Asn Arg Arg Pro Ser 1 5 <210> 566 <211> 32 <212> PRT <213> Homo sapiens <400> 566 Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser 1 5 10 15 Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys 20 25 30 <210> 567 <211> 10 <212> PRT <213> Homo sapiens <400> 567 Ala Ala Trp Asp Asp Ser Leu Asn Trp Val 1 5 10 <210> 568 <211> 10 <212> PRT <213> Homo sapiens <400> 568 Ala Thr Trp Asp Asp Arg Leu Asn Trp Val 1 5 10 <210> 569 <211> 10 <212> PRT <213> Homo sapiens <400> 569 Phe Gly Ala Gly Thr Lys Leu Thr Val Leu 1 5 10 <210> 570 <211> 7 <212> PRT <213> Homo sapiens <400> 570 Tyr Asp Ser Asp Arg Pro Ser 1 5 <210> 571 <211> 7 <212> PRT <213> Homo sapiens <400> 571 Asp Asp Ser Asp Arg Pro Ser 1 5 <210> 572 <211> 32 <212> PRT <213> Homo sapiens <400> 572 Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr 1 5 10 15 Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys 20 25 30 <210> 573 <211> 32 <212> PRT <213> Homo sapiens <400> 573 Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr 1 5 10 15 Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Phe Cys 20 25 30 <210> 574 <211> 11 <212> PRT <213> Homo sapiens <400> 574 Gln Val Trp Asp Ser Ser Ser Asp Pro Val Val 1 5 10 <210> 575 <211> 10 <212> PRT <213> Homo sapiens <400> 575 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 1 5 10

Claims (1)

Methods of treatment for humans.

Images